doc_id;doi;title;assay_id;compound_key;molregno;canonical_smiles;standard_type;standard_value;standard_relation;standard_units;pchembl_value
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;16;146359;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1cccc(Cl)c1;Ki;199.53;=;nM;6.7
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;Mesulergine;10959;CN1C[C@@H](NS(=O)(=O)N(C)C)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;Ki;1.995;=;nM;8.7
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;28;146400;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C#N)cc1;Ki;398.11;=;nM;6.4
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;8;146461;COc1ccc(-c2ccccc2)cc1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O;Ki;10.0;=;nM;8.0
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;26;146851;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(NC(C)=O)cc1;Ki;316.23;=;nM;6.5
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;20;146779;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(F)cc1;Ki;125.89;=;nM;6.9
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;21;146874;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C)cc1;Ki;316.23;=;nM;6.5
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;18;146358;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1;Ki;316.23;=;nM;6.5
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;9;147124;COc1cc(OC)c(-c2ccccc2)cc1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O;Ki;100.0;=;nM;7.0
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;17;145881;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccccc1Cl;Ki;398.11;=;nM;6.4
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;4;145946;COc1ccc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)c1;Ki;125.89;=;nM;6.9
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;22;146778;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C(C)C)cc1;Ki;1258.93;=;nM;5.9
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;13;145876;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccccc1;Ki;630.96;=;nM;6.2
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;15;145769;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(Cl)cc1;Ki;79.43;=;nM;7.1
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;3;147121;COc1ccc(Cl)cc1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O;Ki;50.12;=;nM;7.3
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;5;147122;COc1cc(Cl)ccc1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O;Ki;199.53;=;nM;6.7
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;Spiperone;4634;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;Ki;1258.93;=;nM;5.9
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;24;147343;COc1ccc(S(=O)(=O)Nc2cc(C(=O)CCCCN3CCC4(CC3)NC(=O)NC4=O)c(OC)cc2OC)cc1;Ki;1258.93;=;nM;5.9
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;25;146332;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C(C)=O)cc1;Ki;251.19;=;nM;6.6
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;7;147123;COc1cc(Cl)c(Cl)cc1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O;Ki;6.31;=;nM;8.2
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;23;146873;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(OC(F)(F)F)cc1;Ki;398.11;=;nM;6.4
1883;10.1016/S0960-894X(96)00503-3;Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor;2889;27;146401;COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(S(N)(=O)=O)cc1;Ki;3162.28;=;nM;5.5
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;34;84003;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cnc(Oc3cccnc3C)cc1C)CC2;Ki;251.19;=;nM;6.6
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;21;84305;CCc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;125.89;=;nM;6.9
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;22;84265;Cc1cc2c(cc1Cl)CCN2C(=O)Nc1ccc(Oc2cccnc2C)nc1;Ki;125.89;=;nM;6.9
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;20;84266;Cc1cc2c(cc1Br)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;63.1;=;nM;7.2
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;30;83979;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3Cl)nc1)CC2;Ki;50.12;=;nM;7.3
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;39;84053;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nn1)CC2;Ki;125.89;=;nM;6.9
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;7;83835;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(F)ccc32)cn1;Ki;5011.87;=;nM;5.3
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;15;83760;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3c2ccc(Cl)c3Cl)cn1;Ki;501.19;=;nM;6.3
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;25;83711;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3c2cc(Cl)c(C)c3Cl)cn1;Ki;39.81;=;nM;7.4
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;12;83856;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3ccc(Cl)cc32)cn1;Ki;794.33;=;nM;6.1
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;26;84150;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3c2cc(C(F)(F)F)c2c3CCO2)cn1;Ki;63.1;=;nM;7.2
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;4;83831;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3c(Cl)cccc32)cn1;Ki;2511.89;=;nM;5.6
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;1;14131;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;14;83812;Cc1ccc2c(c1Br)CCN2C(=O)Nc1ccc(Oc2cccnc2C)nc1;Ki;251.19;=;nM;6.6
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;17;84202;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(Cl)c(Cl)cc32)cn1;Ki;316.23;=;nM;6.5
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;29;83456;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C(C)C)nc1)CC2;Ki;199.53;=;nM;6.7
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;33;83972;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cncnc3C)nc1)CC2;Ki;12.59;=;nM;7.9
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;35;84222;Cc1cc2c(cc1Cl)N(C(=O)Nc1cnc(Oc3cccnc3C)c(C)c1)CC2;Ki;31.62;=;nM;7.5
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;41;84091;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cnc(Oc3cccnc3C)cn1)CC2;Ki;79.43;=;nM;7.1
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;19;84163;Cc1cc2c(cc1F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;158.49;=;nM;6.8
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;3;83682;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3ccccc32)cn1;Ki;1995.26;=;nM;5.7
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;2;14132;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;31;83974;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cnccc3C)nc1)CC2;Ki;31.62;=;nM;7.5
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;40;84092;Cc1cc2c(cc1Cl)N(C(=O)Nc1cnc(Oc3cccnc3C)nc1)CC2;Ki;63.1;=;nM;7.2
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;36;84216;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cnc(Oc3cccnc3C)c(Cl)c1)CC2;Ki;39.81;=;nM;7.4
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;11;83893;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(C(F)(F)F)ccc32)cn1;Ki;630.96;=;nM;6.2
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;9;83999;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(Br)ccc32)cn1;Ki;630.96;=;nM;6.2
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;37;84179;Cc1cc2c(cc1Cl)N(C(=O)Nc1cnc(Oc3cccnc3C)c(Cl)c1)CC2;Ki;19.95;=;nM;7.7
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;10;84034;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(I)ccc32)cn1;Ki;316.23;=;nM;6.5
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;27;84114;CCc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(C)c(Cl)cc32)cn1;Ki;50.12;=;nM;7.3
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;28;83457;CCCc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(C)c(Cl)cc32)cn1;Ki;100.0;=;nM;7.0
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;13;83853;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3ccc(C(F)(F)F)cc32)cn1;Ki;398.11;=;nM;6.4
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;8;84035;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(Cl)ccc32)cn1;Ki;1995.26;=;nM;5.7
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;16;83730;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(F)c(Cl)cc32)cn1;Ki;630.96;=;nM;6.2
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;18;84201;Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(Br)c(C(F)(F)F)cc32)cn1;Ki;100.0;=;nM;7.0
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;24;84259;CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;39.81;=;nM;7.4
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;32;83933;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cnccc3Cl)nc1)CC2;Ki;12.59;=;nM;7.9
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;23;14118;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;50.12;=;nM;7.3
3832;10.1016/s0960-894x(00)00364-4;1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.;2884;38;84093;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nn1)CC2;Ki;158.49;=;nM;6.8
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;10;83686;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3cncn3C)nc1)CC2;Ki;6.31;=;nM;8.2
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;4;83815;Cc1cccc(COc2ccc(NC(=O)N3CCc4cc(C)c(C(F)(F)F)cc43)cn2)n1;Ki;25.12;=;nM;7.6
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;19;83876;O=C(Nc1ccc(OCc2ccccn2)nc1)N1CCc2cc(Cl)ccc21;Ki;1000.0;=;nM;6.0
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;1;83784;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3ccccn3)nc1)CC2;Ki;31.62;=;nM;7.5
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;12;83685;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cnc(OCc3ccccn3)c(C)c1)CC2;Ki;7.943;=;nM;8.1
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;16;83848;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(COc3ccccn3)nc1)CC2;Ki;199.53;=;nM;6.7
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;15;83852;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(CCc3ccccn3)nc1)CC2;Ki;19.95;=;nM;7.7
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;17;83808;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCCc3ccccn3)nc1)CC2;Ki;19.95;=;nM;7.7
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;7;83986;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(OCc3ccncc3)nc1)CC2;Ki;7.943;=;nM;8.1
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;2;83816;O=C(Nc1ccc(OCc2ccccn2)nc1)N1CCc2cc(C(F)(F)F)ccc21;Ki;398.11;=;nM;6.4
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;20;83911;O=C(Nc1ccc(OCc2ccccn2)nc1)N1CCc2c(Cl)cccc21;Ki;1000.0;=;nM;6.0
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;9;84271;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(OCc3nccn3C)nc1)CC2;Ki;12.59;=;nM;7.9
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;3;83777;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(OCc3ccccn3)nc1)CC2;Ki;100.0;=;nM;7.0
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;8;83987;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3cnccn3)nc1)CC2;Ki;10.0;=;nM;8.0
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;14;83766;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3ccccn3)cc1)CC2;Ki;25.12;=;nM;7.6
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;18;83877;O=C(Nc1ccc(OCc2ccccn2)nc1)N1CCc2cc(Br)ccc21;Ki;501.19;=;nM;6.3
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;21;83875;O=C(Nc1ccc(OCc2ccccn2)nc1)N1CCc2ccc(C(F)(F)F)cc21;Ki;251.19;=;nM;6.6
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;5;83698;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3ncccc3C)nc1)CC2;Ki;15.85;=;nM;7.8
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;6;84278;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(OCc3cccnc3)nc1)CC2;Ki;25.12;=;nM;7.6
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;11;83734;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(OCc3nccs3)nc1)CC2;Ki;100.0;=;nM;7.0
3833;10.1016/s0960-894x(00)00365-6;1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.;2885;13;84309;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3ccccn3)nn1)CC2;Ki;79.43;=;nM;7.1
4199;10.1016/s0960-894x(00)00597-7;Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).;2888;24;257212;COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2Cl)cc1N1CCNCC1;Ki;1995.26;=;nM;5.7
4199;10.1016/s0960-894x(00)00597-7;Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).;2888;34;257579;COc1ccc(S(=O)(=O)N2CCc3ccc(I)cc32)cc1N1CCNCC1;Ki;630.96;=;nM;6.2
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;2;87323;Cc1cc2cc(NC(=O)Nc3ccnc4ccccc34)ccc2n1C;Ki;3.981;=;nM;8.4
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;18;87478;COc1ccc(NC(=O)Nc2ccnc3ccccc23)cc1Cl;Ki;15.85;=;nM;7.8
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;16;87512;CSc1ccc(NC(=O)Nc2ccnc3ccccc23)cc1;Ki;31.62;=;nM;7.5
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;23;87422;Cc1nc2ccc(NC(=O)Nc3ccnc4ccccc34)cc2o1;Ki;630.96;=;nM;6.2
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;13;87735;CCN(CC)c1ccc(NC(=O)Nc2ccnc3ccccc23)cc1;Ki;50.12;=;nM;7.3
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;11;87627;CN(C)c1ccc(NC(=O)Nc2ccnc3ccccc23)cc1;Ki;79.43;=;nM;7.1
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;5;86778;CN1CCc2cc(NC(=O)Nc3ccnc4ccccc34)ccc21;Ki;12.59;=;nM;7.9
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;1;86733;Cn1ccc2cc(NC(=O)Nc3ccnc4ccccc34)ccc21;Ki;2.512;=;nM;8.6
4321;10.1016/s0960-894x(01)00343-2;1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.;2890;31;87552;Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1;Ki;3981.07;=;nM;5.4
4373;10.1016/s0960-894x(01)00397-3;Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.;2925;1;78315;O=C(/C=C/c1ccc(Cl)c(Cl)c1)NCCCCCN1CCC(c2c[nH]c3ccc(O)cc23)CC1;Ki;25.12;=;nM;7.6
4373;10.1016/s0960-894x(01)00397-3;Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.;2925;8;109611;O=C(/C=C/c1ccc(Cl)c(Cl)c1)N[C@H]1CC[C@@H](CN2[C@@H]3CC[C@H]2C[C@H](c2c[nH]c4ccc(O)cc24)C3)CC1;Ki;501.19;=;nM;6.3
4540;10.1016/s0960-894x(01)00558-3;Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT(6) receptor.;2880;6l;158033;Cc1sc2ccc(Cl)cc2c1S(=O)(=O)Nc1ccc2nccc(N3CCNCC3)c2c1;Ki;1258.93;=;nM;5.9
4829;10.1016/s0960-894x(02)00172-5;Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.;2894;(S)-4;39104;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN2CCC[C@H]2C1;Ki;1258.93;=;nM;5.9
4829;10.1016/s0960-894x(02)00172-5;Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.;2894;(R)-4;39066;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN2CCC[C@@H]2C1;Ki;1258.93;=;nM;5.9
4829;10.1016/s0960-894x(02)00172-5;Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.;2894;3;38499;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN2CCCCC2C1;Ki;1995.26;=;nM;5.7
4829;10.1016/s0960-894x(02)00172-5;Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.;2894;2;39103;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN(C)CC1;Ki;1000.0;=;nM;6.0
5213;10.1016/s0960-894x(02)00690-x;SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.;2892;13, SB-656104;155183;O=S(=O)(c1ccc2cc[nH]c2c1)N1CCC[C@@H]1CCN1CCC(Oc2ccc(Cl)cc2)CC1;Ki;91.2;=;nM;7.04
6166;10.1016/s0960-894x(03)00077-5;Identification of a novel series of selective 5-HT7 receptor antagonists.;2881;25;6149;O=C1c2ccccc2CCCN1CCN1CCC(n2c(O)nc3cc(F)ccc32)CC1;Ki;1000.0;=;nM;6.0
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;48;124056;C[C@H](N)CN1CCc2ccc(Cl)cc21;EC50;6.5;=;nM;8.19
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;50;124058;CSc1ccc2c(c1)N(C[C@H](C)N)CC2;EC50;10.0;=;nM;8.0
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;51;124125;CCSc1ccc2c(c1)N(C[C@H](C)N)CC2;EC50;72.0;=;nM;7.14
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;54;123310;C[C@H](N)CN1CCc2cc(F)c(C(F)(F)F)cc21;EC50;49.0;=;nM;7.31
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;56;123311;CCSc1cc2c(cc1F)CCN2C[C@H](C)N;EC50;31.0;=;nM;7.51
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;49 (VER-3323);124126;C[C@H](N)CN1CCc2ccc(Br)cc21;EC50;11.0;=;nM;7.96
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;53;124184;C[C@H](N)CN1CCc2cc(F)c(I)cc21;EC50;22.0;=;nM;7.66
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;2 (Ro-600175);123335;C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21;EC50;4.3;=;nM;8.37
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.5;=;nM;8.82
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;52;124099;C[C@H](N)CN1CCc2cc(F)c(Cl)cc21;EC50;7.3;=;nM;8.14
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;55 (VER-5593);124158;CSc1cc2c(cc1F)CCN2C[C@H](C)N;EC50;4.1;=;nM;8.39
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;57 (VER-5384);123351;C[C@H](N)CN1CCc2ccc3c(c21)CCO3;EC50;3.0;=;nM;8.52
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2484;58;123314;C[C@H](N)CN1CCc2ccc3c(c21)CCCO3;EC50;36.0;=;nM;7.44
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;48;124056;C[C@H](N)CN1CCc2ccc(Cl)cc21;Ki;54.0;=;nM;7.27
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;50;124058;CSc1ccc2c(c1)N(C[C@H](C)N)CC2;Ki;89.0;=;nM;7.05
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;51;124125;CCSc1ccc2c(c1)N(C[C@H](C)N)CC2;Ki;189.0;=;nM;6.72
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;54;123310;C[C@H](N)CN1CCc2cc(F)c(C(F)(F)F)cc21;Ki;88.0;=;nM;7.06
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;56;123311;CCSc1cc2c(cc1F)CCN2C[C@H](C)N;Ki;62.0;=;nM;7.21
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;49 (VER-3323);124126;C[C@H](N)CN1CCc2ccc(Br)cc21;Ki;46.0;=;nM;7.34
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;53;124184;C[C@H](N)CN1CCc2cc(F)c(I)cc21;Ki;38.0;=;nM;7.42
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;2 (Ro-600175);123335;C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21;Ki;5.1;=;nM;8.29
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;Ki;12.0;=;nM;7.92
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;52;124099;C[C@H](N)CN1CCc2cc(F)c(Cl)cc21;Ki;31.0;=;nM;7.51
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;55 (VER-5593);124158;CSc1cc2c(cc1F)CCN2C[C@H](C)N;Ki;21.0;=;nM;7.68
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;57 (VER-5384);123351;C[C@H](N)CN1CCc2ccc3c(c21)CCO3;Ki;49.0;=;nM;7.31
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;58;123314;C[C@H](N)CN1CCc2ccc3c(c21)CCCO3;Ki;355.0;=;nM;6.45
6857;10.1016/j.bmcl.2003.05.001;Indoline derivatives as 5-HT(2C) receptor agonists.;2865;1 (mCPP);5884;Clc1cccc(N2CCNCC2)c1;Ki;32.0;=;nM;7.5
13481;10.1021/jm960199j;Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.;2488;7b;164236;CC(N)Cc1c2c(c(Br)c3c1OCC3)OCC2;Ki;1.6;=;nM;8.8
13481;10.1021/jm960199j;Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.;2492;7b;164236;CC(N)Cc1c2c(c(Br)c3c1OCC3)OCC2;Ki;1.15;=;nM;8.94
14093;10.1021/jm970219x;Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.;2487;8;167337;COc1cc(CCN)c2c(c1OC)OCC2;Ki;523.0;=;nM;6.28
14093;10.1021/jm970219x;Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.;2487;9;167338;COc1c2c(c(CCN)c3c1OCC3)CCO2;Ki;301.5;=;nM;6.52
14093;10.1021/jm970219x;Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.;2487;23 (Escaline);167339;CCOc1c(OC)cc(CCN)cc1OC;Ki;555.1;=;nM;6.26
14093;10.1021/jm970219x;Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.;2487;1 (Mescaline);37555;COc1cc(CCN)cc(OC)c1OC;Ki;795.1;=;nM;6.1
14093;10.1021/jm970219x;Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.;2489;9;167338;COc1c2c(c(CCN)c3c1OCC3)CCO2;Ki;205.0;=;nM;6.69
14093;10.1021/jm970219x;Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.;2491;8;167337;COc1cc(CCN)c2c(c1OC)OCC2;Ki;311.0;=;nM;6.51
14157;10.1021/jm970424c;6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.;2879;4;14101;CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2;Ki;12.59;=;nM;7.9
14157;10.1021/jm970424c;6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.;2879;1;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;25.12;=;nM;7.6
14157;10.1021/jm970424c;6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.;2879;5;14131;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;47;61910;CCSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2;Ki;10.0;=;nM;8.0
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;1;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;25.12;=;nM;7.6
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;36;62724;CC(C)(C)c1cc2c(cc1Cl)N(C(=O)Nc1cccnc1)CC2;Ki;158.49;=;nM;6.8
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;48;61323;CCCSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2;Ki;15.85;=;nM;7.8
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;56;62778;CSc1cc2c(cc1C(F)(F)C(F)(F)F)N(C(=O)Nc1cccnc1)CC2;Ki;31.62;=;nM;7.5
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;46;14101;CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2;Ki;12.59;=;nM;7.9
14391;10.1021/jm970741j;Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.;2883;53;61788;CC(C)Oc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2;Ki;3.981;=;nM;8.4
14442;10.1021/jm980076u;Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.;2493;4d;105836;COc1cc(Br)c2c3c1C[C@H](N)C[C@@H]3CO2;Ki;255.0;=;nM;6.59
14442;10.1021/jm980076u;Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.;2494;4c;106425;COc1cc(Br)c2c3c1C[C@H](N)C[C@H]3CO2;Ki;11200.0;=;nM;4.95
14442;10.1021/jm980076u;Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.;2494;4d;105836;COc1cc(Br)c2c3c1C[C@H](N)C[C@@H]3CO2;Ki;263.0;=;nM;6.58
14442;10.1021/jm980076u;Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.;2494;3;106259;C[C@@H](N)Cc1c2c(c(Br)c3c1OCC3)OCC2;Ki;1.6;=;nM;8.8
14442;10.1021/jm980076u;Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.;2495;3;106259;C[C@@H](N)Cc1c2c(c(Br)c3c1OCC3)OCC2;Ki;1.15;=;nM;8.94
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;5-methoxy alpha-methyl tryptamine;244157;COc1ccc2[nH]cc(C(C)CN)c2c1;Ki;8.3;=;nM;8.08
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;(+)-1a;244109;N[C@H]1C[C@@H]1c1c[nH]c2ccccc12;Ki;93.5;=;nM;7.03
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;(+/-)-1a;244584;NC1CC1c1c[nH]c2ccccc12;Ki;58.3;=;nM;7.23
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;alpha-methyl tryptamine;244156;CC(CN)c1c[nH]c2ccccc12;Ki;87.0;=;nM;7.06
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;1d;243660;NC1CC1c1c[nH]c2ccc(F)cc12;Ki;5.7;=;nM;8.24
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;1c;243825;COc1ccc2[nH]cc(C3CC3N)c2c1;Ki;38.1;=;nM;7.42
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;(-)-1a;243659;N[C@@H]1C[C@H]1c1c[nH]c2ccccc12;Ki;58.5;=;nM;7.23
14744;10.1021/jm980318q;Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.;2864;1b;244155;COc1cccc2[nH]cc(C3CC3N)c12;Ki;64.9;=;nM;7.19
14755;10.1021/jm9803525;A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.;2863;(+/-)3;246874;CC(N)Cc1c2ccoc2c(Br)c2ccoc12;Ki;0.19;=;nM;9.72
14755;10.1021/jm9803525;A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.;2863;(-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;Ki;42.7;=;nM;7.37
14755;10.1021/jm9803525;A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.;2863;(+/-)2;164236;CC(N)Cc1c2c(c(Br)c3c1OCC3)OCC2;Ki;1.6;=;nM;8.8
15146;10.1021/jm980532e;5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.;2891;1;99770;COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1;Ki;630.96;=;nM;6.2
15146;10.1021/jm980532e;5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.;2891;2;39103;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN(C)CC1;Ki;1000.0;=;nM;6.0
15363;10.1021/jm980692q;Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.;2867;3b;12009;CN(C)CCc1c[nH]c2sccc12;Ki;483.0;=;nM;6.32
15363;10.1021/jm980692q;Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.;2868;1a;9988;CN(C)CCc1c[nH]c2ccccc12;Ki;101.0;=;nM;7.0
15363;10.1021/jm980692q;Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.;2869;3a;12010;CN(C)CCc1c[nH]c2ccsc12;Ki;214.0;=;nM;6.67
15779;10.1021/jm991151j;A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).;2876;15;36730;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1;Ki;10000.0;=;nM;5.0
15779;10.1021/jm991151j;A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).;2876;(R)-10;155230;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc3ccccc23)CC1;Ki;1995.26;=;nM;5.7
15779;10.1021/jm991151j;A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).;2876;(R)-5;1151895;CC1CCN(CC[C@H]2CCCCN2S(=O)(=O)c2cccc3ccccc23)CC1;Ki;3981.07;=;nM;5.4
15779;10.1021/jm991151j;A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).;2882;(RS)-5;190684;CC1CCN(CCC2CCCCN2S(=O)(=O)c2cccc3ccccc23)CC1;Ki;3981.07;=;nM;5.4
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;17;14192;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccc(-c3cccnc3)c1)CC2;Ki;7.943;=;nM;8.1
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;39;14118;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;50.12;=;nM;7.3
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;38;14147;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3)nc1)CC2;Ki;19.95;=;nM;7.7
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;28;14044;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(C)c(-c3cccnc3)c1)CC2;Ki;5.012;=;nM;8.3
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;20;14198;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccc(-c3c(C)ccnc3C)c1)CC2;Ki;12.59;=;nM;7.9
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;25;14364;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(-c3cccnc3)ccc1F)CC2;Ki;1995.26;=;nM;5.7
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;36;14029;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)c(C)c(-c3cccnc3)c1)CC2;Ki;7.943;=;nM;8.1
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;34;14064;CCc1cc(NC(=O)N2CCc3cc(OC)c(C(F)(F)F)cc32)cc(-c2cccnc2)c1;Ki;10.0;=;nM;8.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;24;14336;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(-c3ccncc3)cc1)CC2;Ki;12.59;=;nM;7.9
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;41;14131;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;30;14156;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Cl)c(-c3cccnc3)c1)CC2;Ki;25.12;=;nM;7.6
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;40;14132;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;27;14317;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccc(-c3cccnc3)c1Cl)CC2;Ki;5.012;=;nM;8.3
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;23;14159;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(-c3cccnc3)cc1)CC2;Ki;10.0;=;nM;8.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;35;14037;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(-c3ccccc3)cc(-c3cccnc3)c1)CC2;Ki;15.85;=;nM;7.8
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;21;14196;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(C)c(-c3cnccc3C)c1)CC2;Ki;3.981;=;nM;8.4
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;32;14075;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2;Ki;10.0;=;nM;8.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;19;14199;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccc(-c3cccnc3C)c1)CC2;Ki;15.85;=;nM;7.8
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;29;14163;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(C(C)(C)C)c(-c3cccnc3)c1)CC2;Ki;39.81;=;nM;7.4
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;33;14074;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(Br)cc(-c3cccnc3)c1)CC2;Ki;19.95;=;nM;7.7
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;31;13977;COc1ccc(NC(=O)N2CCc3cc(OC)c(C(F)(F)F)cc32)cc1-c1cccnc1;Ki;15.85;=;nM;7.8
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2877;37;14155;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc3c(c(-c4cccnc4)c1)OCC3)CC2;Ki;7.943;=;nM;8.1
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;6;14303;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3ccc(F)cc3)c1)CC2;Ki;63.1;=;nM;7.2
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;10;14223;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3ccncc3)c1)CC2;Ki;10.0;=;nM;8.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;14;14108;CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccc(-c3ccncc3)c1)CC2;Ki;25.12;=;nM;7.6
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;5;14491;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3ccccc3)c1)CC2;Ki;25.12;=;nM;7.6
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;13;14337;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(-c3cccnc3)nc1)CC2;Ki;10.0;=;nM;8.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;7;14451;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3cc(F)cc(F)c3)c1)CC2;Ki;501.19;=;nM;6.3
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;15;14232;CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccc(-c3cccnc3)c1)CC2;Ki;7.943;=;nM;8.1
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;11;14373;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3cccnc3)c1)CC2;Ki;10.0;=;nM;8.0
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;12;14224;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3cnccc3C)c1)CC2;Ki;6.31;=;nM;8.2
15851;10.1021/jm990388c;Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.;2886;8;14189;COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cncc(-c3c(F)cccc3F)c1)CC2;Ki;100.0;=;nM;7.0
16209;10.1021/jm0155190;N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.;2866;4;214206;Cc1[nH]c2cccc(NC(=O)c3ccc(F)cc3)c2c1CCN(C)C;Ki;676.0;=;nM;6.17
16633;10.1021/jm020153s;Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).;2928;Cis-2a;226214;C[C@@H]1C[C@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;Ki;44.0;=;nM;7.36
16633;10.1021/jm020153s;Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).;2929;RR-2b;226762;C[C@@H]1C[C@@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;Ki;310.0;=;nM;6.51
16633;10.1021/jm020153s;Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).;2929;SS-2c;226635;C[C@H]1C[C@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;Ki;27.0;=;nM;7.57
16633;10.1021/jm020153s;Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).;2930;LSD 1;601;CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;30.0;=;nM;7.52
16946;10.1021/jm020954v;New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.;2927;4a;49078;CCCN1CCC(COc2nc3ccccc3c3c2CCCN3)CC1;IC50;200.0;=;nM;6.7
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;2a;43567;COc1ccc2[nH]cc(CC(C)N)c2c1;Ki;7.8;=;nM;8.11
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;10;220775;C[C@@H](N)Cc1c[nH]c2ccc3c(c12)CCCO3;Ki;19.0;=;nM;7.72
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;11;220768;C[C@H](N)Cc1c[nH]c2ccc3c(c12)CCCO3;Ki;5.3;=;nM;8.28
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;8b;220767;CC(N)Cc1c[nH]c2ccc3c(c12)CCCO3;Ki;13.0;=;nM;7.89
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;4b;36132;NCCc1c[nH]c2ccc3c(c12)CCCO3;Ki;14.0;=;nM;7.85
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;Ki;13.0;=;nM;7.89
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;2b;20819;CC(N)Cc1c[nH]c2ccc(O)cc12;Ki;13.0;=;nM;7.89
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;8a;220874;CC(N)Cc1cn(C)c2ccc3c(c12)CCCO3;Ki;11.0;=;nM;7.96
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;3;221517;COc1cc(C[C@@H](C)N)c(OC)cc1I;Ki;18.0;=;nM;7.75
17200;10.1021/jm030205t;A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.;2871;5;35617;CN(C)CCc1c[nH]c2ccc3c(c12)CCCO3;Ki;26.0;=;nM;7.58
20040;10.1016/j.bmcl.2004.05.051;Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists.;304725;A;307081;Cc1cc(N2CCN(C)CC2)nc2ccc(NC(=O)COc3ccc(Cl)cc3)cc12;IC50;349.0;=;nM;6.46
20040;10.1016/j.bmcl.2004.05.051;Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists.;304725;C;307109;Cc1cc(N2CCN(C)CC2)nc2ccc(NC(=O)COc3ccc(C(F)(F)F)cc3)cc12;IC50;442.0;=;nM;6.36
20040;10.1016/j.bmcl.2004.05.051;Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists.;304725;N;307308;Cc1cc(N2CCN(C)CC2)nc2ccc(NC(=O)COc3cccc(Cl)c3Cl)cc12;IC50;201.0;=;nM;6.7
20040;10.1016/j.bmcl.2004.05.051;Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists.;304725;S (table 2);307039;Cc1cc(NC(C)C)nc2ccc(NC(=O)COc3ccc(C(F)(F)F)cc3)cc12;IC50;400.0;=;nM;6.4
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;13;316035;C[C@@H]1CNC[C@H]2Cc3ccc(CO)cc3N21;Ki;250.0;=;nM;6.6
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;14;315853;Cc1cccc2c1N1[C@@H](CNC[C@H]1C)C2;Ki;59.0;=;nM;7.23
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;1;315926;Clc1ccc2c(c1)N1CCNCC1C2;Ki;53.0;=;nM;7.28
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;15;315885;Cc1ccc2c(c1C)N1[C@@H](CNC[C@H]1C)C2;Ki;13.0;=;nM;7.89
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;16;315680;Cc1ccc2c(c1C)N1[C@H](CNC[C@H]1C)C2;Ki;67.0;=;nM;7.17
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;5;1369695;C[C@H]1CNC[C@@H]2Cc3ccccc3N21;Ki;2600.0;=;nM;5.58
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;17;315681;Cc1c(Cl)ccc2c1N1[C@@H](CNC[C@H]1C)C2;Ki;3.2;=;nM;8.49
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;6;1384306;C[C@@H]1CNC[C@H]2Cc3ccccc3N21;Ki;15.0;=;nM;7.82
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;18;315980;Cc1c(Cl)ccc2c1N1[C@H](CNC[C@H]1C)C2;Ki;19.0;=;nM;7.72
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;19;316009;Cc1c(Cl)ccc2c1N1CCNC[C@H]1C2;Ki;10.0;=;nM;8.0
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;7;1369793;C[C@@H]1CNC[C@@H]2Cc3ccccc3N21;Ki;210.0;=;nM;6.68
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;20;315778;Cc1c(Cl)ccc2c1N1CCNC[C@@H]1C2;Ki;140.0;=;nM;6.85
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;8;1369793;C[C@@H]1CNC[C@@H]2Cc3ccccc3N21;Ki;160.0;=;nM;6.8
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;9;315789;Cc1ccc2c(c1)N1[C@@H](CNC[C@H]1C)C2;Ki;21.0;=;nM;7.68
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;10;315830;C[C@@H]1CNC[C@H]2Cc3ccc(C(F)(F)F)cc3N21;Ki;11.0;=;nM;7.96
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;11;315640;C[C@@H]1CNC[C@H]2Cc3ccc(C#N)cc3N21;Ki;90.0;=;nM;7.05
20595;10.1016/j.bmcl.2005.05.074;Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.;303086;12;315641;CC(=O)Nc1ccc2c(c1)N1[C@@H](CNC[C@H]1C)C2;Ki;960.0;=;nM;6.02
20653;10.1016/j.bmcl.2005.06.024;Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.;304059;3;315433;O=C(/C=C/c1ccccc1)N(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)Cc1cccnc1.O=C(O)C(F)(F)F;Ki;1995.26;=;nM;5.7
20653;10.1016/j.bmcl.2005.06.024;Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.;304059;11a;315545;CN(C)CCN(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)C(=O)CCC1CCCC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F;Ki;1000.0;=;nM;6.0
20653;10.1016/j.bmcl.2005.06.024;Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.;304059;2;315432;CN(C)CCN(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)C(=O)/C=C/c1ccccc1.O=C(O)C(F)(F)F;Ki;1258.93;=;nM;5.9
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;17d;301257;COc1ccc2c(c1)C(C)CNCC2;EC50;780.0;=;nM;6.11
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;18a;301145;CC1CNCCc2c(Cl)cc(Cl)cc21;EC50;840.0;=;nM;6.08
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;18b;301164;CC1CNCCc2cc(Cl)c(Cl)cc21;EC50;78.0;=;nM;7.11
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;18c;301171;CC1CNCCc2ccc(Cl)c(Cl)c21;EC50;1800.0;=;nM;5.75
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;18d;301172;CC1CNCCc2cc(F)c(Cl)cc21;EC50;360.0;=;nM;6.44
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;19;301193;Clc1ccc2c(c1)CCNCC2;EC50;1000.0;=;nM;6.0
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;(R)-15;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;1000.0;=;nM;6.0
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;(S)-15;301216;C[C@@H]1CNCCc2ccc(Cl)cc21;EC50;1400.0;=;nM;5.85
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;8;301045;COc1cc2c(cc1Br)C(C)CNCC2;EC50;100.0;=;nM;7.0
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;9b;301091;COc1cc2c(cc1Cl)C(C)CNCC2;EC50;140.0;=;nM;6.85
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;9c;301092;COc1cc2c(cc1I)C(C)CNCC2;EC50;64.0;=;nM;7.19
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;9d;301093;COc1cc2c(cc1C(F)(F)F)C(C)CNCC2;EC50;130.0;=;nM;6.89
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;10a;301120;CC1CNCCc2cc(O)c(Br)cc21;EC50;190.0;=;nM;6.72
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;10b;301121;CCOc1cc2c(cc1Br)C(C)CNCC2;EC50;180.0;=;nM;6.75
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;10c;301122;CC(C)Oc1cc2c(cc1Br)C(C)CNCC2;EC50;230.0;=;nM;6.64
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;11a;300990;COc1cc2c(cc1Br)CCNCC2;EC50;400.0;=;nM;6.4
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;11b;301012;CCC1CNCCc2cc(OC)c(Br)cc21;EC50;40.0;=;nM;7.4
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;11c;301029;COc1cc2c(cc1Br)C(C(C)C)CNCC2;EC50;1000.0;=;nM;6.0
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;(R)-11d;301183;COc1cc2c(cc1Br)[C@@H](C)CNCC2;EC50;220.0;=;nM;6.66
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;(S)-11e;301184;COc1cc2c(cc1Br)[C@H](C)CNCC2;EC50;30.0;=;nM;7.52
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;15;301200;CC1CNCCc2ccc(Cl)cc21;EC50;1100.0;=;nM;5.96
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;16b;301202;CC1CNCCc2cc(Cl)ccc21;EC50;530.0;=;nM;6.28
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;17b;301223;CC1CNCCc2ccc(Br)cc21;EC50;1500.0;=;nM;5.82
20859;10.1016/j.bmcl.2004.12.080;Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.;310685;17c;301235;CC1CNCCc2ccc(C(F)(F)F)cc21;EC50;380.0;=;nM;6.42
21236;10.1021/jm049039v;Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.;304025;14, SB-714786;321985;Cc1ccc2c(OCCN3CCN(Cc4cccc5cccnc45)CC3)cccc2n1;Ki;1258.93;=;nM;5.9
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;3;331109;CN(C)CCc1cn(C)c2cccc(O)c12;Ki;38.0;=;nM;7.42
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;4;331114;CN(C)CCc1cn(C)c2cccc(OP(=O)(O)O)c12;Ki;5500.0;=;nM;5.26
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;5;331115;CCCCn1cc(CCN(C)C)c2c(O)cccc21;Ki;5.8;=;nM;8.24
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;6;331116;CCCCn1cc(CCN(C)C)c2c(OP(=O)(O)O)cccc21;Ki;170.0;=;nM;6.77
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;7;331122;CN(C)CCc1c[nH]c2cc(O)ccc12;Ki;6300.0;=;nM;5.2
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;9;331124;CN(C)CCc1c[nH]c2cccc(F)c12;Ki;8.39;=;nM;8.08
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;10;331128;CN1CCN(CCc2c[nH]c3cccc(O)c23)CC1;Ki;116.0;=;nM;6.94
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;11;331129;Oc1cccc2[nH]cc(CCN3CCCc4ccccc43)c12;Ki;5566.0;=;nM;5.25
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;12;331133;Oc1cccc2[nH]cc(CCN3CCCC3)c12;Ki;423.0;=;nM;6.37
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;13;331134;CN(C)Cc1c[nH]c2cccc(O)c12;Ki;1242.0;=;nM;5.91
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;14;331139;CN(C)Cc1cn(C)c2cccc(O)c12;Ki;1242.0;=;nM;5.91
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;15;331140;CN(C)CCCc1c[nH]c2cccc(O)c12;Ki;98.0;=;nM;7.01
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;320931;16;331141;CC(Cc1c[nH]c2cccc(O)c12)N(C)C;Ki;745.0;=;nM;6.13
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;322150;9;331124;CN(C)CCc1c[nH]c2cccc(F)c12;EC50;1180.0;=;nM;5.93
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;322150;2;102382;CN(C)CCc1c[nH]c2cccc(O)c12;EC50;58.0;=;nM;7.24
30060;10.1016/j.bmcl.2005.06.104;SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.;322150;1;331146;CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12;EC50;74.0;=;nM;7.13
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;1 table 1;14131;Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;2 table 1;14132;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2;Ki;100.0;=;nM;7.0
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;3 table 1;83784;Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(OCc3ccccn3)nc1)CC2;Ki;31.62;=;nM;7.5
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;4 table 1;330654;COc1cc2c(cc1OCCN1CCCCC1)N(C(=O)/C=C/c1ccccc1Cl)CC2;Ki;125.89;=;nM;6.9
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;5 table 1;330655;COc1ccc(N2CCN(c3ccc(C)c(C(F)(F)F)c3)C2=O)cc1OCCN1CCCCC1;Ki;79.43;=;nM;7.1
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;7 table 1;330667;COc1ccc(N2CCN(c3cccc(Cl)c3Cl)C2=O)cc1OCCN1CCCCC1;Ki;1258.93;=;nM;5.9
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;8 table 1;330668;COc1ccc(N2CCN(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;316.23;=;nM;6.5
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;9 table 1;330678;COc1ccc(N2CCN(c3ccccc3)C2=O)cc1OCCN1CCCCC1;Ki;1258.93;=;nM;5.9
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;10 table 1;330679;COc1ccc(N2CCN(c3cccc(F)c3)C2=O)cc1OCCN1CCCCC1;Ki;501.19;=;nM;6.3
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;11 table 1;330685;COc1ccc(N2CCN(c3cccc(F)c3)C2=O)cc1OCCN1CCOCC1;Ki;794.33;=;nM;6.1
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;12 table 1;330686;COc1ccc(N2CCN(c3cccc(F)c3)C2=O)cc1OCCN(C)C;Ki;1584.89;=;nM;5.8
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;13 table 1;330691;COc1ccc(N2CCN(c3cccc(F)c3)C2=O)cc1OCCO;Ki;1258.93;=;nM;5.9
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;14 table 1;330692;COc1ccc(N2CCN(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCOCC1;Ki;316.23;=;nM;6.5
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;16 table 1;330699;COc1ccc(N2CCN(c3ccc(C)c(C(F)(F)F)c3)C2=O)cc1OCCN1CCOCC1;Ki;125.89;=;nM;6.9
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;17 table 1;330706;O=C1N(c2ccc(OCCN3CCCCC3)nc2)CCN1c1ccc(Cl)c(Cl)c1;Ki;158.49;=;nM;6.8
30133;10.1016/j.bmcl.2005.08.004;A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.;321080;19 table 1;330713;COc1ccc(-n2ccn(-c3cccc(F)c3)c2=O)cc1OCCN1CCCCC1;Ki;1995.26;=;nM;5.7
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;5HT;2214;NCCc1c[nH]c2ccc(O)cc12;Ki;13.0;=;nM;7.89
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;1, R-DOI;221517;COc1cc(C[C@@H](C)N)c(OC)cc1I;Ki;18.0;=;nM;7.75
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;2;20819;CC(N)Cc1c[nH]c2ccc(O)cc12;Ki;13.0;=;nM;7.89
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;6;335729;NCCn1ncc2ccc(O)cc21;Ki;15.0;=;nM;7.82
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;9;335730;C[C@H](N)Cn1ncc2ccc(O)cc21;Ki;8.1;=;nM;8.09
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;10;335829;C[C@@H](N)Cn1ncc2ccc(O)cc21;Ki;35.0;=;nM;7.46
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;12;335712;COc1ccc2cnn(C[C@H](C)N)c2c1;Ki;7.5;=;nM;8.12
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;14;335713;Cc1c(O)ccc2cnn(C[C@H](C)N)c12;Ki;8.7;=;nM;8.06
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;15;335714;C[C@H](N)Cn1ncc2ccc(O)c(F)c21;Ki;1.7;=;nM;8.77
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;16;335908;C[C@H](N)Cn1ncc2ccc(O)c(Cl)c21;Ki;3.8;=;nM;8.42
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;17;335909;C[C@H](N)Cn1ncc2ccc(O)c(I)c21;Ki;6.0;=;nM;8.22
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;18;2232;COc1ccc2[nH]cc(CCN(C)C)c2c1;Ki;52.0;=;nM;7.28
30538;10.1021/jm050663x;1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.;329320;19;43567;COc1ccc2[nH]cc(CC(C)N)c2c1;Ki;7.8;=;nM;8.11
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;37;338169;C=CCN[C@@H](C)Cn1ccc2ccc3ncccc3c21;EC50;91.0;=;nM;7.04
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;38;338149;COc1ccccc1CN[C@@H](C)Cn1ccc2ccc3ncccc3c21;EC50;462.0;=;nM;6.33
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;39;338444;Cc1ccccc1CN[C@@H](C)Cn1ccc2ccc3ncccc3c21;EC50;128.0;=;nM;6.89
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;36;338162;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCC1CCCCC1;EC50;128.0;=;nM;6.89
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;35;338504;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccccc1;EC50;97.0;=;nM;7.01
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;34;338482;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccccc1Cl;EC50;44.0;=;nM;7.36
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;33;338364;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccc2c(c1)OCO2;EC50;20.0;=;nM;7.7
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;32;338355;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccc2ccccc2c1;EC50;27.0;=;nM;7.57
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;31;338363;C[C@H](N)Cn1ccc2ccc3cnccc3c21;EC50;152.0;=;nM;6.82
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;30;338354;C[C@H](N)Cn1ccc2ccc3ccncc3c21;EC50;62.0;=;nM;7.21
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;29;338106;C[C@H](N)Cn1ccc2ccc3cccnc3c21;EC50;45.0;=;nM;7.35
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;28;338175;C[C@H](N)Cn1ccc2cc(Cl)c3ncccc3c21;EC50;2.1;=;nM;8.68
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;27, VER-2692;338610;C[C@H](N)Cn1ccc2ccc3ncccc3c21;EC50;1.1;=;nM;8.96
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;4, Ro-600175;123335;C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21;EC50;4.3;=;nM;8.37
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331165;2;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.5;=;nM;8.82
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;1, mCPP;5884;Clc1cccc(N2CCNCC2)c1;Ki;32.0;=;nM;7.5
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;39;338444;Cc1ccccc1CN[C@@H](C)Cn1ccc2ccc3ncccc3c21;Ki;739.0;=;nM;6.13
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;38;338149;COc1ccccc1CN[C@@H](C)Cn1ccc2ccc3ncccc3c21;Ki;883.0;=;nM;6.05
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;37;338169;C=CCN[C@@H](C)Cn1ccc2ccc3ncccc3c21;Ki;455.0;=;nM;6.34
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;36;338162;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCC1CCCCC1;Ki;624.0;=;nM;6.21
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;35;338504;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccccc1;Ki;515.0;=;nM;6.29
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;34;338482;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccccc1Cl;Ki;380.0;=;nM;6.42
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;33;338364;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccc2c(c1)OCO2;Ki;138.0;=;nM;6.86
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;32;338355;C[C@@H](Cn1ccc2ccc3ncccc3c21)NCc1ccc2ccccc2c1;Ki;136.0;=;nM;6.87
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;31;338363;C[C@H](N)Cn1ccc2ccc3cnccc3c21;Ki;778.0;=;nM;6.11
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;30;338354;C[C@H](N)Cn1ccc2ccc3ccncc3c21;Ki;210.0;=;nM;6.68
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;29;338106;C[C@H](N)Cn1ccc2ccc3cccnc3c21;Ki;115.0;=;nM;6.94
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;28;338175;C[C@H](N)Cn1ccc2cc(Cl)c3ncccc3c21;Ki;18.0;=;nM;7.75
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;27, VER-2692;338610;C[C@H](N)Cn1ccc2ccc3ncccc3c21;Ki;12.0;=;nM;7.92
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;4, Ro-600175;123335;C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21;Ki;5.1;=;nM;8.29
30606;10.1016/j.bmcl.2005.10.029;Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.;331168;2;2214;NCCc1c[nH]c2ccc(O)cc12;Ki;12.0;=;nM;7.92
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;25;342685;Clc1ccc2c(n1)N1CCNCC1C2;Ki;221.0;=;nM;6.66
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;1 (10aR);315681;Cc1c(Cl)ccc2c1N1[C@@H](CNC[C@H]1C)C2;Ki;3.2;=;nM;8.49
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;1 (10aS);315980;Cc1c(Cl)ccc2c1N1[C@H](CNC[C@H]1C)C2;Ki;40.0;=;nM;7.4
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;8b;342564;C[C@@H]1CNC[C@@H]2Cc3ccc(Br)nc3N21;Ki;166.0;=;nM;6.78
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;7b;342563;C[C@@H]1CNC[C@H]2Cc3ccc(Br)nc3N21;Ki;81.0;=;nM;7.09
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;8a;341933;C[C@@H]1CNC[C@@H]2Cc3ccc(Cl)nc3N21;Ki;217.0;=;nM;6.66
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;7a;341932;C[C@@H]1CNC[C@H]2Cc3ccc(Cl)nc3N21;Ki;48.0;=;nM;7.32
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;21;342586;CCO[C@H](C)c1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2;Ki;1306.0;=;nM;5.88
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;20;342580;CCO[C@@H](C)c1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2;Ki;295.0;=;nM;6.53
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;19;342515;C[C@H](O)c1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2;Ki;835.0;=;nM;6.08
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;18;342514;C[C@@H]1CNC[C@H]2Cc3ccc(COCC4CC4)nc3N21;Ki;174.0;=;nM;6.76
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;17;342077;COCc1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2;Ki;379.0;=;nM;6.42
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;16;342071;C[C@@H]1CNC[C@H]2Cc3ccc(CO)nc3N21;Ki;1139.0;=;nM;5.94
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;14;342070;C[C@@H]1CNC[C@H]2Cc3ccc(C(F)(F)F)nc3N21;Ki;68.0;=;nM;7.17
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;13;342069;Cc1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2;Ki;77.0;=;nM;7.11
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;12;342068;COc1ccc2c(n1)N1[C@@H](CNC[C@H]1C)C2;Ki;440.0;=;nM;6.36
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340093;10;342130;C[C@@H]1CNC[C@H]2Cc3ccc(C#N)nc3N21;Ki;1820.0;=;nM;5.74
30866;10.1016/j.bmcl.2005.11.083;Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.;340096;18;342514;C[C@@H]1CNC[C@H]2Cc3ccc(COCC4CC4)nc3N21;EC50;23.0;=;nM;7.64
31006;10.1016/j.bmcl.2006.01.052;Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.;346841;5;344371;COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1;Ki;33.7;=;nM;7.47
31185;10.1021/jm0508641;An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.;357753;8;348336;COc1ccccc1N1CCN(CCCCNS(=O)(=O)c2ccc(C)cc2)CC1;Ki;53.0;=;nM;7.28
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;11;349043;FC(F)(F)c1ccnc(N2CCC3CNCC32)n1;EC50;320.0;=;nM;6.5
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;20;349822;Fc1cccc(N2CC[C@H]3CNC[C@H]32)c1;EC50;108.0;=;nM;6.97
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;19;349821;Clc1cccc(N2CC[C@H]3CNC[C@H]32)c1;EC50;59.0;=;nM;7.23
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;18;349795;FC(F)(F)c1cccc(N2CC[C@H]3CNC[C@H]32)c1;EC50;65.0;=;nM;7.19
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;17;349794;C[C@H]1C[C@H]2CNC[C@H]2N1c1nccc(C(F)(F)F)n1;EC50;151.0;=;nM;6.82
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;16;349793;C[C@@H]1C[C@H]2CNC[C@H]2N1c1nccc(C(F)(F)F)n1;EC50;48.0;=;nM;7.32
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;14;349549;FC(F)(F)c1ccnc(N2CC[C@H]3CNC[C@H]32)n1;EC50;62.0;=;nM;7.21
31301;10.1016/j.bmcl.2006.03.007;The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.;365290;22;349823;FC(F)(F)c1cccc([C@H]2CC[C@H]3CNC[C@H]32)c1;EC50;187.0;=;nM;6.73
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7g;354351;COc1ccc(N2CC=C(c3cccc(F)c3)C2=O)cc1OCCN1CCCCC1;Ki;501.19;=;nM;6.3
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7i;354380;COc1ccc(N2CC=C(c3ccc(F)cc3)C2=O)cc1OCCN1CCCCC1;Ki;1000.0;=;nM;6.0
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7l;354354;COc1ccc(N2CC=C(c3ccc(Br)cc3)C2=O)cc1OCCN1CCCCC1;Ki;199.53;=;nM;6.7
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7m;354382;COc1ccc(N2CC=C(c3cccc(Cl)c3)C2=O)cc1OCCN1CCC(C)CC1;Ki;501.19;=;nM;6.3
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7p;354265;COc1ccc(N2CC=C(c3ccc(F)cc3)C2=O)cc1OCCN1CCC(C)CC1;Ki;1258.93;=;nM;5.9
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7q;354266;COc1ccc(N2CC=C(c3ccc(C)cc3)C2=O)cc1OCCN1CCC(C)CC1;Ki;1584.89;=;nM;5.8
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7t;354174;COc1ccc(N2CC=C(c3cccc(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;630.96;=;nM;6.2
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7z;354078;COc1ccc(N2CC=C(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCC(C)(C)CC1;Ki;316.23;=;nM;6.5
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;6a;354114;COc1ccc(N2CCC(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;1584.89;=;nM;5.8
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;6c;354274;COc1ccc(N2CCC(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCC(C)CC1;Ki;1995.26;=;nM;5.7
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;6d;354275;O=C1C(c2ccc(Cl)c(Cl)c2)CCN1c1ccc(OC(F)(F)F)c(OCCN2CCCCC2)c1;Ki;1584.89;=;nM;5.8
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;23;354153;COc1ccc(N2CCC(C)(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;1000.0;=;nM;6.0
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;8b;354213;COc1ccc(N2CCC(c3ccc(OC)c(OCCN4CCCCC4)c3)C2=O)cc1Cl;Ki;1584.89;=;nM;5.8
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;8d;354055;COc1ccc(C2CCN(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;398.11;=;nM;6.4
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;9a;354123;COc1ccc(C2=CCN(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;125.89;=;nM;6.9
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;9e;353979;COc1ccc(C2=CCN(c3cccc(F)c3)C2=O)cc1OCCN1CCCCC1;Ki;501.19;=;nM;6.3
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;9f;353980;COc1ccc(C2=C(C)CN(c3ccc(Cl)cc3)C2=O)cc1OCCN1CCCCC1;Ki;501.19;=;nM;6.3
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;9g;354015;COc1ccc(C2=C(C)CN(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;199.53;=;nM;6.7
31551;10.1016/j.bmcl.2006.05.034;Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.;384213;7a;354026;COc1ccc(N2CC=C(c3ccc(Cl)c(Cl)c3)C2=O)cc1OCCN1CCCCC1;Ki;630.96;=;nM;6.2
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;1;358295;CN1CCC2(CC1)Oc1ccccc1C1CC(c3ccncc3)=NN12;IC50;95.0;=;nM;7.02
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;51;358530;c1ccc(CCN2CCC3(CC2)Oc2ccccc2C2CC(c4ccncc4)=NN23)cc1;IC50;16.0;=;nM;7.8
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;50;358501;CCCN1CCC2(CC1)Oc1ccccc1C1CC(c3ccccc3Cl)=NN12;IC50;500.0;=;nM;6.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;49;358500;CCCN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(F)cc3)=NN12;IC50;29.0;=;nM;7.54
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;48;358473;CCCN1CCC2(CC1)Oc1ccc(Cl)cc1C1CC(c3ccc(F)cc3)=NN12;IC50;32.0;=;nM;7.5
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;47;358472;CCCN1CCC2(CC1)Oc1ccc(F)cc1C1CC(c3ccc(F)cc3)=NN12;IC50;26.0;=;nM;7.58
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;46;358437;CCCN1CCC2(CC1)Oc1ccc(C)cc1C1CC(c3ccc(F)cc3)=NN12;IC50;115.0;=;nM;6.94
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;45;358356;CCCN1CCC2(CC1)Oc1ccccc1C1CC(c3ccc(F)cc3)=NN12;IC50;1.8;=;nM;8.74
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;43;358311;CCCN1CCC2(CC1)Oc1ccccc1C1CC(c3ccncc3)=NN12;IC50;15.0;=;nM;7.82
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;42;358259;CCCN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(OC)cc3)=NN12;IC50;179.0;=;nM;6.75
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;41;358258;CCCN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(Br)cc3)=NN12;IC50;791.0;=;nM;6.1
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;40;358789;CCCN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(C)cc3)=NN12;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;38;358630;CC(C)N1CCC2(CC1)Oc1ccccc1C1CC(c3ccc(Cl)cc3)=NN12;IC50;133.0;=;nM;6.88
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;37;358590;CC(C)N1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccccc3)=NN12;IC50;188.0;=;nM;6.73
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;36;358589;CC(C)CN1CCC2(CC1)Oc1ccccc1C1CC(c3ccncc3)=NN12;IC50;21.0;=;nM;7.68
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;35;358558;CCN1CCC2(CC1)Oc1ccccc1C1CC(c3ccncc3)=NN12;IC50;42.0;=;nM;7.38
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;33;358529;Clc1ccc(C2=NN3C(C2)c2ccccc2OC32CCN(Cc3ccccc3)CC2)cc1;IC50;350.0;=;nM;6.46
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;25;358719;CC1(C)Oc2ccccc2C2CC(c3ccncc3)=NN21;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;24;358718;COc1cccc2c1OC1(CCN(C)CC1)N1N=C(c3ccc(Br)cc3)CC21;IC50;1281.0;=;nM;5.89
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;23;358689;COc1cccc2c1OC1(CCN(C)CC1)N1N=C(c3ccc(Cl)cc3)CC21;IC50;1470.0;=;nM;5.83
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;22;358350;COc1cccc2c1OC1(CCN(C)CC1)N1N=C(c3ccc(F)cc3)CC21;IC50;46.0;=;nM;7.34
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;21;358305;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc4ccccc4c3)=NN12;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;19;358253;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3cccs3)=NN12;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;18;358252;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccco3)=NN12;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;16;358550;COc1ccc(C2=NN3C(C2)c2cc(Br)ccc2OC32CCN(C)CC2)cc1OC;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;15;358523;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(Cl)c(Cl)c3)=NN12;IC50;542.0;=;nM;6.27
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;14;358522;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(OC(F)F)cc3)=NN12;IC50;175.0;=;nM;6.76
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;13;358494;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccccc3OC(F)F)=NN12;IC50;427.0;=;nM;6.37
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;12;358493;COc1ccc(C2=NN3C(C2)c2cc(Br)ccc2OC32CCN(C)CC2)cc1;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;11;358464;COc1ccccc1C1=NN2C(C1)c1cc(Br)ccc1OC21CCN(C)CC1;IC50;5000.0;=;nM;5.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;10;358463;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccccc3Cl)=NN12;IC50;856.0;=;nM;6.07
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;9;358685;CN1CCC2(CC1)Oc1ccccc1C1CC(c3ccccc3Cl)=NN12;IC50;753.0;=;nM;6.12
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;8;358684;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(Cl)cc3)=NN12;IC50;100.0;=;nM;7.0
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;7;358653;CN1CCC2(CC1)Oc1ccccc1C1CC(c3ccc(Br)cc3)=NN12;IC50;426.0;=;nM;6.37
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;6;358625;CN1CCC2(CC1)Oc1ccccc1C1CC(c3ccc(Cl)cc3)=NN12;IC50;280.0;=;nM;6.55
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;5;358581;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccccc3)=NN12;IC50;92.0;=;nM;7.04
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;4;358580;CN1CCC2(CC1)Oc1ccccc1C1CC(c3ccccc3)=NN12;IC50;50.0;=;nM;7.3
31731;10.1016/j.bmcl.2006.06.068;New spiro-piperidines as 5-HT2B receptor antagonists.;399082;2;358296;CN1CCC2(CC1)Oc1ccc(Br)cc1C1CC(c3ccc(F)cc3)=NN12;IC50;30.0;=;nM;7.52
34683;10.1016/j.bmcl.2006.11.092;Quinazoline and benzimidazole MCH-1R antagonists.;420235;ADS103253;363356;Cc1nc(N2CCCC2)nc2ccc(NC(=O)COc3ccc(Cl)cc3)cc12;IC50;1900.0;=;nM;5.72
34683;10.1016/j.bmcl.2006.11.092;Quinazoline and benzimidazole MCH-1R antagonists.;420235;ADS103274;363391;CN(C)CCN(C)c1nc2ccc(NC(=O)COc3ccc(C(F)(F)F)cc3)cc2n1C;IC50;1500.0;=;nM;5.82
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;19;370505;O=C1c2ccccc2C2CNCCN12;Ki;4540.0;=;nM;5.34
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;30;370549;O=C1c2c(cccc2C(F)(F)F)[C@H]2CNCCN12;Ki;3430.0;=;nM;5.46
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;29;370626;O=C1c2c(cccc2C(F)(F)F)[C@@H]2CNCCN12;Ki;74.0;=;nM;7.13
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;28;370496;CC(C)Oc1cccc2c1C(=O)N1CCNCC21;Ki;1600.0;=;nM;5.8
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;27;370466;O=C1c2c(O)cccc2C2CNCCN12;Ki;3740.0;=;nM;5.43
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;26;370425;CSc1cccc2c1C(=O)N1CCNCC21;Ki;84.0;=;nM;7.08
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;25;370520;N#Cc1cccc2c1C(=O)N1CCNCC21;Ki;3930.0;=;nM;5.41
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;24;370519;O=C1c2c(Cl)cccc2C2CNCCN12;Ki;309.0;=;nM;6.51
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;23;370517;O=C1c2c(F)cccc2C2CNCCN12;Ki;3690.0;=;nM;5.43
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;22;370508;O=C1c2c(OC(F)(F)F)cccc2C2CNCCN12;Ki;550.0;=;nM;6.26
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;21;370507;COc1cccc2c1C(=O)N1CCNCC21;Ki;192.0;=;nM;6.72
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;20;370506;O=C1c2c(cccc2C(F)(F)F)C2CNCCN12;Ki;249.0;=;nM;6.6
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;39;370583;CC[C@@H]1NCCN2C(=O)c3c(cccc3C(F)(F)F)[C@H]12;Ki;235.0;=;nM;6.63
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;38;370582;C[C@@H]1NCCN2C(=O)c3c(cccc3C(F)(F)F)[C@H]12;Ki;24.0;=;nM;7.62
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;37;1385515;CC(C)[C@H]1CNC[C@H]2c3cccc(C(F)(F)F)c3C(=O)N12;Ki;7.0;=;nM;8.15
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;36;370575;C[C@@H]1CNC[C@H]2c3cccc(C(F)(F)F)c3C(=O)N12;Ki;29.0;=;nM;7.54
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;35;370574;C[C@H]1CNC[C@H]2c3cccc(C(F)(F)F)c3C(=O)N12;Ki;116.0;=;nM;6.94
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;34;370573;C[C@@H]1CN2C(=O)c3c(cccc3C(F)(F)F)[C@@H]2CN1;Ki;2350.0;=;nM;5.63
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;33;370567;C[C@H]1CN2C(=O)c3c(cccc3C(F)(F)F)[C@@H]2CN1;Ki;3010.0;=;nM;5.52
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;32;370566;CC1(C)CN2C(=O)c3c(cccc3C(F)(F)F)[C@@H]2CN1;Ki;3190.0;=;nM;5.5
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;31;370565;CN1CCN2C(=O)c3c(cccc3C(F)(F)F)[C@@H]2C1;Ki;1580.0;=;nM;5.8
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;51;370635;CCc1cc(Cl)c2c(c1)[C@@H]1CNCCN1C2=O;Ki;248.0;=;nM;6.61
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;50;370629;COc1cc(Cl)c2c(c1)[C@@H]1CNCCN1C2=O;Ki;890.0;=;nM;6.05
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;49;370628;CCc1cc2c(cc1OC)C(=O)N1CCNC[C@@H]21;Ki;75.0;=;nM;7.12
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;48;370627;COc1cc2c(cc1Cl)[C@@H]1CNCCN1C2=O;Ki;471.0;=;nM;6.33
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;47;370621;CCc1ccc2c(c1OC)C(=O)N1CCNC[C@@H]21;Ki;18.0;=;nM;7.75
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;46;370620;COc1c(Cl)ccc2c1C(=O)N1CCNC[C@@H]21;Ki;86.0;=;nM;7.07
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;45;370614;O=C1c2c(ccc(Cl)c2Cl)[C@@H]2CNCCN12;Ki;70.0;=;nM;7.16
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;44;370613;O=C1c2c(C(F)(F)F)ccc(Cl)c2[C@@H]2CNCCN12;Ki;4030.0;=;nM;5.39
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;43;370612;COc1ccc(Cl)c2c1[C@@H]1CNCCN1C2=O;Ki;1420.0;=;nM;5.85
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;42;370607;CCc1ccc(Cl)c2c1[C@@H]1CNCCN1C2=O;Ki;547.0;=;nM;6.26
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;41;370606;Cc1ccc(Cl)c2c1[C@@H]1CNCCN1C2=O;Ki;730.0;=;nM;6.14
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;65;370545;CC1(c2cc3c(c(C(F)(F)F)c2)C(=O)N2CCNC[C@@H]32)CC1;Ki;29.0;=;nM;7.54
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;64;370544;O=C1c2c(cc(C3CC3)cc2C(F)(F)F)[C@@H]2CNCCN12;Ki;209.0;=;nM;6.68
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;63;370543;C#Cc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;2099.0;=;nM;5.68
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;62;370538;C=Cc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;648.0;=;nM;6.19
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;61;370537;CC(C)c1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;190.0;=;nM;6.72
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;60;370536;CCCCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;220.0;=;nM;6.66
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;59;370530;CCCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;380.0;=;nM;6.42
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;58;370529;CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;153.0;=;nM;6.82
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;57;370528;Cc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;336.0;=;nM;6.47
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;56;370646;CCOc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;1300.0;=;nM;5.89
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;55;370645;COc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;Ki;1090.0;=;nM;5.96
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;54;370644;O=C1c2c(cc(CO)cc2C(F)(F)F)[C@@H]2CNCCN12;Ki;470.0;=;nM;6.33
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428465;mCPP;5884;Clc1cccc(N2CCNCC2)c1;Ki;24.0;=;nM;7.62
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;29;370626;O=C1c2c(cccc2C(F)(F)F)[C@@H]2CNCCN12;EC50;180.0;=;nM;6.75
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;28;370496;CC(C)Oc1cccc2c1C(=O)N1CCNCC21;EC50;825.0;=;nM;6.08
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;26;370425;CSc1cccc2c1C(=O)N1CCNCC21;EC50;87.0;=;nM;7.06
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;24;370519;O=C1c2c(Cl)cccc2C2CNCCN12;EC50;501.0;=;nM;6.3
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;22;370508;O=C1c2c(OC(F)(F)F)cccc2C2CNCCN12;EC50;498.0;=;nM;6.3
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;21;370507;COc1cccc2c1C(=O)N1CCNCC21;EC50;207.0;=;nM;6.68
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;20;370506;O=C1c2c(cccc2C(F)(F)F)C2CNCCN12;EC50;192.0;=;nM;6.72
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;39;370583;CC[C@@H]1NCCN2C(=O)c3c(cccc3C(F)(F)F)[C@H]12;EC50;293.0;=;nM;6.53
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;38;370582;C[C@@H]1NCCN2C(=O)c3c(cccc3C(F)(F)F)[C@H]12;EC50;22.0;=;nM;7.66
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;37;1385515;CC(C)[C@H]1CNC[C@H]2c3cccc(C(F)(F)F)c3C(=O)N12;EC50;14.0;=;nM;7.85
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;36;370575;C[C@@H]1CNC[C@H]2c3cccc(C(F)(F)F)c3C(=O)N12;EC50;40.0;=;nM;7.4
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;35;370574;C[C@H]1CNC[C@H]2c3cccc(C(F)(F)F)c3C(=O)N12;EC50;100.0;=;nM;7.0
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;31;370565;CN1CCN2C(=O)c3c(cccc3C(F)(F)F)[C@@H]2C1;EC50;417.0;=;nM;6.38
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;49;370628;CCc1cc2c(cc1OC)C(=O)N1CCNC[C@@H]21;EC50;33.0;=;nM;7.48
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;47;370621;CCc1ccc2c(c1OC)C(=O)N1CCNC[C@@H]21;EC50;8.0;=;nM;8.1
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;46;370620;COc1c(Cl)ccc2c1C(=O)N1CCNC[C@@H]21;EC50;28.0;=;nM;7.55
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;45;370614;O=C1c2c(ccc(Cl)c2Cl)[C@@H]2CNCCN12;EC50;57.0;=;nM;7.24
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;42;370607;CCc1ccc(Cl)c2c1[C@@H]1CNCCN1C2=O;EC50;274.0;=;nM;6.56
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;41;370606;Cc1ccc(Cl)c2c1[C@@H]1CNCCN1C2=O;EC50;290.0;=;nM;6.54
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;64;370544;O=C1c2c(cc(C3CC3)cc2C(F)(F)F)[C@@H]2CNCCN12;EC50;2980.0;=;nM;5.53
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;62;370538;C=Cc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;EC50;1610.0;=;nM;5.79
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;58;370529;CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;EC50;4926.0;=;nM;5.31
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;57;370528;Cc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;EC50;282.0;=;nM;6.55
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;55;370645;COc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21;EC50;175.0;=;nM;6.76
35188;10.1021/jm0612968;Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.;428468;mCPP;5884;Clc1cccc(N2CCNCC2)c1;EC50;287.0;=;nM;6.54
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;40;394977;COc1ccc(N2Cc3cc(Cl)cc(Cl)c3C2=O)cc1OCCN1CCCCCC1;Ki;199.53;=;nM;6.7
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;39;394976;COc1ccc(N2Cc3cc(Cl)cc(Cl)c3C2=O)cc1OCCN1CCC(C)(C)CC1;Ki;251.19;=;nM;6.6
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;38;394973;COc1ccc(N2Cc3cc(Cl)cc(Cl)c3C2=O)cc1OCCN1[C@H](C)CCC[C@@H]1C;Ki;125.89;=;nM;6.9
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;36;394969;COc1ccc(N2Cc3cc(Cl)cc(Cl)c3C2=O)cc1OCCN1CCCC(C)C1;Ki;125.89;=;nM;6.9
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;34;394963;COc1ccc(N2Cc3cc(C)cc(C)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;316.23;=;nM;6.5
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;33;394961;COc1ccc(N2Cc3cc(F)cc(C(F)(F)F)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;251.19;=;nM;6.6
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;32;394959;COc1ccc(N2Cc3cc(Cl)c(C)c(Cl)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;63.1;=;nM;7.2
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;31;394957;COc1ccc(N2Cc3cc(Cl)c(Cl)c(C)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;100.0;=;nM;7.0
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;30;394955;COc1ccc(N2Cc3ccc(Cl)c(Cl)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;100.0;=;nM;7.0
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;29;394953;COc1ccc(N2Cc3cc(Cl)cc(Cl)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;199.53;=;nM;6.7
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;28;394951;COc1ccc(N2Cc3cc(Cl)c(Cl)cc3C2=O)cc1OCCN1CCC(C)CC1;Ki;199.53;=;nM;6.7
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;27;394950;COc1ccc(N2Cc3c(F)c(F)cc(Cl)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;125.89;=;nM;6.9
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;25;394942;COc1ccc(N2C(=O)c3c(Cl)cccc3C2C)cc1OCCN1CCC(C)CC1;Ki;199.53;=;nM;6.7
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;22;394937;COc1ccc(N2Cc3cccc(C(F)(F)F)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;501.19;=;nM;6.3
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;21;396368;COc1ccc(N2Cc3cccc(C)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;199.53;=;nM;6.7
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;20;394936;COc1ccc(N2Cc3cccc(Br)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;158.49;=;nM;6.8
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;18;394934;COc1ccc(N2Cc3cccc(Cl)c3C2=O)cc1OCCN1CCC(C)CC1;Ki;125.89;=;nM;6.9
36207;10.1016/j.bmcl.2006.10.029;Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.;440773;14;394930;COc1ccc(N2Cc3cccc(Cl)c3C2=O)cc1OCCN1CCCCC1;Ki;316.23;=;nM;6.5
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;10;394323;COc1ccc(N2Cc3c(c4cc(Cl)c(Cl)cc4n3C)C2=O)cc1OCCN1CCCCC1;Ki;199.53;=;nM;6.7
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;19;394336;COc1ccc(N2Cc3c(c4cc(F)ccc4n3C)C2=O)cc1OCCN1CCC(C)CC1;Ki;63.1;=;nM;7.2
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;18;394335;COc1ccc(N2Cc3c(c4ccc(F)cc4n3C)C2=O)cc1OCCN1CCC(C)CC1;Ki;251.19;=;nM;6.6
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;17;394334;COc1ccc(N2Cc3c(c4cccc(F)c4n3C)C2=O)cc1OCCN1CCC(C)CC1;Ki;31.62;=;nM;7.5
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;16;394333;COc1ccc(N2Cc3c(c4cc(Cl)ccc4n3C)C2=O)cc1OCCN1CCC(C)CC1;Ki;39.81;=;nM;7.4
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;15;394332;COc1ccc(N2Cc3c(c4ccc(Cl)cc4n3C)C2=O)cc1OCCN1CCC(C)CC1;Ki;199.53;=;nM;6.7
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;14;394329;COc1ccc2c(c1)c1c(n2C)CN(c2ccc(OC)c(OCCN3CCCCC3)c2)C1=O;Ki;794.33;=;nM;6.1
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;11;394324;COc1ccc(N2Cc3c(c4ccc(Cl)cc4n3C)C2=O)cc1OCCN1CCCCC1;Ki;158.49;=;nM;6.8
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;5;549680;COc1ccc(N2Cc3c(c4ccccc4n3C)C2=O)cc1OCCN1CCCCC1.Cl;Ki;199.53;=;nM;6.7
36210;10.1016/j.bmcl.2006.10.034;5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.;440797;24;394360;COc1ccc(N2Cc3sc4ccccc4c3C2=O)cc1OCCN1CCC(C)CC1;Ki;199.53;=;nM;6.7
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;11;33664;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;Ki;1.585;=;nM;8.8
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;1, SLV310;217302;O=C1c2ccccc2C(=O)N1CCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;Ki;1.585;=;nM;8.8
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;10;7714;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;Ki;19.95;=;nM;7.7
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;9;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;1.259;=;nM;8.9
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;7;34197;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1;Ki;6.31;=;nM;8.2
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;6;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;Ki;3.162;=;nM;8.5
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;3, SLV314;329265;C[C@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccc(F)cc34)CC2)NC1=O;Ki;1.0;=;nM;9.0
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446509;2, SLV313;367153;Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1;Ki;12.59;=;nM;7.9
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446510;8;34234;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;Ki;251.19;=;nM;6.6
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446510;12;389011;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;Ki;316.23;=;nM;6.5
36713;10.1021/jm070516u;Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.;446510;4;6216;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;Ki;39.81;=;nM;7.4
37168;10.1021/jm070521y;Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.;451123;11q;402468;NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12;Ki;458.0;=;nM;6.34
37355;10.1016/j.bmcl.2006.11.031;3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.;453596;33;409194;Cc1ccc2c(OCCN3CCC(Cc4ccc5c(c4F)NC(=O)CO5)CC3)cc(Cl)cc2n1;Ki;1584.89;=;nM;5.8
37355;10.1016/j.bmcl.2006.11.031;3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.;453596;37;409200;Cc1ccc2c(OCCN3CCC(Cc4cc(F)c5c(c4)NC(=O)CO5)CC3)cc(Cl)cc2n1;Ki;3162.28;=;nM;5.5
37355;10.1016/j.bmcl.2006.11.031;3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.;453596;34;409196;Cc1ccc2c(OCCN3CCC(Cc4cc5c(cc4F)OCC(=O)N5)CC3)cc(F)cc2n1;Ki;1000.0;=;nM;6.0
37355;10.1016/j.bmcl.2006.11.031;3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.;453596;1;303772;Cc1ccc2c(OCCN3CCC(Cc4ccc5c(c4)NC(=O)CO5)CC3)cccc2n1;Ki;1584.89;=;nM;5.8
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7b (R,S);301258;CC1CNCCc2ccccc21;EC50;3981.07;=;nM;5.4
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;serotonin;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;25.12;=;nM;7.6
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;Ro-600175;123335;C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21;EC50;1.585;=;nM;8.8
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;nordexfenfluramine;418519;C[C@H](N)Cc1cccc(C(F)(F)F)c1;EC50;15.85;=;nM;7.8
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;mcpp;5884;Clc1cccc(N2CCNCC2)c1;EC50;39.81;=;nM;7.4
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7ff (S);418517;CC[C@@H]1CNCCc2ccc(Cl)cc21;EC50;630.96;=;nM;6.2
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7ee (R);418516;CC[C@H]1CNCCc2ccc(Cl)cc21;EC50;251.19;=;nM;6.6
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7dd;301193;Clc1ccc2c(c1)CCNCC2;EC50;1000.0;=;nM;6.0
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7cc (R,S);301145;CC1CNCCc2c(Cl)cc(Cl)cc21;EC50;794.33;=;nM;6.1
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7aa (R,S);301192;CC1CNCCc2ccc(Cl)c(F)c21;EC50;2511.89;=;nM;5.6
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7z (S);301243;C[C@@H]1CNCCc2ccc(Cl)c(Cl)c21;EC50;1258.93;=;nM;5.9
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7x (R,S);301171;CC1CNCCc2ccc(Cl)c(Cl)c21;EC50;1584.89;=;nM;5.8
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7w (R,S);301172;CC1CNCCc2cc(F)c(Cl)cc21;EC50;316.23;=;nM;6.5
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7v (S);418513;COc1cc2c(cc1Cl)[C@H](C)CNCC2;EC50;39.81;=;nM;7.4
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7u (R);418512;COc1cc2c(cc1Cl)[C@@H](C)CNCC2;EC50;398.11;=;nM;6.4
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7t (R,S);301091;COc1cc2c(cc1Cl)C(C)CNCC2;EC50;63.1;=;nM;7.2
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7s (R,S);418511;COc1cc2c(cc1Cl)CCNCC2C;EC50;199.53;=;nM;6.7
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7r (S);418510;C[C@@H]1CNCCc2cc(Cl)c(Cl)cc21;EC50;251.19;=;nM;6.6
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7q (R);418509;C[C@H]1CNCCc2cc(Cl)c(Cl)cc21;EC50;39.81;=;nM;7.4
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7p (R,S);301164;CC1CNCCc2cc(Cl)c(Cl)cc21;EC50;50.12;=;nM;7.3
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7l (R,S);301202;CC1CNCCc2cc(Cl)ccc21;EC50;501.19;=;nM;6.3
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7k (R,S);301257;COc1ccc2c(c1)C(C)CNCC2;EC50;5011.87;=;nM;5.3
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7i (R,S);301223;CC1CNCCc2ccc(Br)cc21;EC50;1995.26;=;nM;5.7
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7h (S);418507;C[C@@H]1CNCCc2ccc(C(F)(F)F)cc21;EC50;794.33;=;nM;6.1
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7g (R);418506;C[C@H]1CNCCc2ccc(C(F)(F)F)cc21;EC50;501.19;=;nM;6.3
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7f (R,S);301235;CC1CNCCc2ccc(C(F)(F)F)cc21;EC50;794.33;=;nM;6.1
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7e (S);301216;C[C@@H]1CNCCc2ccc(Cl)cc21;EC50;1258.93;=;nM;5.9
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7d (R), Lorcaserin, APD356;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;794.33;=;nM;6.1
38139;10.1021/jm0709034;Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.;460520;7c (R,S);301200;CC1CNCCc2ccc(Cl)cc21;EC50;1000.0;=;nM;6.0
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35a;434769;Cc1nc2c(c(-c3ccc(Cl)cc3)n1)CCNCC2;Ki;270.0;=;nM;6.57
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;36a;435122;Fc1ccc(-c2nc(Cc3ccccc3)nc3c2CNCCC3)cc1;Ki;10000.0;=;nM;5.0
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;19a;435121;Fc1ccc(-c2nc(Cc3ccccc3)nc3c2CCNC3)cc1;Ki;310.0;=;nM;6.51
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;34a;435167;Fc1ccc(-c2nc(Cc3ccccc3)nc3c2CCCNC3)cc1;Ki;1300.0;=;nM;5.89
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18i;435171;Fc1ccc(-c2nc(-c3ccccc3)nc3c2CNCC3)cc1;Ki;1000.0;=;nM;6.0
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18h;435170;CC(C)Cc1nc2c(c(-c3ccc(F)cc3)n1)CNCC2;Ki;400.0;=;nM;6.4
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18g;435207;Fc1ccc(-c2nc(C3CC3)nc3c2CNCC3)cc1;Ki;9000.0;=;nM;5.05
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18f;435210;Fc1ccc(-c2nc(C3CCC3)nc3c2CNCC3)cc1;Ki;210.0;=;nM;6.68
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18e;435209;Fc1ccc(Cc2nc3c(c(-c4ccc(F)cc4)n2)CNCC3)cc1;Ki;2200.0;=;nM;5.66
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18d;435208;CCC(C)c1nc2c(c(-c3ccc(F)cc3)n1)CNCC2;Ki;2250.0;=;nM;5.65
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18c;435212;CC(C)(C)c1nc2c(c(-c3ccc(F)cc3)n1)CNCC2;Ki;70.0;=;nM;7.16
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18b;435250;Fc1ccc(-c2nc(C3CCCC3)nc3c2CNCC3)cc1;Ki;220.0;=;nM;6.66
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;18a;435253;Fc1ccc(-c2nc(Cc3ccccc3)nc3c2CNCC3)cc1;Ki;2500.0;=;nM;5.6
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35j;435252;FC(F)(F)c1ccc(-c2nc(Cc3ccccc3)nc3c2CCNCC3)cc1;Ki;22.0;=;nM;7.66
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35i;435288;Cc1ccc(-c2nc(Cc3ccccc3)nc3c2CCNCC3)cc1;Ki;2.5;=;nM;8.6
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35h;435290;Fc1ccc(-c2nc(Cc3ccccc3)nc3c2CCNCC3)cc1;Ki;30.0;=;nM;7.52
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35g;435292;Fc1ccc(Cc2nc3c(c(-c4ccc(F)cc4)n2)CCNCC3)cc1;Ki;40.0;=;nM;7.4
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35f;435331;N#Cc1ccc(-c2nc(C3CCCC3)nc3c2CCNCC3)cc1;Ki;20.0;=;nM;7.7
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35e;435421;COc1ccc(-c2nc(C3CCCC3)nc3c2CCNCC3)cc1;Ki;4.8;=;nM;8.32
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35d;435424;Cc1ccc(-c2nc(C3CCCC3)nc3c2CCNCC3)cc1;Ki;1.0;=;nM;9.0
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35c;435422;Fc1ccc(-c2nc(C3CCCC3)nc3c2CCNCC3)cc1;Ki;30.0;=;nM;7.52
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463839;35b;434770;CC(C)c1nc2c(c(-c3ccc(F)cc3)n1)CCNCC2;Ki;20.0;=;nM;7.7
38413;10.1016/j.bmcl.2008.01.090;2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.;463845;5;433938;CCN(CC)c1nc2c(c(-c3ccc(C)cc3)n1)CNCC2;Ki;70.0;=;nM;7.16
39082;10.1016/j.bmc.2007.10.100;Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.;472651;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;5.8;=;nM;8.24
39082;10.1016/j.bmc.2007.10.100;Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.;472651;mCPP;433937;Cc1cc(Cl)ccc1OC(C)C(=O)O;EC50;93.0;=;nM;7.03
39082;10.1016/j.bmc.2007.10.100;Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.;472651;7i, YM348;431635;CCc1cc2c(ccc3cnn(C[C@H](C)N)c32)o1;EC50;3.2;=;nM;8.49
39082;10.1016/j.bmc.2007.10.100;Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.;472651;1, Ro-600175;123335;C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21;EC50;2.4;=;nM;8.62
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;1, YM348;431635;CCc1cc2c(ccc3cnn(C[C@H](C)N)c32)o1;Ki;2.5;=;nM;8.6
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;11;431509;c1cc2c3c(ccc2o1)CCNCC3;Ki;90.0;=;nM;7.05
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;10;431512;c1cc2ccc3c(c2o1)CCNCC3;Ki;34.0;=;nM;7.47
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;9;431551;CNc1ccc2c(c1Cl)CCNCC2;Ki;210.0;=;nM;6.68
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;8;431555;COc1ccc2c(c1Cl)CCNCC2;Ki;84.0;=;nM;7.08
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;7;431584;Clc1c(Br)ccc2c1CCNCC2;Ki;25.0;=;nM;7.6
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;6;431583;Clc1ccc2c(c1Cl)CCNCC2;Ki;100.0;=;nM;7.0
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;5;431614;Fc1ccc2c(c1Cl)CCNCC2;Ki;410.0;=;nM;6.39
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;4;431613;N#Cc1ccc2c(c1Cl)CCNCC2;Ki;65.0;=;nM;7.19
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;3;431634;O=[N+]([O-])c1ccc2c(c1Cl)CCNCC2;Ki;300.0;=;nM;6.52
39202;10.1016/j.bmc.2007.12.009;Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.;474630;2;431636;CN1CCc2ccc([N+](=O)[O-])c(Cl)c2CC1;Ki;1000.0;=;nM;6.0
42061;10.1021/jm8001444;Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.;556319;18;486945;Cc1ccc2c(OCCN3CCC(Cc4cccc(NS(C)(=O)=O)c4)CC3)cccc2n1;Ki;1995.26;=;nM;5.7
42137;10.1016/j.bmc.2008.04.050;High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.;556737;[3H]-INBMeO;509390;[3H]C([3H])([3H])Oc1cc(I)c(OC)cc1CCNCc1ccccc1OC([3H])([3H])[3H];Ki;231.0;=;nM;6.64
43815;10.1016/j.bmcl.2008.06.019;Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.;487758;1a;468871;O=C(N[C@H]1CCN(Cc2ccc(OC3CCNCC3)c(Br)c2)C1)c1ccc(Cl)c(Cl)c1;Ki;140.0;=;nM;6.85
43952;10.1016/j.bmc.2008.06.030;Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.;490805;13;490001;O=C(CCCN1CCCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;Ki;495.2;=;nM;6.3
44619;10.1016/j.bmcl.2008.08.010;Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.;535885;20;491133;O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3;Ki;398.11;=;nM;6.4
44675;10.1016/j.bmcl.2008.08.110;Novel 5-HT(1A/1B/1D) receptors antagonists with potent 5-HT reuptake inhibitory activity.;537454;1, SB-744185;493093;Cc1ccc2c(N3CCN(CCc4ccc5c(c4)NC(=O)CO5)CC3)cccc2n1;Ki;316.23;=;nM;6.5
45129;10.1016/j.bmcl.2008.07.103;Highly functionalized 7-azaindoles as selective PPAR gamma modulators.;512437;(R)-13;450662;Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1;IC50;1140.0;=;nM;5.94
45320;10.1021/jm8007618;cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.;494483;(+/-)DOI;436;COc1cc(CC(C)N)c(OC)cc1I;Ki;3.5;=;nM;8.46
45320;10.1021/jm8007618;cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.;494483;(+/-)DOI;436;COc1cc(CC(C)N)c(OC)cc1I;IC50;3.5;=;nM;8.46
45666;10.1021/jm800962k;The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.;516614;8;496883;O=C(Nc1cccc(Cn2ncc(N3CCNCC3)c(Cl)c2=O)c1)c1ccc(-c2ccccc2)cc1;Ki;154.88;=;nM;6.81
45666;10.1021/jm800962k;The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.;516614;9;496884;Cc1ccc(Cn2ncc(N3CCNCC3)c(Cl)c2=O)cc1NC(=O)c1ccc(-c2ccccc2)cc1;Ki;30.2;=;nM;7.52
45666;10.1021/jm800962k;The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.;516614;1;496885;Cc1c(Cn2ncc(N3CCNCC3)c(Cl)c2=O)cccc1NC(=O)c1ccc(-c2ccccc2)cc1;Ki;97.72;=;nM;7.01
45666;10.1021/jm800962k;The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.;516614;22;497035;COc1ccc(-c2ccc(C(=O)Nc3cccc(Cn4ncc(N5CCNCC5)c(Cl)c4=O)c3C)cc2)cn1;Ki;1698.24;=;nM;5.77
45666;10.1021/jm800962k;The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.;516614;36;497148;COc1ccc(-c2ccc(C(=O)Nc3cccc(Cn4ncc(N5CCNCC5)cc4=O)c3C)cc2)cn1;Ki;912.01;=;nM;6.04
45666;10.1021/jm800962k;The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.;516614;37;497204;Cc1c(Cn2ncc(N3CCNCC3)cc2=O)cccc1NC(=O)c1ccc(-c2ccccc2)cc1;Ki;64.57;=;nM;7.19
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;4d;477698;O=S(=O)(c1ccc(F)cc1)c1ccc2c(c1)CCNCC2;EC50;15.0;=;nM;7.82
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3j;477684;CN(CC1CC1)S(=O)(=O)c1ccc2c(c1)CCNCC2;EC50;17.0;=;nM;7.77
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;4a;477695;O=S(=O)(c1ccccc1)c1ccc2c(c1)CCNCC2;EC50;18.0;=;nM;7.75
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;4b;477696;O=S(=O)(c1ccc2c(c1)CCNCC2)c1ccccc1F;EC50;18.0;=;nM;7.75
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;4c;477697;O=S(=O)(c1cccc(F)c1)c1ccc2c(c1)CCNCC2;EC50;33.0;=;nM;7.48
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3l;477686;O=S(=O)(c1ccc2c(c1)CCNCC2)N1CCCCC1;EC50;34.0;=;nM;7.47
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3b;477681;O=S(=O)(Nc1ccccc1)c1ccc2c(c1)CCNCC2;EC50;69.0;=;nM;7.16
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3c;477682;O=S(=O)(Nc1ccccc1F)c1ccc2c(c1)CCNCC2;EC50;75.0;=;nM;7.12
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3f;477607;O=S(=O)(NCC1CC1)c1ccc2c(c1)CCNCC2;EC50;103.0;=;nM;6.99
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3g;477608;CN(C)S(=O)(=O)c1ccc2c(c1)CCNCC2;EC50;125.0;=;nM;6.9
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3a;477680;CCCNS(=O)(=O)c1ccc2c(c1)CCNCC2;EC50;197.0;=;nM;6.71
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3k;477685;O=S(=O)(c1ccc2c(c1)CCNCC2)N1CCCC1;EC50;357.0;=;nM;6.45
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3d;477605;O=S(=O)(Nc1ccccc1Cl)c1ccc2c(c1)CCNCC2;EC50;478.0;=;nM;6.32
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3h;477609;CN(c1ccccc1)S(=O)(=O)c1ccc2c(c1)CCNCC2;EC50;478.0;=;nM;6.32
46184;10.1016/j.bmcl.2009.02.071;7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.;567051;3e;477606;O=S(=O)(NCc1ccccc1Cl)c1ccc2c(c1)CCNCC2;EC50;802.0;=;nM;6.1
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;88;476464;Cl.NC[C@H]1C[C@@H]1c1cccc(C#CCCCCO)c1;EC50;1739.0;=;nM;5.76
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;87;476463;C#Cc1cccc([C@H]2C[C@@H]2CN)c1.Cl;EC50;185.0;=;nM;6.73
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;86;476462;Cl.NC[C@H]1C[C@@H]1c1ccccc1C#CCCCCO;EC50;204.0;=;nM;6.69
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;1;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;0.5;=;nM;9.3
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;34;477177;Cl.NC[C@H]1C[C@@H]1c1cccc(F)c1;EC50;3.6;=;nM;8.44
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;35;477178;Cl.NC[C@H]1C[C@@H]1c1cccc(Cl)c1;EC50;59.0;=;nM;7.23
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;38;477181;Cl.NC[C@H]1C[C@@H]1c1cccc(C(F)(F)F)c1;EC50;77.0;=;nM;7.11
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;28;477101;Cl.NC[C@H]1C[C@@H]1c1ccccc1Cl;EC50;32.0;=;nM;7.5
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;36;477179;Cl.NC[C@H]1C[C@@H]1c1cccc(Br)c1;EC50;141.0;=;nM;6.85
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;29;477104;Cl.NCC1CC1c1ccccc1Br;EC50;4.8;=;nM;8.32
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;41;477184;Cl.NC[C@H]1C[C@@H]1c1ccc(F)cc1;EC50;21.0;=;nM;7.68
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;31;477106;Cl.NC[C@H]1C[C@@H]1c1ccccc1C(F)(F)F;EC50;350.0;=;nM;6.46
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;42;477185;Cl.NC[C@H]1C[C@@H]1c1ccc(Cl)cc1;EC50;404.0;=;nM;6.39
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;27;477100;Cl.NC[C@H]1C[C@@H]1c1ccccc1F;EC50;69.0;=;nM;7.16
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;43;477391;Cl.NC[C@H]1C[C@@H]1c1ccc(Br)cc1;EC50;2737.0;=;nM;5.56
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;50;477398;Cl.NC[C@H]1C[C@@H]1c1c(F)cccc1F;EC50;3342.0;=;nM;5.48
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;14a;477004;Cl.NCC1CC1c1ccccc1;EC50;85.0;=;nM;7.07
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;30;477105;Cc1ccccc1[C@H]1C[C@@H]1CN.Cl;EC50;53.0;=;nM;7.28
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;32;477107;COc1ccccc1[C@H]1C[C@@H]1CN.Cl;EC50;199.0;=;nM;6.7
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;33;477108;Cl.NC[C@H]1C[C@@H]1c1ccccc1O;EC50;492.0;=;nM;6.31
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;37;477180;Cc1cccc([C@H]2C[C@@H]2CN)c1.Cl;EC50;65.0;=;nM;7.19
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;39;477182;COc1cccc([C@H]2C[C@@H]2CN)c1.Cl;EC50;75.0;=;nM;7.12
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;40;477183;Cl.NC[C@H]1C[C@@H]1c1cccc(O)c1;EC50;5.5;=;nM;8.26
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;48;477396;Cl.NC[C@H]1C[C@@H]1c1cccc(F)c1F;EC50;366.0;=;nM;6.44
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;49;477397;Cl.NC[C@H]1C[C@@H]1c1ccc(F)cc1F;EC50;415.0;=;nM;6.38
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;51;477399;Cl.NC[C@H]1C[C@@H]1c1ccc(F)c(F)c1;EC50;28.0;=;nM;7.55
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;52;476086;Cl.NC[C@H]1C[C@@H]1c1ccc(Cl)cc1F;EC50;459.0;=;nM;6.34
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;53;476087;Cl.NC[C@H]1C[C@@H]1c1ccc(F)cc1Cl;EC50;22.0;=;nM;7.66
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;54;476088;Cl.NC[C@H]1C[C@@H]1c1cccc(Cl)c1Cl;EC50;14.0;=;nM;7.85
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;55;476089;Cl.NC[C@H]1C[C@@H]1c1ccc(Cl)cc1Cl;EC50;83.0;=;nM;7.08
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;7;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;219.0;=;nM;6.66
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;(+)-29;477102;Cl.NC[C@H]1C[C@@H]1c1ccccc1Br;EC50;13.0;=;nM;7.89
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;(-)-29;477103;Cl.NC[C@@H]1C[C@H]1c1ccccc1Br;EC50;224.0;=;nM;6.65
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;44;477392;Cc1ccc([C@H]2C[C@@H]2CN)cc1.Cl;EC50;37.0;=;nM;7.43
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;56;476090;Cc1cc([C@H]2C[C@@H]2CN)ccc1F.Cl;EC50;4.9;=;nM;8.31
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;57;476091;Cc1cccc(Cl)c1[C@H]1C[C@@H]1CN.Cl;EC50;7.0;=;nM;8.15
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;58;476092;Cc1ccc([C@H]2C[C@@H]2CN)c(Br)c1.Cl;EC50;116.0;=;nM;6.94
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;59;476093;Cc1cccc([C@H]2C[C@@H]2CN)c1C.Cl;EC50;8.4;=;nM;8.08
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;60;476094;Cc1ccc([C@H]2C[C@@H]2CN)cc1C.Cl;EC50;12.0;=;nM;7.92
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;61;476160;Cc1ccc(Cl)c([C@H]2C[C@@H]2CN)c1F.Cl;EC50;116.0;=;nM;6.94
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;(+)-14a;476917;Cl.NC[C@H]1C[C@@H]1c1ccccc1;EC50;37.0;=;nM;7.43
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;(-)-14a;477003;Cl.NC[C@@H]1C[C@H]1c1ccccc1;EC50;3092.0;=;nM;5.51
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566858;26;477012;Cl.NC[C@H]1C[C@@H]1c1ccc2ccccc2c1;EC50;510.0;=;nM;6.29
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566865;53;476087;Cl.NC[C@H]1C[C@@H]1c1ccc(F)cc1Cl;Ki;16.0;=;nM;7.8
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566865;(+)-29;477102;Cl.NC[C@H]1C[C@@H]1c1ccccc1Br;Ki;16.0;=;nM;7.8
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566865;29;477104;Cl.NCC1CC1c1ccccc1Br;Ki;22.0;=;nM;7.66
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566865;37;477180;Cc1cccc([C@H]2C[C@@H]2CN)c1.Cl;Ki;85.0;=;nM;7.07
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566865;41;477184;Cl.NC[C@H]1C[C@@H]1c1ccc(F)cc1;Ki;89.0;=;nM;7.05
46215;10.1021/jm801354e;Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.;566865;7;301194;C[C@H]1CNCCc2ccc(Cl)cc21;Ki;189.0;=;nM;6.72
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;55, MH.MZ;437622;COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1;Ki;299.0;=;nM;6.52
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;56, (R)-MH.MZ;498961;COc1c(OCCF)cccc1[C@H](O)C1CCN(CCc2ccc(F)cc2)CC1;Ki;320.0;=;nM;6.5
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;53, MA-1;498962;COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1;Ki;960.0;=;nM;6.02
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;32, VK-1;498963;COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1;Ki;1844.0;=;nM;5.73
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;57;498964;COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1;Ki;466.0;=;nM;6.33
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;50;499028;COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1;Ki;559.0;=;nM;6.25
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;54;499029;COc1ccc(CCN2CCC(C(O)c3cccc(OCCF)c3OC)CC2)cc1;Ki;2751.0;=;nM;5.56
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;51;499030;COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1;Ki;1052.0;=;nM;5.98
46285;10.1016/j.bmc.2009.03.021;Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.;563489;52;499031;COc1ccc(CCN2CCC(C(=O)c3cccc(OCCF)c3OC)CC2)cc1;Ki;1972.0;=;nM;5.71
46411;10.1016/j.bmc.2008.11.045;Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.;564581;34d;521742;CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1;IC50;281.84;=;nM;6.55
46411;10.1016/j.bmc.2008.11.045;Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.;564581;32h;521500;CCCCN1CCC(COc2nc3ccsc3n3cccc23)CC1;IC50;52.48;=;nM;7.28
46411;10.1016/j.bmc.2008.11.045;Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.;564581;32f;521498;CCN1CCC(COc2nc3ccsc3n3cccc23)CC1;IC50;9.772;=;nM;8.01
47047;10.1016/j.bmcl.2009.03.071;1-Sulfonylindazoles as potent and selective 5-HT6 ligands.;501399;6a;520148;NCCC(=O)Nc1cccc2c1cnn2S(=O)(=O)c1cccc2ccccc12;Ki;155.0;=;nM;6.81
47047;10.1016/j.bmcl.2009.03.071;1-Sulfonylindazoles as potent and selective 5-HT6 ligands.;501399;7a;520304;O=C(Nc1ccc2cnn(S(=O)(=O)c3cccc4ccccc34)c2c1)C1CCNCC1;Ki;130.0;=;nM;6.89
47047;10.1016/j.bmcl.2009.03.071;1-Sulfonylindazoles as potent and selective 5-HT6 ligands.;501399;7b;520305;O=C(Nc1ccc2cnn(S(=O)(=O)c3cccc4ccccc34)c2c1)C1CCCNC1;Ki;174.0;=;nM;6.76
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;RS-127445;459270;CC(C)c1cc(-c2ccc(F)c3ccccc23)nc(N)n1;IC50;0.7;=;nM;9.15
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;A;459331;N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F;IC50;3.5;=;nM;8.46
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;SB-215505;1382811;Cc1cc2c(cc1Cl)N(C(=O)Nc1cccc3ncccc13)CC2;IC50;13.0;=;nM;7.89
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;34;459267;O=S(=O)(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;0.6;=;nM;9.22
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;35;459268;O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(Cc2ncc[nH]2)CC1;IC50;0.2;=;nM;9.7
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;33;460021;O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;1.1;=;nM;8.96
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;32;460020;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2nc3ccccc3[nH]2)CC1;IC50;1100.0;=;nM;5.96
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;31;460019;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2ncc[nH]2)CC1;IC50;6.5;=;nM;8.19
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;30;460018;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;0.3;=;nM;9.52
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;29;460017;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2nc3ccccc3[nH]2)CC1;IC50;2.3;=;nM;8.64
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;28;459962;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2ncc[nH]2)CC1;IC50;0.4;=;nM;9.4
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;26;459960;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;2.4;=;nM;8.62
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;25;459959;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(c2nc3ccccc3o2)CC1;IC50;1500.0;=;nM;5.82
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;24;459958;Cn1c(C2CCN(C(=O)c3ccc(-c4ccccc4)cc3)CC2)nc2ccccc21;IC50;80.0;=;nM;7.1
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;23;459330;O=C(c1ccc(-c2ccccc2)cc1)N1CC(c2nc3ccccc3[nH]2)C1;IC50;150.0;=;nM;6.82
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;22;459329;O=C(c1ccc(-c2ccccc2)cc1)N1CCN(c2nc3ccccc3[nH]2)CC1;IC50;6900.0;=;nM;5.16
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;21;459328;c1ccc(-c2ccc(CN3CCC(c4nc5ccccc5[nH]4)CC3)cc2)cc1;IC50;65.0;=;nM;7.19
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;20;459327;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;1.9;=;nM;8.72
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;19;459326;O=C(c1ccc(-c2ccccc2)[nH]c1=O)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;22.0;=;nM;7.66
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;18;459266;CCOc1nc(-c2ccccc2)ncc1C(=O)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;6.0;=;nM;8.22
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;17;459265;COc1cc(-c2ccccc2)ccc1C(=O)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;4.0;=;nM;8.4
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;16;459264;O=C(c1cnc(-c2ccccc2)nc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;2.5;=;nM;8.6
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;15;459957;O=C(c1ccc(-c2ccccc2)cn1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;12.0;=;nM;7.92
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;14;459956;O=C(C1CCC(c2ccccc2)CC1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;610.0;=;nM;6.21
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;12;459954;O=C(c1ccc(-c2ccc(OC(F)(F)F)cc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;95.0;=;nM;7.02
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;11;459906;COc1ccc(-c2ccc(C(=O)N3CCC(c4nc5ccccc5[nH]4)CC3)cc2)cc1;IC50;3.4;=;nM;8.47
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;10;459905;O=C(c1ccc(N2CCOCC2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;2300.0;=;nM;5.64
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;9;459904;O=C(c1ccc(N2CCCCC2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;48.0;=;nM;7.32
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;8;459903;O=C(c1ccc(C2CCCCC2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;31.0;=;nM;7.51
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;7;459325;O=C(c1ccc(-c2ncccn2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;120.0;=;nM;6.92
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;6;459324;O=C(c1ccc(-c2ccccn2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;15.0;=;nM;7.82
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;5;459323;O=C(c1ccc(-c2cccnc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;340.0;=;nM;6.47
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499777;1;459261;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;2.4;=;nM;8.62
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;RS-127445;459270;CC(C)c1cc(-c2ccc(F)c3ccccc23)nc(N)n1;IC50;19.0;=;nM;7.72
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;A;459331;N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F;IC50;270.0;=;nM;6.57
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;SB-215505;1382811;Cc1cc2c(cc1Cl)N(C(=O)Nc1cccc3ncccc13)CC2;IC50;64.0;=;nM;7.19
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;34;459267;O=S(=O)(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;30.0;=;nM;7.52
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;35;459268;O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(Cc2ncc[nH]2)CC1;IC50;7.0;=;nM;8.15
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;33;460021;O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;35.0;=;nM;7.46
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;31;460019;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2ncc[nH]2)CC1;IC50;990.0;=;nM;6.0
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;30;460018;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;32.0;=;nM;7.5
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;29;460017;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2nc3ccccc3[nH]2)CC1;IC50;300.0;=;nM;6.52
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;28;459962;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(Cc2ncc[nH]2)CC1;IC50;14.0;=;nM;7.85
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;26;459960;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(c2ncc[nH]2)CC1;IC50;76.0;=;nM;7.12
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;24;459958;Cn1c(C2CCN(C(=O)c3ccc(-c4ccccc4)cc3)CC2)nc2ccccc21;IC50;10000.0;=;nM;5.0
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;21;459328;c1ccc(-c2ccc(CN3CCC(c4nc5ccccc5[nH]4)CC3)cc2)cc1;IC50;7300.0;=;nM;5.14
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;20;459327;O=S(=O)(c1ccc(-c2ccccc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;840.0;=;nM;6.08
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;18;459266;CCOc1nc(-c2ccccc2)ncc1C(=O)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;910.0;=;nM;6.04
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;17;459265;COc1cc(-c2ccccc2)ccc1C(=O)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;1200.0;=;nM;5.92
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;16;459264;O=C(c1cnc(-c2ccccc2)nc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;710.0;=;nM;6.15
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;12;459954;O=C(c1ccc(-c2ccc(OC(F)(F)F)cc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;16000.0;=;nM;4.8
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;11;459906;COc1ccc(-c2ccc(C(=O)N3CCC(c4nc5ccccc5[nH]4)CC3)cc2)cc1;IC50;3200.0;=;nM;5.5
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;9;459904;O=C(c1ccc(N2CCCCC2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;12000.0;=;nM;4.92
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;8;459903;O=C(c1ccc(C2CCCCC2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;1100.0;=;nM;5.96
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;6;459324;O=C(c1ccc(-c2ccccn2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;1700.0;=;nM;5.77
47182;10.1016/j.bmcl.2009.02.126;A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.;499778;1;459261;O=C(c1ccc(-c2ccccc2)cc1)N1CCC(c2nc3ccccc3[nH]2)CC1;IC50;1200.0;=;nM;5.92
48460;10.1016/j.bmcl.2009.09.002;Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.;592328;2;27553;CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2NC1;IC50;54.0;=;nM;7.27
48460;10.1016/j.bmcl.2009.09.002;Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.;592328;1;570958;CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1;IC50;2470.0;=;nM;5.61
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;11.0;=;nM;7.96
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;mCPP;5884;Clc1cccc(N2CCNCC2)c1;EC50;125.0;=;nM;6.9
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;11;576228;O=c1cc2c(nn1Cc1ccccc1)CCNCC2;EC50;358.0;=;nM;6.45
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;12;576229;O=c1cc2c(nn1Cc1ccccc1Cl)CCNCC2;EC50;94.0;=;nM;7.03
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;13;576230;O=c1cc2c(nn1Cc1cccc(Cl)c1)CCNCC2;EC50;81.0;=;nM;7.09
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;14;576244;O=c1cc2c(nn1Cc1ccc(Cl)cc1)CCNCC2;EC50;267.0;=;nM;6.57
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;16;576256;O=c1cc2c(nn1Cc1ccc(C(F)(F)F)cc1)CCNCC2;EC50;473.0;=;nM;6.33
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;18;576261;O=c1cc2c(nn1Cc1ccccc1OC(F)(F)F)CCNCC2;EC50;142.0;=;nM;6.85
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;19;576281;O=c1cc2c(nn1Cc1ccc(C3CC3)cc1)CCNCC2;EC50;84.0;=;nM;7.08
48846;10.1016/j.bmcl.2009.07.063;Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.;599277;26;576340;c1ccc(COc2n[nH]c3c2CCNCC3)cc1;EC50;353.0;=;nM;6.45
48939;10.1016/j.bmcl.2009.07.136;Design and synthesis of pyridazinone-based 5-HT(2C) agonists.;598880;12;578705;C[C@@H](COc1ccccc1Cl)n1nc(N2CCNCC2)ccc1=O;EC50;506.0;=;nM;6.3
48939;10.1016/j.bmcl.2009.07.136;Design and synthesis of pyridazinone-based 5-HT(2C) agonists.;598880;mCPP;5884;Clc1cccc(N2CCNCC2)c1;EC50;125.0;=;nM;6.9
48939;10.1016/j.bmcl.2009.07.136;Design and synthesis of pyridazinone-based 5-HT(2C) agonists.;598880;1;578734;Clc1ccccc1CCOc1cncc(N2CCNCC2)n1;EC50;187.0;=;nM;6.73
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;22, diastereomer;580876;O=C1Cc2c(ccc3c2OC[C@H](CNCCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;Ki;610.0;=;nM;6.21
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;23, diastereomer;580876;O=C1Cc2c(ccc3c2OC[C@H](CNCCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;Ki;400.0;=;nM;6.4
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;24, diastereomer;580755;O=C1Cc2c(ccc3c2OC[C@H](CNCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;Ki;130.0;=;nM;6.89
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;25, diastereomer;580755;O=C1Cc2c(ccc3c2OC[C@H](CNCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;Ki;6.0;=;nM;8.22
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;31, enantiomer;580771;O=c1[nH]c2cccc(N3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;Ki;680.0;=;nM;6.17
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;34;580893;O=c1[nH]c2cccc(OCC3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;Ki;110.0;=;nM;6.96
48944;10.1016/j.bmcl.2009.08.050;Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.;599590;39, diastereomer;580743;O=c1[nH]c2cccc(N3C[C@H]4C[C@@H]3CN4CC3CCc4[nH]c5ccc(F)cc5c4C3)c2o1;Ki;165.0;=;nM;6.78
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;ATC-0175;302900;CN(C)c1nc(N[C@H]2CC[C@@H](NC(=O)c3ccc(F)c(F)c3)CC2)nc2ccccc12;IC50;150.0;=;nM;6.82
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4b;576649;Cc1cc(N(C)C)nc(N[C@H]2CC[C@@H](NC(=O)c3ccc(Cl)cc3)CC2)n1;IC50;170.0;=;nM;6.77
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4h;576743;Cc1cc(N(C)C)nc(N[C@H]2CC[C@@H](NC(=O)c3ccc(Cl)c(Cl)c3)CC2)n1;IC50;130.0;=;nM;6.89
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4j;576760;Cc1cccc(C(=O)N[C@H]2CC[C@@H](Nc3ncc(C)c(N(C)C)n3)CC2)c1;IC50;31.0;=;nM;7.51
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4k;576659;Cc1ccc(C(=O)N[C@H]2CC[C@@H](Nc3ncc(C)c(N(C)C)n3)CC2)cc1;IC50;120.0;=;nM;6.92
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4l;576672;Cc1cnc(N[C@H]2CC[C@@H](NC(=O)c3ccc(F)cc3)CC2)nc1N(C)C;IC50;300.0;=;nM;6.52
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4m;576686;Cc1cnc(N[C@H]2CC[C@@H](NC(=O)c3ccc(Cl)cc3)CC2)nc1N(C)C;IC50;300.0;=;nM;6.52
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4t;576677;Cc1cnc(N[C@H]2CC[C@@H](CNC(=O)c3ccc(F)c(F)c3)CC2)nc1N(C)C;IC50;320.0;=;nM;6.5
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594563;4x;576732;Cc1cnc(N[C@H]2CC[C@@H](CNC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2)nc1N(C)C;IC50;3100.0;=;nM;5.51
48980;10.1016/j.bmcl.2009.09.003;Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.;594564;ATC-0175;302900;CN(C)c1nc(N[C@H]2CC[C@@H](NC(=O)c3ccc(F)c(F)c3)CC2)nc2ccccc12;IC50;9.66;=;nM;8.02
49186;10.1016/j.bmc.2009.07.007;Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.;601694;5b;593205;CN(C)Cc1nc(-c2ccc(C(C)(C)C)cc2)n(-c2cccc(O)c2)n1;IC50;7745.0;=;nM;5.11
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;32;596247;Cc1ccc(F)cc1CO[C@H]1CCc2ccc(N3CCNC[C@H]3C)nc21;EC50;566.0;=;nM;6.25
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;25;596241;Clc1ccccc1O[C@H]1CCCc2ccc(N3CCNCC3)nc21;EC50;397.0;=;nM;6.4
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;26;596228;Clc1ccccc1O[C@@H]1CCCc2ccc(N3CCNCC3)nc21;EC50;998.0;=;nM;6.0
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;27;596242;Clc1ccccc1OC1CCc2ccc(N3CCNCC3)nc21;EC50;187.0;=;nM;6.73
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;28;596207;Clc1ccccc1O[C@H]1CCc2ccc(N3CCNCC3)nc21;EC50;300.0;=;nM;6.52
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;29;596218;Clc1ccccc1O[C@@H]1CCc2ccc(N3CCNCC3)nc21;EC50;748.0;=;nM;6.13
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606262;scheme 3, 28;596209;Fc1ccc(F)c(CO[C@H]2CCc3ccc(N4CCNCC4)nc32)c1;EC50;2700.0;=;nM;5.57
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606263;32;596247;Cc1ccc(F)cc1CO[C@H]1CCc2ccc(N3CCNC[C@H]3C)nc21;IC50;28.0;=;nM;7.55
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606265;32;596247;Cc1ccc(F)cc1CO[C@H]1CCc2ccc(N3CCNC[C@H]3C)nc21;Ki;7.7;=;nM;8.11
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606265;scheme 3, 28;596209;Fc1ccc(F)c(CO[C@H]2CCc3ccc(N4CCNCC4)nc32)c1;Ki;153.0;=;nM;6.82
49402;10.1016/j.bmcl.2009.10.112;Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.;606265;scheme 3, 29;596219;C[C@@H]1CNCCN1c1ccc2c(n1)[C@@H](OCc1cc(F)ccc1F)CC2;Ki;83.0;=;nM;7.08
49480;10.1016/j.bmcl.2009.11.053;Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.;604271;1;480354;COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4;Ki;543.0;=;nM;6.26
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10a;596962;NC1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)CC1;Ki;100.0;=;nM;7.0
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10b;597025;NC1CCN(c2ccc3[nH]nc(S(=O)(=O)c4ccc5ccccc5c4)c3c2)CC1;Ki;1362.0;=;nM;5.87
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10c;597026;Cc1ccc(S(=O)(=O)c2n[nH]c3ccc(N4CCC(N)CC4)cc23)c2ccccc12;Ki;493.0;=;nM;6.31
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10d;597027;NC1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5c(Cl)cccc45)c3c2)CC1;Ki;78.0;=;nM;7.11
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10e;597028;NC1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc(Cl)c4)c3c2)CC1;Ki;442.0;=;nM;6.36
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10g;597087;N[C@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1;Ki;21.0;=;nM;7.68
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10h;597088;N[C@@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1;Ki;274.0;=;nM;6.56
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10i;597089;NC1CN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1;Ki;97.9;=;nM;7.01
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10j;597090;CN(C)[C@@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1;Ki;423.0;=;nM;6.37
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;10k;597091;CN(C)[C@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1;Ki;583.0;=;nM;6.23
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;18a;597155;Cn1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CC[C@@H](N)C3)ccc21;Ki;185.0;=;nM;6.73
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;18b;597156;CC(C)n1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CC[C@@H](N)C3)ccc21;Ki;191.0;=;nM;6.72
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;19a;597158;Cn1nc2ccc(N3CC[C@@H](N)C3)cc2c1S(=O)(=O)c1cccc2ccccc12;Ki;455.0;=;nM;6.34
49713;10.1021/jm901674f;5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.;610400;19c;597228;CC(C)Cn1nc2ccc(N3CC[C@@H](N)C3)cc2c1S(=O)(=O)c1cccc2ccccc12;Ki;260.0;=;nM;6.58
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;3a, enantiomer;599085;Cc1cccc2c1C(=O)NC1CCNCCN21;Ki;10.0;=;nM;8.0
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;3b, enantiomer;599086;O=C1NC2CCNCCN2c2cccc(Cl)c21;Ki;23.0;=;nM;7.64
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;(-)-3c;599087;Cc1ccc2c(c1)N1CCNCCC1NC2=O;Ki;51.0;=;nM;7.29
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;(+)-3c;599087;Cc1ccc2c(c1)N1CCNCCC1NC2=O;Ki;41.0;=;nM;7.39
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;rac-4a;599157;O=C1NC2CNCCCN2c2cccc(Cl)c21;Ki;734.0;=;nM;6.13
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;mCPP;5884;Clc1cccc(N2CCNCC2)c1;Ki;24.0;=;nM;7.62
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;3, enantiomer;599084;O=C1NC2CCNCCN2c2ccccc21;Ki;67.0;=;nM;7.17
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2j, enantiomer;599082;O=C1NC2CNCCN2c2cccc(C(F)(F)F)c21;Ki;13.0;=;nM;7.89
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2f, enantiomer;599081;O=C1NC2CNCCN2c2ccc(Cl)cc21;Ki;72.0;=;nM;7.14
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2e, enantiomer;599022;O=C1NC2CNCCN2c2cccc(Cl)c21;Ki;18.0;=;nM;7.75
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2d, enantiomer;599021;Cc1cccc2c1N1CCNCC1NC2=O;Ki;2395.0;=;nM;5.62
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2c, enantiomer;599020;Cc1ccc2c(c1)N1CCNCC1NC2=O;Ki;280.0;=;nM;6.55
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2b, enantiomer;599019;Cc1ccc2c(c1)C(=O)NC1CNCCN21;Ki;61.0;=;nM;7.21
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;(-)-2a;599018;Cc1cccc2c1C(=O)NC1CNCCN21;Ki;206.0;=;nM;6.69
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;(+)-2a;599018;Cc1cccc2c1C(=O)NC1CNCCN21;Ki;8.6;=;nM;8.07
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609155;2, enantiomer;599017;O=C1NC2CNCCN2c2ccccc21;Ki;137.0;=;nM;6.86
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609156;3, enantiomer;599084;O=C1NC2CCNCCN2c2ccccc21;EC50;101.0;=;nM;7.0
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609156;3a, enantiomer;599085;Cc1cccc2c1C(=O)NC1CCNCCN21;EC50;61.0;=;nM;7.21
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609156;3b, enantiomer;599086;O=C1NC2CCNCCN2c2cccc(Cl)c21;EC50;46.0;=;nM;7.34
49854;10.1016/j.bmcl.2009.12.014;Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.;609156;mCPP;5884;Clc1cccc(N2CCNCC2)c1;EC50;287.0;=;nM;6.54
50171;10.1016/j.bmcl.2009.09.024;Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.;621606;16;402018;CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1OC;Ki;41.0;=;nM;7.39
50171;10.1016/j.bmcl.2009.09.024;Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.;621606;38;402023;CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1Cl;Ki;74.0;=;nM;7.13
50171;10.1016/j.bmcl.2009.09.024;Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.;621606;46;617822;CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)cc(OC2CCOCC2)c1;Ki;94.0;=;nM;7.03
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625152;3b;619868;O=C(NCc1ccc(-c2ccc(Cl)cc2)cc1F)N1CCNCC1;Ki;3500.0;=;nM;5.46
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625152;4;619963;O=C(NCc1ccc(C2CCCCC2)cc1)[C@@H]1CCCN1;Ki;4120.0;=;nM;5.38
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625152;6;619965;O=C(NCc1ccc(Oc2cccc(F)c2)cc1)[C@@H]1CCCN1;Ki;2400.0;=;nM;5.62
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625152;7;619966;O=C(NCc1ccc(OCc2ccccc2)cc1)[C@@H]1CCCN1;Ki;1720.0;=;nM;5.76
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625152;8;619967;COc1cc(OC2CCC(C)(C)CC2)c(F)cc1CNC(=O)[C@@H]1CCCN1;Ki;3940.0;=;nM;5.41
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625152;9;619968;CC1(C)CCC(Oc2cc(F)c(CNC(=O)[C@@H]3CCCN3)cc2F)CC1;Ki;1670.0;=;nM;5.78
50648;10.1016/j.bmcl.2010.01.107;Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.;625299;11;620042;COc1cc(OCC2CCCCC2)c(F)cc1CNC(=O)[C@@H]1CCCN1;EC50;4027.0;=;nM;5.39
50671;10.1016/j.bmcl.2010.02.046;Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonists.;626175;1(1);621116;CSc1nn2c3c(cnc2c1S(=O)(=O)c1ccccc1)CCC3;IC50;118.0;=;nM;6.93
50671;10.1016/j.bmcl.2010.02.046;Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonists.;626175;1(2);621117;CSc1nn2c3c(cnc2c1S(=O)(=O)c1ccccc1)CCCC3;IC50;411.0;=;nM;6.39
50671;10.1016/j.bmcl.2010.02.046;Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonists.;626175;1(6);621119;CSc1nn2c3c(c(C)nc2c1S(=O)(=O)c1ccccc1)CCCC3;IC50;161.0;=;nM;6.79
50671;10.1016/j.bmcl.2010.02.046;Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonists.;626175;2(6);621120;CSc1nn2c(C)c3c(nc2c1S(=O)(=O)c1ccccc1)CCCC3;IC50;127.0;=;nM;6.9
51276;10.1021/jm100350r;(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.;633200;2;630451;CNc1nn2cc3c(nc2c1S(=O)(=O)c1ccccc1)CCCC3;Ki;169.0;=;nM;6.77
51276;10.1021/jm100350r;(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.;633200;7;630453;CNc1nn2c3c(cnc2c1S(=O)(=O)c1ccccc1)CCC3;Ki;464.0;=;nM;6.33
51276;10.1021/jm100350r;(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.;633200;8;630495;CNc1nn2c3c(cnc2c1S(=O)(=O)c1ccccc1)CCCC3;Ki;153.0;=;nM;6.82
51276;10.1021/jm100350r;(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.;633200;9;630496;CNc1nn2c3c(c(C)nc2c1S(=O)(=O)c1ccccc1)CCC3;Ki;188.0;=;nM;6.73
51887;;PubChem BioAssay data set;737558;SID92093123;747499;CN1c2ccccc2Sc2cc(N)ccc21;Ki;556.0;=;nM;6.25
52006;10.1016/j.bmcl.2010.06.033;Smoothened antagonists for hair inhibition.;644062;10k;682957;COc1ccc(OC)c(C2CCN(Cc3cnn(-c4ccccc4F)c3C)C2)c1;Ki;180.0;=;nM;6.75
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;10;686686;c1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;497.0;=;nM;6.3
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;13;686687;COc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;15.0;=;nM;7.82
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;27;686688;CCOc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;262.0;=;nM;6.58
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;30;686749;FC(F)CCOc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;96.0;=;nM;7.02
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;33;686750;CCCOc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;655.0;=;nM;6.18
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;36;686751;FCCCOc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;232.0;=;nM;6.63
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;12;686752;COc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;28.0;=;nM;7.55
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;26;686753;CCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;302.0;=;nM;6.52
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;29;686817;FCCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;244.0;=;nM;6.61
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;32;686818;CCCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;259.0;=;nM;6.59
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;35;686819;FCCCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;188.0;=;nM;6.73
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;11;686820;COc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;Ki;9.7;=;nM;8.01
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;25;686821;CCOc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;Ki;72.0;=;nM;7.14
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;28;686895;FCCOc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;Ki;57.0;=;nM;7.24
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;31;686896;CCCOc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;Ki;116.0;=;nM;6.94
52226;10.1021/jm100639f;Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands.;649643;34;686897;FCCCOc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;Ki;184.0;=;nM;6.74
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;5a;688989;C1=C(N2CCNCC2)c2nccn2Cc2ccccc21;Ki;316.23;=;nM;6.5
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;9;688991;CC(C)(CN1CCN(C2=Cc3ccccc3Cn3ccnc32)CC1)C(=O)O;Ki;1584.89;=;nM;5.8
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;11;689062;CC1CN(C2=Cc3ccccc3Cn3ccnc32)CC(C)N1CCC(=O)O;Ki;630.96;=;nM;6.2
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;15, isomer 1;689131;O=C(O)C1CCC(N2CCN(C3=Cc4ccccc4Cn4ccnc43)CC2)CC1;Ki;39.81;=;nM;7.4
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;16, isomer 2;689131;O=C(O)C1CCC(N2CCN(C3=Cc4ccccc4Cn4ccnc43)CC2)CC1;Ki;25.12;=;nM;7.6
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;17;689132;Cc1nc2n(c1C)Cc1ccccc1C=C2N1CCN(CC(C)(C)C(=O)O)CC1;Ki;15.85;=;nM;7.8
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;18;689133;Cc1cn2c(n1)C(N1CCN(CC(C)(C)C(=O)O)CC1)=Cc1ccccc1C2;Ki;63.1;=;nM;7.2
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;19;689134;CC(C)(CN1CCN(C2=Cc3ccccc3Cn3cc(Cl)nc32)CC1)C(=O)O;Ki;100.0;=;nM;7.0
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;20;689202;CC(C)(CN1CCN(C2=Cc3ccccc3Cn3c(Cl)cnc32)CC1)C(=O)O;Ki;25.12;=;nM;7.6
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;21;689203;CC(C)(CN1CCN(C2=Cc3ccccc3Cn3cc(F)nc32)CC1)C(=O)O;Ki;316.23;=;nM;6.5
52414;10.1016/j.bmcl.2010.07.029;Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.;651970;22;689204;COc1cnc2n1Cc1ccccc1C=C2N1CCN(CC(C)(C)C(=O)O)CC1;Ki;158.49;=;nM;6.8
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;5;690483;O=C(Nc1ccccc1)N1OCC2CSc3ccc(F)cc3C21;Ki;223.0;=;nM;6.65
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;6;690484;CC(C)NC(=O)N1OCC2CSc3ccc(F)cc3C21;Ki;569.0;=;nM;6.25
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;7;690485;CCCNC(=O)N1OCC2CSc3ccc(F)cc3C21;Ki;384.0;=;nM;6.42
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;8;690486;O=C(NC1CCCCC1)N1OCC2CSc3ccc(F)cc3C21;Ki;42.0;=;nM;7.38
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;9;690487;CCCCNC(=O)N1OCC2CSc3ccc(F)cc3C21;Ki;489.0;=;nM;6.31
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;11;690488;O=C(Nc1ccccc1)N1OCC2COc3ccccc3C21;Ki;1606.0;=;nM;5.79
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;13;690555;CCCNC(=O)N1OCC2COc3ccccc3C21;Ki;6596.0;=;nM;5.18
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;14;690556;O=C(NC1CCCCC1)N1OCC2COc3ccccc3C21;Ki;1773.0;=;nM;5.75
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652347;17;690559;Cc1ccccc1NC(=O)N1OCC2COc3ccccc3C21;Ki;3999.0;=;nM;5.4
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652478;8;690486;O=C(NC1CCCCC1)N1OCC2CSc3ccc(F)cc3C21;IC50;42.66;=;nM;7.37
52454;10.1016/j.bmcl.2010.07.074;N-tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B.;652482;8;690486;O=C(NC1CCCCC1)N1OCC2CSc3ccc(F)cc3C21;EC50;3.981;=;nM;8.4
53047;10.1016/j.bmcl.2010.07.135;Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).;664297;10;707736;CCCCOc1ccc(-c2nn3c(C)cc(C)nc3c2CC(=O)N(CC)CC)cc1;Ki;8357.0;=;nM;5.08
53110;10.1021/jm100668r;Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.;664929;8;707231;CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1;Ki;66.0;=;nM;7.18
53110;10.1021/jm100668r;Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.;664929;13;707462;CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1;Ki;2861.0;=;nM;5.54
53110;10.1021/jm100668r;Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.;664929;17;707683;CCCCN1CCC(COC(=O)c2cc(F)c(N)c3c2OCCO3)CC1;Ki;168.0;=;nM;6.78
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8af;713898;CN1CCN(c2ccc3[nH]nc(S(=O)(=O)c4ccccc4)c3c2)CC1;Ki;978.0;=;nM;6.01
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8as;713077;CN1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)CC1;Ki;601.0;=;nM;6.22
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8at;713078;O=S(=O)(c1cccc2ccccc12)c1n[nH]c2ccc(N3CCNCC3)cc12;Ki;236.0;=;nM;6.63
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8be;713543;Cn1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CCNCC3)ccc21;Ki;87.0;=;nM;7.06
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8bk;713818;CC(C)n1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CCNCC3)ccc21;Ki;96.0;=;nM;7.02
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8bm;713900;CC(C)Cn1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CCNCC3)ccc21;Ki;281.0;=;nM;6.55
53881;10.1021/jm1007825;5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.;684958;8bo;713983;O=S(=O)(c1cccc2ccccc12)c1nn(Cc2ccccc2)c2ccc(N3CCNCC3)cc12;Ki;141.0;=;nM;6.85
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;73;713287;O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1;Ki;794.33;=;nM;6.1
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;70;713190;O=C(O)C1CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1;Ki;1584.89;=;nM;5.8
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;67;713008;O=C(O)C=C1CN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;251.19;=;nM;6.6
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;66;713007;O=C(O)CC1CN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;39.81;=;nM;7.4
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;65;712920;O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;79.43;=;nM;7.1
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;64;712919;O=C(O)[C@]12C[C@H]1CN(C1CC[C@]3(Cc4ccccc4Cc4ccccc43)C1)C2;Ki;398.11;=;nM;6.4
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;62;712830;O=C(O)CC1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;1000.0;=;nM;6.0
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;61;714186;CC1(C(=O)O)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;10.0;=;nM;8.0
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;60;714185;O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;100.0;=;nM;7.0
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;59;714096;O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CCN1;Ki;1258.93;=;nM;5.9
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;56;713562;O=C(O)[C@@H]1CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;1258.93;=;nM;5.9
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;55;713563;O=C(O)CC1CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1;Ki;1000.0;=;nM;6.0
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;53;713658;O=C(O)C1(O)CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1;Ki;251.19;=;nM;6.6
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;52;713749;CC1(C(=O)O)CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1;Ki;3.162;=;nM;8.5
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;51;713750;O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1;Ki;158.49;=;nM;6.8
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;46;714003;COC(=O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1;Ki;1258.93;=;nM;5.9
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;9'a;714099;CN(C)C1CC[C@]2(Cc3ccccc3Cc3ccccc32)C1;Ki;15.85;=;nM;7.8
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;MDL-100907;120674;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;Ki;1258.93;=;nM;5.9
53898;10.1021/jm100856p;Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.;685207;Ketotifen;12957;CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1;Ki;31.62;=;nM;7.5
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;1;208142;COc1cc2c(CCNC(C)=O)c[nH]c2cc1F;Ki;2495.0;=;nM;5.6
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;2;368666;COc1ccc2[nH]c3c(c2c1)CCNC3C;Ki;491.0;=;nM;6.31
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;4, DO-897;33870;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;Ki;33.1;=;nM;7.48
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;5;418483;CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1;Ki;3217.0;=;nM;5.49
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;6;66238;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;Ki;151.4;=;nM;6.82
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;7;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;0.8;=;nM;9.1
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;8, PIM-35;712013;COc1ccc2[nH]cc(CN)c2c1;Ki;1617.0;=;nM;5.79
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;9, PNU-96415E;127837;Fc1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1;Ki;69.6;=;nM;7.16
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;10;6914;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;Ki;69.0;=;nM;7.16
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;SB-206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;4.3;=;nM;8.37
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685644;chlorpromazine;6216;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;Ki;52.0;=;nM;7.28
53923;10.1021/jm100600y;Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.;685645;7;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;EC50;21.38;=;nM;7.67
54241;10.1016/j.bmc.2010.10.011;Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.;697185;13;1055210;COC(=O)CCCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1;Ki;316.23;=;nM;6.5
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;41;1054199;Cc1ccc2c(N3CCN(CCc4cccc(-n5cccn5)c4)CC3)cccc2n1;Ki;79.43;=;nM;7.1
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;16;1055266;Cc1ccc2c(N3CCN(CCc4cccc(NC(=O)c5ccccc5)c4)CC3)cccc2n1;Ki;125.89;=;nM;6.9
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;12;1055262;CC(=O)Nc1cccc(CCN2CCN(c3cccc4nc(C)ccc34)CC2)c1;Ki;158.49;=;nM;6.8
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;33;1054184;COC(=O)Nc1cccc(CCN2CCN(c3cccc4nc(C)ccc34)CC2)c1;Ki;199.53;=;nM;6.7
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;26;1055276;CCNC(=O)Nc1cccc(CCN2CCN(c3cccc4nc(C)ccc34)CC2)c1;Ki;398.11;=;nM;6.4
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;10;1054187;Cc1ccc2c(N3CCN(CCc4cccc(NS(C)(=O)=O)c4)CC3)cccc2n1;Ki;398.11;=;nM;6.4
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;36, GSK-163090;1054194;Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1;Ki;501.19;=;nM;6.3
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;23;1055273;Cc1ccc2c(N3CCN(CCc4cccc(NC(=O)c5cnccn5)c4)CC3)cccc2n1;Ki;794.33;=;nM;6.1
54329;10.1021/jm100714c;Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.;689723;38;1054196;Cc1ccc2c(N3CCN(CCc4cccc(N5CCOC5=O)c4)CC3)cccc2n1;Ki;1258.93;=;nM;5.9
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7c;1058291;Fc1cccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)c1;EC50;13.0;=;nM;7.89
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;10;1058568;O=C1Cc2cc(OC3CN(c4c5c(nc6ccnn46)CCNCC5)C3)ccc2N1;EC50;73.0;=;nM;7.14
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;6a;1058284;c1cc2nc3c(c(N4CCC4)n2n1)CCNCC3;EC50;94.0;=;nM;7.03
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7b;1058290;Fc1ccccc1OC1CN(c2c3c(nc4ccnn24)CCNCC3)C1;EC50;94.0;=;nM;7.03
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7d;1058292;Fc1ccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)cc1;EC50;163.0;=;nM;6.79
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7f;1058562;COc1cccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)c1;EC50;215.0;=;nM;6.67
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7a;1058289;c1ccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)cc1;EC50;218.0;=;nM;6.66
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7e;1058293;COc1ccccc1OC1CN(c2c3c(nc4ccnn24)CCNCC3)C1;EC50;379.0;=;nM;6.42
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;7g;1058563;COc1ccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)cc1;EC50;503.0;=;nM;6.3
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;6e;1058288;CCNc1c2c(nc3ccnn13)CCNCC2;EC50;602.0;=;nM;6.22
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;8a;1058564;c1ccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)nc1;EC50;706.0;=;nM;6.15
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;6d;1058287;CCN(C)c1c2c(nc3ccnn13)CCNCC2;EC50;842.0;=;nM;6.08
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;8c;1058566;c1cc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)ccn1;EC50;1158.0;=;nM;5.94
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;9;1058567;CC(=O)N(C)c1ccc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)cc1;EC50;1184.0;=;nM;5.93
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;8b;1058565;c1cncc(OC2CN(c3c4c(nc5ccnn35)CCNCC4)C2)c1;EC50;1478.0;=;nM;5.83
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;6b;1058285;c1cc2nc3c(c(N4CCCC4)n2n1)CCNCC3;EC50;2242.0;=;nM;5.65
54712;10.1016/j.bmcl.2010.11.089;Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.;700614;6c;1058286;c1cc2nc3c(c(N4CCCCC4)n2n1)CCNCC3;EC50;2848.0;=;nM;5.54
54715;10.1016/j.bmcl.2010.11.075;Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.;700883;13;1058620;CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41;Ki;6086.0;=;nM;5.22
54715;10.1016/j.bmcl.2010.11.075;Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.;700883;11;1058618;Fc1cccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)c1;Ki;6983.0;=;nM;5.16
54755;10.1016/j.bmc.2010.10.033;Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.;699284;18b;1057331;Cl.O=S(=O)(c1cccc2ccccc12)c1n[nH]c2ccc(NC3CCNCC3)cc12;Ki;675.0;=;nM;6.17
54755;10.1016/j.bmc.2010.10.033;Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.;699284;18g;1057362;Cl.O=S(=O)(c1cccc(Cl)c1)c1n[nH]c2ccc(NC3CCNCC3)cc12;Ki;155.0;=;nM;6.81
54755;10.1016/j.bmc.2010.10.033;Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.;699284;18k;1057366;CC(C)c1ccc(S(=O)(=O)c2n[nH]c3ccc(NC4CCNCC4)cc23)cc1.Cl;Ki;1760.0;=;nM;5.75
54755;10.1016/j.bmc.2010.10.033;Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.;699284;18n;1057369;Cl.O=S(=O)(c1ccc2ccccc2c1)c1n[nH]c2ccc(NC3CCNCC3)cc12;Ki;675.0;=;nM;6.17
54755;10.1016/j.bmc.2010.10.033;Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.;699284;21a;1057345;Cl.NCCC(=O)Nc1ccc2[nH]nc(S(=O)(=O)c3cccc4ccccc34)c2c1;Ki;344.0;=;nM;6.46
54755;10.1016/j.bmc.2010.10.033;Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.;699284;23a;1057346;Cl.O=C(Nc1ccc2[nH]nc(S(=O)(=O)c3cccc4ccccc34)c2c1)C1CCNCC1;Ki;33.0;=;nM;7.48
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;1;1063277;OC[C@@H]1CSC(c2ccccc2O)=N1;Ki;1360.0;=;nM;5.87
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;2;1063278;NC(=O)c1csc(-c2ccccc2O)n1;Ki;1031.0;=;nM;5.99
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;3;1063279;NC(=O)C1CSC(c2ccccc2O)=N1;Ki;1260.0;=;nM;5.9
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;4;1063280;C[C@@H]1SC(c2ccccc2O)=N[C@H]1[C@@H]1SC[C@](C)(C(=O)O)N1C;Ki;3922.0;=;nM;5.41
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;5;1063281;C[C@@H]1SC(c2ccccc2O)=N[C@H]1[C@H]1SC[C@](C)(C(=O)O)N1C;Ki;4695.0;=;nM;5.33
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;6;1063282;C[C@@H]1SC(c2ccccc2O)=N[C@@H]1CO;Ki;505.0;=;nM;6.3
55211;10.1021/np100588c;Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria.;714921;9;1063283;Cc1sc(-c2ccccc2O)nc1C=O;Ki;1541.0;=;nM;5.81
57165;10.1016/j.ejmech.2011.01.038;2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists.;740240;18;1067352;CNc1nn2c(C)cc(C)nc2c1S(=O)(=O)c1ccccc1;IC50;5130.0;=;nM;5.29
57165;10.1016/j.ejmech.2011.01.038;2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists.;740241;18;1067352;CNc1nn2c(C)cc(C)nc2c1S(=O)(=O)c1ccccc1;Ki;1040.0;=;nM;5.98
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7k;1142682;Clc1cccc(Cc2ncc3c(n2)CCNCC3)c1;EC50;30.0;=;nM;7.52
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7l;1142683;Clc1ccc(Cc2ncc3c(n2)CCNCC3)cc1;EC50;60.0;=;nM;7.22
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7n;1142685;FC(F)(F)c1cccc(Cc2ncc3c(n2)CCNCC3)c1;EC50;160.0;=;nM;6.8
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7i;1142680;Cc1ccc(Cc2ncc3c(n2)CCNCC3)cc1;EC50;164.0;=;nM;6.79
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7j;1142681;Clc1ccccc1Cc1ncc2c(n1)CCNCC2;EC50;178.0;=;nM;6.75
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7e;1142676;Fc1cccc(Cc2ncc3c(n2)CCNCC3)c1;EC50;183.0;=;nM;6.74
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7d;1142675;Fc1ccccc1Cc1ncc2c(n1)CCNCC2;EC50;220.0;=;nM;6.66
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7h;1142679;Cc1cccc(Cc2ncc3c(n2)CCNCC3)c1;EC50;410.0;=;nM;6.39
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7f;1142677;Fc1ccc(Cc2ncc3c(n2)CCNCC3)cc1;EC50;610.0;=;nM;6.21
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744733;7g;1142678;Cc1ccccc1Cc1ncc2c(n1)CCNCC2;EC50;1200.0;=;nM;5.92
57389;10.1016/j.bmcl.2010.11.120;Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.;744739;1, APD-356;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;943.0;=;nM;6.03
58558;10.1021/jm2006782;Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.;761946;(+/-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;Ki;2.0;=;nM;8.7
59050;10.1016/j.bmc.2011.08.033;CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.;769757;2;70931;Nc1nccc(-c2c[nH]c3cccc(O)c23)n1;Ki;150.0;=;nM;6.82
59050;10.1016/j.bmc.2011.08.033;CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.;769757;3;1176660;COc1cccc2[nH]cc(-c3ccnc(N)n3)c12;Ki;88.0;=;nM;7.06
59068;10.1016/j.bmcl.2011.06.124;Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.;770880;15, Lu AA33810;1180380;CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1;Ki;245.0;=;nM;6.61
59113;10.1021/jm200466r;N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.;771280;42;1178388;CCN/C(=N\S(=O)(=O)c1cccc(Cl)c1)N1CC(C)(C)C=N1;Ki;7943.28;=;nM;5.1
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;16;1178293;c1ccc(CCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;310.0;=;nM;6.51
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;17;1178294;COc1ccccc1CCN1CCN(Cc2cc3ccccc3o2)CC1;Ki;120.0;=;nM;6.92
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;18;1178295;COc1cccc(CCN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;290.0;=;nM;6.54
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;19;1178296;COc1ccc(CCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;463.0;=;nM;6.33
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;26;1178297;c1ccc(CCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;147.0;=;nM;6.83
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;27;1178298;COc1ccccc1CCCN1CCN(Cc2cc3ccccc3o2)CC1;Ki;628.0;=;nM;6.2
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;28;1178299;COc1cccc(CCCN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;243.0;=;nM;6.61
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;29;1178300;COc1ccc(CCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;155.0;=;nM;6.81
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;20;1178301;c1ccc(CCCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;275.0;=;nM;6.56
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;30;1178302;COc1ccccc1CCCCN1CCN(Cc2cc3ccccc3o2)CC1;Ki;332.0;=;nM;6.48
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;31;1178303;COc1cccc(CCCCN2CCN(Cc3cc4ccccc4o3)CC2)c1;Ki;343.0;=;nM;6.46
59119;10.1016/j.bmcl.2011.08.029;Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine σ₁ receptor ligands.;771230;21;1178304;COc1ccc(CCCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;Ki;352.0;=;nM;6.45
59306;;DrugMatrix in vitro pharmacology data;774715;BENZBROMARONE;374182;CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1;IC50;1804.0;=;nM;5.74
59306;;DrugMatrix in vitro pharmacology data;774715;BENZBROMARONE;374182;CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1;Ki;1148.0;=;nM;5.94
59306;;DrugMatrix in vitro pharmacology data;774715;BERBERINE CHLORIDE;9459;COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2.[Cl-];IC50;3437.0;=;nM;5.46
59306;;DrugMatrix in vitro pharmacology data;774715;BERBERINE CHLORIDE;9459;COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2.[Cl-];Ki;2187.0;=;nM;5.66
59306;;DrugMatrix in vitro pharmacology data;774715;BUSPIRONE;3599;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;IC50;750.0;=;nM;6.12
59306;;DrugMatrix in vitro pharmacology data;774715;BUSPIRONE;3599;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;Ki;477.0;=;nM;6.32
59306;;DrugMatrix in vitro pharmacology data;774715;BETA-ESTRADIOL 3-BENZOATE;39821;C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O;IC50;11565.0;=;nM;4.94
59306;;DrugMatrix in vitro pharmacology data;774715;BETA-ESTRADIOL 3-BENZOATE;39821;C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O;Ki;7359.0;=;nM;5.13
59306;;DrugMatrix in vitro pharmacology data;774715;CAMPTOTHECIN;5105;CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1;IC50;970.0;=;nM;6.01
59306;;DrugMatrix in vitro pharmacology data;774715;CAMPTOTHECIN;5105;CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1;Ki;617.0;=;nM;6.21
59306;;DrugMatrix in vitro pharmacology data;774715;BITHIONOL;46656;Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O;IC50;6789.0;=;nM;5.17
59306;;DrugMatrix in vitro pharmacology data;774715;BITHIONOL;46656;Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O;Ki;4320.0;=;nM;5.37
59306;;DrugMatrix in vitro pharmacology data;774715;BROMOCRIPTINE;7065;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;IC50;8.316;=;nM;8.08
59306;;DrugMatrix in vitro pharmacology data;774715;BROMOCRIPTINE;7065;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;Ki;5.292;=;nM;8.28
59306;;DrugMatrix in vitro pharmacology data;774715;BW-723C86;704815;CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12;IC50;81.1;=;nM;7.09
59306;;DrugMatrix in vitro pharmacology data;774715;BW-723C86;704815;CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12;Ki;51.6;=;nM;7.29
59306;;DrugMatrix in vitro pharmacology data;774715;BENZTROPINE;675154;CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2;IC50;200.0;=;nM;6.7
59306;;DrugMatrix in vitro pharmacology data;774715;BENZTROPINE;675154;CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2;Ki;127.0;=;nM;6.9
59306;;DrugMatrix in vitro pharmacology data;774715;ASTEMIZOLE;65605;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;IC50;12.0;=;nM;7.92
59306;;DrugMatrix in vitro pharmacology data;774715;ASTEMIZOLE;65605;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;Ki;7.487;=;nM;8.13
59306;;DrugMatrix in vitro pharmacology data;774715;BOPINDOLOL;255377;Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1;IC50;1523.0;=;nM;5.82
59306;;DrugMatrix in vitro pharmacology data;774715;BOPINDOLOL;255377;Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1;Ki;969.0;=;nM;6.01
59306;;DrugMatrix in vitro pharmacology data;774715;ACLARUBICIN;462845;CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC;IC50;1106.0;=;nM;5.96
59306;;DrugMatrix in vitro pharmacology data;774715;ACLARUBICIN;462845;CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC;Ki;704.0;=;nM;6.15
59306;;DrugMatrix in vitro pharmacology data;774715;AMOXAPINE;155045;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;IC50;10.0;=;nM;8.0
59306;;DrugMatrix in vitro pharmacology data;774715;AMOXAPINE;155045;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;Ki;6.569;=;nM;8.18
59306;;DrugMatrix in vitro pharmacology data;774715;1-NAPHTHYL ISOTHIOCYANATE;804982;S=C=Nc1cccc2ccccc12;IC50;25158.0;=;nM;4.6
59306;;DrugMatrix in vitro pharmacology data;774715;1-NAPHTHYL ISOTHIOCYANATE;804982;S=C=Nc1cccc2ccccc12;Ki;16009.0;=;nM;4.8
59306;;DrugMatrix in vitro pharmacology data;774715;ALOSETRON;153342;Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O;IC50;100.0;=;nM;7.0
59306;;DrugMatrix in vitro pharmacology data;774715;ALOSETRON;153342;Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O;Ki;64.0;=;nM;7.19
59306;;DrugMatrix in vitro pharmacology data;774715;1-(2-CHLOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE;1248972;O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1;IC50;1508.0;=;nM;5.82
59306;;DrugMatrix in vitro pharmacology data;774715;1-(2-CHLOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE;1248972;O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1;Ki;960.0;=;nM;6.02
59306;;DrugMatrix in vitro pharmacology data;774715;AMIODARONE;27185;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;IC50;923.0;=;nM;6.04
59306;;DrugMatrix in vitro pharmacology data;774715;AMIODARONE;27185;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;Ki;587.0;=;nM;6.23
59306;;DrugMatrix in vitro pharmacology data;774715;ALPHA-ERGOCRYPTINE;827165;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;IC50;13.0;=;nM;7.89
59306;;DrugMatrix in vitro pharmacology data;774715;ALPHA-ERGOCRYPTINE;827165;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;Ki;8.217;=;nM;8.09
59306;;DrugMatrix in vitro pharmacology data;774715;AMITRIPTYLINE;27072;CN(C)CCC=C1c2ccccc2CCc2ccccc21;IC50;70.0;=;nM;7.16
59306;;DrugMatrix in vitro pharmacology data;774715;AMITRIPTYLINE;27072;CN(C)CCC=C1c2ccccc2CCc2ccccc21;Ki;45.0;=;nM;7.35
59306;;DrugMatrix in vitro pharmacology data;774715;1-(2-METHYLBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE;1248974;Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1;IC50;1860.0;=;nM;5.73
59306;;DrugMatrix in vitro pharmacology data;774715;1-(2-METHYLBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE;1248974;Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1;Ki;1183.0;=;nM;5.93
59306;;DrugMatrix in vitro pharmacology data;774715;2-ACETYLAMINOFLUORENE;134083;CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2;IC50;3170.0;=;nM;5.5
59306;;DrugMatrix in vitro pharmacology data;774715;2-ACETYLAMINOFLUORENE;134083;CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2;Ki;2017.0;=;nM;5.7
59306;;DrugMatrix in vitro pharmacology data;774715;2-HYDROXYPROPYL-BETA-CYCLODEXTRIN;580727;CC(O)COC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]8COCC(C)O)O[C@@H]7COCC(C)O)O[C@@H]6COCC(C)O)O[C@@H]5COCC(C)O)O[C@@H]4COCC(C)O)O[C@@H]3COCC(C)O;IC50;63.0;=;nM;7.2
59306;;DrugMatrix in vitro pharmacology data;774715;2-HYDROXYPROPYL-BETA-CYCLODEXTRIN;580727;CC(O)COC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]8COCC(C)O)O[C@@H]7COCC(C)O)O[C@@H]6COCC(C)O)O[C@@H]5COCC(C)O)O[C@@H]4COCC(C)O)O[C@@H]3COCC(C)O;Ki;40.0;=;nM;7.4
59306;;DrugMatrix in vitro pharmacology data;774715;4-(PHENYLMETHYL)-1-[2-(TRIFLUOROMETHYL)BENZOYL]-PIPERIDINE;1248975;O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1;IC50;1549.0;=;nM;5.81
59306;;DrugMatrix in vitro pharmacology data;774715;4-(PHENYLMETHYL)-1-[2-(TRIFLUOROMETHYL)BENZOYL]-PIPERIDINE;1248975;O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1;Ki;986.0;=;nM;6.01
59306;;DrugMatrix in vitro pharmacology data;774715;EBASTINE;111060;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;IC50;312.6;=;nM;6.5
59306;;DrugMatrix in vitro pharmacology data;774715;EBASTINE;111060;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;Ki;198.9;=;nM;6.7
59306;;DrugMatrix in vitro pharmacology data;774715;ECONAZOLE;52874;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;IC50;6833.0;=;nM;5.17
59306;;DrugMatrix in vitro pharmacology data;774715;ECONAZOLE;52874;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;Ki;4348.0;=;nM;5.36
59306;;DrugMatrix in vitro pharmacology data;774715;HEXACHLOROPHENE;8167;Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl;IC50;5694.7;=;nM;5.25
59306;;DrugMatrix in vitro pharmacology data;774715;HEXACHLOROPHENE;8167;Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl;Ki;3623.9;=;nM;5.44
59306;;DrugMatrix in vitro pharmacology data;774715;GUANABENZ;1202;N=C(N)N/N=C/c1c(Cl)cccc1Cl;IC50;97.0;=;nM;7.01
59306;;DrugMatrix in vitro pharmacology data;774715;GUANABENZ;1202;N=C(N)N/N=C/c1c(Cl)cccc1Cl;Ki;62.0;=;nM;7.21
59306;;DrugMatrix in vitro pharmacology data;774715;ESTRONE;342897;C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O;IC50;13630.0;=;nM;4.87
59306;;DrugMatrix in vitro pharmacology data;774715;ESTRONE;342897;C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O;Ki;8676.0;=;nM;5.06
59306;;DrugMatrix in vitro pharmacology data;774715;ERGOCORNINE;809724;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;IC50;11.0;=;nM;7.96
59306;;DrugMatrix in vitro pharmacology data;774715;ERGOCORNINE;809724;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;Ki;6.855;=;nM;8.16
59306;;DrugMatrix in vitro pharmacology data;774715;GUANFACINE;66029;N=C(N)NC(=O)Cc1c(Cl)cccc1Cl;IC50;2098.0;=;nM;5.68
59306;;DrugMatrix in vitro pharmacology data;774715;GUANFACINE;66029;N=C(N)NC(=O)Cc1c(Cl)cccc1Cl;Ki;1335.0;=;nM;5.88
59306;;DrugMatrix in vitro pharmacology data;774715;FLUNARIZINE;38764;Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1;IC50;1088.0;=;nM;5.96
59306;;DrugMatrix in vitro pharmacology data;774715;FLUNARIZINE;38764;Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1;Ki;692.0;=;nM;6.16
59306;;DrugMatrix in vitro pharmacology data;774715;ERGONOVINE;196351;C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;IC50;4.139;=;nM;8.38
59306;;DrugMatrix in vitro pharmacology data;774715;ERGONOVINE;196351;C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;2.634;=;nM;8.58
59306;;DrugMatrix in vitro pharmacology data;774715;FLUPHENAZINE;36842;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;IC50;39.0;=;nM;7.41
59306;;DrugMatrix in vitro pharmacology data;774715;FLUPHENAZINE;36842;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;Ki;25.0;=;nM;7.6
59306;;DrugMatrix in vitro pharmacology data;774715;ERGOTAMINE;2203;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21;IC50;3.461;=;nM;8.46
59306;;DrugMatrix in vitro pharmacology data;774715;ERGOTAMINE;2203;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21;Ki;2.203;=;nM;8.66
59306;;DrugMatrix in vitro pharmacology data;774715;DROPERIDOL;152751;O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;IC50;1342.0;=;nM;5.87
59306;;DrugMatrix in vitro pharmacology data;774715;DROPERIDOL;152751;O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;Ki;854.0;=;nM;6.07
59306;;DrugMatrix in vitro pharmacology data;774715;HALOPERIDOL;3859;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;IC50;2050.0;=;nM;5.69
59306;;DrugMatrix in vitro pharmacology data;774715;HALOPERIDOL;3859;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;Ki;1305.0;=;nM;5.88
59306;;DrugMatrix in vitro pharmacology data;774715;CARVEDILOL;36662;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;IC50;23.0;=;nM;7.64
59306;;DrugMatrix in vitro pharmacology data;774715;CARVEDILOL;36662;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;Ki;15.0;=;nM;7.82
59306;;DrugMatrix in vitro pharmacology data;774715;CETYLPYRIDINIUM BROMIDE;195273;CCCCCCCCCCCCCCCC[n+]1ccccc1.[Br-];IC50;5690.0;=;nM;5.25
59306;;DrugMatrix in vitro pharmacology data;774715;CETYLPYRIDINIUM BROMIDE;195273;CCCCCCCCCCCCCCCC[n+]1ccccc1.[Br-];Ki;3621.0;=;nM;5.44
59306;;DrugMatrix in vitro pharmacology data;774715;DIPHENHYDRAMINE;27629;CN(C)CCOC(c1ccccc1)c1ccccc1;IC50;1118.0;=;nM;5.95
59306;;DrugMatrix in vitro pharmacology data;774715;DIPHENHYDRAMINE;27629;CN(C)CCOC(c1ccccc1)c1ccccc1;Ki;711.0;=;nM;6.15
59306;;DrugMatrix in vitro pharmacology data;774715;DOXEPIN;1051118;CN(C)CCC=C1c2ccccc2COc2ccccc21;IC50;89.0;=;nM;7.05
59306;;DrugMatrix in vitro pharmacology data;774715;DOXEPIN;1051118;CN(C)CCC=C1c2ccccc2COc2ccccc21;Ki;56.0;=;nM;7.25
59306;;DrugMatrix in vitro pharmacology data;774715;CLEMASTINE;469763;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;IC50;36.0;=;nM;7.44
59306;;DrugMatrix in vitro pharmacology data;774715;CLEMASTINE;469763;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;Ki;23.0;=;nM;7.64
59306;;DrugMatrix in vitro pharmacology data;774715;DAPIPRAZOLE;675167;Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1;IC50;1056.0;=;nM;5.98
59306;;DrugMatrix in vitro pharmacology data;774715;DAPIPRAZOLE;675167;Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1;Ki;672.0;=;nM;6.17
59306;;DrugMatrix in vitro pharmacology data;774715;CISAPRIDE;557741;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;IC50;110.0;=;nM;6.96
59306;;DrugMatrix in vitro pharmacology data;774715;CISAPRIDE;557741;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;Ki;70.0;=;nM;7.16
59306;;DrugMatrix in vitro pharmacology data;774715;DOXAZOSIN;33373;COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC;IC50;368.0;=;nM;6.43
59306;;DrugMatrix in vitro pharmacology data;774715;DOXAZOSIN;33373;COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC;Ki;234.0;=;nM;6.63
59306;;DrugMatrix in vitro pharmacology data;774715;DICYCLOMINE;165774;CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1;IC50;1301.0;=;nM;5.89
59306;;DrugMatrix in vitro pharmacology data;774715;DICYCLOMINE;165774;CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1;Ki;828.0;=;nM;6.08
59306;;DrugMatrix in vitro pharmacology data;774715;CYCLIZINE;27546;CN1CCN(C(c2ccccc2)c2ccccc2)CC1;IC50;373.0;=;nM;6.43
59306;;DrugMatrix in vitro pharmacology data;774715;CYCLIZINE;27546;CN1CCN(C(c2ccccc2)c2ccccc2)CC1;Ki;238.0;=;nM;6.62
59306;;DrugMatrix in vitro pharmacology data;774715;CITALOPRAM;14367;CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;IC50;1839.0;=;nM;5.74
59306;;DrugMatrix in vitro pharmacology data;774715;CITALOPRAM;14367;CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;Ki;1171.0;=;nM;5.93
59306;;DrugMatrix in vitro pharmacology data;774715;DIHYDROERGOCRISTINE MESYLATE;704818;CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O;IC50;6.601;=;nM;8.18
59306;;DrugMatrix in vitro pharmacology data;774715;DIHYDROERGOCRISTINE MESYLATE;704818;CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O;Ki;4.201;=;nM;8.38
59306;;DrugMatrix in vitro pharmacology data;774715;DISULFIRAM;94571;CCN(CC)C(=S)SSC(=S)N(CC)CC;IC50;34547.0;=;nM;4.46
59306;;DrugMatrix in vitro pharmacology data;774715;DISULFIRAM;94571;CCN(CC)C(=S)SSC(=S)N(CC)CC;Ki;21984.0;=;nM;4.66
59306;;DrugMatrix in vitro pharmacology data;774715;CLOTRIMAZOLE;13494;Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1;IC50;11604.0;=;nM;4.93
59306;;DrugMatrix in vitro pharmacology data;774715;CLOTRIMAZOLE;13494;Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1;Ki;7385.0;=;nM;5.13
59306;;DrugMatrix in vitro pharmacology data;774715;DIHYDROERGOTAMINE;558566;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;IC50;6.804;=;nM;8.17
59306;;DrugMatrix in vitro pharmacology data;774715;DIHYDROERGOTAMINE;558566;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;Ki;4.33;=;nM;8.36
59306;;DrugMatrix in vitro pharmacology data;774715;DESLORATADINE;191342;Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1;IC50;43.0;=;nM;7.37
59306;;DrugMatrix in vitro pharmacology data;774715;DESLORATADINE;191342;Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1;Ki;28.0;=;nM;7.55
59306;;DrugMatrix in vitro pharmacology data;774715;DIETHYLSTILBESTROL;860;CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1;IC50;3140.0;=;nM;5.5
59306;;DrugMatrix in vitro pharmacology data;774715;DIETHYLSTILBESTROL;860;CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1;Ki;1998.0;=;nM;5.7
59306;;DrugMatrix in vitro pharmacology data;774715;CHLOROXYLENOL;419430;Cc1cc(O)cc(C)c1Cl;IC50;1856.0;=;nM;5.73
59306;;DrugMatrix in vitro pharmacology data;774715;CHLOROXYLENOL;419430;Cc1cc(O)cc(C)c1Cl;Ki;1181.0;=;nM;5.93
59306;;DrugMatrix in vitro pharmacology data;774715;CLOZAPINE;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;IC50;11.0;=;nM;7.96
59306;;DrugMatrix in vitro pharmacology data;774715;CLOZAPINE;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;Ki;7.18;=;nM;8.14
59306;;DrugMatrix in vitro pharmacology data;774715;CINNARIZINE;66311;C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1;IC50;731.0;=;nM;6.14
59306;;DrugMatrix in vitro pharmacology data;774715;CINNARIZINE;66311;C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1;Ki;465.0;=;nM;6.33
59306;;DrugMatrix in vitro pharmacology data;774715;CLOMIPHENE;92984;CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1;IC50;1363.0;=;nM;5.87
59306;;DrugMatrix in vitro pharmacology data;774715;CLOMIPHENE;92984;CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1;Ki;867.0;=;nM;6.06
59306;;DrugMatrix in vitro pharmacology data;774715;DIMENHYDRINATE;674357;CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O;IC50;1724.0;=;nM;5.76
59306;;DrugMatrix in vitro pharmacology data;774715;DIMENHYDRINATE;674357;CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O;Ki;1097.0;=;nM;5.96
59306;;DrugMatrix in vitro pharmacology data;774715;CHLORPROMAZINE;6216;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;IC50;126.0;=;nM;6.9
59306;;DrugMatrix in vitro pharmacology data;774715;CHLORPROMAZINE;6216;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;Ki;80.0;=;nM;7.1
59306;;DrugMatrix in vitro pharmacology data;774715;CLOMIPRAMINE;996;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;IC50;239.0;=;nM;6.62
59306;;DrugMatrix in vitro pharmacology data;774715;CLOMIPRAMINE;996;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;Ki;152.0;=;nM;6.82
59306;;DrugMatrix in vitro pharmacology data;774715;CYPROHEPTADINE;11005;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;IC50;9.441;=;nM;8.03
59306;;DrugMatrix in vitro pharmacology data;774715;CYPROHEPTADINE;11005;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;Ki;6.008;=;nM;8.22
59306;;DrugMatrix in vitro pharmacology data;774715;DOMPERIDONE;364745;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;IC50;2600.0;=;nM;5.58
59306;;DrugMatrix in vitro pharmacology data;774715;DOMPERIDONE;364745;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;Ki;1655.0;=;nM;5.78
59306;;DrugMatrix in vitro pharmacology data;774715;ORPHENADRINE;77779;Cc1ccccc1C(OCCN(C)C)c1ccccc1;IC50;3391.0;=;nM;5.47
59306;;DrugMatrix in vitro pharmacology data;774715;ORPHENADRINE;77779;Cc1ccccc1C(OCCN(C)C)c1ccccc1;Ki;2158.0;=;nM;5.67
59306;;DrugMatrix in vitro pharmacology data;774715;OXYMETAZOLINE;42520;Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1;IC50;3056.0;=;nM;5.51
59306;;DrugMatrix in vitro pharmacology data;774715;OXYMETAZOLINE;42520;Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1;Ki;1945.0;=;nM;5.71
59306;;DrugMatrix in vitro pharmacology data;774715;NOCODAZOLE;5575;COC(=O)Nc1nc2cc(C(=O)c3cccs3)ccc2[nH]1;IC50;20180.0;=;nM;4.7
59306;;DrugMatrix in vitro pharmacology data;774715;NOCODAZOLE;5575;COC(=O)Nc1nc2cc(C(=O)c3cccs3)ccc2[nH]1;Ki;12845.0;=;nM;4.89
59306;;DrugMatrix in vitro pharmacology data;774715;PROMAZINE;16391;CN(C)CCCN1c2ccccc2Sc2ccccc21;IC50;347.0;=;nM;6.46
59306;;DrugMatrix in vitro pharmacology data;774715;PROMAZINE;16391;CN(C)CCCN1c2ccccc2Sc2ccccc21;Ki;221.0;=;nM;6.66
59306;;DrugMatrix in vitro pharmacology data;774715;PRAZOSIN;97;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;IC50;4118.0;=;nM;5.38
59306;;DrugMatrix in vitro pharmacology data;774715;PRAZOSIN;97;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;Ki;2621.0;=;nM;5.58
59306;;DrugMatrix in vitro pharmacology data;774715;PROMETHAZINE;27368;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;IC50;68.0;=;nM;7.17
59306;;DrugMatrix in vitro pharmacology data;774715;PROMETHAZINE;27368;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;Ki;43.0;=;nM;7.37
59306;;DrugMatrix in vitro pharmacology data;774715;PERGOLIDE;12494;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;IC50;76.0;=;nM;7.12
59306;;DrugMatrix in vitro pharmacology data;774715;PERGOLIDE;12494;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;Ki;49.0;=;nM;7.31
59306;;DrugMatrix in vitro pharmacology data;774715;PROPAFENONE;27112;CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1;IC50;92.0;=;nM;7.04
59306;;DrugMatrix in vitro pharmacology data;774715;PROPAFENONE;27112;CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1;Ki;58.0;=;nM;7.24
59306;;DrugMatrix in vitro pharmacology data;774715;PYRILAMINE;10661;COc1ccc(CN(CCN(C)C)c2ccccn2)cc1;IC50;2788.0;=;nM;5.55
59306;;DrugMatrix in vitro pharmacology data;774715;PYRILAMINE;10661;COc1ccc(CN(CCN(C)C)c2ccccn2)cc1;Ki;1774.0;=;nM;5.75
59306;;DrugMatrix in vitro pharmacology data;774715;PIPAMAZINE;1248996;NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;IC50;49.0;=;nM;7.31
59306;;DrugMatrix in vitro pharmacology data;774715;PIPAMAZINE;1248996;NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;Ki;31.0;=;nM;7.51
59306;;DrugMatrix in vitro pharmacology data;774715;OLANZAPINE;34197;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1;IC50;57.0;=;nM;7.24
59306;;DrugMatrix in vitro pharmacology data;774715;OLANZAPINE;34197;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1;Ki;36.0;=;nM;7.44
59306;;DrugMatrix in vitro pharmacology data;774715;PHENTOLAMINE;20131;Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1;IC50;3807.0;=;nM;5.42
59306;;DrugMatrix in vitro pharmacology data;774715;PHENTOLAMINE;20131;Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1;Ki;2422.0;=;nM;5.62
59306;;DrugMatrix in vitro pharmacology data;774715;PROPOFOL;11819;CC(C)c1cccc(C(C)C)c1O;IC50;5499.0;=;nM;5.26
59306;;DrugMatrix in vitro pharmacology data;774715;PROPOFOL;11819;CC(C)c1cccc(C(C)C)c1O;Ki;3499.0;=;nM;5.46
59306;;DrugMatrix in vitro pharmacology data;774715;NORTRIPTYLINE;2262;CNCCC=C1c2ccccc2CCc2ccccc21;IC50;136.0;=;nM;6.87
59306;;DrugMatrix in vitro pharmacology data;774715;NORTRIPTYLINE;2262;CNCCC=C1c2ccccc2CCc2ccccc21;Ki;86.0;=;nM;7.07
59306;;DrugMatrix in vitro pharmacology data;774715;OXICONAZOLE;242303;Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;IC50;4606.4;=;nM;5.34
59306;;DrugMatrix in vitro pharmacology data;774715;OXICONAZOLE;242303;Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;Ki;2931.4;=;nM;5.53
59306;;DrugMatrix in vitro pharmacology data;774715;PROPRANOLOL;1370;CC(C)NCC(O)COc1cccc2ccccc12;IC50;342.0;=;nM;6.47
59306;;DrugMatrix in vitro pharmacology data;774715;PROPRANOLOL;1370;CC(C)NCC(O)COc1cccc2ccccc12;Ki;218.0;=;nM;6.66
59306;;DrugMatrix in vitro pharmacology data;774715;QUETIAPINE;34234;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;IC50;213.5;=;nM;6.67
59306;;DrugMatrix in vitro pharmacology data;774715;QUETIAPINE;34234;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;Ki;135.9;=;nM;6.87
59306;;DrugMatrix in vitro pharmacology data;774715;OXYBUTYNIN;229058;CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1;IC50;792.0;=;nM;6.1
59306;;DrugMatrix in vitro pharmacology data;774715;OXYBUTYNIN;229058;CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1;Ki;504.0;=;nM;6.3
59306;;DrugMatrix in vitro pharmacology data;774715;PROCHLORPERAZINE;37266;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;IC50;102.0;=;nM;6.99
59306;;DrugMatrix in vitro pharmacology data;774715;PROCHLORPERAZINE;37266;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;Ki;65.0;=;nM;7.19
59306;;DrugMatrix in vitro pharmacology data;774715;ONDANSETRON;3183;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O;IC50;717.0;=;nM;6.14
59306;;DrugMatrix in vitro pharmacology data;774715;ONDANSETRON;3183;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O;Ki;456.0;=;nM;6.34
59306;;DrugMatrix in vitro pharmacology data;774715;METHYSERGIDE;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;IC50;0.563;=;nM;9.25
59306;;DrugMatrix in vitro pharmacology data;774715;METHYSERGIDE;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;Ki;0.358;=;nM;9.45
59306;;DrugMatrix in vitro pharmacology data;774715;MEXILETINE;15958;Cc1cccc(C)c1OCC(C)N;IC50;1138.0;=;nM;5.94
59306;;DrugMatrix in vitro pharmacology data;774715;MEXILETINE;15958;Cc1cccc(C)c1OCC(C)N;Ki;724.0;=;nM;6.14
59306;;DrugMatrix in vitro pharmacology data;774715;ISOTRETINOIN;13928;CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1;IC50;848.0;=;nM;6.07
59306;;DrugMatrix in vitro pharmacology data;774715;ISOTRETINOIN;13928;CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1;Ki;540.0;=;nM;6.27
59306;;DrugMatrix in vitro pharmacology data;774715;KETOTIFEN;12957;CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1;IC50;46.0;=;nM;7.34
59306;;DrugMatrix in vitro pharmacology data;774715;KETOTIFEN;12957;CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1;Ki;29.0;=;nM;7.54
59306;;DrugMatrix in vitro pharmacology data;774715;MAPROTILINE;27713;CNCCCC12CCC(c3ccccc31)c1ccccc12;IC50;336.0;=;nM;6.47
59306;;DrugMatrix in vitro pharmacology data;774715;MAPROTILINE;27713;CNCCCC12CCC(c3ccccc31)c1ccccc12;Ki;214.0;=;nM;6.67
59306;;DrugMatrix in vitro pharmacology data;774715;METOCLOPRAMIDE;7736;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;IC50;630.0;=;nM;6.2
59306;;DrugMatrix in vitro pharmacology data;774715;METOCLOPRAMIDE;7736;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;Ki;401.0;=;nM;6.4
59306;;DrugMatrix in vitro pharmacology data;774715;MIANSERIN;573;CN1CCN2c3ccccc3Cc3ccccc3C2C1;IC50;7.295;=;nM;8.14
59306;;DrugMatrix in vitro pharmacology data;774715;MIANSERIN;573;CN1CCN2c3ccccc3Cc3ccccc3C2C1;Ki;4.642;=;nM;8.33
59306;;DrugMatrix in vitro pharmacology data;774715;MICONAZOLE;8917;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;IC50;5545.0;=;nM;5.26
59306;;DrugMatrix in vitro pharmacology data;774715;MICONAZOLE;8917;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;Ki;3529.0;=;nM;5.45
59306;;DrugMatrix in vitro pharmacology data;774715;METERGOLINE;21938;CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;IC50;0.442;=;nM;9.36
59306;;DrugMatrix in vitro pharmacology data;774715;METERGOLINE;21938;CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;Ki;0.281;=;nM;9.55
59306;;DrugMatrix in vitro pharmacology data;774715;LISURIDE;263558;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;IC50;5.095;=;nM;8.29
59306;;DrugMatrix in vitro pharmacology data;774715;LISURIDE;263558;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;3.242;=;nM;8.49
59306;;DrugMatrix in vitro pharmacology data;774715;LY-294002;157152;O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12;IC50;36707.0;=;nM;4.43
59306;;DrugMatrix in vitro pharmacology data;774715;LY-294002;157152;O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12;Ki;23359.0;=;nM;4.63
59306;;DrugMatrix in vitro pharmacology data;774715;MONTELUKAST;47447;CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1;IC50;6256.0;=;nM;5.2
59306;;DrugMatrix in vitro pharmacology data;774715;MONTELUKAST;47447;CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1;Ki;3981.0;=;nM;5.4
59306;;DrugMatrix in vitro pharmacology data;774715;N,N'-DIPHENYL-P-PHENYLENEDIAMINE;757396;c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1;IC50;142.0;=;nM;6.85
59306;;DrugMatrix in vitro pharmacology data;774715;N,N'-DIPHENYL-P-PHENYLENEDIAMINE;757396;c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1;Ki;90.0;=;nM;7.05
59306;;DrugMatrix in vitro pharmacology data;774715;METHAPYRILENE;835863;CN(C)CCN(Cc1cccs1)c1ccccn1;IC50;843.0;=;nM;6.07
59306;;DrugMatrix in vitro pharmacology data;774715;METHAPYRILENE;835863;CN(C)CCN(Cc1cccs1)c1ccccn1;Ki;537.0;=;nM;6.27
59306;;DrugMatrix in vitro pharmacology data;774715;LYSERGOL;1248989;CO[C@@H]1[C@@H](OC)[C@H](C)[C@@](O)(CC(=O)O)O[C@H]1[C@H](C)[C@H]1O[C@@]2(CC[C@@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@](C)(O)[C@H](C)C[C@@H]5C)C[C@@H]4O[C@@H]4C[C@H](OC)[C@@H](OC)[C@H](C)O4)O3)O2)C[C@H](O)[C@H]1C;IC50;33.0;=;nM;7.48
59306;;DrugMatrix in vitro pharmacology data;774715;LYSERGOL;1248989;CO[C@@H]1[C@@H](OC)[C@H](C)[C@@](O)(CC(=O)O)O[C@H]1[C@H](C)[C@H]1O[C@@]2(CC[C@@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@](C)(O)[C@H](C)C[C@@H]5C)C[C@@H]4O[C@@H]4C[C@H](OC)[C@@H](OC)[C@H](C)O4)O3)O2)C[C@H](O)[C@H]1C;Ki;21.0;=;nM;7.68
59306;;DrugMatrix in vitro pharmacology data;774715;MOSAPRIDE;93995;CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1;IC50;295.9;=;nM;6.53
59306;;DrugMatrix in vitro pharmacology data;774715;MOSAPRIDE;93995;CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1;Ki;188.3;=;nM;6.72
59306;;DrugMatrix in vitro pharmacology data;774715;LABETALOL;1785;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;IC50;3037.0;=;nM;5.52
59306;;DrugMatrix in vitro pharmacology data;774715;LABETALOL;1785;CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1;Ki;1933.0;=;nM;5.71
59306;;DrugMatrix in vitro pharmacology data;774715;MEPAZINE;396101;CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1;IC50;514.0;=;nM;6.29
59306;;DrugMatrix in vitro pharmacology data;774715;MEPAZINE;396101;CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1;Ki;327.0;=;nM;6.49
59306;;DrugMatrix in vitro pharmacology data;774715;METHYLERGONOVINE;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;IC50;1.505;=;nM;8.82
59306;;DrugMatrix in vitro pharmacology data;774715;METHYLERGONOVINE;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;0.958;=;nM;9.02
59306;;DrugMatrix in vitro pharmacology data;774715;LOPERAMIDE;62259;CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1;IC50;4105.0;=;nM;5.39
59306;;DrugMatrix in vitro pharmacology data;774715;LOPERAMIDE;62259;CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1;Ki;2613.0;=;nM;5.58
59306;;DrugMatrix in vitro pharmacology data;774715;MITOTANE;504310;Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1;IC50;4832.0;=;nM;5.32
59306;;DrugMatrix in vitro pharmacology data;774715;MITOTANE;504310;Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1;Ki;3075.0;=;nM;5.51
59306;;DrugMatrix in vitro pharmacology data;774715;LORATADINE;110803;CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1;IC50;245.0;=;nM;6.61
59306;;DrugMatrix in vitro pharmacology data;774715;LORATADINE;110803;CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1;Ki;156.0;=;nM;6.81
59306;;DrugMatrix in vitro pharmacology data;774715;U-78517F;230163;Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2;IC50;519.0;=;nM;6.29
59306;;DrugMatrix in vitro pharmacology data;774715;U-78517F;230163;Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2;Ki;330.0;=;nM;6.48
59306;;DrugMatrix in vitro pharmacology data;774715;TROGLITAZONE;666;Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2;IC50;1312.0;=;nM;5.88
59306;;DrugMatrix in vitro pharmacology data;774715;TROGLITAZONE;666;Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2;Ki;835.0;=;nM;6.08
59306;;DrugMatrix in vitro pharmacology data;774715;TRAZODONE;26401;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;IC50;107.0;=;nM;6.97
59306;;DrugMatrix in vitro pharmacology data;774715;TRAZODONE;26401;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;Ki;68.0;=;nM;7.17
59306;;DrugMatrix in vitro pharmacology data;774715;VERAPAMIL;1219;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;IC50;165.0;=;nM;6.78
59306;;DrugMatrix in vitro pharmacology data;774715;VERAPAMIL;1219;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;Ki;105.0;=;nM;6.98
59306;;DrugMatrix in vitro pharmacology data;774715;YOHIMBINE;15191;COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O;IC50;74.0;=;nM;7.13
59306;;DrugMatrix in vitro pharmacology data;774715;YOHIMBINE;15191;COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O;Ki;47.0;=;nM;7.33
59306;;DrugMatrix in vitro pharmacology data;774715;TRETINOIN;2208;CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1;IC50;358.0;=;nM;6.45
59306;;DrugMatrix in vitro pharmacology data;774715;TRETINOIN;2208;CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1;Ki;228.0;=;nM;6.64
59306;;DrugMatrix in vitro pharmacology data;774715;TIRILAZAD;1052744;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1;IC50;18507.0;=;nM;4.73
59306;;DrugMatrix in vitro pharmacology data;774715;TIRILAZAD;1052744;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1;Ki;11777.0;=;nM;4.93
59306;;DrugMatrix in vitro pharmacology data;774715;THIORIDAZINE;5970;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;IC50;129.0;=;nM;6.89
59306;;DrugMatrix in vitro pharmacology data;774715;THIORIDAZINE;5970;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;Ki;82.0;=;nM;7.09
59306;;DrugMatrix in vitro pharmacology data;774715;TAMOXIFEN;6968;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;IC50;2084.0;=;nM;5.68
59306;;DrugMatrix in vitro pharmacology data;774715;TAMOXIFEN;6968;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;Ki;1326.0;=;nM;5.88
59306;;DrugMatrix in vitro pharmacology data;774715;SULCONAZOLE;223819;Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;IC50;3020.0;=;nM;5.52
59306;;DrugMatrix in vitro pharmacology data;774715;SULCONAZOLE;223819;Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;Ki;1922.0;=;nM;5.72
59306;;DrugMatrix in vitro pharmacology data;774715;RISPERIDONE;7714;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;IC50;23.0;=;nM;7.64
59306;;DrugMatrix in vitro pharmacology data;774715;RISPERIDONE;7714;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;Ki;15.0;=;nM;7.82
59306;;DrugMatrix in vitro pharmacology data;774715;R-(+)-PROPRANOLOL;10099;CC(C)NC[C@@H](O)COc1cccc2ccccc12;IC50;438.0;=;nM;6.36
59306;;DrugMatrix in vitro pharmacology data;774715;R-(+)-PROPRANOLOL;10099;CC(C)NC[C@@H](O)COc1cccc2ccccc12;Ki;279.0;=;nM;6.55
59306;;DrugMatrix in vitro pharmacology data;774715;S-(-)-PROPRANOLOL;454176;CC(C)NC[C@H](O)COc1cccc2ccccc12;IC50;411.0;=;nM;6.39
59306;;DrugMatrix in vitro pharmacology data;774715;S-(-)-PROPRANOLOL;454176;CC(C)NC[C@H](O)COc1cccc2ccccc12;Ki;262.0;=;nM;6.58
59306;;DrugMatrix in vitro pharmacology data;774715;SERTRALINE;53616;CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21;IC50;3393.5;=;nM;5.47
59306;;DrugMatrix in vitro pharmacology data;774715;SERTRALINE;53616;CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21;Ki;2159.5;=;nM;5.67
59306;;DrugMatrix in vitro pharmacology data;774715;SULOCTIDIL;418491;CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1;IC50;939.0;=;nM;6.03
59306;;DrugMatrix in vitro pharmacology data;774715;SULOCTIDIL;418491;CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1;Ki;597.5;=;nM;6.22
59306;;DrugMatrix in vitro pharmacology data;774715;TOLNAFTATE;134040;Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1;IC50;2007.0;=;nM;5.7
59306;;DrugMatrix in vitro pharmacology data;774715;TOLNAFTATE;134040;Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1;Ki;1277.0;=;nM;5.89
59306;;DrugMatrix in vitro pharmacology data;774715;TERFENADINE;19569;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;IC50;48.0;=;nM;7.32
59306;;DrugMatrix in vitro pharmacology data;774715;TERFENADINE;19569;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;Ki;30.0;=;nM;7.52
59306;;DrugMatrix in vitro pharmacology data;774715;RALOXIFENE;6914;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;IC50;355.0;=;nM;6.45
59306;;DrugMatrix in vitro pharmacology data;774715;RALOXIFENE;6914;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;Ki;226.0;=;nM;6.65
59484;10.1016/j.ejmech.2011.06.023;Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor.;774875;WAY-100635;548957;COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1.Cl.Cl.Cl;Ki;24.0;=;nM;7.62
59484;10.1016/j.ejmech.2011.06.023;Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor.;774875;6b;1249730;COc1ccccc1N1CCN(CCN(C(=O)C23C4C5C2C2C3C4C52CF)c2ccccn2)CC1;Ki;99.0;=;nM;7.0
59484;10.1016/j.ejmech.2011.06.023;Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor.;774875;6c;1249731;COc1ccccc1N1CCN(CCN(C(=O)C23CCC(CF)(CC2)CC3)c2ccccn2)CC1;Ki;79.0;=;nM;7.1
59484;10.1016/j.ejmech.2011.06.023;Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor.;774875;6d;1249732;COc1ccccc1N1CCN(CCN(C(=O)C23CCC(CF)(CC2)C3)c2ccccn2)CC1;Ki;88.0;=;nM;7.06
60282;10.1016/j.bmcl.2011.09.086;Usabamycins A-C: new anthramycin-type analogues from a marine-derived actinomycete.;790999;1;1266133;CC/C=C1\C[C@H]2CNc3c(OC)cccc3C(=O)N2C1;IC50;12400.0;=;nM;4.91
60282;10.1016/j.bmcl.2011.09.086;Usabamycins A-C: new anthramycin-type analogues from a marine-derived actinomycete.;790999;2;1266134;C/C=C1\C[C@H]2CNc3c(OC)cccc3C(=O)N2C1;IC50;8450.0;=;nM;5.07
60282;10.1016/j.bmcl.2011.09.086;Usabamycins A-C: new anthramycin-type analogues from a marine-derived actinomycete.;790999;3;1266135;CC/C=C1\C[C@H]2CNc3ccccc3C(=O)N2C1;IC50;8240.0;=;nM;5.08
60282;10.1016/j.bmcl.2011.09.086;Usabamycins A-C: new anthramycin-type analogues from a marine-derived actinomycete.;790999;1;1266133;CC/C=C1\C[C@H]2CNc3c(OC)cccc3C(=O)N2C1;Ki;7890.0;=;nM;5.1
60282;10.1016/j.bmcl.2011.09.086;Usabamycins A-C: new anthramycin-type analogues from a marine-derived actinomycete.;790999;2;1266134;C/C=C1\C[C@H]2CNc3c(OC)cccc3C(=O)N2C1;Ki;5380.0;=;nM;5.27
60282;10.1016/j.bmcl.2011.09.086;Usabamycins A-C: new anthramycin-type analogues from a marine-derived actinomycete.;790999;3;1266135;CC/C=C1\C[C@H]2CNc3ccccc3C(=O)N2C1;Ki;5240.0;=;nM;5.28
60677;10.1016/j.bmcl.2011.11.050;Novel brain penetrant benzofuropiperidine 5-HT₆ receptor antagonists.;796328;2, ent-1;1273081;O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3;IC50;1500.0;=;nM;5.82
61114;10.1016/j.bmcl.2011.12.026;Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT₆ receptor antagonist showing activity in rat social recognition test.;804662;15k, enantiomer 1;1278902;COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1.Cl;Ki;6200.0;=;nM;5.21
61736;10.1016/j.bmcl.2012.03.032;4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators.;816617;1;1338240;c1ccc(-n2cc(-c3ccnc4ccccc34)cn2)cc1;IC50;1600.0;=;nM;5.8
61824;10.1021/ml200206z;Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.;815599;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;0.86;=;nM;9.07
61824;10.1021/ml200206z;Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.;815599;11a;1337551;CCOc1ccccc1[C@H]1C[C@@H]1CN.Cl;EC50;331.0;=;nM;6.48
61824;10.1021/ml200206z;Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.;815599;11b;1337552;CCCOc1ccccc1[C@H]1C[C@@H]1CN.Cl;EC50;304.0;=;nM;6.52
61824;10.1021/ml200206z;Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.;815599;11h;1337558;Cl.NC[C@H]1C[C@@H]1c1ccccc1OCc1ccccc1;EC50;1080.0;=;nM;5.97
61824;10.1021/ml200206z;Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.;815599;8;1338735;NC[C@H]1C[C@@H]1c1cc(F)ccc1OCC1CC1;EC50;289.0;=;nM;6.54
61935;10.1021/jm201690h;Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.;818801;9;299508;C[C@@H]1CCCN1CCc1cc2cc(C(=O)c3ccc(F)cc3)ccc2o1;Ki;3152.0;=;nM;5.5
65622;10.1016/j.bmcl.2012.02.023;Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents.;856029;44r;1425243;COc1ccc(N2CCN(CC[C@@H](OC(N)=O)c3ccccc3)CC2)cc1;Ki;164.0;=;nM;6.79
65791;10.1021/jm300338m;Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.;858220;Sorafenib;276734;CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1;Ki;56.0;=;nM;7.25
65818;10.1016/j.bmcl.2012.05.119;Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors.;859969;3i;1427780;O=C(C1CCCCC1)N(CCN1CC=C(c2ccccc2)CC1)c1ccccn1;Ki;105.0;=;nM;6.98
65818;10.1016/j.bmcl.2012.05.119;Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors.;859969;3e;1427776;O=C(C1CCCCC1)N(CCN1CCN(c2ccccc2)CC1)c1ccccn1;Ki;327.0;=;nM;6.49
65855;10.1021/jm300603y;Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.;859672;35;1428571;Clc1cccc(C2CCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;Ki;0.6;=;nM;9.22
65855;10.1021/jm300603y;Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.;859672;19;1428560;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;0.6;=;nM;9.22
65935;10.1016/j.bmcl.2012.05.036;Antagonists of 5-HT₆ receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-Synthesis and 'structure-activity' relationship.;863339;5, AVN322;1431687;CNc1nn2c3c(cnc2c1S(=O)(=O)c1ccccc1)CN(C)CC3;IC50;6160.0;=;nM;5.21
65948;10.1021/jm3007323;Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).;861895;28, S1RA, E-52862;1429542;Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1;Ki;328.0;=;nM;6.48
65948;10.1021/jm3007323;Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).;861896;28, S1RA, E-52862;1429542;Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1;IC50;4700.0;=;nM;5.33
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;4u;1441993;CCCN1CCC(COc2nc3ccccc3c3ncccc23)CC1;Ki;627.0;=;nM;6.2
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;11d;1441988;Fc1cccc2c1nc(OCC1CCN(CCCc3ccc(I)cc3)CC1)c1cccnc12;Ki;340.0;=;nM;6.47
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;11a;1441991;CCCN1CCC(COc2nc3c(I)cccc3c3ccccc23)CC1;Ki;162.0;=;nM;6.79
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;4v;1441992;CCCN1CCC(COc2nc3c(F)cccc3c3ncccc23)CC1;Ki;136.0;=;nM;6.87
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;4l;1442011;CCCN1CCC(COc2nc3c(Cl)cccc3c3ccccc23)CC1;Ki;98.0;=;nM;7.01
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;4m;1442012;CCCN1CCC(COc2nc3c(F)cccc3c3ccccc23)CC1;Ki;40.4;=;nM;7.39
66679;10.1021/jm300943r;Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.;878525;4k;1442010;CCCN1CCC(COc2nc3c(OC)cccc3c3ccccc23)CC1;Ki;29.3;=;nM;7.53
66793;10.1021/ml3002715;From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.;880419;15;1443156;c1ccc(OCc2cc(OC[C@@H]3CCCN3)no2)cc1;Ki;5097.0;=;nM;5.29
66880;10.1016/j.bmcl.2012.08.046;A σ(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).;884325;31;1445441;COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC;Ki;2254.0;=;nM;5.65
66880;10.1016/j.bmcl.2012.08.046;A σ(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).;884325;29;1445439;COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1;Ki;2971.0;=;nM;5.53
66880;10.1016/j.bmcl.2012.08.046;A σ(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).;884325;28;1445464;COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53;Ki;855.0;=;nM;6.07
66923;10.1016/j.bmc.2012.09.044;Synthesis of N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamides as new selective ligands for sigma receptors.;884852;KSCM-5;1444984;Cc1c(C(=O)N(CCCN2CCCCC2)c2ccccc2)oc2ccccc12;Ki;936.0;=;nM;6.03
66923;10.1016/j.bmc.2012.09.044;Synthesis of N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamides as new selective ligands for sigma receptors.;884852;KSCM-11;1444983;COc1ccc2c(C)c(C(=O)N(CCCN3CCCCC3)c3ccccc3)oc2c1;Ki;204.0;=;nM;6.69
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938244;15;1517741;COC(OC)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;IC50;13.0;=;nM;7.89
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938244;14;1517740;CN(C)CCCNC(=O)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;IC50;37.0;=;nM;7.43
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938244;9;1517739;CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;IC50;22.0;=;nM;7.66
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938245;Cabergoline;675038;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;EC50;13.0;=;nM;7.89
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938245;8;13099;CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;EC50;16.0;=;nM;7.8
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938245;1;1517738;C=CCN1C[C@H](C(=O)N(CCCN2CCOCC2)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;EC50;13.0;=;nM;7.89
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938246;15;1517741;COC(OC)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;Ki;0.54;=;nM;9.27
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938246;14;1517740;CN(C)CCCNC(=O)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;Ki;0.97;=;nM;9.01
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938246;9;1517739;CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;Ki;1.0;=;nM;9.0
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938246;8;13099;CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;2.2;=;nM;8.66
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938246;1;1517738;C=CCN1C[C@H](C(=O)N(CCCN2CCOCC2)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;Ki;7.1;=;nM;8.15
72035;10.1021/ml3003814;Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.;938246;Cabergoline;675038;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;Ki;1.4;=;nM;8.85
72177;10.1021/jm3017078;The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.;941693;12a, (3S,4S)-12a;1516761;COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2Cc2ccccc2)C(C)C)ccc1OC.Cl;IC50;1000.0;=;nM;6.0
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944013;3;1526778;COc1ccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCC3)c(C(F)(F)F)c1;Ki;14.0;=;nM;7.85
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944013;2;1526779;c1cc2c3c(c1)[C@@H]1CNCC[C@@H]1N3CCCS2;Ki;15.0;=;nM;7.82
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944013;1;301194;C[C@H]1CNCCc2ccc(Cl)cc21;Ki;1.3;=;nM;8.89
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;43;1527179;CCc1ccc(Cl)c2c1[C@H]1CNC[C@@H]1NC2=O.Cl;EC50;2330.0;=;nM;5.63
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;50;1526781;Cc1cc(C(C)C)cc2c1C(=O)N[C@H]1CNC[C@H]21.Cl;EC50;706.0;=;nM;6.15
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;40;1527176;Cc1cc(Cl)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;EC50;523.0;=;nM;6.28
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;44;1527180;Cl.O=C1N[C@H]2CNC[C@@H]2c2ccc(Cl)c(Cl)c21;EC50;414.0;=;nM;6.38
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;52;1527168;CCc1cc2c(c(C(F)(F)F)c1)C(=O)N(C)[C@H]1CNC[C@H]21.Cl;EC50;268.0;=;nM;6.57
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;47;1527183;Cc1cc(C)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;EC50;207.0;=;nM;6.68
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;51;1526782;CCc1cc2c(c(C(F)(F)F)c1)C(=O)N[C@H]1CNC[C@H]21.Cl;EC50;101.0;=;nM;7.0
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;38;1527174;Cc1cccc2c1C(=O)N[C@H]1CNC[C@H]21.Cl;EC50;94.0;=;nM;7.03
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;36;1527172;CN1C(=O)c2c(cccc2C(F)(F)F)[C@H]2CNC[C@@H]21.Cl;EC50;32.0;=;nM;7.5
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;37;1527173;Cl.O=C1N[C@H]2CNC[C@@H]2c2cccc(Cl)c21;EC50;31.0;=;nM;7.51
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944531;35, enantiomer;1527170;Cl.O=C1N[C@H]2CNC[C@@H]2c2cccc(C(F)(F)F)c21;EC50;9.9;=;nM;8.0
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;34;1527171;Cl.O=C1N[C@@H]2CNC[C@H]2c2cccc(C(F)(F)F)c21;Ki;6244.0;=;nM;5.21
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;39;1527175;Cl.O=C1N[C@H]2CNC[C@@H]2c2ccccc21;Ki;5812.0;=;nM;5.24
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;(+/-)-13;1527169;Cl.O=C1N[C@H]2CNC[C@H]2c2cccc(C(F)(F)F)c21;Ki;2373.0;=;nM;5.62
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;46;1527182;CCc1cc(Cl)c2c(c1)[C@H]1CNC[C@@H]1N(C)C2=O.Cl;Ki;1717.0;=;nM;5.76
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;41;1527177;CCc1cc(Cl)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;Ki;905.0;=;nM;6.04
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;42;1527178;CCCc1cc(Cl)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;Ki;776.0;=;nM;6.11
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;50;1526781;Cc1cc(C(C)C)cc2c1C(=O)N[C@H]1CNC[C@H]21.Cl;Ki;535.0;=;nM;6.27
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;40;1527176;Cc1cc(Cl)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;Ki;478.0;=;nM;6.32
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;47;1527183;Cc1cc(C)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;Ki;191.0;=;nM;6.72
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;48;1527184;CCc1cc(C)c2c(c1)[C@H]1CNC[C@@H]1NC2=O.Cl;Ki;188.0;=;nM;6.73
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;49;1526780;Cc1cc(C2CC2)cc2c1C(=O)N[C@H]1CNC[C@H]21.Cl;Ki;177.0;=;nM;6.75
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;52;1527168;CCc1cc2c(c(C(F)(F)F)c1)C(=O)N(C)[C@H]1CNC[C@H]21.Cl;Ki;140.0;=;nM;6.85
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;51;1526782;CCc1cc2c(c(C(F)(F)F)c1)C(=O)N[C@H]1CNC[C@H]21.Cl;Ki;87.0;=;nM;7.06
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;43;1527179;CCc1ccc(Cl)c2c1[C@H]1CNC[C@@H]1NC2=O.Cl;Ki;79.0;=;nM;7.1
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;(+/-)-14;1527170;Cl.O=C1N[C@H]2CNC[C@@H]2c2cccc(C(F)(F)F)c21;Ki;73.0;=;nM;7.14
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;44;1527180;Cl.O=C1N[C@H]2CNC[C@@H]2c2ccc(Cl)c(Cl)c21;Ki;48.0;=;nM;7.32
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;37;1527173;Cl.O=C1N[C@H]2CNC[C@@H]2c2cccc(Cl)c21;Ki;40.0;=;nM;7.4
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;35, enantiomer;1527170;Cl.O=C1N[C@H]2CNC[C@@H]2c2cccc(C(F)(F)F)c21;Ki;33.0;=;nM;7.48
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;36;1527172;CN1C(=O)c2c(cccc2C(F)(F)F)[C@H]2CNC[C@@H]21.Cl;Ki;24.0;=;nM;7.62
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;38;1527174;Cc1cccc2c1C(=O)N[C@H]1CNC[C@H]21.Cl;Ki;23.0;=;nM;7.64
72339;10.1016/j.bmcl.2012.10.091;Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.;944534;45;1527181;Cc1ccc2c(c1Cl)C(=O)N[C@H]1CNC[C@H]21.Cl;Ki;4.0;=;nM;8.4
72532;10.1016/j.bmcl.2013.01.009;Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.;946217;24;1524636;CC(C)c1cccc(-c2c(-c3ccc4nn(C)cc4c3)nsc2NC(=O)[C@@H]2C[C@H]2C)n1.Cl;Ki;3160.0;=;nM;5.5
72714;10.1021/jm400181k;Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.;947842;32c;1528032;CC(C)CCOc1ccc2c(c1)[C@H]1OCCC[C@H]1[C@@H](C1CCOCC1)N2;Ki;5300.0;=;nM;5.28
73872;10.1016/j.bmcl.2013.01.025;Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.;965432;ketanserin;3683;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;Ki;180.0;=;nM;6.75
73872;10.1016/j.bmcl.2013.01.025;Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.;965432;ketanserin;3683;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;IC50;290.0;=;nM;6.54
73877;10.1016/j.ejmech.2013.01.044;Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.;966038;(+/-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;Ki;2.0;=;nM;8.7
73877;10.1016/j.ejmech.2013.01.044;Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.;966038;(+/-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;IC50;4.0;=;nM;8.4
73877;10.1016/j.ejmech.2013.01.044;Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.;966242;10m;1565932;COc1ccccc1N1CCN(CCCCCN2Cc3c(Cl)nc4ccccc4c3C2=O)CC1;IC50;63.0;=;nM;7.2
73877;10.1016/j.ejmech.2013.01.044;Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.;966242;10k;1565930;COc1ccccc1N1CCN(CCCCCN2Cc3ccc4ccccc4c3C2=O)CC1;IC50;43.0;=;nM;7.37
73887;10.1016/j.ejmech.2013.02.020;Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.;963829;6n;1566833;Cl.c1ccc(Cc2nc3c(c(Nc4ccccc4)n2)CCNCC3)cc1;IC50;89.0;=;nM;7.05
73887;10.1016/j.ejmech.2013.02.020;Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.;963829;6p;1566835;Cl.Clc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1;IC50;32.0;=;nM;7.5
73892;10.1016/j.bmc.2013.03.016;Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.;964170;DOI;436;COc1cc(CC(C)N)c(OC)cc1I;IC50;3.2;=;nM;8.49
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;964932;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.1;=;nM;8.96
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;964932;18, 5-MeO-DALT;1565114;C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12;EC50;5.5;=;nM;8.26
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;964932;17, AMT, alpha-MT;44615;CC(N)Cc1c[nH]c2ccccc12;EC50;75.8;=;nM;7.12
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;964932;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.072;=;nM;8.97
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;964932;18, 5-MeO-DALT;1565114;C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12;EC50;5.495;=;nM;8.26
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;964932;17, AMT, alpha-MT;44615;CC(N)Cc1c[nH]c2ccccc12;EC50;75.86;=;nM;7.12
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;965133;18, 5-MeO-DALT;1565114;C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12;Ki;34.0;=;nM;7.47
73897;10.1016/j.bmcl.2013.03.066;An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.;965133;18, 5-MeO-DALT;1565114;C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12;Ki;31.62;=;nM;7.5
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968328;42;1568393;COc1ccc2c(c1)C(=O)N1CCNC[C@H]1C2;EC50;56.0;=;nM;7.25
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968328;41;1568392;O=C1c2cc(Cl)ccc2C[C@@H]2CNCCN12;EC50;9.0;=;nM;8.05
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968328;39;1568413;CCc1ccc2c(c1)C(=O)N1CCNC[C@H]1C2;EC50;28.0;=;nM;7.55
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968328;38;1568412;Cc1ccc2c(c1)C(=O)N1CCNC[C@H]1C2;EC50;12.0;=;nM;7.92
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968359;60;1568429;COc1c(C)ccc2c1C[C@@H]1CNCCN1C2=O;EC50;827.0;=;nM;6.08
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968359;58;1568427;CCc1cc(C)c2c(c1)C[C@@H]1CNCCN1C2=O;EC50;2366.0;=;nM;5.63
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968359;30;1568404;C[C@@H]1c2ccccc2C(=O)N2CCNC[C@@H]12;EC50;271.0;=;nM;6.57
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968359;29;1568403;C[C@@H]1CNC[C@H]2Cc3ccccc3C(=O)N21;EC50;37.0;=;nM;7.43
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;21;1568430;O=C1c2ccc3c(c2C[C@@H]2CNCCN12)OCCC3;Ki;21.0;=;nM;7.68
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;60;1568429;COc1c(C)ccc2c1C[C@@H]1CNCCN1C2=O;Ki;217.0;=;nM;6.66
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;59;1568428;COc1ccc(C)c2c1C[C@@H]1CNCCN1C2=O;Ki;17.0;=;nM;7.77
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;58;1568427;CCc1cc(C)c2c(c1)C[C@@H]1CNCCN1C2=O;Ki;40.0;=;nM;7.4
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;57;1568426;Cc1cc(C)c2c(c1)C[C@@H]1CNCCN1C2=O;Ki;21.0;=;nM;7.68
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;56;1568425;CCCOc1cccc2c1C[C@@H]1CNCCN1C2=O;Ki;129.0;=;nM;6.89
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;55;1568424;CCOc1cccc2c1C[C@@H]1CNCCN1C2=O;Ki;63.0;=;nM;7.2
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;54;1568423;COc1cccc2c1C[C@@H]1CNCCN1C2=O;Ki;78.0;=;nM;7.11
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;53;1568422;O=C1c2cccc(C(F)(F)F)c2C[C@@H]2CNCCN12;Ki;5513.0;=;nM;5.26
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;52;1568421;CCc1cccc2c1C[C@@H]1CNCCN1C2=O;Ki;930.0;=;nM;6.03
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;51;1568420;Cc1cccc2c1C[C@@H]1CNCCN1C2=O;Ki;118.0;=;nM;6.93
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;50;1568419;N#Cc1ccc2c(c1)C[C@@H]1CNCCN1C2=O;Ki;5816.0;=;nM;5.24
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;49;1568418;COc1ccc2c(c1)C[C@@H]1CNCCN1C2=O;Ki;196.0;=;nM;6.71
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;48;1568417;O=C1c2ccc(Cl)cc2C[C@@H]2CNCCN12;Ki;127.0;=;nM;6.9
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;47;1568416;O=C1c2ccc(C(F)(F)F)cc2C[C@@H]2CNCCN12;Ki;778.0;=;nM;6.11
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;46;1568415;CCCc1ccc2c(c1)C[C@@H]1CNCCN1C2=O;Ki;340.0;=;nM;6.47
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;45;1568414;CCc1ccc2c(c1)C[C@@H]1CNCCN1C2=O;Ki;227.0;=;nM;6.64
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;44;1568395;Cc1ccc2c(c1)C[C@@H]1CNCCN1C2=O;Ki;105.0;=;nM;6.98
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;42;1568393;COc1ccc2c(c1)C(=O)N1CCNC[C@H]1C2;Ki;115.0;=;nM;6.94
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;41;1568392;O=C1c2cc(Cl)ccc2C[C@@H]2CNCCN12;Ki;54.0;=;nM;7.27
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;40;1568431;O=C1c2cc(C(F)(F)F)ccc2C[C@@H]2CNCCN12;Ki;340.0;=;nM;6.47
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;39;1568413;CCc1ccc2c(c1)C(=O)N1CCNC[C@H]1C2;Ki;47.0;=;nM;7.33
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;38;1568412;Cc1ccc2c(c1)C(=O)N1CCNC[C@H]1C2;Ki;32.0;=;nM;7.5
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;37;1568411;N#Cc1cccc2c1C(=O)N1CCNC[C@H]1C2;Ki;510.0;=;nM;6.29
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;36;1568410;COc1cccc2c1C(=O)N1CCNC[C@H]1C2;Ki;139.0;=;nM;6.86
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;35;1568409;O=C1c2c(Cl)cccc2C[C@@H]2CNCCN12;Ki;8.0;=;nM;8.1
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;34;1568408;O=C1c2c(cccc2C(F)(F)F)C[C@@H]2CNCCN12;Ki;47.0;=;nM;7.33
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;33;1568407;O=C1c2c(cccc2C2CC2)C[C@@H]2CNCCN12;Ki;6.0;=;nM;8.22
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;32;1568406;CCc1cccc2c1C(=O)N1CCNC[C@H]1C2;Ki;2.0;=;nM;8.7
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;31;1568405;Cc1cccc2c1C(=O)N1CCNC[C@H]1C2;Ki;13.0;=;nM;7.89
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;30;1568404;C[C@@H]1c2ccccc2C(=O)N2CCNC[C@@H]12;Ki;402.0;=;nM;6.4
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;29;1568403;C[C@@H]1CNC[C@H]2Cc3ccccc3C(=O)N21;Ki;39.0;=;nM;7.41
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;28;1568402;C[C@H]1CNC[C@H]2Cc3ccccc3C(=O)N21;Ki;1637.0;=;nM;5.79
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;27;1568401;C[C@H]1CN2C(=O)c3ccccc3C[C@@H]2CN1;Ki;681.0;=;nM;6.17
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;26;1568400;C[C@@H]1CN2C(=O)c3ccccc3C[C@@H]2CN1;Ki;1340.0;=;nM;5.87
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;23;1568399;CN1CCN2C(=O)c3ccccc3C[C@@H]2C1;Ki;488.0;=;nM;6.31
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;25;1568398;C[C@@]12CNCCN1C(=O)c1ccccc1C2;Ki;3445.0;=;nM;5.46
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;24;1568397;O=C1c2ccccc2C[C@H]2CNCCN12;Ki;5710.0;=;nM;5.24
74039;10.1016/j.bmcl.2013.04.061;Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.;968360;22;1568396;O=C1c2ccccc2C[C@@H]2CNCCN12;Ki;213.0;=;nM;6.67
74159;10.1016/j.bmcl.2013.04.082;Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.;969188;7;468055;O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21;Ki;100.0;=;nM;7.0
74159;10.1016/j.bmcl.2013.04.082;Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.;969188;6;468054;CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21;Ki;630.0;=;nM;6.2
74159;10.1016/j.bmcl.2013.04.082;Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.;969188;5;401738;O=C(Cc1ccc2ccccc2c1)N1c2ccccc2Sc2ccccc21;Ki;2000.0;=;nM;5.7
74159;10.1016/j.bmcl.2013.04.082;Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.;969188;3;401717;CC(C(=O)N1c2ccccc2Sc2ccccc21)c1ccccc1;Ki;170.0;=;nM;6.77
74212;10.1016/j.bmcl.2013.05.018;Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.;971552;Propulsid;557741;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;Ki;39.81;=;nM;7.4
74511;10.1016/j.bmc.2013.05.050;Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.;977154;CUMI-101;1574376;COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1;Ki;73.6;=;nM;7.13
74511;10.1016/j.bmc.2013.05.050;Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.;977154;2, FECUMI-101;1574375;Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O;Ki;300.0;=;nM;6.52
74577;10.1016/j.bmcl.2013.06.057;Selective orexin receptor antagonists.;977026;6, SB-408124;758349;Cc1cc(NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2n1;Ki;320.0;=;nM;6.5
74896;10.1016/j.bmcl.2013.07.045;Investigation of an F-18 oxytocin receptor selective ligand via PET imaging.;981506;1;1580600;Cl.O=C(Cc1ccc(OC2CCNCC2)cc1OCCF)N1CCC(N2C(=O)CCc3ccccc32)CC1;Ki;500.0;=;nM;6.3
75009;10.1016/j.bmc.2013.07.045;N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.;985414;9i;1584114;COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC;Ki;1965.0;=;nM;5.71
75009;10.1016/j.bmc.2013.07.045;N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.;985414;9f;1058618;Fc1cccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)c1;Ki;6983.0;=;nM;5.16
75009;10.1016/j.bmc.2013.07.045;N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.;985414;14f;1058620;CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41;Ki;6086.0;=;nM;5.22
75009;10.1016/j.bmc.2013.07.045;N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.;985414;14e;1584121;CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41;Ki;2711.0;=;nM;5.57
75138;10.1016/j.bmcl.2013.08.072;2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.;988334;4, A6CDQ;1585706;Cl.NC1=Nc2ccc(Cl)cc2CN1;Ki;562.34;=;nM;6.25
75138;10.1016/j.bmcl.2013.08.072;2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.;988334;4, A6CDQ;1585706;Cl.NC1=Nc2ccc(Cl)cc2CN1;Ki;565.0;=;nM;6.25
75274;10.1021/ml400312j;Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.;991513;A;1588135;Cc1ccc2nc(C(F)(F)F)cc(N3CCNCC3)c2c1;Ki;407.0;=;nM;6.39
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3z;1588787;C/N=C1/N/C(=C/c2c[nH]c3ccccc23)C(=O)N1C;Ki;5055.0;=;nM;5.3
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3ee;445543;C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3ccccc23)N1C;Ki;4554.0;=;nM;5.34
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3u;425187;CN1C(=N)N(C)/C(=C/c2c[nH]c3ccccc23)C1=O;Ki;4449.0;=;nM;5.35
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;5d;1354460;O=C1NC(=S)N/C1=C\c1c[nH]c2cc(Br)ccc12;Ki;2714.0;=;nM;5.57
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3x;464752;CN1C(=N)N(C)/C(=C/c2c[nH]c3cc(Br)ccc23)C1=O;Ki;2671.0;=;nM;5.57
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3hh;1354189;C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3cc(Br)ccc23)N1C;Ki;2468.0;=;nM;5.61
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;5c;1354459;O=C1NC(=S)N/C1=C\c1c[nH]c2ccc(Br)cc12;Ki;1676.0;=;nM;5.78
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3gg;1354188;C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3ccc(Br)cc23)N1C;Ki;1620.0;=;nM;5.79
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3j;1354170;CN1C(=N)NC(=O)/C1=C\c1c[nH]c2c(Br)cccc12;Ki;1422.0;=;nM;5.85
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3i;1354169;CN1C(=N)NC(=O)/C1=C\c1c[nH]c2cc(Br)ccc12;Ki;1378.0;=;nM;5.86
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;6c;1354463;CSC1=NC(=O)/C(=C/c2c[nH]c3ccc(Br)cc23)N1;Ki;1346.0;=;nM;5.87
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3k;464750;CN1C(=N)N/C(=C/c2c[nH]c3ccccc23)C1=O;Ki;1284.0;=;nM;5.89
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3cc;1588790;C/N=C1/N/C(=C/c2c[nH]c3cc(Br)ccc23)C(=O)N1C;Ki;1274.0;=;nM;5.89
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3w;650257;CN1C(=N)N(C)/C(=C/c2c[nH]c3ccc(Br)cc23)C1=O;Ki;1248.0;=;nM;5.9
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;6d;1354464;CSC1=NC(=O)/C(=C/c2c[nH]c3cc(Br)ccc23)N1;Ki;1136.0;=;nM;5.95
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;6e;1354465;CSC1=NC(=O)/C(=C/c2c[nH]c3c(Br)cccc23)N1;Ki;993.0;=;nM;6.0
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3ii;1354190;C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3c(Br)cccc23)N1C;Ki;965.0;=;nM;6.01
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3f;650254;CN1C(=N)NC(=O)/C1=C\c1c[nH]c2ccccc12;Ki;964.0;=;nM;6.02
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3ff;1354187;C/N=C1\N(C)C(=O)/C(=C\c2c[nH]c3cccc(Br)c23)N1C;Ki;897.0;=;nM;6.05
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3r;1354177;C/N=C1\NC(=O)/C(=C\c2c[nH]c3ccc(Br)cc23)N1C;Ki;883.0;=;nM;6.05
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3h;650809;CN1C(=N)NC(=O)/C1=C\c1c[nH]c2ccc(Br)cc12;Ki;852.0;=;nM;6.07
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3dd;1588791;C/N=C1/N/C(=C/c2c[nH]c3c(Br)cccc23)C(=O)N1C;Ki;839.0;=;nM;6.08
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3g;1354168;CN1C(=N)NC(=O)/C1=C\c1c[nH]c2cccc(Br)c12;Ki;784.0;=;nM;6.11
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;6b;1354462;CSC1=NC(=O)/C(=C/c2c[nH]c3cccc(Br)c23)N1;Ki;780.0;=;nM;6.11
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3aa;1588788;C/N=C1/N/C(=C/c2c[nH]c3cccc(Br)c23)C(=O)N1C;Ki;774.0;=;nM;6.11
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3p;445542;C/N=C1\NC(=O)/C(=C\c2c[nH]c3ccccc23)N1C;Ki;716.0;=;nM;6.14
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3t;1354179;C/N=C1\NC(=O)/C(=C\c2c[nH]c3c(Br)cccc23)N1C;Ki;661.0;=;nM;6.18
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3o;1588799;CN1C(=N)N/C(=C/c2c[nH]c3c(Br)cccc23)C1=O;Ki;593.0;=;nM;6.23
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3v;1354180;CN1C(=N)N(C)/C(=C/c2c[nH]c3cccc(Br)c23)C1=O;Ki;589.0;=;nM;6.23
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3bb;1588789;C/N=C1/N/C(=C/c2c[nH]c3ccc(Br)cc23)C(=O)N1C;Ki;520.0;=;nM;6.28
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3s;1354178;C/N=C1\NC(=O)/C(=C\c2c[nH]c3cc(Br)ccc23)N1C;Ki;489.0;=;nM;6.31
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3e;1588796;N=C1NC(=O)/C(=C\c2c[nH]c3c(Br)cccc23)N1;Ki;457.0;=;nM;6.34
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3b;1588793;N=C1NC(=O)/C(=C\c2c[nH]c3cccc(Br)c23)N1;Ki;447.0;=;nM;6.35
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;5b;1354458;O=C1NC(=S)N/C1=C\c1c[nH]c2cccc(Br)c12;Ki;369.0;=;nM;6.43
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;7e;1354470;C/N=C1\NC(=O)/C(=C/c2c[nH]c3c(Br)cccc23)N1;Ki;353.0;=;nM;6.45
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3y;1354181;CN1C(=N)N(C)/C(=C/c2c[nH]c3c(Br)cccc23)C1=O;Ki;349.0;=;nM;6.46
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;7a;1354466;C/N=C1\NC(=O)/C(=C/c2c[nH]c3ccccc23)N1;Ki;287.0;=;nM;6.54
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3d;1588795;N=C1NC(=O)/C(=C\c2c[nH]c3cc(Br)ccc23)N1;Ki;269.0;=;nM;6.57
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3a;1588792;N=C1NC(=O)/C(=C\c2c[nH]c3ccccc23)N1;Ki;232.0;=;nM;6.63
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3l;1588797;CN1C(=N)N/C(=C/c2c[nH]c3cccc(Br)c23)C1=O;Ki;228.0;=;nM;6.64
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3n;464751;CN1C(=N)N/C(=C/c2c[nH]c3cc(Br)ccc23)C1=O;Ki;190.0;=;nM;6.72
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;7d;1354469;C/N=C1\NC(=O)/C(=C/c2c[nH]c3cc(Br)ccc23)N1;Ki;154.0;=;nM;6.81
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3q;1354176;C/N=C1\NC(=O)/C(=C\c2c[nH]c3cccc(Br)c23)N1C;Ki;99.0;=;nM;7.0
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3m;1588798;CN1C(=N)N/C(=C/c2c[nH]c3ccc(Br)cc23)C1=O;Ki;94.0;=;nM;7.03
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;7c;1354468;C/N=C1\NC(=O)/C(=C/c2c[nH]c3ccc(Br)cc23)N1;Ki;93.0;=;nM;7.03
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;3c;1588794;N=C1NC(=O)/C(=C\c2c[nH]c3ccc(Br)cc23)N1;Ki;51.0;=;nM;7.29
75355;10.1016/j.bmc.2013.09.011;In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.;989094;7b;1354467;C/N=C1\NC(=O)/C(=C/c2c[nH]c3cccc(Br)c23)N1;Ki;50.0;=;nM;7.3
75966;10.1021/jm4012033;Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.;1276674;11;1605661;Cc1csc(C(C)(O)c2nnc(NC(=O)Cc3c(F)cccc3F)s2)n1;IC50;64000.0;=;nM;4.19
76160;10.1016/j.bmc.2013.08.061;Design of fluorinated 5-HT(4)R antagonists: influence of the basicity and lipophilicity toward the 5-HT(4)R binding affinities.;1278512;6e;1607565;Fc1cccc2c1nc(OCC1CCN(CCCC(F)(F)F)CC1)c1cccnc12;Ki;190.0;=;nM;6.72
76160;10.1016/j.bmc.2013.08.061;Design of fluorinated 5-HT(4)R antagonists: influence of the basicity and lipophilicity toward the 5-HT(4)R binding affinities.;1278512;6d;1607564;Fc1cccc2c1nc(OCC1CCN(CCC(F)(F)F)CC1)c1cccnc12;Ki;230.0;=;nM;6.64
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279264;10;1607133;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1ccccc1-2;IC50;19.6;=;nM;7.71
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279264;4;1607127;NC(N)=NC(=O)c1ccc2c(c1)Cc1ccccc1-2;IC50;36.4;=;nM;7.44
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;14;1607137;Cl.NC(N)=NC(=O)/C=C/c1ccc2c(c1)C(O)c1ccccc1-2;Ki;52.0;=;nM;7.28
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;13;1607136;Cl.NC(N)=NC(=O)c1cccc2c1-c1ccccc1C2;Ki;27.4;=;nM;7.56
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;12;1607135;Cl.NC(N)=NC(=O)c1ccc2c(c1)-c1ccccc1C2O;Ki;86.8;=;nM;7.06
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;11;1607134;Cl.NC(N)=NC(=O)c1cccc2c1Cc1ccccc1-2;Ki;1.1;=;nM;8.96
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;10;1607133;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1ccccc1-2;Ki;1.8;=;nM;8.74
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;9;1607132;NC(N)=NC(=O)c1ccc2c(c1)C(=O)c1ccccc1-2;Ki;0.4;=;nM;9.4
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;8;1607131;Cl.NC(N)=NC(=O)c1ccc2c(c1)Oc1ccccc1N2;Ki;2.4;=;nM;8.62
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;7;1607130;Cl.NC(N)=NC(=O)c1ccc2c(c1)Nc1ccccc1O2;Ki;3.6;=;nM;8.44
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;6;1607129;Cl.NC(N)=NC(=O)c1ccc2c(c1)[nH]c1ccccc12;Ki;10.0;=;nM;8.0
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;5;1607128;Cl.NC(N)=NC(=O)c1ccc2c(c1)oc1ccccc12;Ki;2.1;=;nM;8.68
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;4;1607127;NC(N)=NC(=O)c1ccc2c(c1)Cc1ccccc1-2;Ki;1.8;=;nM;8.74
76215;10.1016/j.bmc.2013.10.010;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.;1279272;1;65404;CN1CCC(=C2c3ccccc3CCc3sccc32)CC1;Ki;2.0;=;nM;8.7
76320;10.1016/j.bmcl.2013.10.045;Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).;1282783;18;1610682;COc1ccc(CNC(=O)c2cc(-c3cc(Cl)cc(Cl)c3)cnc2-c2cccnc2)cc1OC;Ki;662.0;=;nM;6.18
76320;10.1016/j.bmcl.2013.10.045;Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).;1282783;18;1610682;COc1ccc(CNC(=O)c2cc(-c3cc(Cl)cc(Cl)c3)cnc2-c2cccnc2)cc1OC;IC50;1040.0;=;nM;5.98
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;SB206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;12.02;=;nM;7.92
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;methysergide;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;Ki;7.586;=;nM;8.12
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;SB206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;12.0;=;nM;7.92
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;methysergide;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;Ki;7.6;=;nM;8.12
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;9, 21634;1612171;CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1;Ki;104.0;=;nM;6.98
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;8, 21635;1612170;CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1;Ki;57.0;=;nM;7.24
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;7, 20344;1612169;CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1;Ki;87.0;=;nM;7.06
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;9, 21634;1612171;CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1;Ki;104.71;=;nM;6.98
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;8, 21635;1612170;CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1;Ki;56.23;=;nM;7.25
76537;10.1016/j.bmcl.2013.12.024;The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.;1283851;7, 20344;1612169;CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1;Ki;87.1;=;nM;7.06
77227;10.1016/j.bmcl.2014.02.029;5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor.;1296928;5, 5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;Ki;13.49;=;nM;7.87
77227;10.1016/j.bmcl.2014.02.029;5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor.;1296928;4, 5-HPEC;481363;O=c1cc(CCc2ccccc2)oc2cccc(O)c12;Ki;2454.71;=;nM;5.61
77227;10.1016/j.bmcl.2014.02.029;5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor.;1297166;4, 5-HPEC;481363;O=c1cc(CCc2ccccc2)oc2cccc(O)c12;IC50;8912.51;=;nM;5.05
81881;10.1039/C2MD00311B;The synthesis and receptor binding affinities of DDD-016, a novel, potential, atypical antipsychotic;1329310;10d, DDD-016;1724359;CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3;Ki;5.012;=;nM;8.3
83031;10.1021/ml500045k;Quinoline Derivatives as 5-HT6 Receptor PET Ligands.;1351621;Example 1;1745258;CN1CCC(c2cccc3cc(S(=O)(=O)c4ccccn4)cnc23)CC1;Ki;144.0;=;nM;6.84
83036;10.1021/ml500082j;Selective 5-HT Receptor Modulators May Deliver Focused Targeting with Fewer Adverse Effects.;1351821;2;1745281;Clc1cccc(COc2ccc(Br)cc2OC2CNC2)c1;Ki;74.0;=;nM;7.13
83036;10.1021/ml500082j;Selective 5-HT Receptor Modulators May Deliver Focused Targeting with Fewer Adverse Effects.;1351821;29;1745282;Cc1nc(COc2ccc(Cl)cc2OC2CNC2)cs1;Ki;529.0;=;nM;6.28
83036;10.1021/ml500082j;Selective 5-HT Receptor Modulators May Deliver Focused Targeting with Fewer Adverse Effects.;1351821;184;1745283;FC(F)(COc1ccc(Cl)cc1OC1CNC1)c1ccccc1;Ki;12.0;=;nM;7.92
83036;10.1021/ml500082j;Selective 5-HT Receptor Modulators May Deliver Focused Targeting with Fewer Adverse Effects.;1351821;200;1745284;C[C@@H](Oc1ccc(C(F)(F)F)cc1OC1CNC1)c1cccc(C(F)(F)F)c1;Ki;7568.0;=;nM;5.12
83750;10.1021/jm401431x;Prostanoid receptor EP2 as a therapeutic target.;1364742;12, TG4-155;791889;COc1cc(/C=C/C(=O)NCCn2c(C)cc3ccccc32)cc(OC)c1OC;IC50;2600.0;=;nM;5.58
83750;10.1021/jm401431x;Prostanoid receptor EP2 as a therapeutic target.;1364742;13, TG6-10-1;1749190;COc1cc(/C=C/C(=O)NCCn2c(C(F)(F)F)cc3ccccc32)cc(OC)c1OC;IC50;7500.0;=;nM;5.12
83788;10.1016/j.bmc.2014.04.026;Identification of a new selective dopamine D4 receptor ligand.;1365244;28;1760206;c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1;Ki;47.0;=;nM;7.33
83788;10.1016/j.bmc.2014.04.026;Identification of a new selective dopamine D4 receptor ligand.;1365244;28;1760206;c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1;Ki;46.77;=;nM;7.33
83907;10.1021/jm5003292;Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.;1361181;11;1757082;c1ccc(Cc2nc3c(c(N4CCOCC4)n2)CCNCC3)cc1;EC50;247.0;=;nM;6.61
83907;10.1021/jm5003292;Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.;1361181;12, enantiomer-1;1757083;CNc1nc(C(C)c2ccccc2)nc2c1CCNCC2;EC50;1000.0;=;nM;6.0
83907;10.1021/jm5003292;Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.;1361193;17, PF-4479745;1757074;CNc1nc(Cc2ccccc2)nc2c1CCNC[C@@H]2C;IC50;67.0;=;nM;7.17
83907;10.1021/jm5003292;Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.;1361193;18, PF-4522654;1757075;CNc1nc(C(F)(F)c2ccccc2)nc2c1CCNCC2;IC50;110.0;=;nM;6.96
83920;10.1021/ml400473x;Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.;1362193;16h, PF-5190457;1757743;Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1;IC50;3700.0;=;nM;5.43
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;4;1779220;CC1(O)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;4.3;=;nM;8.37
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;7a;1795819;CCC1(O)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;41.0;=;nM;7.39
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;7b;1795820;CCCCC1(O)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;31.0;=;nM;7.51
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;7c;1795821;COC1(C)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;3.3;=;nM;8.48
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;7d;1795822;CCC1(OC)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;4.8;=;nM;8.32
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;7e;1795823;COCC1(OC)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;2.0;=;nM;8.7
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;13a;1795824;Cl.NC(N)=NC(=O)c1ccc2c(c1)C1(CC1)c1ccccc1-2;Ki;0.51;=;nM;9.29
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;13b;1795825;Cl.NC(N)=NC(=O)c1ccc2c(c1)C1(CCCC1)c1ccccc1-2;Ki;1.7;=;nM;8.77
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;17;1795826;Cl.NC(N)=NC(=O)c1ccc2c(c1)C1(CCCO1)c1ccccc1-2;Ki;5.1;=;nM;8.29
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;22;1795827;Cl.NC(N)=NC(=O)c1ccc2c(c1)C1(CCOCC1)c1ccccc1-2;Ki;9.1;=;nM;8.04
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;(-)-(S)-17;1795828;NC(N)=NC(=O)c1ccc2c(c1)[C@]1(CCCO1)c1ccccc1-2;Ki;2.7;=;nM;8.57
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440700;(+)-(R)-17;1795829;NC(N)=NC(=O)c1ccc2c(c1)[C@@]1(CCCO1)c1ccccc1-2;Ki;5.1;=;nM;8.29
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440708;17;1795826;Cl.NC(N)=NC(=O)c1ccc2c(c1)C1(CCCO1)c1ccccc1-2;IC50;55.0;=;nM;7.26
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440708;(-)-(S)-17;1795828;NC(N)=NC(=O)c1ccc2c(c1)[C@]1(CCCO1)c1ccccc1-2;IC50;35.0;=;nM;7.46
89517;10.1016/j.bmc.2014.09.005;Synthesis and pharmacological evaluation of optically pure, novel carbonyl guanidine derivatives as dual 5-HT2B and 5-HT7 receptor antagonists.;1440708;(+)-(R)-17;1795829;NC(N)=NC(=O)c1ccc2c(c1)[C@@]1(CCCO1)c1ccccc1-2;IC50;73.0;=;nM;7.14
90188;10.1016/j.bmcl.2014.05.016;DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.;1450028;4, DDD-028;1612171;CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1;Ki;104.0;=;nM;6.98
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;16a;1779216;CC(=O)NC1c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;34.0;=;nM;7.47
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;16c;1779217;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(N)c1ccccc1-2;Ki;18.0;=;nM;7.75
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;19;1779218;Cl.N=C(N)NC(=O)c1ccc2c(c1)C(F)c1ccccc1-2;Ki;0.9;=;nM;9.05
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;21;1779219;CC1c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;4.4;=;nM;8.36
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;24a;1779220;CC1(O)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;Ki;4.3;=;nM;8.37
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;24b;1779816;Cc1cccc2c1-c1ccc(C(=O)N=C(N)N)cc1C2(C)O.Cl;Ki;1.1;=;nM;8.96
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;24c;1779817;CCc1cccc2c1-c1ccc(C(=O)N=C(N)N)cc1C2(C)O.Cl;Ki;0.71;=;nM;9.15
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10j;1779215;COCc1cccc2c1-c1ccc(C(=O)N=C(N)N)cc1C2O.Cl;Ki;6.3;=;nM;8.2
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10i;1779214;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1cccc(CO)c1-2;Ki;6.6;=;nM;8.18
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10h;1779213;Cc1cccc2c1C(O)c1cc(C(=O)N=C(N)N)ccc1-2.Cl;Ki;0.67;=;nM;9.17
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10g;1779212;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1c(Cl)cccc1-2;Ki;0.11;=;nM;9.96
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10f;1779211;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1ccc(Cl)cc1-2;Ki;11.0;=;nM;7.96
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10e;1779210;CCc1cccc2c1-c1ccc(C(=O)N=C(N)N)cc1C2O;Ki;1.6;=;nM;8.8
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10d;1779209;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1cccc(F)c1-2;Ki;0.91;=;nM;9.04
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10c;1779208;Cc1cccc2c1-c1ccc(C(=O)N=C(N)N)cc1C2O.Cl;Ki;0.81;=;nM;9.09
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10b;1779207;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1cc(Cl)ccc1-2;Ki;1.7;=;nM;8.77
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;10a;1779206;Cl.NC(N)=NC(=O)c1ccc2c(c1)C(O)c1cccc(Cl)c1-2;Ki;1.5;=;nM;8.82
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447539;4;1628519;NC(N)=NC(=O)c1ccc2c(c1)C(O)c1ccccc1-2;Ki;1.8;=;nM;8.74
90255;10.1016/j.bmc.2014.05.027;Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT₂B and 5-HT₇ receptor antagonists. Part 2.;1447547;24a;1779220;CC1(O)c2ccccc2-c2ccc(C(=O)N=C(N)N)cc21.Cl;IC50;52.0;=;nM;7.28
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;2;1275256;OC1(c2ccc(Cl)cc2)CCN(CCCCc2ccc(F)cc2)CC1;Ki;723.0;=;nM;6.14
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;3;1275258;OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1;Ki;1622.0;=;nM;5.79
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;4;1275257;OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1;Ki;790.0;=;nM;6.1
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;6;1784345;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1ccc(F)cc1;Ki;1381.0;=;nM;5.86
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;7;1784346;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCOc1ccc(F)cc1;Ki;898.0;=;nM;6.05
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;8;1784347;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccc(F)cc1;Ki;1057.0;=;nM;5.98
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;9;1784348;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1cccc(F)c1;Ki;270.0;=;nM;6.57
90622;10.1016/j.bmcl.2014.07.018;Further evaluation of the tropane analogs of haloperidol.;1452248;10;1784349;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccccc1F;Ki;520.0;=;nM;6.28
90955;10.1021/ml500414n;Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists.;1461974;7m;1828015;COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1;IC50;7600.0;=;nM;5.12
90955;10.1021/ml500414n;Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists.;1461974;2;1581804;COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5ncccn5)ccc42)C3)cc1;IC50;4300.0;=;nM;5.37
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5e;1832882;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2cccc([N+](=O)[O-])c2)C1.Cl;Ki;70.0;=;nM;7.16
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5f;1832881;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccc(F)cc2)C1.Cl;Ki;66.0;=;nM;7.18
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5f;1832880;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccc(F)cc2)C1.Cl;Ki;400.0;=;nM;6.4
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5g;1832879;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)cc2)C1.Cl;Ki;80.0;=;nM;7.1
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5g;1832878;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)cc2)C1.Cl;Ki;300.0;=;nM;6.52
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5h;1832877;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccc(Br)cc2)C1.Cl;Ki;30.0;=;nM;7.52
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5h;1832876;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccc(Br)cc2)C1.Cl;Ki;210.0;=;nM;6.68
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5i;1832875;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccc(C(F)(F)F)cc2)C1.Cl;Ki;250.0;=;nM;6.6
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5i;1832874;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccc(C(F)(F)F)cc2)C1.Cl;Ki;540.0;=;nM;6.27
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;5j;1832873;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccc([N+](=O)[O-])cc2)C1.Cl;Ki;4100.0;=;nM;5.39
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5k;1832872;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccccc2Br)C1.Cl;Ki;4100.0;=;nM;5.39
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5k;1832871;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccccc2Br)C1.Cl;Ki;650.0;=;nM;6.19
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5l;1832870;CN(C)[C@H]1Cc2ccccc2[C@H](C2CCCCC2)C1.Cl;Ki;170.0;=;nM;6.77
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5l;1832869;CN(C)[C@@H]1Cc2ccccc2[C@@H](C2CCCCC2)C1.Cl;Ki;20.0;=;nM;7.7
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5m;1832868;CN(C)[C@H]1Cc2ccccc2[C@H](C2CCCCCCC2)C1.Cl;Ki;40.0;=;nM;7.4
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5m;1832893;CN(C)[C@@H]1Cc2ccccc2[C@@H](C2CCCCCCC2)C1.Cl;Ki;10.0;=;nM;8.0
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5n;1832894;CN(C)[C@H]1Cc2ccccc2[C@H](c2cccc(-c3ccccc3)c2)C1.Cl;Ki;200.0;=;nM;6.7
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5n;1832895;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2cccc(-c3ccccc3)c2)C1.Cl;Ki;73.0;=;nM;7.14
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5o;1832896;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccccc2Cl)C1.Cl;Ki;710.0;=;nM;6.15
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5o;1832897;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccccc2Cl)C1.Cl;Ki;300.0;=;nM;6.52
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5p;1832898;Cc1ccccc1[C@@H]1C[C@@H](N(C)C)Cc2ccccc21.Cl;Ki;6000.0;=;nM;5.22
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5p;1832899;Cc1ccccc1[C@H]1C[C@H](N(C)C)Cc2ccccc21.Cl;Ki;800.0;=;nM;6.1
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-PAT;1832892;CN(C)[C@H]1Cc2ccccc2[C@H](c2ccccc2)C1;Ki;240.0;=;nM;6.62
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-PAT;208736;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccccc2)C1;Ki;94.0;=;nM;7.03
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5a;1832891;CN(C)[C@H]1Cc2ccccc2[C@H](c2cccc(F)c2)C1.Cl;Ki;110.0;=;nM;6.96
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5a;1832890;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2cccc(F)c2)C1.Cl;Ki;70.0;=;nM;7.16
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5b;1832889;CN(C)[C@H]1Cc2ccccc2[C@H](c2cccc(Cl)c2)C1.Cl;Ki;50.0;=;nM;7.3
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5b;1832888;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2cccc(Cl)c2)C1.Cl;Ki;30.0;=;nM;7.52
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5c;1832887;CN(C)[C@H]1Cc2ccccc2[C@H](c2cccc(Br)c2)C1.Cl;Ki;40.0;=;nM;7.4
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5e;1832883;CN(C)[C@H]1Cc2ccccc2[C@H](c2cccc([N+](=O)[O-])c2)C1.Cl;Ki;20.0;=;nM;7.7
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5d;1832884;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2cccc(C(F)(F)F)c2)C1.Cl;Ki;60.0;=;nM;7.22
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(+)-5d;1832885;CN(C)[C@H]1Cc2ccccc2[C@H](c2cccc(C(F)(F)F)c2)C1.Cl;Ki;200.0;=;nM;6.7
91105;10.1016/j.bmc.2015.01.060;Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.;1465387;(-)-5c;1832886;CN(C)[C@@H]1Cc2ccccc2[C@@H](c2cccc(Br)c2)C1.Cl;Ki;8.0;=;nM;8.1
91301;10.1021/jm501021n;In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.;1469968;1;194619;CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)ncnc32)[C@H](O)[C@@H]1O;Ki;1080.0;=;nM;5.97
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472892;1, belviq;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;943.0;=;nM;6.03
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472895;4, CP-809,101;478225;Clc1cccc(COc2cncc(N3CCNCC3)n2)c1;EC50;65.3;=;nM;7.18
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472898;8;1338735;NC[C@H]1C[C@@H]1c1cc(F)ccc1OCC1CC1;EC50;289.0;=;nM;6.54
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13a;1839228;CCOc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.Cl;EC50;2307.0;=;nM;5.64
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13a;1839229;CCOc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl;EC50;86.0;=;nM;7.07
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13b;1839230;CCCOc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.Cl;EC50;3004.0;=;nM;5.52
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13b;1839231;CCCOc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl;EC50;3436.0;=;nM;5.46
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13d;1839234;CC(C)Oc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.O=C(O)C(F)(F)F;EC50;5660.0;=;nM;5.25
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13d;1839235;CC(C)Oc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.O=C(O)C(F)(F)F;EC50;997.0;=;nM;6.0
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13e;1839236;Cl.NC[C@@H]1C[C@H]1c1cc(Cl)ccc1OCC1CC1;EC50;3034.0;=;nM;5.52
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13e;1839237;Cl.NC[C@H]1C[C@@H]1c1cc(Cl)ccc1OCC1CC1;EC50;5012.0;=;nM;5.3
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13f;1839238;COCCOc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.Cl;EC50;5300.0;=;nM;5.28
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13h;1839242;C=CCOc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.O=C(O)C(F)(F)F;EC50;4295.0;=;nM;5.37
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13h;1839243;C=CCOc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.O=C(O)C(F)(F)F;EC50;2211.0;=;nM;5.66
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13i;1839244;C#CCOc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.Cl;EC50;4411.0;=;nM;5.36
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13i;1839245;C#CCOc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl;EC50;4602.0;=;nM;5.34
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13j;1839246;C=C(F)COc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.Cl;EC50;6877.0;=;nM;5.16
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13j;1839247;C=C(F)COc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl;EC50;1688.0;=;nM;5.77
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13k;1839248;C=C(C)COc1ccc(Cl)cc1[C@@H]1C[C@H]1CN.Cl;EC50;6094.0;=;nM;5.21
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13k;1839249;C=C(C)COc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl;EC50;422.0;=;nM;6.38
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13l;1839250;Cl.NC[C@@H]1C[C@H]1c1cc(Cl)ccc1OCCF;EC50;4521.0;=;nM;5.34
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13l;1839251;Cl.NC[C@H]1C[C@@H]1c1cc(Cl)ccc1OCCF;EC50;632.0;=;nM;6.2
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13m;1839252;Cl.NC[C@@H]1C[C@H]1c1cc(Cl)ccc1OCC(F)F;EC50;1485.0;=;nM;5.83
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13m;1839253;Cl.NC[C@H]1C[C@@H]1c1cc(Cl)ccc1OCC(F)F;EC50;839.0;=;nM;6.08
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-13n;1839254;Cl.NC[C@@H]1C[C@H]1c1cc(Cl)ccc1OCCCF;EC50;6166.0;=;nM;5.21
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-13n;1839255;Cl.NC[C@H]1C[C@@H]1c1cc(Cl)ccc1OCCCF;EC50;4911.0;=;nM;5.31
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(-)-16a;1839256;CCCOc1ccc(F)cc1[C@@H]1C[C@H]1CN.Cl;EC50;735.0;=;nM;6.13
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;(+)-16a;1839257;CCCOc1ccc(F)cc1[C@H]1C[C@@H]1CN.Cl;EC50;1994.0;=;nM;5.7
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;0.92;=;nM;9.04
91487;10.1021/jm5019274;Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.;1472903;1, belviq;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;478.0;=;nM;6.32
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;7, PF-04781340;1843131;CNc1nc(Cc2ccccc2)cc2c1CCNCC2;EC50;1484.0;=;nM;5.83
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;21a;1843132;CCNc1nc(Cc2ccccc2)cc2c1CCNCC2;EC50;18.0;=;nM;7.75
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;21c;1843134;c1ccc(Cc2cc3c(c(NCC4CC4)n2)CCNCC3)cc1;EC50;22.0;=;nM;7.66
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;21d;1843135;CCCNc1nc(Cc2ccccc2)cc2c1CCNCC2;EC50;27.0;=;nM;7.57
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;21e;1843136;CC(C)Nc1nc(Cc2ccccc2)cc2c1CCNCC2;EC50;33.0;=;nM;7.48
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;21g;1843138;CN(C)c1nc(Cc2ccccc2)cc2c1CCNCC2;EC50;30.0;=;nM;7.52
91785;10.1021/ml500507v;Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.;1477948;21h;1843139;c1ccc(Cc2cc3c(cn2)CCNCC3)cc1;EC50;27.0;=;nM;7.57
92451;10.1021/np500893h;Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors.;1499637;1;462554;COc1cc2c(cc1O)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;323.0;=;nM;6.49
92877;10.1021/acs.jnatprod.5b00118;Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.;1506145;22c;1952549;O=c1cc(CCc2cccc(O)c2)oc2cccc(O)c12;Ki;1258.93;=;nM;5.9
92877;10.1021/acs.jnatprod.5b00118;Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.;1506145;22d;1952550;O=c1cc(CCc2ccc(O)cc2)oc2cccc(O)c12;Ki;1000.0;=;nM;6.0
92877;10.1021/acs.jnatprod.5b00118;Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.;1506145;22e;1622916;O=c1cc(CCc2cccs2)oc2cccc(O)c12;Ki;1000.0;=;nM;6.0
92877;10.1021/acs.jnatprod.5b00118;Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.;1506145;22f;1952551;O=c1cc(CCc2ccco2)oc2cccc(O)c12;Ki;1995.26;=;nM;5.7
92877;10.1021/acs.jnatprod.5b00118;Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.;1506145;22h, 5-HPPC;1622913;O=c1cc(CCCc2ccccc2)oc2cccc(O)c12;Ki;251.19;=;nM;6.6
92877;10.1021/acs.jnatprod.5b00118;Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT2B Ligands.;1506145;22i;1952552;O=c1cc(COCc2ccccc2)oc2cccc(O)c12;Ki;1584.89;=;nM;5.8
92991;10.1039/C4MD00113C;Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1;1508153;27, PF-04822163;1956459;COc1ccc2c([C@H]3CCc4ccc(Cl)cc43)nccc2c1OC;IC50;250.0;=;nM;6.6
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5a;1959304;COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;96.0;=;nM;7.02
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5b;1959305;CCOc1c(OC)cc2c3c1-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;209.0;=;nM;6.68
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5c;1960001;CCCOc1c(OC)cc2c3c1-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;307.0;=;nM;6.51
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5d;1960002;CCCCOc1c(OC)cc2c3c1-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;601.0;=;nM;6.22
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5e;1960003;CCCCCCOc1c(OC)cc2c3c1-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;663.0;=;nM;6.18
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5f;1960004;COc1cc2c3c(c1OCC1CC1)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;299.0;=;nM;6.52
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5g;1960005;C=CCOc1c(OC)cc2c3c1-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;416.0;=;nM;6.38
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5i;1960007;COc1cc2c3c(c1O)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4;Ki;715.0;=;nM;6.15
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5j;1960008;CCN1CC(c2ccccc2)c2cc(OC)c(OC)c3c2C1Cc1cc2c(cc1-3)OCO2;Ki;419.0;=;nM;6.38
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;5k;1960009;COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(CC1CC1)CC2c1ccccc1)OCO4;Ki;1429.0;=;nM;5.84
93256;10.1016/j.bmcl.2015.07.012;C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.;1512579;(+/-)-1;480354;COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4;Ki;543.0;=;nM;6.26
93333;10.1021/acsmedchemlett.5b00150;Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.;1515688;20;1961647;CCNc1cc(C#Cc2ccc(Cl)s2)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(C(=O)NC)C[C@H]12;Ki;2500.0;=;nM;5.6
93584;10.1021/acs.jmedchem.5b00179;Therapeutic Potential of 5-HT6 Receptor Agonists.;1521778;3, ST1936;327512;Cc1[nH]c2ccc(Cl)cc2c1CCN(C)C;Ki;245.0;=;nM;6.61
93893;10.1021/acs.jmedchem.5b01240;Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.;1525542;18b;1972017;O=c1ccc(-c2ccc(OCc3ccc4ccccc4n3)cc2)c(-c2ccc(F)cc2)[nH]1;IC50;6.7;=;nM;8.17
93893;10.1021/acs.jmedchem.5b01240;Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.;1525545;18b;1972017;O=c1ccc(-c2ccc(OCc3ccc4ccccc4n3)cc2)c(-c2ccc(F)cc2)[nH]1;IC50;220.0;=;nM;6.66
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6i;2050785;COc1cccc(CCCN(CCc2ccc(OC)c(OC)c2)Cc2ccc3c(c2)OCO3)c1;Ki;59.0;=;nM;7.23
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6j;2050786;COc1ccc(CCN(CCCc2cc(OC)c(OC)c(OC)c2)Cc2ccc3c(c2)OCO3)cc1OC;Ki;231.0;=;nM;6.64
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6k;2050787;COc1ccc(CCN(CC/C=C\c2ccccc2)Cc2ccc3c(c2)OCO3)cc1OC;Ki;21.0;=;nM;7.68
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;SB-206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;21.0;=;nM;7.68
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6h;2050784;COc1ccc(CCN(CCCc2cc(OC)c(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;4.1;=;nM;8.39
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6g;2050783;COc1ccc(OC)c(CCCN(CCc2ccc(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)c1;Ki;36.0;=;nM;7.44
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6f;2050782;COc1ccc(CCCN(CCc2ccc(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)cc1;Ki;6.8;=;nM;8.17
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6e;2050781;COc1cccc(CCCN(CCc2ccc(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)c1;Ki;4.6;=;nM;8.34
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6d;2050780;COc1ccccc1CCCN(CCc1ccc(OC)c(OC)c1)CCc1ccc2c(c1)OCO2;Ki;5.8;=;nM;8.24
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6c;2050779;COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;26.0;=;nM;7.58
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6b;2050778;COc1ccc(CCN(CCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;17.0;=;nM;7.77
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538705;6a;2050777;COc1ccc(CCN(CCc2ccc3c(c2)OCO3)Cc2ccccc2)cc1OC;Ki;59.0;=;nM;7.23
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6b;2050778;COc1ccc(CCN(CCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;IC50;10000.0;=;nM;5.0
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6c;2050779;COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;IC50;794.33;=;nM;6.1
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6d;2050780;COc1ccccc1CCCN(CCc1ccc(OC)c(OC)c1)CCc1ccc2c(c1)OCO2;IC50;10000.0;=;nM;5.0
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6e;2050781;COc1cccc(CCCN(CCc2ccc(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)c1;IC50;1258.93;=;nM;5.9
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6f;2050782;COc1ccc(CCCN(CCc2ccc(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)cc1;IC50;3981.07;=;nM;5.4
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6g;2050783;COc1ccc(OC)c(CCCN(CCc2ccc(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)c1;IC50;7943.28;=;nM;5.1
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6h;2050784;COc1ccc(CCN(CCCc2cc(OC)c(OC)c(OC)c2)CCc2ccc3c(c2)OCO3)cc1OC;IC50;1258.93;=;nM;5.9
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6j;2050786;COc1ccc(CCN(CCCc2cc(OC)c(OC)c(OC)c2)Cc2ccc3c(c2)OCO3)cc1OC;IC50;12589.25;=;nM;4.9
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538710;6k;2050787;COc1ccc(CCN(CC/C=C\c2ccccc2)Cc2ccc3c(c2)OCO3)cc1OC;IC50;6309.57;=;nM;5.2
97277;10.1039/C4MD00418C;Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists;1538874;6c;2050779;COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;Kd;549.54;=;nM;6.26
97803;10.1016/j.bmcl.2015.12.053;Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.;1550138;2;2058443;C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12;Ki;16.6;=;nM;7.78
97803;10.1016/j.bmcl.2015.12.053;Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.;1550138;3;2058444;C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12;Ki;30.2;=;nM;7.52
97803;10.1016/j.bmcl.2015.12.053;Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.;1550138;4;2058445;C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12;Ki;52.48;=;nM;7.28
97803;10.1016/j.bmcl.2015.12.053;Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.;1550138;5;2058446;C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12;Ki;60.26;=;nM;7.22
97803;10.1016/j.bmcl.2015.12.053;Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.;1550138;6;1565114;C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12;Ki;58.88;=;nM;7.23
97803;10.1016/j.bmcl.2015.12.053;Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.;1550138;"1; DALT";2058442;C=CCN(CC=C)CCc1c[nH]c2ccccc12;Ki;61.66;=;nM;7.21
98365;10.1016/j.bmcl.2016.01.021;Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.;1555329;27;2068136;Cc1ccc(C(C)(C)O)cc1-c1ccc2c(n1)n(C)c(=O)n2CC(C)(C)C;Ki;1900.0;=;nM;5.72
98402;10.1016/j.ejmech.2016.01.043;Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.;1554567;29;2068350;Cl.O=C(CCCCN1CCN(c2ccccc2O)CC1)n1c2ccccc2c2ccccc21;Ki;83.0;=;nM;7.08
98402;10.1016/j.ejmech.2016.01.043;Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.;1554567;27;2068348;COc1ccccc1N1CCN(CCCCC(=O)n2c3ccccc3c3ccccc32)CC1.Cl;Ki;93.0;=;nM;7.03
98402;10.1016/j.ejmech.2016.01.043;Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.;1554567;28;2068349;COc1ccccc1N1CCN(CCCCCC(=O)n2c3ccccc3c3ccccc32)CC1.Cl;Ki;419.0;=;nM;6.38
98402;10.1016/j.ejmech.2016.01.043;Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.;1554567;30;2068351;Cl.O=C(CCCCCN1CCN(c2ccccc2O)CC1)n1c2ccccc2c2ccccc21;Ki;101.0;=;nM;7.0
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557237;1;572903;CC1(C)N=C(N)N=C(Nc2cccc(Br)c2)N1;Ki;20.5;=;nM;7.69
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557237;9;2070942;CCOC(=O)c1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;Ki;7.2;=;nM;8.14
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557237;14;2070945;CCOC(=O)c1cccc(NC2=NC(N(C)C)=NC3(CCCCC3)N2)c1;Ki;38.5;=;nM;7.42
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557237;15;2070946;NC1=NC2(CCCCC2)NC(Nc2cccc(Br)c2)=N1;Ki;6.2;=;nM;8.21
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557237;22;2070952;CCNC(=O)c1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;Ki;27.5;=;nM;7.56
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;1;572903;CC1(C)N=C(N)N=C(Nc2cccc(Br)c2)N1;IC50;327.6;=;nM;6.49
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;5;2070941;COc1cccc(NC2=NC(N)=NC3(CCCC3)N2)c1;IC50;1056.0;=;nM;5.98
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;9;2070942;CCOC(=O)c1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;27.3;=;nM;7.56
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;13;2070944;CCOC(=O)c1cccc(NC2=NC(NC)=NC3(CCCCC3)N2)c1;IC50;49.4;=;nM;7.31
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;14;2070945;CCOC(=O)c1cccc(NC2=NC(N(C)C)=NC3(CCCCC3)N2)c1;IC50;284.5;=;nM;6.55
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;15;2070946;NC1=NC2(CCCCC2)NC(Nc2cccc(Br)c2)=N1;IC50;33.4;=;nM;7.48
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;16;834964;COc1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;280.0;=;nM;6.55
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;21;2070951;CCCC(=O)c1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;35.8;=;nM;7.45
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;22;2070952;CCNC(=O)c1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;104.0;=;nM;6.98
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;23;2070953;CCCOC(=O)c1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;18.1;=;nM;7.74
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;26;2070956;Cc1ccc(NC2=NC(N)=NC3(CCCCC3)N2)cc1;IC50;485.9;=;nM;6.31
98466;10.1021/acs.jmedchem.5b01631;Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.;1557251;27;2070957;NC1=NC2(CCCCC2)NC(Nc2ccc(Cl)cc2)=N1;IC50;531.0;=;nM;6.28
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;1;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;328.0;=;nM;6.48
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20a;2070963;COc1cc(F)c(F)cc1C1CC1CN.Cl;EC50;400.0;=;nM;6.4
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20a;2070963;COc1cc(F)c(F)cc1C1CC1CN.Cl;EC50;27.0;=;nM;7.57
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21a;2070964;Cl.NCC1CC1c1cc(F)c(F)cc1OCCF;EC50;453.0;=;nM;6.34
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22a;2070965;C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl;EC50;1745.0;=;nM;5.76
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20b;2070962;COc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;462.0;=;nM;6.33
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20b;2070962;COc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;209.0;=;nM;6.68
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21b;2070959;Cl.NCC1CC1c1c(OCCF)ccc(F)c1F;EC50;2182.0;=;nM;5.66
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-22b;2070960;C=CCOc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;4464.0;=;nM;5.35
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22b;2070960;C=CCOc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;3339.0;=;nM;5.48
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20c;2070961;COc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;329.0;=;nM;6.48
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20c;2070961;COc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;25.0;=;nM;7.6
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-21c;2070966;Cl.NCC1CC1c1cc(Cl)c(F)cc1OCCF;EC50;2521.0;=;nM;5.6
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21c;2070966;Cl.NCC1CC1c1cc(Cl)c(F)cc1OCCF;EC50;506.0;=;nM;6.3
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-22c;2070967;C=CCOc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;1957.0;=;nM;5.71
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22c;2070967;C=CCOc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;1001.0;=;nM;6.0
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20d;2070968;COc1ccc(Cl)c(F)c1C1CC1CN.Cl;EC50;165.0;=;nM;6.78
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20d;2070968;COc1ccc(Cl)c(F)c1C1CC1CN.Cl;EC50;354.0;=;nM;6.45
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20e;2070971;COc1cc(Cl)c(Cl)cc1C1CC1CN.Cl;EC50;31.0;=;nM;7.51
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22e;2070973;C=CCOc1cc(Cl)c(Cl)cc1C1CC1CN.Cl;EC50;714.0;=;nM;6.15
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20f;2070974;COc1ccc(Cl)c(Cl)c1C1CC1CN.Cl;EC50;30.0;=;nM;7.52
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20f;2070974;COc1ccc(Cl)c(Cl)c1C1CC1CN.Cl;EC50;605.0;=;nM;6.22
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20g;2070977;COc1ccc(F)c(Cl)c1C1CC1CN.Cl;EC50;101.0;=;nM;7.0
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21g;2070978;Cl.NCC1CC1c1c(OCCF)ccc(F)c1Cl;EC50;961.0;=;nM;6.02
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22g;2070979;C=CCOc1ccc(F)c(Cl)c1C1CC1CN.Cl;EC50;927.0;=;nM;6.03
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;5-HT;262631;N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O;EC50;1.288;=;nM;8.89
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;5-HT;262631;N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O;EC50;1.0;=;nM;9.0
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;1;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;512.86;=;nM;6.29
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20a;2070963;COc1cc(F)c(F)cc1C1CC1CN.Cl;EC50;398.11;=;nM;6.4
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20a;2070963;COc1cc(F)c(F)cc1C1CC1CN.Cl;EC50;27.54;=;nM;7.56
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21a;2070964;Cl.NCC1CC1c1cc(F)c(F)cc1OCCF;EC50;457.09;=;nM;6.34
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22a;2070965;C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl;EC50;1737.8;=;nM;5.76
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20b;2070962;COc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;457.09;=;nM;6.34
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20b;2070962;COc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;208.93;=;nM;6.68
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21b;2070959;Cl.NCC1CC1c1c(OCCF)ccc(F)c1F;EC50;2187.76;=;nM;5.66
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-22b;2070960;C=CCOc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;4466.84;=;nM;5.35
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22b;2070960;C=CCOc1ccc(F)c(F)c1C1CC1CN.Cl;EC50;3311.31;=;nM;5.48
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20c;2070961;COc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;331.13;=;nM;6.48
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20c;2070961;COc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;25.12;=;nM;7.6
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-21c;2070966;Cl.NCC1CC1c1cc(Cl)c(F)cc1OCCF;EC50;2511.89;=;nM;5.6
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21c;2070966;Cl.NCC1CC1c1cc(Cl)c(F)cc1OCCF;EC50;501.19;=;nM;6.3
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-22c;2070967;C=CCOc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;1949.84;=;nM;5.71
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22c;2070967;C=CCOc1cc(F)c(Cl)cc1C1CC1CN.Cl;EC50;1000.0;=;nM;6.0
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20d;2070968;COc1ccc(Cl)c(F)c1C1CC1CN.Cl;EC50;467.74;=;nM;6.33
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20d;2070968;COc1ccc(Cl)c(F)c1C1CC1CN.Cl;EC50;354.81;=;nM;6.45
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20e;2070971;COc1cc(Cl)c(Cl)cc1C1CC1CN.Cl;EC50;30.9;=;nM;7.51
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22e;2070973;C=CCOc1cc(Cl)c(Cl)cc1C1CC1CN.Cl;EC50;724.44;=;nM;6.14
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20f;2070974;COc1ccc(Cl)c(Cl)c1C1CC1CN.Cl;EC50;30.2;=;nM;7.52
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-20f;2070974;COc1ccc(Cl)c(Cl)c1C1CC1CN.Cl;EC50;602.56;=;nM;6.22
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(-)-20g;2070977;COc1ccc(F)c(Cl)c1C1CC1CN.Cl;EC50;102.33;=;nM;6.99
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-21g;2070978;Cl.NCC1CC1c1c(OCCF)ccc(F)c1Cl;EC50;954.99;=;nM;6.02
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557255;(+)-22g;2070979;C=CCOc1ccc(F)c(Cl)c1C1CC1CN.Cl;EC50;933.25;=;nM;6.03
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557328;(+)-22a;2070965;C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl;Ki;69.18;=;nM;7.16
98467;10.1021/acs.jmedchem.5b01153;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.;1557328;(+)-22a;2070965;C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl;Ki;68.0;=;nM;7.17
98621;10.1016/j.bmc.2016.03.006;Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.;1559793;(+/-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;IC50;2.5;=;nM;8.6
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;1;2050779;COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;26.0;=;nM;7.58
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9a;2089989;COc1ccc(CCN(CCCc2ccc(F)cc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;14.0;=;nM;7.85
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9b;2089990;COc1ccc(CCN(CCCc2ccc(Cl)cc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;54.0;=;nM;7.27
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9c;2089991;COc1ccc(CCN(CCCc2ccc(Br)cc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;45.0;=;nM;7.35
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9d;2089992;COc1ccc(CCN(CCCc2ccc(I)cc2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;51.0;=;nM;7.29
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9e;2089993;COc1ccc(CCN(CCCc2cccc(F)c2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;18.0;=;nM;7.75
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9f;2089994;COc1ccc(CCN(CCCc2cccc(Cl)c2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;17.0;=;nM;7.77
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9g;2089995;COc1ccc(CCN(CCCc2cccc(Br)c2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;14.0;=;nM;7.85
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9h;2089996;COc1ccc(CCN(CCCc2cccc(I)c2)CCc2ccc3c(c2)OCO3)cc1OC;Ki;18.0;=;nM;7.75
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9i;2089997;COc1ccc(CCN(CCCc2ccccc2F)CCc2ccc3c(c2)OCO3)cc1OC;Ki;1.7;=;nM;8.77
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9j;2089998;COc1ccc(CCN(CCCc2ccccc2Cl)CCc2ccc3c(c2)OCO3)cc1OC;Ki;3.1;=;nM;8.51
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9k;2089999;COc1ccc(CCN(CCCc2ccccc2Br)CCc2ccc3c(c2)OCO3)cc1OC;Ki;3.4;=;nM;8.47
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;9l;2090000;COc1ccc(CCN(CCCc2ccccc2I)CCc2ccc3c(c2)OCO3)cc1OC;Ki;13.0;=;nM;7.89
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582551;SB-206553;134824;Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc21;Ki;21.0;=;nM;7.68
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582556;9i;2089997;COc1ccc(CCN(CCCc2ccccc2F)CCc2ccc3c(c2)OCO3)cc1OC;IC50;135.0;=;nM;6.87
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582556;9j;2089998;COc1ccc(CCN(CCCc2ccccc2Cl)CCc2ccc3c(c2)OCO3)cc1OC;IC50;99.0;=;nM;7.0
99511;10.1016/j.bmcl.2016.05.079;New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.;1582556;9k;2089999;COc1ccc(CCN(CCCc2ccccc2Br)CCc2ccc3c(c2)OCO3)cc1OC;IC50;326.0;=;nM;6.49
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;2;2091757;O=C1c2ccccc2C(=O)N1CCCCN1CCC2CCCCC2C1;Ki;400.0;=;nM;6.4
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;5;2091760;Cl.Fc1ccc2c(c1)CC(CCN1CCc3ccccc3C1)C2;Ki;1247.0;=;nM;5.9
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;6;2091761;Cl.Fc1ccc(CCCCN2CCc3ccccc3C2)cc1;Ki;1713.0;=;nM;5.77
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;7;2091762;Cl.Fc1ccc(OCCCN2CCc3ccccc3C2)cc1;Ki;561.0;=;nM;6.25
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;8;2091763;Cl.Fc1ccc(SCCCN2CCc3ccccc3C2)cc1;Ki;204.0;=;nM;6.69
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;9;2091764;Cl.[O-][S+](CCCN1CCc2ccccc2C1)c1ccc(F)cc1;Ki;1166.0;=;nM;5.93
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;10;2091765;O=C(CCCN1CCc2ccccc2C1)c1ccc(F)cc1;Ki;614.0;=;nM;6.21
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;11;2091766;O=C(CCCN1CCc2ccccc2C1)c1ccccc1;Ki;273.0;=;nM;6.56
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;12;2091767;N#Cc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;Ki;152.0;=;nM;6.82
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;13;2091768;NC(=O)c1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;Ki;587.0;=;nM;6.23
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;14;2091769;COc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;Ki;723.0;=;nM;6.14
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;15;2091770;O=C(CCCN1CCc2ccccc2C1)c1ccc(O)cc1;Ki;358.0;=;nM;6.45
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;16;2091771;O=C(CCCN1CCc2ccccc2C1)c1ccc(Cl)cc1;Ki;232.0;=;nM;6.63
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;Aripiprazole;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;0.36;=;nM;9.44
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;2;2091757;O=C1c2ccccc2C(=O)N1CCCCN1CCC2CCCCC2C1;Ki;398.11;=;nM;6.4
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;5;2091760;Cl.Fc1ccc2c(c1)CC(CCN1CCc3ccccc3C1)C2;Ki;1258.93;=;nM;5.9
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;6;2091761;Cl.Fc1ccc(CCCCN2CCc3ccccc3C2)cc1;Ki;1698.24;=;nM;5.77
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;7;2091762;Cl.Fc1ccc(OCCCN2CCc3ccccc3C2)cc1;Ki;562.34;=;nM;6.25
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;8;2091763;Cl.Fc1ccc(SCCCN2CCc3ccccc3C2)cc1;Ki;204.17;=;nM;6.69
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;9;2091764;Cl.[O-][S+](CCCN1CCc2ccccc2C1)c1ccc(F)cc1;Ki;1174.9;=;nM;5.93
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;11;2091766;O=C(CCCN1CCc2ccccc2C1)c1ccccc1;Ki;275.42;=;nM;6.56
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;12;2091767;N#Cc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;Ki;151.36;=;nM;6.82
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;13;2091768;NC(=O)c1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;Ki;588.84;=;nM;6.23
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;14;2091769;COc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;Ki;724.44;=;nM;6.14
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;15;2091770;O=C(CCCN1CCc2ccccc2C1)c1ccc(O)cc1;Ki;354.81;=;nM;6.45
99655;10.1016/j.bmc.2016.05.053;Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.;1586511;16;2091771;O=C(CCCN1CCc2ccccc2C1)c1ccc(Cl)cc1;Ki;234.42;=;nM;6.63
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;7;2091228;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3s1)CC2;Ki;122.0;=;nM;6.91
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;8;2091229;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3cc(Cl)ccc3s1)CC2;Ki;36.0;=;nM;7.44
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;9;1347071;O=C(CCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1nc2ccccc2s1;Ki;1578.0;=;nM;5.8
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;10;2091421;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3o1)CC2;Ki;905.0;=;nM;6.04
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;11;2091422;O=C1NCN(c2ccccc2)C12CCN(CCCCc1c[nH]c3ccccc13)CC2;Ki;202.0;=;nM;6.7
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;14;2091424;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3o2)CC1;Ki;515.0;=;nM;6.29
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;15;2091425;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2c[nH]c3ccccc23)CC1;Ki;51.0;=;nM;7.29
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;21;2091430;Cl.OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1nc2ccccc2s1;Ki;342.0;=;nM;6.47
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;22;2091431;Cl.O=C(CCCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1;Ki;758.0;=;nM;6.12
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;7;2091228;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3s1)CC2;Ki;123.03;=;nM;6.91
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;8;2091229;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3cc(Cl)ccc3s1)CC2;Ki;36.31;=;nM;7.44
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;9;1347071;O=C(CCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1nc2ccccc2s1;Ki;1584.89;=;nM;5.8
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;10;2091421;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3o1)CC2;Ki;912.01;=;nM;6.04
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;11;2091422;O=C1NCN(c2ccccc2)C12CCN(CCCCc1c[nH]c3ccccc13)CC2;Ki;204.17;=;nM;6.69
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;14;2091424;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3o2)CC1;Ki;512.86;=;nM;6.29
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;15;2091425;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2c[nH]c3ccccc23)CC1;Ki;51.29;=;nM;7.29
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;21;2091430;Cl.OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1nc2ccccc2s1;Ki;338.84;=;nM;6.47
99672;10.1016/j.bmc.2016.06.011;Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.;1586245;22;2091431;Cl.O=C(CCCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1;Ki;758.58;=;nM;6.12
101012;10.1039/C6MD00245E;;1611855;"2; PAL-287";517669;CC(N)Cc1ccc2ccccc2c1;EC50;40.0;=;nM;7.4
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1b;2099524;Br.c1ccc2c(c1)CCN(CCCc1nc3ccccc3s1)C2;Ki;18.0;=;nM;7.75
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1e;2108470;Cl.Clc1cccc2c1CN(CCCCc1nc3ccccc3s1)CC2;Ki;239.0;=;nM;6.62
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1f;2179670;Cl.Clc1ccc2sc(CCCCN3CCc4ccccc4C3)nc2c1;Ki;16.0;=;nM;7.8
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1g;2180754;Cl.Clc1ccc2sc(CCCCN3CCc4c(Cl)cccc4C3)nc2c1;Ki;327.0;=;nM;6.49
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1h;2151166;Cl.Clc1ccc2sc(CCCCN3CCC4CCCCC4C3)nc2c1;Ki;64.0;=;nM;7.19
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1i;2169290;COc1cc2c(cc1OC)CN(CCCCc1nc3cc(Cl)ccc3s1)CC2.Cl;Ki;7.0;=;nM;8.15
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;2a;2100212;C1=C(CCN2CCc3ccccc3C2)Cc2ccccc21;Ki;149.0;=;nM;6.83
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;2b;2180365;C1=C(CCN2CCc3ccccc3C2)CCc2ccccc21;Ki;126.0;=;nM;6.9
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;2e;2118241;CC1(C)CC(=O)N(CCCCN2Cc3ccccc3C2)C(=O)C1;Ki;531.0;=;nM;6.28
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3e;2133936;Cl.O=C(CCCN1CCCc2ccccc2C1)c1ccc(Cl)cc1;Ki;501.0;=;nM;6.3
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3f;2161622;Cl.O=C(CCCN1CCc2ccccc2CC1)c1ccc(Cl)cc1;Ki;549.0;=;nM;6.26
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3g;2196298;O=C1Cc2cc(C(=O)CCCN3CCc4ccccc4C3)ccc2N1;Ki;483.0;=;nM;6.32
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3h;2167586;O=C1c2ccc(F)cc2CC1CCN1CCc2ccccc2C1;Ki;294.0;=;nM;6.53
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3i;2188013;Cl.O=C1c2ccccc2CC1CCN1CCc2ccccc2C1;Ki;391.0;=;nM;6.41
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3j;2107621;Cl.O=C1c2ccc(Cl)cc2CC1CCN1CCc2ccccc2C1;Ki;109.0;=;nM;6.96
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1b;2099524;Br.c1ccc2c(c1)CCN(CCCc1nc3ccccc3s1)C2;Ki;18.2;=;nM;7.74
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1e;2108470;Cl.Clc1cccc2c1CN(CCCCc1nc3ccccc3s1)CC2;Ki;239.88;=;nM;6.62
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1f;2179670;Cl.Clc1ccc2sc(CCCCN3CCc4ccccc4C3)nc2c1;Ki;15.49;=;nM;7.81
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1g;2180754;Cl.Clc1ccc2sc(CCCCN3CCc4c(Cl)cccc4C3)nc2c1;Ki;323.59;=;nM;6.49
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1h;2151166;Cl.Clc1ccc2sc(CCCCN3CCC4CCCCC4C3)nc2c1;Ki;64.57;=;nM;7.19
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;1i;2169290;COc1cc2c(cc1OC)CN(CCCCc1nc3cc(Cl)ccc3s1)CC2.Cl;Ki;7.079;=;nM;8.15
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;2a;2100212;C1=C(CCN2CCc3ccccc3C2)Cc2ccccc21;Ki;147.91;=;nM;6.83
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;2b;2180365;C1=C(CCN2CCc3ccccc3C2)CCc2ccccc21;Ki;125.89;=;nM;6.9
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;2e;2118241;CC1(C)CC(=O)N(CCCCN2Cc3ccccc3C2)C(=O)C1;Ki;524.81;=;nM;6.28
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3e;2133936;Cl.O=C(CCCN1CCCc2ccccc2C1)c1ccc(Cl)cc1;Ki;501.19;=;nM;6.3
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3f;2161622;Cl.O=C(CCCN1CCc2ccccc2CC1)c1ccc(Cl)cc1;Ki;549.54;=;nM;6.26
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3g;2196298;O=C1Cc2cc(C(=O)CCCN3CCc4ccccc4C3)ccc2N1;Ki;478.63;=;nM;6.32
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621379;3j;2107621;Cl.O=C1c2ccc(Cl)cc2CC1CCN1CCc2ccccc2C1;Ki;109.65;=;nM;6.96
101422;10.1016/j.bmc.2016.09.019;Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.;1621385;SB269970;36730;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1;Ki;5.0;=;nM;8.3
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;1;2123373;Clc1cccc(CNc2nc(Cl)nc3[nH]cnc23)c1;Ki;2160.0;=;nM;5.67
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;2;2151351;Fc1ccc(C#Cc2nc(NCc3cccc(Cl)c3)c3nc[nH]c3n2)cc1F;Ki;4000.0;=;nM;5.4
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;3;492022;O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NCc3cccc(Cl)c3)nc(Cl)nc21;Ki;2390.0;=;nM;5.62
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;4;1333748;O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc21;Ki;675.0;=;nM;6.17
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;10;194619;CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)ncnc32)[C@H](O)[C@@H]1O;Ki;1080.0;=;nM;5.97
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;11;76361;CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O;Ki;2770.0;=;nM;5.56
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;13;36105;CNc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12;Ki;6470.0;=;nM;5.19
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;14;2133241;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;11.1;=;nM;7.96
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;15;2114188;CCC(CC)Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12;Ki;476.0;=;nM;6.32
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;16;2142191;CC[C@@H](Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12)C1CC1;Ki;186.0;=;nM;6.73
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;17;2185950;CC[C@H](Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12)C1CC1;Ki;73.0;=;nM;7.14
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;18;2115221;CC(C)[C@@H](Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12)C1CC1;Ki;163.0;=;nM;6.79
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;19;2194016;CC(C)[C@H](Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12)C1CC1;Ki;163.0;=;nM;6.79
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;20;2124214;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(N[C@H](C4CCC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;34.0;=;nM;7.47
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;21;2141118;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(N[C@@H](C4CCC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;77.0;=;nM;7.11
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;22;2168581;CN(C)c1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12;Ki;4800.0;=;nM;5.32
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;23;2185492;CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;23.0;=;nM;7.64
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;24;2151109;CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(N(C)C)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;2100.0;=;nM;5.68
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;25;2179412;COC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;19.0;=;nM;7.72
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;26;2164890;CCOC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;15.0;=;nM;7.82
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;27;2165902;CCCOC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;45.0;=;nM;7.35
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;28;2138354;O=C(O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;1480.0;=;nM;5.83
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;29;2176984;CCOC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(N(C)C)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;671.0;=;nM;6.17
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;30;2147377;CN(C)c1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(C(=O)O)C[C@H]12;Ki;4700.0;=;nM;5.33
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;33;2122664;CC(=O)NCCNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;332.0;=;nM;6.48
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621577;34;2192514;CC(=O)NCCCNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;534.0;=;nM;6.27
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621594;1;2123373;Clc1cccc(CNc2nc(Cl)nc3[nH]cnc23)c1;IC50;890.0;=;nM;6.05
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621594;35;296221;CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCc4cccc(Cl)c4)nc(Cl)nc31)[C@H](O)[C@@H]2O;IC50;3260.0;=;nM;5.49
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621594;14;2133241;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;22.3;=;nM;7.65
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621594;23;2185492;CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;4.4;=;nM;8.36
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621594;25;2179412;COC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;3.2;=;nM;8.49
101438;10.1021/acs.jmedchem.6b01183;Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.;1621594;26;2164890;CCOC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;1.8;=;nM;8.74
101740;10.1016/j.bmcl.2016.10.065;Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples.;1627285;10b;2145660;CN1CC[C@H]2CC(=O)[C@H](Cc3ccccc3)[C@H]3CCC[C@@H]1[C@H]23;Ki;1905.0;=;nM;5.72
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;mCPP;5884;Clc1cccc(N2CCNCC2)c1;EC50;39.81;=;nM;7.4
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;2;2101173;c1ccc2c(c1)CCC1CCNCCCN21;EC50;1000.0;=;nM;6.0
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;2R;2129232;c1ccc2c(c1)CC[C@@H]1CCNCCCN21;EC50;501.19;=;nM;6.3
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;6;2138133;Clc1ccc2c(c1)CCC1CCNCCCN21;EC50;630.96;=;nM;6.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;7;2170397;Clc1cccc2c1N1CCCNCCC1CC2;EC50;100.0;=;nM;7.0
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10a;2142934;Fc1ccc2c(c1)CC[C@@H]1CNCCCN21;EC50;630.96;=;nM;6.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10b;2161700;COc1ccc2c(c1)CC[C@@H]1CNCCCN21;EC50;1258.93;=;nM;5.9
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10c;2134015;COc1cc2c(cc1Cl)N1CCCNC[C@H]1CC2;EC50;158.49;=;nM;6.8
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10e;2175598;COc1ccc2c(c1)N1CCCNC[C@H]1CC2;EC50;630.96;=;nM;6.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10f;2144015;COc1ccc2c(c1Cl)N1CCCNC[C@H]1CC2;EC50;7.943;=;nM;8.1
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10g;2104555;COc1cc2c(cc1Cl)CC[C@@H]1CNCCCN21;EC50;63.1;=;nM;7.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10j;2148264;COc1cccc2c1N1CCCNC[C@H]1CC2;EC50;100.0;=;nM;7.0
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;11;2155648;c1ccc2c(c1)CC[C@@H]1CNCCN21;EC50;63.1;=;nM;7.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12a;2184964;COc1ccc2c(c1)CCC1CNCCN21;EC50;794.33;=;nM;6.1
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12b;2146765;Cc1cccc2c1N1CCNCC1CC2;EC50;50.12;=;nM;7.3
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12c;2176478;Fc1ccc2c(c1)N1CCNCC1CC2;EC50;31.62;=;nM;7.5
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12h;2137759;Fc1ccc2c(c1Cl)N1CCNCC1CC2;EC50;1.995;=;nM;8.7
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12i;2165367;Fc1ccc2c(c1)CCC1CNCCN21;EC50;125.89;=;nM;6.9
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12j;2139545;Cc1cccc2c1CCC1CNCCN21;EC50;31.62;=;nM;7.5
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12k;2156647;CCCc1cccc2c1CCC1CNCCN21;EC50;199.53;=;nM;6.7
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12l;2191989;c1cc(C2CCC2)c2c(c1)N1CCNCC1CC2;EC50;39.81;=;nM;7.4
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12m;2122092;c1cc(CC2CCC2)c2c(c1)N1CCNCC1CC2;EC50;1995.26;=;nM;5.7
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12n;2108820;c1ccc(-c2cccc3c2CCC2CNCCN32)cc1;EC50;2511.89;=;nM;5.6
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12o;2129166;c1ccc(Cc2cccc3c2CCC2CNCCN32)cc1;EC50;2511.89;=;nM;5.6
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12p;2165765;Fc1ccc2c(c1Cc1ccccc1)CCC1CNCCN21;EC50;630.96;=;nM;6.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12q;2188253;COCc1cccc2c1CCC1CNCCN21;EC50;1258.93;=;nM;5.9
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12r;2189177;CCSc1cccc2c1CCC1CNCCN21;EC50;79.43;=;nM;7.1
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12s;2160217;CCCc1ccc2c(c1)CCC1CNCCN21;EC50;630.96;=;nM;6.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12t;2099863;CCCc1ccc2c(c1)N1CCNCC1CC2;EC50;199.53;=;nM;6.7
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12u;2168941;c1csc(Cc2cccc3c2CCC2CNCCN32)c1;EC50;398.11;=;nM;6.4
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12v;2144710;c1cc(Cc2ccc3c(c2)OCO3)c2c(c1)N1CCNCC1CC2;EC50;3981.07;=;nM;5.4
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12w;2116770;c1cc(OC2CCC2)c2c(c1)N1CCNCC1CC2;EC50;794.33;=;nM;6.1
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;12x;2165507;c1ccc(Oc2cccc3c2CCC2CNCCN32)cc1;EC50;6309.57;=;nM;5.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;20c;2105343;CC1(C)Cc2cccc(Cl)c2N2CCNCC21;EC50;100.0;=;nM;7.0
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;25;2170960;Fc1ccc2c(c1Cc1ccccc1)CC[C@@H]1CNCCCN21;EC50;7943.28;=;nM;5.1
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629225;10i;2156803;COc1cccc2c1CC[C@@H]1CNCCCN21;EC50;398.11;=;nM;6.4
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;mCPP;5884;Clc1cccc(N2CCNCC2)c1;Ki;10.0;=;nM;8.0
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;12k;2156647;CCCc1cccc2c1CCC1CNCCN21;Ki;25.12;=;nM;7.6
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;12m;2122092;c1cc(CC2CCC2)c2c(c1)N1CCNCC1CC2;Ki;63.1;=;nM;7.2
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;12o;2129166;c1ccc(Cc2cccc3c2CCC2CNCCN32)cc1;Ki;39.81;=;nM;7.4
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;12p;2165765;Fc1ccc2c(c1Cc1ccccc1)CCC1CNCCN21;Ki;12.59;=;nM;7.9
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;12u;2168941;c1csc(Cc2cccc3c2CCC2CNCCN32)c1;Ki;25.12;=;nM;7.6
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;12v;2144710;c1cc(Cc2ccc3c(c2)OCO3)c2c(c1)N1CCNCC1CC2;Ki;125.89;=;nM;6.9
101891;10.1016/j.bmcl.2016.11.016;Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.;1629228;20c;2105343;CC1(C)Cc2cccc(Cl)c2N2CCNCC21;Ki;6.31;=;nM;8.2
102070;10.1016/j.bmc.2016.11.014;Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3.;1633601;DOI;436;COc1cc(CC(C)N)c(OC)cc1I;IC50;2.5;=;nM;8.6
102284;;Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases;1637723;clozapine;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;EC50;20.0;=;nM;7.7
102677;;Functionally selective ligands of dopamine D2 receptors;1640645;BDBM50130293;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;1.4;=;nM;8.85
102677;;Functionally selective ligands of dopamine D2 receptors;1640645;BDBM50395569;1428553;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)nc2N1;Ki;1.1;=;nM;8.96
102677;;Functionally selective ligands of dopamine D2 receptors;1640645;BDBM50395587;1428560;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;0.6;=;nM;9.22
103338;;Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators;1642400;BDBM249358;2192910;C=CCN1CC(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)OC1=O;IC50;126.0;=;nM;6.9
103338;;Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators;1642400;BDBM249359;2154595;CC(C)N1CC(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)OC1=O;IC50;274.0;=;nM;6.56
103338;;Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators;1642400;BDBM249360;2189394;O=C1OC(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)CN1C1CCC1;IC50;190.0;=;nM;6.72
103338;;Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators;1642400;BDBM249361;2108366;O=C1OC(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)CN1C1CCCC1;IC50;41.0;=;nM;7.39
103338;;Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators;1642400;BDBM249362;2130999;CC(C)(C)N1CC(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)OC1=O;IC50;1871.0;=;nM;5.73
103338;;Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators;1642400;BDBM249363;2172704;O=C1OC(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)CN1C1CC1;IC50;298.0;=;nM;6.53
103403;;(Thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists;1642549;BDBM255474;2108540;Cc1ccc2c(c1)Oc1sc(Cl)cc1C(N1CCN(CC(C)(C)C(=O)O)CC1)=N2;Ki;121.0;=;nM;6.92
103970;10.1021/acs.jmedchem.6b01422;Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.;1651924;(+/-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;IC50;3.2;=;nM;8.49
103970;10.1021/acs.jmedchem.6b01422;Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.;1651924;(+/-)-DOI;436;COc1cc(CC(C)N)c(OC)cc1I;Ki;1.6;=;nM;8.8
104481;10.1021/acs.jmedchem.7b00385;Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists.;1663651;67;2240127;CCn1nc(-c2cccc3cccnc23)cc1-c1cccnn1;EC50;3.0;=;nM;8.52
104481;10.1021/acs.jmedchem.7b00385;Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists.;1663651;69;2221158;CCn1nc(-c2cccc3cccnc23)cc1-c1ccc(N)nn1;EC50;48.0;=;nM;7.32
104481;10.1021/acs.jmedchem.7b00385;Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists.;1663651;mCPP;5884;Clc1cccc(N2CCNCC2)c1;EC50;287.0;=;nM;6.54
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+)-41;2231583;COc1ccccc1CNC[C@H]1C[C@@H]1c1cc(F)ccc1OCCF.Cl;EC50;24.55;=;nM;7.61
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-31;2215061;COc1ccccc1CCNCC1CC1c1cc(F)ccc1OC.Cl;EC50;95.5;=;nM;7.02
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+)-41;2231583;COc1ccccc1CNC[C@H]1C[C@@H]1c1cc(F)ccc1OCCF.Cl;EC50;24.0;=;nM;7.62
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(-)-19;2241105;COc1ccccc1CNC[C@@H]1C[C@H]1c1cc(F)ccc1OC.Cl;EC50;570.0;=;nM;6.24
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-39;2204846;COc1ccc(F)cc1C1CC1CNCc1cccc2cccnc12.Cl;EC50;87.0;=;nM;7.06
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-23;2226197;COc1ccc(F)cc1C1CC1CNCc1ccccc1OCCF.Cl;EC50;56.23;=;nM;7.25
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-37;2213440;COc1ccc(F)cc1C1CC1CNCc1cccc2ccsc12.Cl;EC50;807.0;=;nM;6.09
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+)-15a;2222138;CNC[C@H]1C[C@@H]1c1cc(F)ccc1OC.Cl;EC50;89.0;=;nM;7.05
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;436.52;=;nM;6.36
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+)-15a;2222138;CNC[C@H]1C[C@@H]1c1cc(F)ccc1OC.Cl;EC50;89.13;=;nM;7.05
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-16;2230895;COc1ccc(F)cc1C1CC1CNC1CC1.Cl;EC50;645.65;=;nM;6.19
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-31;2215061;COc1ccccc1CCNCC1CC1c1cc(F)ccc1OC.Cl;EC50;96.0;=;nM;7.02
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-24;2204720;COc1ccc(F)cc1C1CC1CNCc1ccccc1C#N.Cl;EC50;238.0;=;nM;6.62
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+)-40;2203804;C=CCOc1ccc(F)cc1[C@H]1C[C@@H]1CNCc1ccccc1OC.Cl;EC50;112.2;=;nM;6.95
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-25;2233965;COc1ccc(F)cc1C1CC1CNCc1ccccc1C(N)=O.Cl;EC50;331.13;=;nM;6.48
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+)-40;2203804;C=CCOc1ccc(F)cc1[C@H]1C[C@@H]1CNCc1ccccc1OC.Cl;EC50;113.0;=;nM;6.95
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-16;2230895;COc1ccc(F)cc1C1CC1CNC1CC1.Cl;EC50;641.0;=;nM;6.19
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-39;2204846;COc1ccc(F)cc1C1CC1CNCc1cccc2cccnc12.Cl;EC50;87.1;=;nM;7.06
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-24;2204720;COc1ccc(F)cc1C1CC1CNCc1ccccc1C#N.Cl;EC50;239.88;=;nM;6.62
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-36;2234075;COc1ccc(F)cc1C1CC1CNCc1cccnc1OC;EC50;274.0;=;nM;6.56
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(-)-19;2241105;COc1ccccc1CNC[C@@H]1C[C@H]1c1cc(F)ccc1OC.Cl;EC50;575.44;=;nM;6.24
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;433.0;=;nM;6.36
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-37;2213440;COc1ccc(F)cc1C1CC1CNCc1cccc2ccsc12.Cl;EC50;812.83;=;nM;6.09
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-25;2233965;COc1ccc(F)cc1C1CC1CNCc1ccccc1C(N)=O.Cl;EC50;335.0;=;nM;6.47
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-36;2234075;COc1ccc(F)cc1C1CC1CNCc1cccnc1OC;EC50;275.42;=;nM;6.56
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;(+/-)-23;2226197;COc1ccc(F)cc1C1CC1CNCc1ccccc1OCCF.Cl;EC50;56.0;=;nM;7.25
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.445;=;nM;8.84
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664077;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.46;=;nM;8.84
104494;10.1021/acs.jmedchem.7b00584;Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.;1664086;(+)-19;2212633;COc1ccccc1CNC[C@H]1C[C@@H]1c1cc(F)ccc1OC.Cl;Ki;411.0;=;nM;6.39
104643;10.1016/j.bmcl.2017.03.085;Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice.;1667957;5;2201704;O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F;IC50;3800.0;=;nM;5.42
105391;10.1021/acs.jmedchem.7b00561;Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.;1689224;7nn;2206695;Cc1cccc(Cl)c1-c1nc(CN2CCC(C(=O)NCCCN3C[C@H](C)C[C@H](C)C3)CC2)c(C)o1;Ki;415.0;=;nM;6.38
105748;10.1016/j.bmcl.2017.09.020;Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis.;1696905;Azelastine;27309;CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1;Ki;19.95;=;nM;7.7
105748;10.1016/j.bmcl.2017.09.020;Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis.;1696905;33b;2227947;CCCCc1cc(OC2CCN(CCCCNS(=O)(=O)CC)CC2)c2ncccc2c1.Cl.Cl;Ki;794.33;=;nM;6.1
106267;10.1016/j.bmcl.2018.03.093;Identification and biological evaluation of thiazole-based inverse agonists of RORγt.;1711452;1j;2260617;CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12;IC50;3.2;=;nM;8.49
106561;10.1021/acsmedchemlett.7b00293;Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.;1719237;"CDZ173; 3h";1976141;CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1;IC50;7700.0;=;nM;5.11
107039;10.1021/acs.jmedchem.8b00654;Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).;1729988;12;2271156;O=C(Nc1ccc(F)cc1)c1cccc(C(=O)NC2CCCCC2)c1;IC50;90.0;=;nM;7.05
107039;10.1021/acs.jmedchem.8b00654;Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).;1729988;54;2262502;Cc1cc(NC(=O)c2cccc(S(=O)(=O)N[C@H]3CCOC3)c2)ccc1F;IC50;4000.0;=;nM;5.4
107039;10.1021/acs.jmedchem.8b00654;Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).;1729988;63;2276994;CC(C)NS(=O)(=O)c1cccc(C(=O)Nc2ccc(F)c(F)c2)c1;IC50;230.0;=;nM;6.64
107339;10.1016/j.ejmech.2018.02.024;Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.;1737632;20b;2272783;c1ccc(CN2CCc3cc(N4CCOCC4)ccc3C2)cc1;Ki;360.0;=;nM;6.44
107339;10.1016/j.ejmech.2018.02.024;Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.;1737632;21a;2270346;COc1cccc(-c2ccc3c(c2)CN(Cc2ccccc2)C3)c1;Ki;389.5;=;nM;6.41
107339;10.1016/j.ejmech.2018.02.024;Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.;1737632;21b;2263095;COc1cccc(-c2ccc3c(c2)CCN(Cc2ccccc2)C3)c1;Ki;65.0;=;nM;7.19
107339;10.1016/j.ejmech.2018.02.024;Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.;1737632;24a;2266459;CN1CCN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)C3)CC1;Ki;1117.0;=;nM;5.95
107339;10.1016/j.ejmech.2018.02.024;Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.;1737632;27b;2268894;O=C(OCc1ccccc1)N1CCc2ccc(N3CCN(C4CCCC4)CC3)cc2C1;Ki;894.0;=;nM;6.05
107339;10.1016/j.ejmech.2018.02.024;Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.;1737632;28b;2272720;CCOC(=O)CCN1CCN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)CC3)CC1;Ki;505.0;=;nM;6.3
108041;10.1021/acs.jmedchem.8b00168;Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor.;1755208;3c;2295549;CC(C)(C)OC(=O)NCCCCCCn1cc(CCCCN2CCC(c3ccc(-c4cc(C(=O)O)cc5cc(-c6ccc(C(F)(F)F)cc6)ccc45)cc3)CC2)nn1;Ki;2780.0;=;nM;5.56
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;11;2295011;COC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H]1N=C(c2ccccc2O)S[C@@H]1C;Ki;1000.0;=;nM;6.0
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;12;2285680;COC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1N=C(c2ccccc2O)S[C@@H]1C;Ki;1400.0;=;nM;5.85
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;13;2290586;C[C@@H]1SC(c2ccccc2O)=N[C@H]1Cc1c[nH]cn1;Ki;47.0;=;nM;7.33
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;14;2283215;Oc1ccccc1C1=NC(Cc2c[nH]cn2)CS1;Ki;100.0;=;nM;7.0
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;15;2288093;Oc1ccccc1C1=NC(Cc2c[nH]cn2)C(c2ccccc2)S1;Ki;100.0;=;nM;7.0
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;17;2284569;C[C@@H]1SC(c2ccccc2)=N[C@H]1CO;Ki;3000.0;=;nM;5.52
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;18;2293892;CNc1ccccc1C1=N[C@@H](CO)[C@H](C)S1;Ki;1200.0;=;nM;5.92
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;19;2288938;C[C@@H]1SC(c2cc3ccccc3cc2O)=N[C@H]1CO;Ki;810.0;=;nM;6.09
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;20;2280733;C[C@@H]1SC(c2c[nH]c3ccccc23)=N[C@H]1CO;Ki;2400.0;=;nM;5.62
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;22;2285090;C[C@@H]1SC(c2cccs2)=N[C@H]1CO;Ki;1400.0;=;nM;5.85
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;23;2296830;C[C@@H]1SC(c2ccsc2)=N[C@H]1CO;Ki;1500.0;=;nM;5.82
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;24;2290397;CCCCOc1ccc(C2=N[C@@H](CO)[C@H](C)S2)cc1;Ki;7500.0;=;nM;5.12
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;25;2285506;CCCCCCOc1ccc(C2=N[C@@H](CO)[C@H](C)S2)cc1;Ki;4300.0;=;nM;5.37
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;27;2282727;C[C@@H]1SC(c2ccccc2)=N[C@H]1Cc1c[nH]cn1;Ki;380.0;=;nM;6.42
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;28;2282187;C[C@@H]1SC(c2ccccc2)=N[C@@H]1Cc1c[nH]cn1;Ki;690.0;=;nM;6.16
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;29;2287065;C[C@@H]1SC(c2ccc(-c3ccccc3)cc2)=N[C@H]1Cc1c[nH]cn1;Ki;1100.0;=;nM;5.96
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;30;2286527;C[C@H]1SC(c2ccc(-c3ccccc3)cc2)=N[C@H]1Cc1c[nH]cn1;Ki;1400.0;=;nM;5.85
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;4;2295961;C[C@H]1SC(c2ccccc2O)=N[C@H]1CO;Ki;400.0;=;nM;6.4
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;3;2296382;C[C@H]1SC(c2ccccc2O)=N[C@@H]1CO;Ki;620.0;=;nM;6.21
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757981;1;2285453;C[C@@H]1SC(c2ccccc2O)=N[C@H]1CO;Ki;130.0;=;nM;6.89
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;2;1063282;C[C@@H]1SC(c2ccccc2O)=N[C@@H]1CO;Ki;510.0;=;nM;6.29
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;5;1063278;NC(=O)c1csc(-c2ccccc2O)n1;Ki;1000.0;=;nM;6.0
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;6;1063279;NC(=O)C1CSC(c2ccccc2O)=N1;Ki;1300.0;=;nM;5.89
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;7;1063277;OC[C@@H]1CSC(c2ccccc2O)=N1;Ki;1400.0;=;nM;5.85
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;8;2294488;O=Cc1csc(-c2ccccc2O)n1;Ki;1500.0;=;nM;5.82
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;9;1063281;C[C@@H]1SC(c2ccccc2O)=N[C@H]1[C@H]1SC[C@](C)(C(=O)O)N1C;Ki;3900.0;=;nM;5.41
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1757992;10;1063280;C[C@@H]1SC(c2ccccc2O)=N[C@H]1[C@@H]1SC[C@](C)(C(=O)O)N1C;Ki;4700.0;=;nM;5.33
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1758002;1;2285453;C[C@@H]1SC(c2ccccc2O)=N[C@H]1CO;IC50;18000.0;=;nM;4.75
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1758002;2;1063282;C[C@@H]1SC(c2ccccc2O)=N[C@@H]1CO;IC50;30000.0;=;nM;4.52
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1758002;11;2295011;COC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H]1N=C(c2ccccc2O)S[C@@H]1C;IC50;10000.0;=;nM;5.0
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1758002;13;2290586;C[C@@H]1SC(c2ccccc2O)=N[C@H]1Cc1c[nH]cn1;IC50;800.0;=;nM;6.1
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1758002;15;2288093;Oc1ccccc1C1=NC(Cc2c[nH]cn2)C(c2ccccc2)S1;IC50;3800.0;=;nM;5.42
108191;10.1021/acs.jnatprod.7b00317;Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.;1758002;27;2282727;C[C@@H]1SC(c2ccccc2)=N[C@H]1Cc1c[nH]cn1;IC50;10000.0;=;nM;5.0
108430;10.1021/acs.jmedchem.8b00642;Discovery of β-Arrestin Biased Ligands of 5-HT7R.;1764107;1d;2287425;Fc1ccc(-c2n[nH]c3c2CCNCC3)cc1;Ki;97.0;=;nM;7.01
108430;10.1021/acs.jmedchem.8b00642;Discovery of β-Arrestin Biased Ligands of 5-HT7R.;1764107;1g;2286035;Clc1ccc(-c2n[nH]c3c2CCNCC3)cc1;Ki;100.0;=;nM;7.0
108430;10.1021/acs.jmedchem.8b00642;Discovery of β-Arrestin Biased Ligands of 5-HT7R.;1764107;1j;2288933;Cc1ccc(-c2n[nH]c3c2CCNCC3)cc1;Ki;106.0;=;nM;6.97
108430;10.1021/acs.jmedchem.8b00642;Discovery of β-Arrestin Biased Ligands of 5-HT7R.;1764107;2d;2296823;Fc1ccc(-c2noc3c2CCNCC3)cc1;Ki;505.0;=;nM;6.3
108430;10.1021/acs.jmedchem.8b00642;Discovery of β-Arrestin Biased Ligands of 5-HT7R.;1764107;2g;2296952;Clc1ccc(-c2noc3c2CCNCC3)cc1;Ki;247.0;=;nM;6.61
108430;10.1021/acs.jmedchem.8b00642;Discovery of β-Arrestin Biased Ligands of 5-HT7R.;1764107;2j;2294026;Cc1ccc(-c2noc3c2CCNCC3)cc1;Ki;150.0;=;nM;6.82
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;176;2291598;c1cc(CC2CCC2)c2c(n1)N1CCNC[C@H]1CC2;EC50;165.0;=;nM;6.78
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;173;2296525;CCCc1cncc2c1CC[C@@H]1CNCCN21;EC50;1290.0;=;nM;5.89
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;153;2295997;c1cc2c(cn1)N1CCNC[C@H]1CC2;EC50;779.0;=;nM;6.11
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;152;2284277;FC(F)(F)CCc1ccnc2c1CC[C@@H]1CNCCN21;EC50;1290.0;=;nM;5.89
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;149;2282861;c1cc(C2CCC2)c2c(n1)N1CCNC[C@H]1CC2;EC50;21.7;=;nM;7.66
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;148;2287723;c1cnc2c(c1)CC[C@@H]1CNCCN21;EC50;61.2;=;nM;7.21
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;137;2287203;c1cc(CC2CCC2)c2c(n1)N1CCNCC1CC2;EC50;4020.0;=;nM;5.4
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;136;2292122;Brc1ccnc2c1CC[C@@H]1CNCCN21;EC50;489.0;=;nM;6.31
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;128;2290985;Fc1ccc(Cc2ccnc3c2CC[C@@H]2CNCCN32)cc1;EC50;307.0;=;nM;6.51
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;121;2295938;CC(C)(C)Cc1ccnc2c1CC[C@@H]1CNCCN21;EC50;478.0;=;nM;6.32
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;115;2286603;Fc1cccc(Cc2ccnc3c2CC[C@@H]2CNCCN32)c1;EC50;115.0;=;nM;6.94
108551;10.1021/acsmedchemlett.8b00328;5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity.;1766968;106;2291530;c1ccc(Cc2ccnc3c2CC[C@@H]2CNCCN32)cc1;EC50;758.0;=;nM;6.12
108877;10.1016/j.ejmech.2018.01.002;Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.;1773006;Serotonin;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;4.5;=;nM;8.35
109458;10.1039/C7MD00656J;Discovery of 7-hydroxyaporphines as conformationally restricted ligands for beta-1 and beta-2 adrenergic receptors.;1787101;"2; AK-2-202";2324729;COc1cc2c3c(c1OC)-c1ccccc1[C@@H](O)[C@@H]3NCC2;Ki;246.0;=;nM;6.61
109501;10.1039/C8MD00204E;Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.;1788003;7;2331774;O=C(NCCc1c[nH]c2ccccc12)C1CCN(C(=O)c2ccc(-c3ccccc3)cc2)CC1;IC50;14.1;=;nM;7.85
109501;10.1039/C8MD00204E;Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.;1788008;SB-206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;22.2;=;nM;7.65
109501;10.1039/C8MD00204E;Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.;1788008;11;2321565;O=C(NCCc1c[nH]c2ccccc12)C1CCN(C(=O)c2ccccc2)CC1;Ki;79.3;=;nM;7.1
109501;10.1039/C8MD00204E;Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.;1788008;8;2332167;O=C(NCc1ccccc1)C1CCN(C(=O)c2ccc(-c3ccccc3)cc2)CC1;Ki;569.0;=;nM;6.25
109501;10.1039/C8MD00204E;Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.;1788008;7;2331774;O=C(NCCc1c[nH]c2ccccc12)C1CCN(C(=O)c2ccc(-c3ccccc3)cc2)CC1;Ki;4.5;=;nM;8.35
109501;10.1039/C8MD00204E;Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.;1788011;7;2331774;O=C(NCCc1c[nH]c2ccccc12)C1CCN(C(=O)c2ccc(-c3ccccc3)cc2)CC1;IC50;18.7;=;nM;7.73
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;6;2327071;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;Ki;2199.0;=;nM;5.66
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;11a;2330496;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1;Ki;177.0;=;nM;6.75
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;11b;2317916;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1;Ki;509.0;=;nM;6.29
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;8a;1060034;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;Ki;423.0;=;nM;6.37
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;8b;1060036;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccccc2)c2ccccc2)CC1;Ki;374.0;=;nM;6.43
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;8c;2332755;COc1ccc(N(CCCCN2CCC(O)(c3ccc(Cl)c(C(F)(F)F)c3)CC2)c2ccc(OC)cc2)cc1;Ki;729.0;=;nM;6.14
109544;10.1016/j.bmcl.2018.10.036;Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.;1789066;PFL;66843;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;Ki;184.0;=;nM;6.74
109632;10.1039/C7MD00247E;Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.;1791039;6c;2333798;NCCCCNC(=O)COc1ccc(CCCn2ncc3c2nc(N)n2nc(-c4ccco4)nc32)cc1;Ki;3.36;=;nM;8.47
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;3;2070947;NC1=NC2(CCCCC2)NC(Nc2ccccc2)=N1;IC50;1641.3;=;nM;5.79
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;4;2325868;NC1=NC2(CCCCC2)NC(Nc2cccc(F)c2)=N1;IC50;403.4;=;nM;6.39
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;5;2333086;NC1=NC2(CCCCC2)NC(Nc2cccc(Cl)c2)=N1;IC50;46.9;=;nM;7.33
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;2;2070946;NC1=NC2(CCCCC2)NC(Nc2cccc(Br)c2)=N1;IC50;35.4;=;nM;7.45
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;6;2329693;NC1=NC2(CCCCC2)NC(Nc2cccc(I)c2)=N1;IC50;23.3;=;nM;7.63
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;7;797534;Cc1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;459.4;=;nM;6.34
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;9;2334171;NC1=NC2(CCCCC2)NC(Nc2cc(Br)cc(Br)c2)=N1;IC50;215.0;=;nM;6.67
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;10;2331616;NC1=NC2(CCCCC2)NC(Nc2cc(F)cc(Br)c2)=N1;IC50;74.9;=;nM;7.13
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797423;11;2320994;CCOC(=O)c1cc(Br)cc(NC2=NC(N)=NC3(CCCCC3)N2)c1;IC50;1962.5;=;nM;5.71
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;3;2070947;NC1=NC2(CCCCC2)NC(Nc2ccccc2)=N1;Ki;151.3;=;nM;6.82
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;4;2325868;NC1=NC2(CCCCC2)NC(Nc2cccc(F)c2)=N1;Ki;53.3;=;nM;7.27
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;5;2333086;NC1=NC2(CCCCC2)NC(Nc2cccc(Cl)c2)=N1;Ki;6.3;=;nM;8.2
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;2;2070946;NC1=NC2(CCCCC2)NC(Nc2cccc(Br)c2)=N1;Ki;5.8;=;nM;8.24
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;6;2329693;NC1=NC2(CCCCC2)NC(Nc2cccc(I)c2)=N1;Ki;1.7;=;nM;8.77
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;7;797534;Cc1cccc(NC2=NC(N)=NC3(CCCCC3)N2)c1;Ki;19.8;=;nM;7.7
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;8;2326267;NC1=NC2(CCCCC2)NC(Nc2cccc(O)c2)=N1;Ki;313.5;=;nM;6.5
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;12;2330055;CN(C)CC/C=C1\c2ccc(F)cc2COc2ccccc21;Ki;16.6;=;nM;7.78
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;13;2322177;CN(C)CC/C=C1\c2ccc(Cl)cc2COc2ccccc21;Ki;3.0;=;nM;8.52
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;14;2326641;CN(C)CC/C=C1\c2ccc(Br)cc2COc2ccccc21;Ki;2.5;=;nM;8.6
109887;10.1021/acsmedchemlett.8b00300;Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.;1797425;doxepin;66012;CN(C)CC/C=C1\c2ccccc2COc2ccccc21;Ki;25.3;=;nM;7.6
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4c;2364763;C[C@@]12CN(c3ccccc3)c3ccccc3[C@@H]1CCN2;Ki;501.19;=;nM;6.3
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3a;2379712;CC[C@H]1c2cc(OC)ccc2CC[C@@]1(C)N;Ki;144.54;=;nM;6.84
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3b;2399082;CC[C@H]1c2cc(C)ccc2OC[C@@]1(C)N;Ki;177.83;=;nM;6.75
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3c;2442598;CC[C@H]1c2ccccc2N(c2ccccc2)C[C@@]1(C)N;Ki;794.33;=;nM;6.1
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3e;2365108;CC[C@H]1c2cc(OC)ccc2OC[C@@]1(C)N;Ki;251.19;=;nM;6.6
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3f;2401410;CC[C@H]1c2cc(-c3ccccc3)ccc2OC[C@@]1(C)N;Ki;125.89;=;nM;6.9
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3g;2454340;CC[C@H]1c2ccc3ccccc3c2OC[C@@]1(C)N;Ki;2.512;=;nM;8.6
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3h;2385341;CC[C@H]1c2c(ccc3ccccc23)OC[C@@]1(C)N;Ki;19.95;=;nM;7.7
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4f;2461439;C[C@@]12COc3ccc(-c4ccccc4)cc3[C@@H]1CCN2;Ki;251.19;=;nM;6.6
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4e;2426725;COc1ccc2c(c1)[C@@H]1CCN[C@]1(C)CO2;Ki;630.96;=;nM;6.2
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4i;2459881;C[C@@]12COc3cc(OCc4ccccc4)ccc3[C@@H]1CCN2;Ki;125.89;=;nM;6.9
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-10d;2434736;CN1CC[C@H]2c3ccc(O)cc3OC[C@]21C;Ki;1000.0;=;nM;6.0
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4j;2354984;COc1cc(OC)c2c(c1)OC[C@@]1(C)NCC[C@@H]21;Ki;251.19;=;nM;6.6
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4k;2363204;Cc1cc(C)c2c(c1)OC[C@@]1(C)NCC[C@@H]21;Ki;79.43;=;nM;7.1
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4l;2342246;C[C@@]12COc3c(-c4ccccc4)cccc3[C@@H]1CCN2;Ki;158.49;=;nM;6.8
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-10l;2380706;CN1CC[C@H]2c3cccc(-c4ccccc4)c3OC[C@]21C;Ki;251.19;=;nM;6.6
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-11l;2348630;CC(=O)N1CC[C@H]2c3cccc(-c4ccccc4)c3OC[C@]21C;Ki;501.19;=;nM;6.3
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4m;2371706;C[C@@]12COc3c(Br)cccc3[C@@H]1CCN2;Ki;19.95;=;nM;7.7
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-10c;2366018;CN1CC[C@H]2c3ccccc3N(c3ccccc3)C[C@]21C;Ki;199.53;=;nM;6.7
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4n;2383402;Cc1ccc(N2C[C@@]3(C)NCC[C@H]3c3cc(C)ccc32)cc1;Ki;316.23;=;nM;6.5
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-4o;2461539;C[C@@]12CN(c3ccc(Br)cc3)c3ccc(Br)cc3[C@@H]1CCN2;Ki;316.23;=;nM;6.5
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3g;2454340;CC[C@H]1c2ccc3ccccc3c2OC[C@@]1(C)N;Ki;3.5;=;nM;8.46
110440;10.1021/acsmedchemlett.9b00225;3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands.;1809250;(+/-)-3h;2385341;CC[C@H]1c2c(ccc3ccccc23)OC[C@@]1(C)N;Ki;20.0;=;nM;7.7
110453;10.1021/acs.jmedchem.8b00401;Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.;1809672;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;Ki;174.0;=;nM;6.76
110602;10.1016/j.ejmech.2019.111736;Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.;1814787;OPC-34712;1378030;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;Ki;0.3981;=;nM;9.4
110602;10.1016/j.ejmech.2019.111736;Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.;1814787;Methysergide maleate;674889;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1.O=C(O)/C=C\C(=O)O;Ki;1.9;=;nM;8.72
111452;10.1016/j.bmc.2019.02.044;Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.;1842350;PRX-08066;459331;N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F;Ki;3.4;=;nM;8.47
111816;10.1021/acs.jmedchem.9b01256;4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain.;1855932;15au;2368783;O=C1N(c2cccnc2C(F)(F)F)CC2(CCN(CCc3ccccc3F)CC2)OC12CC2;Ki;754.0;=;nM;6.12
111882;10.1021/acs.jmedchem.9b00260;Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.;1859527;27;2344115;CO[C@H](C(=O)Nc1nnc(N[C@@H]2CCN(c3cccnn3)C2)s1)c1ccccc1;IC50;13000.0;=;nM;4.89
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;Serotonin;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;0.8511;=;nM;9.07
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;79.43;=;nM;7.1
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+/-)-12;2386822;COc1ccc(F)cc1C1(F)CC1CN.Cl;EC50;114.82;=;nM;6.94
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+/-)-13;2412048;COc1ccccc1CNCC1CC1(F)c1cc(F)ccc1OC.Cl;EC50;281.84;=;nM;6.55
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-21a;1368487;Cl.NC[C@H]1C[C@]1(F)c1ccccc1;EC50;10.0;=;nM;8.0
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(-)-21a;2379839;Cl.NC[C@@H]1C[C@@]1(F)c1ccccc1;EC50;912.01;=;nM;6.04
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-21c;2373600;Cl.NC[C@H]1C[C@]1(F)c1cccc(F)c1;EC50;2.291;=;nM;8.64
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-21d;2388346;Cl.NC[C@H]1C[C@]1(F)c1cccc(Cl)c1;EC50;21.88;=;nM;7.66
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-22;2408068;CNC[C@H]1C[C@]1(F)c1ccccc1.Cl;EC50;562.34;=;nM;6.25
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-23;2445594;COc1ccccc1CNC[C@H]1C[C@]1(F)c1ccccc1.Cl;EC50;363.08;=;nM;6.44
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+/-)-24;2364849;Cl.NCC1C(c2ccccc2)C1(F)F;EC50;2344.23;=;nM;5.63
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;Serotonin;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;0.86;=;nM;9.07
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;80.0;=;nM;7.1
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+/-)-12;2386822;COc1ccc(F)cc1C1(F)CC1CN.Cl;EC50;116.0;=;nM;6.94
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+/-)-13;2412048;COc1ccccc1CNCC1CC1(F)c1cc(F)ccc1OC.Cl;EC50;285.0;=;nM;6.54
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-21a;1368487;Cl.NC[C@H]1C[C@]1(F)c1ccccc1;EC50;10.0;=;nM;8.0
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(-)-21a;2379839;Cl.NC[C@@H]1C[C@@]1(F)c1ccccc1;EC50;903.0;=;nM;6.04
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-21c;2373600;Cl.NC[C@H]1C[C@]1(F)c1cccc(F)c1;EC50;2.0;=;nM;8.7
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-21d;2388346;Cl.NC[C@H]1C[C@]1(F)c1cccc(Cl)c1;EC50;22.0;=;nM;7.66
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-22;2408068;CNC[C@H]1C[C@]1(F)c1ccccc1.Cl;EC50;565.0;=;nM;6.25
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+)-23;2445594;COc1ccccc1CNC[C@H]1C[C@]1(F)c1ccccc1.Cl;EC50;363.0;=;nM;6.44
111965;10.1016/j.ejmech.2019.111626;Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.;1862254;(+/-)-24;2364849;Cl.NCC1C(c2ccccc2)C1(F)F;EC50;2347.0;=;nM;5.63
112109;10.1016/j.bmcl.2019.126679;Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.;1867645;19;2378068;Cl.Cl.O=c1c2cc(Cl)ccc2oc2ccc(CN3CCN(CCOCCO)CC3)cc12;Ki;2900.0;=;nM;5.54
112129;10.1039/C8MD00317C;Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A<sub>3</sub> adenosine receptor antagonists.;1868111;"25; MRS7320";2451999;Oc1ccc(CCNc2nc(C#Cc3ccc(Cl)s3)nc3[nH]cnc23)cc1O;Ki;1210.0;=;nM;5.92
112129;10.1039/C8MD00317C;Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A<sub>3</sub> adenosine receptor antagonists.;1868111;"19; MRS7326";2458382;O[C@H]1CCC[C@@H]1Nc1nc(C#Cc2ccc(Cl)s2)nc2[nH]cnc12;Ki;1860.0;=;nM;5.73
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"7; MRS5474";1333748;O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc21;Ki;641.0;=;nM;6.19
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"19; MRS7399";2378721;O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NC(C3CCC3)C3CCC3)nc(Cl)nc21;Ki;2900.0;=;nM;5.54
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;24;2343795;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CCC4)C4CCC4)ncnc31)[C@H](O)[C@@H]2O;Ki;214.0;=;nM;6.67
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"25; MRS7421";2377089;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CCC4)C4CCC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;153.0;=;nM;6.82
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"26; MRS7588";2424723;O[C@H]1[C@H](n2cnc3c(NC(C4CCC4)C4CCC4)ncnc32)[C@H]2C[C@@]2(CCl)[C@H]1O;Ki;2010.0;=;nM;5.7
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"27; MRS7436";2394275;O[C@H]1[C@H](n2cnc3c(NC(C4CCC4)C4CCC4)nc(Cl)nc32)[C@H]2C[C@@]2(CCl)[C@H]1O;Ki;1520.0;=;nM;5.82
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;28;2454571;O[C@H]1[C@H](n2cnc3c(NC(C4CCC4)C4CCC4)nc(Cl)nc32)[C@H]2C[C@@]2(CSc2ccccc2F)[C@H]1O;Ki;334.0;=;nM;6.48
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;32;2164890;CCOC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;15.0;=;nM;7.82
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;34;2185492;CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;23.0;=;nM;7.64
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"35; MRS7423";2443336;CCOC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CCC4)C4CCC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;97.0;=;nM;7.01
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;6;331610;CNC(=O)[C@]12C[C@@H]1[C@@H](n1cnc3c(NC4CCCC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;12.0;=;nM;7.92
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"36; MRS7412";2370811;O=C(NC1CC1)[C@@]12C[C@@H]1[C@@H](n1cnc3c(N[C@H]4C[C@H]5CC[C@@H]4C5)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;1570.0;=;nM;5.8
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"37; MRS7413";2450081;O=C(NCCO)[C@@]12C[C@@H]1[C@@H](n1cnc3c(N[C@H]4C[C@H]5CC[C@@H]4C5)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;718.0;=;nM;6.14
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"40; MRS7451";2380748;NC(=O)c1ncn([C@H]2[C@H](O)[C@H](O)[C@]3(CO)C[C@H]23)n1;Ki;1910.0;=;nM;5.72
112173;10.1021/acs.jmedchem.8b01662;Design and in Vivo Characterization of A<sub>1</sub> Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.;1868866;"29; MRS7341";2457575;OC[C@@]12C[C@@H]1[C@@H](n1cnc3c(N[C@H]4C[C@H]5CC[C@@H]4C5)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;472.0;=;nM;6.33
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871670;11b;2451194;CCCN1CCc2cc(OC)cc3c2[C@H]1Cc1cccc(OC(=O)c2ccc(F)cc2)c1-3.Cl;Ki;106.0;=;nM;6.97
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871670;8b;2435778;CCCN1CCc2cc(OC)cc3c2[C@H]1Cc1cccc(OCCF)c1-3.Cl;Ki;3044.0;=;nM;5.52
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871670;11a;2439943;COc1cc2c3c(c1)-c1c(cccc1OC(=O)c1ccc(F)cc1)C[C@H]3N(C)CC2.Cl;Ki;102.0;=;nM;6.99
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871670;10a;2343614;COc1cc2c3c(c1)-c1c(cccc1OCc1ccc(F)cc1)C[C@H]3N(C)CC2.Cl;Ki;2681.0;=;nM;5.57
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871670;9a;2372672;COc1cc2c3c(c1)-c1c(cccc1OCCCF)C[C@H]3N(C)CC2.Cl;Ki;422.0;=;nM;6.38
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871670;8a;2383891;COc1cc2c3c(c1)-c1c(cccc1OCCF)C[C@H]3N(C)CC2.Cl;Ki;552.0;=;nM;6.26
112271;10.1016/j.bmcl.2018.11.050;Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.;1871675;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;Ki;174.0;=;nM;6.76
112322;10.1039/C9MD00050J;Synthesis of endolides A and B: naturally occurring <i>N</i>-methylated cyclic tetrapeptides.;1872633;2;2389982;CC(C)[C@@H]1NC(=O)[C@H](Cc2ccoc2)N(C)C(=O)[C@H](Cc2ccoc2)NC(=O)[C@H](Cc2ccoc2)N(C)C1=O;Ki;770.0;=;nM;6.11
112863;10.1021/acs.jmedchem.9b00351;Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D<sub>1</sub> Receptor Agonists.;1890387;"1; PF-6142";2316715;Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12;Ki;4100.0;=;nM;5.39
112863;10.1021/acs.jmedchem.9b00351;Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D<sub>1</sub> Receptor Agonists.;1890387;17;2443045;Cc1ncc2nccn2c1-c1ccc(Oc2nccc3occc23)cc1C(F)(F)F;Ki;6700.0;=;nM;5.17
112863;10.1021/acs.jmedchem.9b00351;Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D<sub>1</sub> Receptor Agonists.;1890387;41;2376857;FC(F)(F)c1cc(Oc2nccc3occc23)ccc1-c1cccc2nccn12;Ki;830.0;=;nM;6.08
112863;10.1021/acs.jmedchem.9b00351;Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D<sub>1</sub> Receptor Agonists.;1890387;46;2373492;FC(F)(F)c1cc(Oc2nccc3ccsc23)ccc1-c1cccc2nccn12;Ki;1100.0;=;nM;5.96
113038;10.1016/j.ejmech.2019.04.064;Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity.;1894259;"40; E40";2449551;CC(C)CCO[C@@H]1[C@H]2OC(C)(C)O[C@H]2[C@H]2Cn3cc(nn3)COCCCCCCN(CCc3ccc4ccccc4c3)CC[C@H]1O2;Ki;870.0;=;nM;6.06
113038;10.1016/j.ejmech.2019.04.064;Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity.;1894259;"40; E40";2449551;CC(C)CCO[C@@H]1[C@H]2OC(C)(C)O[C@H]2[C@H]2Cn3cc(nn3)COCCCCCCN(CCc3ccc4ccccc4c3)CC[C@H]1O2;IC50;1600.0;=;nM;5.8
113038;10.1016/j.ejmech.2019.04.064;Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity.;1894259;MEC-B;2432731;CC(C)CCO[C@@H]1[C@H]2OC(C)(C)O[C@H]2[C@H]2COCc3cn(nn3)C[C@H]3O[C@H](CCN(CCc4ccc5ccccc5c4)CC[C@H]1O2)[C@H](OCCC(C)C)[C@H]1OC(C)(C)O[C@H]13;Ki;8200.0;=;nM;5.09
113038;10.1016/j.ejmech.2019.04.064;Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity.;1894259;MEC-B;2432731;CC(C)CCO[C@@H]1[C@H]2OC(C)(C)O[C@H]2[C@H]2COCc3cn(nn3)C[C@H]3O[C@H](CCN(CCc4ccc5ccccc5c4)CC[C@H]1O2)[C@H](OCCC(C)C)[C@H]1OC(C)(C)O[C@H]13;IC50;15000.0;=;nM;4.82
113038;10.1016/j.ejmech.2019.04.064;Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity.;1894259;Mesulergine;10959;CN1C[C@@H](NS(=O)(=O)N(C)C)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;Ki;2.8;=;nM;8.55
113038;10.1016/j.ejmech.2019.04.064;Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity.;1894259;Mesulergine;10959;CN1C[C@@H](NS(=O)(=O)N(C)C)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;IC50;5.2;=;nM;8.28
113076;10.1021/acs.jmedchem.9b00412;Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs).;1895345;1;2224173;COc1ccccc1N1CCC2(CCN(CCCSc3nnc(-c4ccccc4)n3C)CC2)CC1;Ki;2144.0;=;nM;5.67
113076;10.1021/acs.jmedchem.9b00412;Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs).;1895345;31;2223163;COc1ccccc1N1CCN(CCCSc2nnc(-c3ccccc3)n2C)CC1;Ki;42.0;=;nM;7.38
113363;10.1021/acs.jmedchem.0c00424;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.;1904340;Serotonin;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;4.5;=;nM;8.35
113363;10.1021/acs.jmedchem.0c00424;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.;1904341;SB206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;EC50;13.0;=;nM;7.89
113363;10.1021/acs.jmedchem.0c00424;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.;1904383;"20; ML417";2383790;COc1ccc(OCCN2CCN(C(=O)c3cc4ccccc4[nH]3)CC2)cc1;Ki;674.0;=;nM;6.17
113363;10.1021/acs.jmedchem.0c00424;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.;1904383;CJ-1639;1443010;CCCN(CC[C@]1(O)C[C@H](NC(=O)c2ccc3ccccc3c2)C1)[C@H]1CCc2nc(N)sc2C1;Ki;1178.0;=;nM;5.93
113363;10.1021/acs.jmedchem.0c00424;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.;1904384;"20; ML417";2383790;COc1ccc(OCCN2CCN(C(=O)c3cc4ccccc4[nH]3)CC2)cc1;Ki;5997.0;=;nM;5.22
113363;10.1021/acs.jmedchem.0c00424;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.;1904384;CJ-1639;1443010;CCCN(CC[C@]1(O)C[C@H](NC(=O)c2ccc3ccccc3c2)C1)[C@H]1CCc2nc(N)sc2C1;Ki;762.0;=;nM;6.12
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904957;78;2372521;Nc1nc(NCCCc2ccccc2)nc(-c2cc(Cl)ccc2CO)n1;Ki;295.0;=;nM;6.53
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904957;77;2431444;Nc1nc(NCCc2ccccc2)nc(-c2cc(Cl)ccc2CO)n1;Ki;209.0;=;nM;6.68
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904957;"71; MS48107";2356721;Nc1nc(NCc2ccc(Oc3ccccc3)cc2)nc(-c2c(F)cccc2CO)n1;Ki;219.0;=;nM;6.66
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904957;78;2372521;Nc1nc(NCCCc2ccccc2)nc(-c2cc(Cl)ccc2CO)n1;Ki;316.23;=;nM;6.5
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904957;77;2431444;Nc1nc(NCCc2ccccc2)nc(-c2cc(Cl)ccc2CO)n1;Ki;316.23;=;nM;6.5
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904957;"71; MS48107";2356721;Nc1nc(NCc2ccc(Oc3ccccc3)cc2)nc(-c2c(F)cccc2CO)n1;Ki;316.23;=;nM;6.5
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904960;78;2372521;Nc1nc(NCCCc2ccccc2)nc(-c2cc(Cl)ccc2CO)n1;Ki;212.0;=;nM;6.67
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904960;77;2431444;Nc1nc(NCCc2ccccc2)nc(-c2cc(Cl)ccc2CO)n1;Ki;678.0;=;nM;6.17
113385;10.1021/acs.jmedchem.9b00869;Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).;1904960;"71; MS48107";2356721;Nc1nc(NCc2ccc(Oc3ccccc3)cc2)nc(-c2c(F)cccc2CO)n1;Ki;310.0;=;nM;6.51
113933;10.1016/j.ejmech.2018.12.048;Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential Sigma-1 (σ<sub>1</sub>) receptor selective ligands.;1920491;UVM147;2386083;CC1=NC2(CCN(C)CC2)C(=O)N(c2c(C)cccc2C)C1=O;Ki;231.0;=;nM;6.64
113933;10.1016/j.ejmech.2018.12.048;Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential Sigma-1 (σ<sub>1</sub>) receptor selective ligands.;1920491;39;2422726;Cc1cccc(C)c1N1C(=O)[C@H](CO)NC2(CCN(C)CC2)C1=O;Ki;2051.0;=;nM;5.69
113933;10.1016/j.ejmech.2018.12.048;Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential Sigma-1 (σ<sub>1</sub>) receptor selective ligands.;1920491;17;2432865;Cc1cccc(C)c1N1C(=O)[C@H](CC2CNc3ccccc32)NC2(CCN(C)CC2)C1=O;Ki;840.0;=;nM;6.08
113933;10.1016/j.ejmech.2018.12.048;Synthesis of spiro-2,6-dioxopiperazine and spiro-2,6-dioxopyrazine scaffolds using amino acids in a three-component reaction to generate potential Sigma-1 (σ<sub>1</sub>) receptor selective ligands.;1920491;8;2379260;Cc1cccc(C)c1N1C(=O)CNC2(CCN(C)CC2)C1=O;Ki;742.0;=;nM;6.13
113947;10.1016/j.ejmech.2018.12.070;Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT<sub>2C</sub> and negative allosteric modulator of 5-HT<sub>2B</sub> receptors.;1920942;40a;2404383;O=C(c1ccc(-n2ccnc2)cc1)C1CC1;EC50;1.259;=;nM;8.9
113947;10.1016/j.ejmech.2018.12.070;Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT<sub>2C</sub> and negative allosteric modulator of 5-HT<sub>2B</sub> receptors.;1920942;41a;2367613;O=C(c1ccc(-n2cnc([N+](=O)[O-])c2)cc1)C1CC1;EC50;1.259;=;nM;8.9
113947;10.1016/j.ejmech.2018.12.070;Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT<sub>2C</sub> and negative allosteric modulator of 5-HT<sub>2B</sub> receptors.;1920942;58;2438117;O=C(c1ccc(N2CCN(Cc3ccccc3)CC2)cc1)C1CC1;EC50;11.75;=;nM;7.93
114082;10.1016/j.bmcl.2016.06.060;Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.;1923999;7;576228;O=c1cc2c(nn1Cc1ccccc1)CCNCC2;EC50;360.0;=;nM;6.44
114082;10.1016/j.bmcl.2016.06.060;Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.;1923999;15b;2442072;Clc1ccc(Cc2cc3c(nn2)CCNCC3)cc1;EC50;410.0;=;nM;6.39
114082;10.1016/j.bmcl.2016.06.060;Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.;1923999;15c;2370597;Clc1ccccc1Cc1cc2c(nn1)CCNCC2;EC50;800.0;=;nM;6.1
114082;10.1016/j.bmcl.2016.06.060;Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.;1923999;15d;2409091;FC(F)(F)c1cccc(Cc2cc3c(nn2)CCNCC3)c1;EC50;450.0;=;nM;6.35
114166;10.1021/acs.jmedchem.6b00689;South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.;1925625;"55; MRS4380";2423323;OC[C@@]12C[C@@H]1[C@@H](n1cc(-c3ccccc3)c3c(Nc4ccccc4)ncnc31)[C@H](O)[C@@H]2O;Ki;51.0;=;nM;7.29
115302;10.6019/CHEMBL4507294;Data for DCP probe MSD-CYP11B2;2139513;EUB0000313;1948545;CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1;IC50;5330.0;=;nM;5.27
116010;10.1021/acs.jnatprod.9b01107;Isolation and Synthesis of Veranamine, an Antidepressant Lead from the Marine Sponge <i>Verongula rigida</i>.;1979101;1;2478843;Cc1nccc2c1C(C)(C)Nc1cc(Br)ccc1-2;Ki;390.0;=;nM;6.41
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7b;2479314;Clc1ccc2c3c1CCN3CCNC2;EC50;5930.0;=;nM;5.23
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;12b;2475365;Clc1ccc2c3c1CCCN3CCNC2;EC50;2110.0;=;nM;5.68
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;14;2471396;Clc1ccc2c3c1SCCN3CCNC2;EC50;391.0;=;nM;6.41
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;29a;2480866;c1cc2c3c(c1)CNCCN3CCCC2;EC50;500.0;=;nM;6.3
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7e;2472412;Brc1ccc2c3c1CCN3CCNC2;EC50;2150.0;=;nM;5.67
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7f;2483968;FC(F)(F)c1ccc2c3c1CCN3CCNC2;EC50;1680.0;=;nM;5.78
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7g;2475673;COc1ccc2c3c1CCN3CCNC2;EC50;19000.0;=;nM;4.72
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7i;2480125;CCc1ccc2c3c1CCN3CCNC2;EC50;1750.0;=;nM;5.76
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7j;2474226;CCCc1ccc2c3c1CCN3CCNC2;EC50;1220.0;=;nM;5.91
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7k;2475612;CC(C)Cc1ccc2c3c1CCN3CCNC2;EC50;320.0;=;nM;6.5
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7l;2473052;c1cc(C2CC2)c2c3c1CNCCN3CC2;EC50;260.0;=;nM;6.58
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7p;2472572;C[C@@H]1c2cccc3c2N(CCNC3)[C@@H]1C;EC50;6000.0;=;nM;5.22
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7r;2476528;FC(F)(F)CC1CN2CCNCc3cccc1c32;EC50;3400.0;=;nM;5.47
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7u;2472754;c1cc2c3c(c1)C1(CCC1)CN3CCNC2;EC50;6420.0;=;nM;5.19
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7w;2483169;Cc1ccc2c3c1C(C)CN3CCNC2;EC50;175.0;=;nM;6.76
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7x;2471501;CC1CN2CCNCc3ccc(Cl)c1c32;EC50;325.0;=;nM;6.49
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7y;2475648;CC1CN2CCNCc3ccc(Br)c1c32;EC50;160.0;=;nM;6.8
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7z;2483123;FC(F)(F)CC1CN2CCNCc3ccc(Br)c1c32;EC50;125.0;=;nM;6.9
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7ab;2469033;CC1CN2CCNCc3cc(Cl)c(Cl)c1c32;EC50;800.0;=;nM;6.1
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7ac;2481423;Cc1cc2c3c(c1Cl)C(C)CN3CCNC2;EC50;300.0;=;nM;6.52
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7ag;2473535;CC1(C)CN2CCNCc3ccc(Br)c1c32;EC50;200.0;=;nM;6.7
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7ah;2471664;CC1(C)CN2CCNCc3ccc(Cl)c1c32;EC50;320.0;=;nM;6.5
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7ai;2474440;CC1(C)CN2CCNCc3ccc(F)c1c32;EC50;10600.0;=;nM;4.97
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983947;7aj;2475437;Cc1ccc2c3c1C(C)(C)CN3CCNC2;EC50;215.0;=;nM;6.67
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;1;301194;C[C@H]1CNCCc2ccc(Cl)cc21;Ki;220.0;=;nM;6.66
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7b;2479314;Clc1ccc2c3c1CCN3CCNC2;Ki;637.0;=;nM;6.2
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;12b;2475365;Clc1ccc2c3c1CCCN3CCNC2;Ki;226.0;=;nM;6.65
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;13;2485008;Clc1ccc2c3c1OCCN3CCNC2;Ki;360.0;=;nM;6.44
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;14;2471396;Clc1ccc2c3c1SCCN3CCNC2;Ki;3730.0;=;nM;5.43
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;24;2471851;[O-][S+]1CCN2CCNCc3ccc(Cl)c1c32;Ki;442.0;=;nM;6.36
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7e;2472412;Brc1ccc2c3c1CCN3CCNC2;Ki;127.0;=;nM;6.9
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7f;2483968;FC(F)(F)c1ccc2c3c1CCN3CCNC2;Ki;105.0;=;nM;6.98
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7g;2475673;COc1ccc2c3c1CCN3CCNC2;Ki;3500.0;=;nM;5.46
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7m;2482287;c1ccc(Cc2ccc3c4c2CCN4CCNC3)cc1;Ki;925.0;=;nM;6.03
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7n;2468979;CC1CN2CCNCc3cccc1c32;Ki;4350.0;=;nM;5.36
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7r;2476528;FC(F)(F)CC1CN2CCNCc3cccc1c32;Ki;395.0;=;nM;6.4
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7s;2482325;CC1(C)CN2CCNCc3cccc1c32;Ki;1800.0;=;nM;5.75
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7u;2472754;c1cc2c3c(c1)C1(CCC1)CN3CCNC2;Ki;550.0;=;nM;6.26
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7w;2483169;Cc1ccc2c3c1C(C)CN3CCNC2;Ki;22.0;=;nM;7.66
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7x;2471501;CC1CN2CCNCc3ccc(Cl)c1c32;Ki;46.0;=;nM;7.34
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7y;2475648;CC1CN2CCNCc3ccc(Br)c1c32;Ki;21.0;=;nM;7.68
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7z;2483123;FC(F)(F)CC1CN2CCNCc3ccc(Br)c1c32;Ki;18.0;=;nM;7.75
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7ab;2469033;CC1CN2CCNCc3cc(Cl)c(Cl)c1c32;Ki;168.0;=;nM;6.78
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7ac;2481423;Cc1cc2c3c(c1Cl)C(C)CN3CCNC2;Ki;150.0;=;nM;6.82
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7ag;2473535;CC1(C)CN2CCNCc3ccc(Br)c1c32;Ki;28.0;=;nM;7.55
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7ah;2471664;CC1(C)CN2CCNCc3ccc(Cl)c1c32;Ki;18.0;=;nM;7.75
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7ai;2474440;CC1(C)CN2CCNCc3ccc(F)c1c32;Ki;320.0;=;nM;6.5
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983949;7aj;2475437;Cc1ccc2c3c1C(C)(C)CN3CCNC2;Ki;24.0;=;nM;7.62
116213;10.1016/j.bmcl.2019.126929;Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assays.;1983999;"3; SCA-136";2471345;C1=CC2CNCCN3C[C@@H]4CCC[C@@H]4C(=C1)C23;Ki;13.8;=;nM;7.86
116420;10.1021/acs.jmedchem.0c00807;2-Arylbenzo[<i>d</i>]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy.;1987910;(+)-27;2475150;CCP(=O)(OC)c1ccc2oc(-c3ccc(F)cc3)nc2c1;EC50;9300.0;=;nM;5.03
116420;10.1021/acs.jmedchem.0c00807;2-Arylbenzo[<i>d</i>]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy.;1987910;(-)-27;2475150;CCP(=O)(OC)c1ccc2oc(-c3ccc(F)cc3)nc2c1;EC50;50000.0;=;nM;4.3
116556;10.1016/j.bmcl.2020.127214;Azetidine-based selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties.;1990763;26;2476986;COc1c(S(C)(=O)=O)ccc(O[C@@H](C)C(F)(F)F)c1C(=O)N1CC(c2ncc(C(F)(F)F)cc2Cl)C1;IC50;1500.0;=;nM;5.82
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016545;"3d; 5-HCPC";2532693;N#Cc1cccc(CCCc2cc(=O)c3c(O)cccc3o2)c1;IC50;6309.57;=;nM;5.2
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016546;"3d; 5-HCPC";2532693;N#Cc1cccc(CCCc2cc(=O)c3c(O)cccc3o2)c1;EC50;501.19;=;nM;6.3
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016546;"1; 5-HT";2214;NCCc1c[nH]c2ccc(O)cc12;EC50;0.07079;=;nM;10.15
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3a;2511198;Cc1cccc(CCCc2cc(=O)c3c(O)cccc3o2)c1;Ki;1995.26;=;nM;5.7
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3b;2517118;O=c1cc(CCCc2cccc(C(F)(F)F)c2)oc2cccc(O)c12;Ki;1000.0;=;nM;6.0
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3c;2526821;O=c1cc(CCCc2cccc(Cl)c2)oc2cccc(O)c12;Ki;1995.26;=;nM;5.7
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;"3d; 5-HCPC";2532693;N#Cc1cccc(CCCc2cc(=O)c3c(O)cccc3o2)c1;Ki;79.43;=;nM;7.1
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3e;2520415;O=c1cc(CCCc2cccc(F)c2)oc2cccc(O)c12;Ki;2511.89;=;nM;5.6
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3f;2502681;COc1cccc(CCCc2cc(=O)c3c(O)cccc3o2)c1;Ki;1258.93;=;nM;5.9
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3g;2489444;Cc1ccc(CCCc2cc(=O)c3c(O)cccc3o2)cc1;Ki;1584.89;=;nM;5.8
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3h;2490983;O=c1cc(CCCc2ccc(C(F)(F)F)cc2)oc2cccc(O)c12;Ki;2511.89;=;nM;5.6
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3i;2493496;O=c1cc(CCCc2ccc(Cl)cc2)oc2cccc(O)c12;Ki;2511.89;=;nM;5.6
117318;10.1016/j.bmcl.2020.127511;Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT receptor antagonist scaffold.;2016548;3k;2532189;COc1ccc(CCCc2cc(=O)c3c(O)cccc3o2)cc1;Ki;1000.0;=;nM;6.0
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4j;2500848;CC(C)n1nc2c(c1-c1ccc(F)cc1)CCNCC2;Ki;25.12;=;nM;7.6
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4k;2525676;CNc1ccc(-c2c3c(nn2C(C)C)CCNCC3)cc1;Ki;24.0;=;nM;7.62
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4r;2518596;Fc1ccc(-c2c3c(nn2C2CCC2)CCNCC3)cc1;Ki;4.0;=;nM;8.4
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4q;2510223;Fc1ccc(-c2c3c(nn2C2CC2)CCNCC3)cc1;Ki;20.0;=;nM;7.7
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4p;2492413;CC(C)n1nc2c(c1-c1ccc(Cl)cc1Cl)CCNCC2;Ki;43.0;=;nM;7.37
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4o;2512145;CC(C)n1nc2c(c1-c1ccc(Cl)c(Cl)c1)CCNCC2;Ki;31.0;=;nM;7.51
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4n;2508121;CC(C)n1nc2c(c1-c1ccc(OC(F)(F)F)cc1)CCNCC2;Ki;20.0;=;nM;7.7
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4m;2528237;CC(C)n1nc2c(c1-c1ccc(C(F)(F)F)cc1)CCNCC2;Ki;5.0;=;nM;8.3
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4l;2490940;CC(C)n1nc2c(c1-c1ccc(C#N)cc1)CCNCC2;Ki;12.0;=;nM;7.92
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4j;2500848;CC(C)n1nc2c(c1-c1ccc(F)cc1)CCNCC2;Ki;19.0;=;nM;7.72
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4i;2521436;CC(C)n1nc2c(c1-c1ccc(Cl)cc1)CCNCC2;Ki;1.0;=;nM;9.0
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4h;2499436;COc1ccc(-c2c3c(nn2C(C)C)CCNCC3)cc1;Ki;1.0;=;nM;9.0
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4g;2494095;Cc1ccc(-c2c3c(nn2C(C)C)CCNCC3)cc1;Ki;2.0;=;nM;8.7
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4f;2497751;c1ccc(-c2c3c(nn2-c2ccccc2)CCNCC3)cc1;Ki;15.0;=;nM;7.82
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4e;2524918;c1ccc(-c2c3c(nn2C2CCC2)CCNCC3)cc1;Ki;3.0;=;nM;8.52
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4d;2522061;c1ccc(-c2c3c(nn2C2CC2)CCNCC3)cc1;Ki;20.0;=;nM;7.7
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4c;2521015;CC(C)(C)n1nc2c(c1-c1ccccc1)CCNCC2;Ki;43.0;=;nM;7.37
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4b;2524814;CC(C)n1nc2c(c1-c1ccccc1)CCNCC2;Ki;19.0;=;nM;7.72
117572;10.1016/j.bmcl.2020.127669;Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT inhibitors leading to the identification of a clinical candidate.;2023531;4a;2532347;CCn1nc2c(c1-c1ccccc1)CCNCC2;Ki;75.0;=;nM;7.12
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;1;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.445;=;nM;8.84
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;1;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.46;=;nM;8.84
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-6a;2513894;COc1ccc2c(c1[C@@H]1C[C@H]1CN)CCO2.O=C(O)C(F)(F)F;EC50;275.42;=;nM;6.56
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-6a;2513894;COc1ccc2c(c1[C@@H]1C[C@H]1CN)CCO2.O=C(O)C(F)(F)F;EC50;279.0;=;nM;6.55
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-6b;2525901;CCOc1ccc2c(c1[C@@H]1C[C@H]1CN)CCO2.Cl;EC50;776.25;=;nM;6.11
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-6b;2525901;CCOc1ccc2c(c1[C@@H]1C[C@H]1CN)CCO2.Cl;EC50;781.0;=;nM;6.11
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7a;2487605;COc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;724.44;=;nM;6.14
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7a;2487605;COc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;725.0;=;nM;6.14
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7e;2509562;Cl.NC[C@@H]1C[C@H]1c1c(OCCF)ccc2occc12;EC50;446.68;=;nM;6.35
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7e;2509562;Cl.NC[C@@H]1C[C@H]1c1c(OCCF)ccc2occc12;EC50;448.0;=;nM;6.35
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7f;2499941;Cl.NC[C@@H]1C[C@H]1c1c(OCC2CC2)ccc2occc12;EC50;512.86;=;nM;6.29
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7f;2499941;Cl.NC[C@@H]1C[C@H]1c1c(OCC2CC2)ccc2occc12;EC50;524.0;=;nM;6.28
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7g;2523422;CC(C)Oc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;457.09;=;nM;6.34
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7g;2523422;CC(C)Oc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;453.0;=;nM;6.34
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7h;2535890;C=C(F)COc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;588.84;=;nM;6.23
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7h;2535890;C=C(F)COc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;585.0;=;nM;6.23
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7i;2510059;C=C(C)COc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;724.44;=;nM;6.14
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(-)-7i;2510059;C=C(C)COc1ccc2occc2c1[C@@H]1C[C@H]1CN.Cl;EC50;733.0;=;nM;6.13
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6a;2508863;COc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.O=C(O)C(F)(F)F;EC50;75.86;=;nM;7.12
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6a;2508863;COc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.O=C(O)C(F)(F)F;EC50;77.0;=;nM;7.11
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6b;2527243;CCOc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.Cl;EC50;58.88;=;nM;7.23
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6b;2527243;CCOc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.Cl;EC50;54.0;=;nM;7.27
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6c;2499749;CCCOc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.Cl;EC50;257.04;=;nM;6.59
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6c;2499749;CCCOc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.Cl;EC50;258.0;=;nM;6.59
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6d;2491335;C=CCOc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.Cl;EC50;257.04;=;nM;6.59
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6d;2491335;C=CCOc1ccc2c(c1[C@H]1C[C@@H]1CN)CCO2.Cl;EC50;258.0;=;nM;6.59
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6e;2505978;Cl.NC[C@H]1C[C@@H]1c1c(OCC2CC2)ccc2c1CCO2;EC50;269.15;=;nM;6.57
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-6e;2505978;Cl.NC[C@H]1C[C@@H]1c1c(OCC2CC2)ccc2c1CCO2;EC50;269.0;=;nM;6.57
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7a;2499318;COc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;109.65;=;nM;6.96
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7a;2499318;COc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;111.0;=;nM;6.96
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7b;2504240;CCOc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;85.11;=;nM;7.07
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7b;2504240;CCOc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;84.0;=;nM;7.08
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7d;2527583;C=CCOc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;346.74;=;nM;6.46
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7d;2527583;C=CCOc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;348.0;=;nM;6.46
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7e;2515851;Cl.NC[C@H]1C[C@@H]1c1c(OCCF)ccc2occc12;EC50;45.71;=;nM;7.34
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7e;2515851;Cl.NC[C@H]1C[C@@H]1c1c(OCCF)ccc2occc12;EC50;46.0;=;nM;7.34
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7f;2504551;Cl.NC[C@H]1C[C@@H]1c1c(OCC2CC2)ccc2occc12;EC50;338.84;=;nM;6.47
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7f;2504551;Cl.NC[C@H]1C[C@@H]1c1c(OCC2CC2)ccc2occc12;EC50;180.0;=;nM;6.75
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7g;2506518;CC(C)Oc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;173.78;=;nM;6.76
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7g;2506518;CC(C)Oc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;174.0;=;nM;6.76
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7h;2507215;C=C(F)COc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;128.82;=;nM;6.89
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7h;2507215;C=C(F)COc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;128.0;=;nM;6.89
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7i;2501149;C=C(C)COc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;151.36;=;nM;6.82
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-7i;2501149;C=C(C)COc1ccc2occc2c1[C@H]1C[C@@H]1CN.Cl;EC50;150.0;=;nM;6.82
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8a;2495468;CCc1cc2c([C@H]3C[C@@H]3CN)c(OC)ccc2o1.Cl;EC50;60.26;=;nM;7.22
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8a;2495468;CCc1cc2c([C@H]3C[C@@H]3CN)c(OC)ccc2o1.Cl;EC50;60.0;=;nM;7.22
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8b;2488014;CCOc1ccc2oc(CC)cc2c1[C@H]1C[C@@H]1CN.Cl;EC50;309.03;=;nM;6.51
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8b;2488014;CCOc1ccc2oc(CC)cc2c1[C@H]1C[C@@H]1CN.Cl;EC50;309.0;=;nM;6.51
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8d;2508401;CCc1cc2c([C@H]3C[C@@H]3CN)c(OCCF)ccc2o1.Cl;EC50;549.54;=;nM;6.26
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8d;2508401;CCc1cc2c([C@H]3C[C@@H]3CN)c(OCCF)ccc2o1.Cl;EC50;550.0;=;nM;6.26
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8e;2517754;C=CCOc1ccc2oc(CC)cc2c1[C@H]1C[C@@H]1CN.Cl;EC50;436.52;=;nM;6.36
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;(+)-8e;2517754;C=CCOc1ccc2oc(CC)cc2c1[C@H]1C[C@@H]1CN.Cl;EC50;433.0;=;nM;6.36
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;436.52;=;nM;6.36
117728;10.1021/acs.jmedchem.6b01194;Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.;2026935;Lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;EC50;433.0;=;nM;6.36
118450;10.1016/j.bmcl.2020.127599;Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.;2048797;18;2515227;OC[C@@]12C[C@@H]1[C@@H](n1ccc3c(NC(C4CCC4)C4CCC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;1310.0;=;nM;5.88
118450;10.1016/j.bmcl.2020.127599;Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.;2048797;15;2525474;CC(C)C(Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12)C(C)C;Ki;552.0;=;nM;6.26
118450;10.1016/j.bmcl.2020.127599;Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.;2048797;19;2490417;CC(C)[C@@H](Nc1nc(I)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CO)C[C@H]12)C1CC1;Ki;170.0;=;nM;6.77
118450;10.1016/j.bmcl.2020.127599;Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.;2048797;20;2491534;CSc1nc(N[C@H](C(C)C)C2CC2)c2ncn([C@H]3[C@H](O)[C@H](O)[C@]4(CO)C[C@H]34)c2n1;Ki;170.0;=;nM;6.77
118450;10.1016/j.bmcl.2020.127599;Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.;2048797;"48; MRS7704";2499055;CC(C)[C@@H](Nc1nc(Cl)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(CF)C[C@H]12)C1CC1;Ki;934.0;=;nM;6.03
118745;10.1021/acs.jmedchem.0c01912;Ifenprodil Stereoisomers: Synthesis, Absolute Configuration, and Correlation with Biological Activity.;2058198;(1R,2S)-1a;76010;C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1;Ki;95.0;=;nM;7.02
118745;10.1021/acs.jmedchem.0c01912;Ifenprodil Stereoisomers: Synthesis, Absolute Configuration, and Correlation with Biological Activity.;2058198;(1S,2R)-1b;189813;C[C@H]([C@@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1;Ki;66.0;=;nM;7.18
118745;10.1021/acs.jmedchem.0c01912;Ifenprodil Stereoisomers: Synthesis, Absolute Configuration, and Correlation with Biological Activity.;2058198;(1R,2R)-1c;469228;C[C@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1;Ki;708.0;=;nM;6.15
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;R-2a;2513148;CCCc1cccc2c1CC[C@@H]1CNCCN21;EC50;100.0;=;nM;7.0
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;R-2c;2505055;FC(F)(F)CCc1cccc2c1CC[C@@H]1CNCCN21;EC50;3162.28;=;nM;5.5
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3a;2287723;c1cnc2c(c1)CC[C@@H]1CNCCN21;EC50;63.1;=;nM;7.2
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3b;2497553;Clc1ccnc2c1CC[C@@H]1CNCCN21;EC50;50.12;=;nM;7.3
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3c;2494649;Cc1ccnc2c1CC[C@@H]1CNCCN21;EC50;39.81;=;nM;7.4
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3d;2514695;c1cc(C2CC2)c2c(n1)N1CCNC[C@H]1CC2;EC50;15.85;=;nM;7.8
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3e;2512411;CCCc1ccnc2c1CC[C@@H]1CNCCN21;EC50;199.53;=;nM;6.7
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3f;2291598;c1cc(CC2CCC2)c2c(n1)N1CCNC[C@H]1CC2;EC50;158.49;=;nM;6.8
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3g;2291530;c1ccc(Cc2ccnc3c2CC[C@@H]2CNCCN32)cc1;EC50;794.33;=;nM;6.1
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3h;2514443;CC(C)Cc1ccnc2c1CC[C@@H]1CNCCN21;EC50;316.23;=;nM;6.5
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3i;2284277;FC(F)(F)CCc1ccnc2c1CC[C@@H]1CNCCN21;EC50;1258.93;=;nM;5.9
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;3j;2522157;COCc1ccnc2c1CC[C@@H]1CNCCN21;EC50;794.33;=;nM;6.1
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059283;4a;2295997;c1cc2c(cn1)N1CCNC[C@H]1CC2;EC50;794.33;=;nM;6.1
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;R-2a;2513148;CCCc1cccc2c1CC[C@@H]1CNCCN21;Ki;12.59;=;nM;7.9
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;R-2c;2505055;FC(F)(F)CCc1cccc2c1CC[C@@H]1CNCCN21;Ki;100.0;=;nM;7.0
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;3e;2512411;CCCc1ccnc2c1CC[C@@H]1CNCCN21;Ki;10.0;=;nM;8.0
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;3f;2291598;c1cc(CC2CCC2)c2c(n1)N1CCNC[C@H]1CC2;Ki;39.81;=;nM;7.4
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;3g;2291530;c1ccc(Cc2ccnc3c2CC[C@@H]2CNCCN32)cc1;Ki;25.12;=;nM;7.6
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;3h;2514443;CC(C)Cc1ccnc2c1CC[C@@H]1CNCCN21;Ki;31.62;=;nM;7.5
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;3i;2284277;FC(F)(F)CCc1ccnc2c1CC[C@@H]1CNCCN21;Ki;199.53;=;nM;6.7
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;3j;2522157;COCc1ccnc2c1CC[C@@H]1CNCCN21;Ki;125.89;=;nM;6.9
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;4b;2296525;CCCc1cncc2c1CC[C@@H]1CNCCN21;Ki;125.89;=;nM;6.9
118788;10.1016/j.bmcl.2021.127872;Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT receptor.;2059288;4c;2515161;c1ccc(Cc2cncc3c2CC[C@@H]2CNCCN32)cc1;Ki;251.19;=;nM;6.6
119347;10.1021/acsmedchemlett.9b00637;Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A Receptor Agonists.;2075499;"15; MRS7161, PDSP 48644";1961648;CCCNc1cc(C#Cc2ccc(Cl)s2)nc2c1ncn2[C@H]1[C@H](O)[C@H](O)[C@]2(C(=O)NC)C[C@H]12;Ki;760.0;=;nM;6.12
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2a;2569964;Cc1cccc(-c2n[nH]cc2N2CCCNCC2)c1;Ki;532.0;=;nM;6.27
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2b;2557639;Cc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1;Ki;1047.0;=;nM;5.98
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2c;2571374;Clc1cccc(-c2n[nH]cc2N2CCCNCC2)c1;Ki;416.0;=;nM;6.38
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2d;2548376;Clc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1;Ki;988.0;=;nM;6.0
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2e;2560183;Fc1cccc(-c2n[nH]cc2N2CCCNCC2)c1;Ki;1443.0;=;nM;5.84
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2f;2563466;Fc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1;Ki;3121.0;=;nM;5.51
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2g;2561331;COc1ccccc1-c1n[nH]cc1N1CCCNCC1;Ki;2333.0;=;nM;5.63
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2h;2554274;COc1cccc(-c2n[nH]cc2N2CCCNCC2)c1;Ki;988.0;=;nM;6.0
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2i;2556807;COc1ccc(-c2n[nH]cc2N2CCCNCC2)cc1;Ki;1859.0;=;nM;5.73
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;2j;2561806;c1ccc(-c2n[nH]cc2N2CCCNCC2)cc1;Ki;1546.0;=;nM;5.81
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3a;2569807;COc1ccccc1-c1n[nH]cc1N1CCNCC1;Ki;1248.0;=;nM;5.9
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3b;2564446;COc1cccc(-c2n[nH]cc2N2CCNCC2)c1;Ki;357.0;=;nM;6.45
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3c;2570822;COc1ccc(-c2n[nH]cc2N2CCNCC2)cc1;Ki;1332.0;=;nM;5.88
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3d;2556516;c1ccc(-c2n[nH]cc2N2CCNCC2)cc1;Ki;643.0;=;nM;6.19
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3f;2542076;Clc1cccc(-c2n[nH]cc2N2CCNCC2)c1;Ki;61.0;=;nM;7.21
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3g;2552109;Clc1ccc(-c2n[nH]cc2N2CCNCC2)cc1;Ki;258.0;=;nM;6.59
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3h;2568625;Fc1ccccc1-c1n[nH]cc1N1CCNCC1;Ki;2127.0;=;nM;5.67
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3i;2550473;Fc1cccc(-c2n[nH]cc2N2CCNCC2)c1;Ki;215.0;=;nM;6.67
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3j;2565751;Fc1ccc(-c2n[nH]cc2N2CCNCC2)cc1;Ki;791.0;=;nM;6.1
120788;10.1021/acs.jmedchem.1c01093;Discovery of G Protein-Biased Antagonists against 5-HT<sub>7</sub>R.;2119293;3k;2546393;Cc1ccc(-c2n[nH]cc2N2CCNCC2)cc1;Ki;447.0;=;nM;6.35
120856;10.1016/j.ejmech.2021.113782;Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT<sub>1F</sub> receptor agonists for migraine therapy.;2121433;C5;2544815;CN1CCC(=C(F)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1;IC50;8605.0;=;nM;5.07
121348;10.1021/acs.jmedchem.1c00224;Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT<sub>3</sub> and 5-HT<sub>6</sub> Receptor Antagonist with Antipsychotic and Procognitive Properties.;2134930;"17; FPPQ";2561336;O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21;Ki;170.0;=;nM;6.77
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1a;2170430;CNCc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;13.0;=;nM;7.89
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1b;2719331;CCNCc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;19.0;=;nM;7.72
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1c;2725830;CCCNCc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;12.0;=;nM;7.92
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1d;2739131;CCCCNCc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;15.0;=;nM;7.82
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1e;2141260;COc1ccccc1-c1cc(CN(C)C)ccc1Cl;Ki;11.0;=;nM;7.96
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1f;2716435;CCN(CC)Cc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;67.0;=;nM;7.17
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;1g;2726628;CCCN(CCC)Cc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;80.0;=;nM;7.1
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2a;2735824;CNCCc1ccc(Cl)c(-c2ccccc2OC)c1.Cl;Ki;69.0;=;nM;7.16
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2b;2738685;CCNCCc1ccc(Cl)c(-c2ccccc2OC)c1.Cl;Ki;130.0;=;nM;6.89
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2c;2737793;CCCNCCc1ccc(Cl)c(-c2ccccc2OC)c1.Cl;Ki;170.0;=;nM;6.77
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2d;2735335;CCCCNCCc1ccc(Cl)c(-c2ccccc2OC)c1.Cl;Ki;130.0;=;nM;6.89
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2e;2718641;COc1ccccc1-c1cc(CCN(C)C)ccc1Cl;Ki;280.0;=;nM;6.55
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2f;2728700;CCN(CC)CCc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;320.0;=;nM;6.5
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;2g;2738944;CCCN(CCC)CCc1ccc(Cl)c(-c2ccccc2OC)c1;Ki;230.0;=;nM;6.64
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;3a;2721744;COc1ccccc1-c1cc(C2CCNC2)ccc1Cl;Ki;50.0;=;nM;7.3
121796;10.1021/acs.jmedchem.1c00110;Discovery of G Protein-Biased Ligands against 5-HT<sub>7</sub>R.;2155120;3b;2728058;COc1ccccc1-c1cc(C2CCN(C)C2)ccc1Cl;Ki;170.0;=;nM;6.77
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168955;Speciogynine;2553629;CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;23.0;=;nM;7.64
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168955;Paynantheine;2542288;C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;20.0;=;nM;7.7
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168955;DOI;221517;COc1cc(C[C@@H](C)N)c(OC)cc1I;Ki;2.2;=;nM;8.66
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168957;Mitragynine;92231;CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;1260.0;=;nM;5.9
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168957;Speciogynine;2553629;CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;108.0;=;nM;6.97
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168957;Paynantheine;2542288;C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;83.1;=;nM;7.08
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168957;Gambirine;2716704;CC[C@H]1CN2CCc3c([nH]c4cccc(O)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;508.1;=;nM;6.29
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168957;Gambireine;2734064;C=C[C@H]1CN2CCc3c([nH]c4cccc(O)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC;Ki;335.8;=;nM;6.47
122228;10.1021/acs.jmedchem.1c00726;"Activity of <i>Mitragyna speciosa</i> (""Kratom"") Alkaloids at Serotonin Receptors.";2168957;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;Ki;10.8;=;nM;7.97
122357;10.1021/acsmedchemlett.1c00578;Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.;2173326;Psilocin;102382;CN(C)CCc1c[nH]c2cccc(O)c12;IC50;1.07;=;nM;8.97
122357;10.1021/acsmedchemlett.1c00578;Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.;2173326;Ex.# 1;331109;CN(C)CCc1cn(C)c2cccc(O)c12;IC50;31.7;=;nM;7.5
122357;10.1021/acsmedchemlett.1c00578;Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.;2173326;Ex.# 12;2729506;CCN(C)CCc1cn(C)c2cccc(O)c12;IC50;83.0;=;nM;7.08
122357;10.1021/acsmedchemlett.1c00578;Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.;2173326;Ex.# 13;2723521;CC(C)N(C)CCc1cn(C)c2cccc(O)c12;IC50;42.1;=;nM;7.38
122357;10.1021/acsmedchemlett.1c00578;Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.;2173326;Ex.# 16;2726088;CN(CCc1cn(C)c2cccc(O)c12)CC1CC1;IC50;0.245;=;nM;9.61
122567;10.1021/acs.jmedchem.2c01170;Structure-Activity Studies of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators.;2188354;14;2744892;CCCC(CCC)c1nc2c(Nc3ccc(Cl)c(Cl)c3)nc3ccccc3c2[nH]1;Ki;1360.0;=;nM;5.87
122567;10.1021/acs.jmedchem.2c01170;Structure-Activity Studies of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators.;2188354;27;2745436;Clc1ccc(Nc2nc3ccccc3c3[nH]c([C@@H]4C[C@@H]5CCC[C@@H](C5)C4)nc23)cc1Cl;Ki;3250.0;=;nM;5.49
122567;10.1021/acs.jmedchem.2c01170;Structure-Activity Studies of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators.;2188354;35;2766766;Ic1ccc(Nc2nc3ccccc3c3[nH]c(C4CCCCC4)nc23)cc1;Ki;2600.0;=;nM;5.58
122712;10.1021/acs.jmedchem.1c01887;Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.;2192403;5;2375769;C[C@H]1c2cccc(-c3cnn(C)c3)c2C[C@H](CO)N1C(=O)Cc1c(Cl)cccc1Cl;EC50;1000.0;=;nM;6.0
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197354;"(R)-RWAY; (R)-9";2764409;COc1ccccc1N1CCN(CC[C@@H](C(=O)N2CCCCCC2)c2ccccc2)CC1;Ki;7.2;=;nM;8.14
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197392;"53; SL702";130144;O=C(NCCN1CCN(c2cccc3c2OCCO3)CC1)c1ccc(F)cc1;Ki;46.0;=;nM;7.34
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197477;"Cimbi-5; 91";1248782;COc1cc(CCNCc2ccccc2OC)c(OC)cc1I;Ki;2.3;=;nM;8.64
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197492;"117; FPP";478226;C[C@H](Cc1cccc(F)c1)Oc1nc(N2CCNC[C@H]2C)ncc1F;Ki;7.9;=;nM;8.1
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197517;"186; LY266097";153382;COc1ccc(CC2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC;Ki;0.2;=;nM;9.7
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197522;"198; RS-127445";459270;CC(C)c1cc(-c2ccc(F)c3ccccc23)nc(N)n1;Ki;0.3;=;nM;9.52
122921;10.1021/acs.jmedchem.2c00633;Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.;2197523;199;2764880;Cc1c(C(=O)N2CCC(c3ncc[nH]3)CC2)n[nH]c1-c1ccc(Cl)cc1;Ki;0.3;=;nM;9.52
123120;10.1016/j.bmcl.2022.128879;Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700.;2205180;"10; Lu AF35700";2762372;[2H]c1c([2H])c([2H])c([C@@H]2C[C@@H](N3CCN(C([2H])([2H])[2H])C(C)(C)C3)c3cc(Cl)ccc32)c([2H])c1[2H];Ki;0.4;=;nM;9.4
123120;10.1016/j.bmcl.2022.128879;Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700.;2205180;12;2773214;[2H]c1c([2H])c([2H])c([C@@H]2C[C@@H](N3CCNC(C)(C)C3)c3cc(Cl)ccc32)c([2H])c1[2H];Ki;0.39;=;nM;9.41
123203;10.1016/j.ejmech.2021.113931;Design and synthesis of new potent 5-HT<sub>7</sub> receptor ligands as a candidate for the treatment of central nervous system diseases.;2208238;Aripiprazole;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;5.6;=;nM;8.25
123746;10.1016/j.ejmech.2022.114246;Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT<sub>2A</sub> receptor antagonists/inverse agonists.;2222151;7-16;2777134;CN1CCC(N(Cc2ccc(F)cn2)C(=O)NCc2ccc(OCC(F)(F)F)cc2)CC1;Ki;138.7;=;nM;6.86
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;5-HT;549378;Cl.NCCc1c[nH]c2ccc(O)cc12;EC50;0.3631;=;nM;9.44
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;5-HT;549378;Cl.NCCc1c[nH]c2ccc(O)cc12;EC50;0.36;=;nM;9.44
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;83;2756661;Cl.Oc1c(Cl)cccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;106.0;=;nM;6.97
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;84;2776660;Cl.Oc1c(Cl)cccc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;88.0;=;nM;7.06
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;87;2773134;Cl.Oc1cc(Cl)ccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;25.0;=;nM;7.6
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;88;2767753;Cl.Oc1cc(Cl)ccc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;128.0;=;nM;6.89
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;89;2773066;Cl.Oc1cc(Br)ccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;204.0;=;nM;6.69
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;90;2756705;Cl.Oc1cc(Br)ccc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;59.0;=;nM;7.23
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;92;2763858;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(OC)c1.Cl;EC50;98.0;=;nM;7.01
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;93;2742015;COc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)c(O)c1;EC50;3.1;=;nM;8.51
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;94;2775302;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(O)c1;EC50;1.3;=;nM;8.89
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;95;2750518;Cc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)c(C)c1.Cl;EC50;977.0;=;nM;6.01
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;96;2757242;Cc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(C)c1.Cl;EC50;537.0;=;nM;6.27
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;97;2779360;Cl.Oc1ccc(Cl)cc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;1995.0;=;nM;5.7
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;98;2778254;Cl.Oc1ccc(Br)cc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;457.0;=;nM;6.34
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;99;2748715;Cl.Oc1ccc(Br)cc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;338.0;=;nM;6.47
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;100;2763120;Cc1ccc(O)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)c1.Cl;EC50;4265.0;=;nM;5.37
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;101;2748949;Cc1ccc(O)c(C2NCCc3c2[nH]c2ccc(F)cc32)c1.Cl;EC50;316.0;=;nM;6.5
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;103;2772701;Cl.Oc1ccc(O)c(C2NCCc3c2[nH]c2ccc(F)cc32)c1;EC50;25.0;=;nM;7.6
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;104;2766674;COc1ccc(OC)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)c1.Cl;EC50;416.0;=;nM;6.38
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;105;2769607;COc1ccc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)c1.Cl;EC50;588.0;=;nM;6.23
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;106;2778760;COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)cc1OC.Cl;EC50;0.58;=;nM;9.24
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;107;2754174;COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC.Cl;EC50;10.0;=;nM;8.0
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;108;2780095;COc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)cc1OC.Cl;EC50;34.0;=;nM;7.47
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;109;2755181;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC.Cl;EC50;102.0;=;nM;6.99
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;83;2756661;Cl.Oc1c(Cl)cccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;107.15;=;nM;6.97
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;84;2776660;Cl.Oc1c(Cl)cccc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;87.1;=;nM;7.06
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;85;2765454;Cl.Oc1c(Br)cccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;87.1;=;nM;7.06
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;87;2773134;Cl.Oc1cc(Cl)ccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;24.55;=;nM;7.61
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;88;2767753;Cl.Oc1cc(Cl)ccc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;125.89;=;nM;6.9
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;89;2773066;Cl.Oc1cc(Br)ccc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;204.17;=;nM;6.69
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;90;2756705;Cl.Oc1cc(Br)ccc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;58.88;=;nM;7.23
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;92;2763858;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(OC)c1.Cl;EC50;97.72;=;nM;7.01
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;93;2742015;COc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)c(O)c1;EC50;3.162;=;nM;8.5
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;94;2775302;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(O)c1;EC50;1.318;=;nM;8.88
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;95;2750518;Cc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)c(C)c1.Cl;EC50;977.24;=;nM;6.01
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;96;2757242;Cc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(C)c1.Cl;EC50;537.03;=;nM;6.27
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;97;2779360;Cl.Oc1ccc(Cl)cc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;1995.26;=;nM;5.7
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;98;2778254;Cl.Oc1ccc(Br)cc1C1NCCc2c1[nH]c1ccc(Cl)cc21;EC50;457.09;=;nM;6.34
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;99;2748715;Cl.Oc1ccc(Br)cc1C1NCCc2c1[nH]c1ccc(F)cc21;EC50;338.84;=;nM;6.47
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;100;2763120;Cc1ccc(O)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)c1.Cl;EC50;4265.8;=;nM;5.37
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;101;2748949;Cc1ccc(O)c(C2NCCc3c2[nH]c2ccc(F)cc32)c1.Cl;EC50;316.23;=;nM;6.5
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;103;2772701;Cl.Oc1ccc(O)c(C2NCCc3c2[nH]c2ccc(F)cc32)c1;EC50;25.12;=;nM;7.6
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;104;2766674;COc1ccc(OC)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)c1.Cl;EC50;416.87;=;nM;6.38
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;105;2769607;COc1ccc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)c1.Cl;EC50;588.84;=;nM;6.23
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;106;2778760;COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)cc1OC.Cl;EC50;0.5754;=;nM;9.24
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;107;2754174;COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC.Cl;EC50;10.96;=;nM;7.96
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;108;2780095;COc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)cc1OC.Cl;EC50;33.88;=;nM;7.47
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222509;109;2755181;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC.Cl;EC50;102.33;=;nM;6.99
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222529;93;2742015;COc1ccc(C2NCCc3c2[nH]c2ccc(Cl)cc32)c(O)c1;Ki;4.53;=;nM;8.34
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222529;94;2775302;COc1ccc(C2NCCc3c2[nH]c2ccc(F)cc32)c(O)c1;Ki;4.42;=;nM;8.36
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222529;106;2778760;COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(Cl)cc32)cc1OC.Cl;Ki;2.93;=;nM;8.53
123761;10.1021/acsmedchemlett.1c00694;Discovery of Highly Potent Serotonin 5-HT<sub>2</sub> Receptor Agonists Inspired by Heteroyohimbine Natural Products.;2222529;107;2754174;COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC.Cl;Ki;55.7;=;nM;7.25
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10a;2751247;C=CCOc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;16.0;=;nM;7.8
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10b;2758244;COc1cc2c(cc1OC)-c1c(OC)c(OCCF)cc3c1[C@H](C2)N(C)CC3;Ki;629.0;=;nM;6.2
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10c;2752543;CCOc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;153.0;=;nM;6.82
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10d;2745597;CCCCOc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;15.0;=;nM;7.82
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10e;2755030;CCCCCOc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;47.0;=;nM;7.33
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10f;2765288;CCCCCCOc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;105.0;=;nM;6.98
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10g;2755890;COc1cc2c(cc1OC)-c1c(OC)c(OC(C)C)cc3c1[C@H](C2)N(C)CC3;Ki;156.0;=;nM;6.81
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10h;2759402;CCC(C)Oc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;96.0;=;nM;7.02
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10i;2774534;CCCC(C)Oc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;25.0;=;nM;7.6
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10j;2747204;CCCCC(C)Oc1cc2c3c(c1OC)-c1cc(OC)c(OC)cc1C[C@@H]3N(C)CC2;Ki;82.0;=;nM;7.09
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10k;2756317;COc1cc2c(cc1OC)-c1c(OC)c(OCC3CC3)cc3c1[C@H](C2)N(C)CC3;Ki;40.0;=;nM;7.4
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10l;2780113;COc1cc2c(cc1OC)-c1c(OC)c(OC3CCCCC3)cc3c1[C@H](C2)N(C)CC3;Ki;92.0;=;nM;7.04
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10m;2766472;COc1cc2c(cc1OC)-c1c(OC)c(OCc3ccc(Br)cc3)cc3c1[C@H](C2)N(C)CC3;Ki;359.0;=;nM;6.45
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;10n;2776044;COc1cc2c(cc1OC)-c1c(OC)c(OCc3ccccc3)cc3c1[C@H](C2)N(C)CC3;Ki;48.0;=;nM;7.32
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;SB206553;62720;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;Ki;20.0;=;nM;7.7
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11a;376569;COc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;119.0;=;nM;6.92
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11b;1947298;CCOc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;80.0;=;nM;7.1
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11c;1947299;CCCCOc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;56.0;=;nM;7.25
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11d;1947300;CCCCCOc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;57.0;=;nM;7.24
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11e;1947301;CCCCCCOc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;53.0;=;nM;7.28
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11f;1947302;COc1cc2c(cc1OCCF)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;48.0;=;nM;7.32
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11g;1947303;COc1cc2c(cc1OC(C)C)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;45.0;=;nM;7.35
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11h;1947304;CCC(C)Oc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;22.0;=;nM;7.66
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11i;1947305;CCCC(C)Oc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;10.0;=;nM;8.0
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11j;1947306;CCCCC(C)Oc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;33.0;=;nM;7.48
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11k;1947307;COc1cc2c(cc1OCC1CC1)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;29.0;=;nM;7.54
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11l;1947308;COc1cc2c(cc1OC1CCCCC1)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;53.0;=;nM;7.28
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11m;1947309;C=CCOc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3;Ki;55.0;=;nM;7.26
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11n;1947310;COc1cc2c(cc1OCc1ccccc1)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;192.0;=;nM;6.72
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229479;11o;1947311;COc1cc2c(cc1OCc1ccc(Br)cc1)C[C@H]1c3c(cc(OC)c(OC)c3-2)CCN1C;Ki;42.0;=;nM;7.38
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229485;10m;2766472;COc1cc2c(cc1OC)-c1c(OC)c(OCc3ccc(Br)cc3)cc3c1[C@H](C2)N(C)CC3;IC50;3000.0;=;nM;5.52
123975;10.1021/acs.jnatprod.2c00365;Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.;2229485;10n;2776044;COc1cc2c(cc1OC)-c1c(OC)c(OCc3ccccc3)cc3c1[C@H](C2)N(C)CC3;IC50;1227.0;=;nM;5.91
124537;10.1021/acs.jmedchem.1c02132;Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.;2247010;43;2741807;COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(C)n2)ccn1;IC50;540.0;=;nM;6.27
124541;10.1021/acs.jmedchem.1c01759;Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.;2247170;1;2759055;CCc1cc(=O)[nH]c(-n2nc(C)cc2NC(=O)c2ccccc2F)n1;Ki;1300.0;=;nM;5.89
124541;10.1021/acs.jmedchem.1c01759;Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.;2247170;16;2760180;CCc1cc(=O)[nH]c(-n2nc(C)cc2NC(=O)c2cccc(C)c2)n1;Ki;900.0;=;nM;6.05
124541;10.1021/acs.jmedchem.1c01759;Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.;2247175;1;2759055;CCc1cc(=O)[nH]c(-n2nc(C)cc2NC(=O)c2ccccc2F)n1;IC50;420.0;=;nM;6.38
124541;10.1021/acs.jmedchem.1c01759;Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.;2247175;16;2760180;CCc1cc(=O)[nH]c(-n2nc(C)cc2NC(=O)c2cccc(C)c2)n1;IC50;420.0;=;nM;6.38
124541;10.1021/acs.jmedchem.1c01759;Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.;2247175;20;2773260;CCc1cccc(C(=O)Nc2cc(C)nn2-c2nc(CC)cc(=O)[nH]2)c1;IC50;420.0;=;nM;6.38
124541;10.1021/acs.jmedchem.1c01759;Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.;2247175;39;2753634;CCc1cc(=O)[nH]c(-n2nc(C)cc2NC(=O)c2ccc(C)c(C)c2)n1;IC50;420.0;=;nM;6.38
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258400;EUB0000305b;2408104;C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1;Ki;1305.2;=;nM;5.88
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258420;EUB0000312b;2434554;Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21;Ki;1881.0;=;nM;5.73
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258431;EUB0000700a;2427454;C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1;Ki;538.0;=;nM;6.27
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258482;EUB0000703a;2396782;Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1;Ki;2146.0;=;nM;5.67
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258502;EUB0000704a;2400832;Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1;Ki;1058.0;=;nM;5.98
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258551;EUB0000710a;2414167;Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2ccccc21;Ki;1881.0;=;nM;5.73
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258617;EUB0000715a;2238788;C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1;IC50;1200.0;=;nM;5.92
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258644;EUB0000717a;1423627;O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21;Ki;172.4;=;nM;6.76
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258794;EUB0000726a;1792389;COc1cccc(CNC(=O)c2nc3scc(CN(C)Cc4ccccc4)c3c(=O)[nH]2)c1;Ki;1604.0;=;nM;5.79
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258896;EUB0000313b;1948545;CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1;IC50;5330.0;=;nM;5.27
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258897;EUB0000313b;1948545;CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1;Ki;1537.5;=;nM;5.81
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2258905;EUB0000733a;1948528;FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1;Ki;1073.0;=;nM;5.97
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259060;EUB0000741a;2428946;CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1;Ki;21.0;=;nM;7.68
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259081;EUB0000743a;2392199;CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1;Ki;74.56;=;nM;7.13
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259138;EUB0000748a;2416235;Cn1c(-c2csc(C3CCN(CC4=NC5N=CC=CC5N4)CC3)n2)nc2ccccc21;Ki;1532.12;=;nM;5.82
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259175;EUB0000752a;2535420;c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1;Ki;558.19;=;nM;6.25
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259197;EUB0000328a;2321712;CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O;Ki;1292.04;=;nM;5.89
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259273;EUB0000199c;2060428;O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O;IC50;4000.0;=;nM;5.4
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259469;EUB0000289bCl;2533394;CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC.Cl;Ki;6516.0;=;nM;5.19
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259497;EUB0000340a;2463303;O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1;Ki;5254.0;=;nM;5.28
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259570;EUB0000354a;2419117;Nc1nc(NCc2ccccc2)nc(-c2ccccc2CO)n1;Ki;496.4;=;nM;6.3
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259578;EUB0000539a;1896651;Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1;Ki;236.67;=;nM;6.63
124770;10.6019/CHEMBL5212743;Selectivity Literature for EUbOPEN Chemogenomics Library wave 3;2259597;EUB0000540a;2517049;O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1;Ki;1338.0;=;nM;5.87
125279;10.1039/D1MD00167A;Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.;2273277;CI-IB-MECA;76361;CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O;Ki;2770.0;=;nM;5.56
125279;10.1039/D1MD00167A;Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.;2273277;14;2806588;OC[C@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;11.1;=;nM;7.96
125279;10.1039/D1MD00167A;Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.;2273277;23;2790723;CNC(=O)[C@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;23.0;=;nM;7.64
125279;10.1039/D1MD00167A;Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.;2273277;26;2807706;CCOC(=O)[C@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O;Ki;15.0;=;nM;7.82
125341;10.1021/acs.jmedchem.0c01887;β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.;2275540;119b;2788306;Oc1ccc2[nH]c3c(-c4c[nH]c5ccccc45)nccc3c2c1;Ki;170.0;=;nM;6.77
125341;10.1021/acs.jmedchem.0c01887;β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.;2275540;120;2805214;COc1ccc2[nH]c3c(-c4cn(C)c5ccccc45)nccc3c2c1;Ki;100.0;=;nM;7.0
125341;10.1021/acs.jmedchem.0c01887;β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.;2275540;118;2800000;c1ccc2cc(-c3nccc4c3[nH]c3ccccc34)ccc2c1;Ki;1500.0;=;nM;5.82
125341;10.1021/acs.jmedchem.0c01887;β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.;2275540;119a;1779019;c1ccc2c(-c3nccc4c3[nH]c3ccccc34)c[nH]c2c1;Ki;170.0;=;nM;6.77
125341;10.1021/acs.jmedchem.0c01887;β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.;2275540;117;2184696;c1ccc(-c2nccc3c2[nH]c2ccccc23)cc1;Ki;1400.0;=;nM;5.85
126109;10.1021/acsmedchemlett.7b00112;Design of Phthalazinone Amide Histamine H<sub>1</sub> Receptor Antagonists for Use in Rhinitis.;2300721;3g.TFA;2802038;COCCCC(=O)NCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O.O=C(O)C(F)(F)F;Ki;15.85;=;nM;7.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;rizatriptan;79047;CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;almotriptan;420985;CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;drospirenone;421032;C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12;AC50;25999.8;=;nM;4.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;oxymetazoline;42520;Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1;AC50;266.4;=;nM;6.57
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;imiquimod;250908;CC(C)Cn1cnc2c(N)nc3ccccc3c21;AC50;18999.8;=;nM;4.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;rotigotine;258371;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;AC50;430.0;=;nM;6.37
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;vinpocetine;110947;CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32;AC50;12999.9;=;nM;4.89
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;aripiprazole;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;AC50;303.3;=;nM;6.52
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;quinagolide;1449134;CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21;AC50;3666.1;=;nM;5.44
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;guanfacine;66029;N=C(N)NC(=O)Cc1c(Cl)cccc1Cl;AC50;358.0;=;nM;6.45
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;spiperone;4634;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;AC50;5209.6;=;nM;5.28
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;otilonium bromide;1376043;CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1.[Br-];AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;AC50;150.0;=;nM;6.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;quinidine;255477;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;AC50;1161.8;=;nM;5.93
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;metaraminol;675270;C[C@H](N)[C@H](O)c1cccc(O)c1;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;dihydroergocornine;1541550;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;AC50;21999.9;=;nM;4.66
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;xylometazoline;114810;Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1;AC50;1163.9;=;nM;5.93
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;metapramine;1379189;CNC1Cc2ccccc2N(C)c2ccccc21;AC50;950.0;=;nM;6.02
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;pyrimethamine;2080;CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1;AC50;36999.9;=;nM;4.43
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;ropinirole;19316;CCCN(CCC)CCc1cccc2c1CC(=O)N2;AC50;2764.2;=;nM;5.56
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;dipyridamole;86042;OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;cabergoline;675038;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;188.7;=;nM;6.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;sumatriptan;27111;CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1;AC50;12999.9;=;nM;4.89
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;mefloquine;51162;OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1;AC50;20000.0;=;nM;4.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;pergolide;12494;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;15.5;=;nM;7.81
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;methylergometrine;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;AC50;25.7;=;nM;7.59
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;dihydroergotamine;558566;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;2771.7;=;nM;5.56
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;bromocriptine;7065;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;AC50;25000.0;=;nM;4.6
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;pregabalin;136161;CC(C)C[C@H](CN)CC(=O)O;AC50;28000.1;=;nM;4.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;paroxetine;6643;Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1;AC50;9900.1;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;clemizole;831827;Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1;AC50;670.0;=;nM;6.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2304999;perhexiline;119288;C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305000;oxitriptan;262631;N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O;AC50;10081.6;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305000;cabergoline;675038;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;3.2;=;nM;8.49
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305000;fenoldopam;19278;Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1;AC50;245.8;=;nM;6.61
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305000;oxaflozane;1379266;CC(C)N1CCOC(c2cccc(C(F)(F)F)c2)C1;AC50;1009.5;=;nM;6.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;doxepin;1051118;CN(C)CCC=C1c2ccccc2COc2ccccc21;AC50;1200.0;=;nM;5.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;amitriptyline;27072;CN(C)CCC=C1c2ccccc2CCc2ccccc21;AC50;1100.0;=;nM;5.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;cyclobenzaprine;28119;CN(C)CCC=C1c2ccccc2C=Cc2ccccc21;AC50;1246.6;=;nM;5.9
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;melitracen;176875;CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21;AC50;4335.9;=;nM;5.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;dosulepin;916384;CN(C)CC/C=C1\c2ccccc2CSc2ccccc21;AC50;3600.0;=;nM;5.44
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;escitalopram;421007;CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;AC50;21999.9;=;nM;4.66
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;citalopram;14367;CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;AC50;678.2;=;nM;6.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;iprindole;209838;CN(C)CCCn1c2c(c3ccccc31)CCCCCC2;AC50;2600.0;=;nM;5.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;imipramine;605;CN(C)CCCN1c2ccccc2CCc2ccccc21;AC50;5000.0;=;nM;5.3
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;clomipramine;996;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;AC50;5600.0;=;nM;5.25
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;promazine;16391;CN(C)CCCN1c2ccccc2Sc2ccccc21;AC50;5699.9;=;nM;5.24
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;chlorpromazine;6216;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;AC50;2078.5;=;nM;5.68
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nitracrine;32553;CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12;AC50;760.0;=;nM;6.12
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;irbesartan;421066;CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1;AC50;35000.2;=;nM;4.46
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;estradiol;27626;C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;thiothixene;209829;CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;AC50;4900.0;=;nM;5.31
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;exemestane;674325;C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12;AC50;35999.8;=;nM;4.44
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;duloxetine;192908;CNCC[C@H](Oc1cccc2ccccc12)c1cccs1;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;atomoxetine;27342;CNCC[C@@H](Oc1ccccc1C)c1ccccc1;AC50;25000.0;=;nM;4.6
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;desipramine;6243;CNCCCN1c2ccccc2CCc2ccccc21;AC50;26999.8;=;nM;4.57
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mefloquine;51162;OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1;AC50;25000.0;=;nM;4.6
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;meclozine;469632;Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;vismodegib;460092;CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;chlorhexidine;48849;N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1;AC50;1264.9;=;nM;5.9
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nafamostat;7289;N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1;AC50;29000.1;=;nM;4.54
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;thiotepa;28310;S=P(N1CC1)(N1CC1)N1CC1;AC50;1600.0;=;nM;5.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ifenprodil;104385;CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1;AC50;2300.0;=;nM;5.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;propiomazine;675161;CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2;AC50;230.0;=;nM;6.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;alprenolol;822;C=CCc1ccccc1OCC(O)CNC(C)C;AC50;16000.0;=;nM;4.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;imiquimod;250908;CC(C)Cn1cnc2c(N)nc3ccccc3c21;AC50;13784.0;=;nM;4.86
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tetracaine;32027;CCCCNc1ccc(C(=O)OCCN(C)C)cc1;AC50;32999.7;=;nM;4.48
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;osimertinib;1817518;C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C;AC50;832.5;=;nM;6.08
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;astemizole;65605;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;AC50;620.0;=;nM;6.21
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;chlorphentermine;675220;CC(C)(N)Cc1ccc(Cl)cc1;AC50;25000.0;=;nM;4.6
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;oxamniquine;63445;CC(C)NCC1CCc2cc(CO)c([N+](=O)[O-])cc2N1;AC50;25999.8;=;nM;4.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;maprotiline;27713;CNCCCC12CCC(c3ccccc31)c1ccccc12;AC50;1200.0;=;nM;5.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nortriptyline;2262;CNCCC=C1c2ccccc2CCc2ccccc21;AC50;730.0;=;nM;6.14
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;protriptyline;28112;CNCCCC1c2ccccc2C=Cc2ccccc21;AC50;3800.0;=;nM;5.42
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;propranolol;1370;CC(C)NCC(O)COc1cccc2ccccc12;AC50;5000.0;=;nM;5.3
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;propafenone;27112;CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1;AC50;9600.0;=;nM;5.02
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;chlorproguanil;685397;CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1;AC50;12222.9;=;nM;4.91
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;cinitapride;1376793;CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1;AC50;190.0;=;nM;6.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;cabozantinib;1377987;COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC;AC50;5800.0;=;nM;5.24
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;azatadine;89672;CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1;AC50;1600.0;=;nM;5.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;pizotifen;65404;CN1CCC(=C2c3ccccc3CCc3sccc32)CC1;AC50;27.9;=;nM;7.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ketotifen;12957;CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1;AC50;90.0;=;nM;7.05
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;diphemanil;675291;C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1;AC50;29000.1;=;nM;4.54
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;azelastine;27309;CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1;AC50;5400.0;=;nM;5.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;clemastine;469763;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;AC50;2600.0;=;nM;5.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;sertindole;10813;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;AC50;600.0;=;nM;6.22
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;camazepam;624268;CN(C)C(=O)OC1N=C(c2ccccc2)c2cc(Cl)ccc2N(C)C1=O;AC50;17999.9;=;nM;4.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;sertraline;53616;CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21;AC50;7502.4;=;nM;5.12
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;flupentixol;2491225;OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;AC50;63.0;=;nM;7.2
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;zuclopenthixol;80351;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1;AC50;920.0;=;nM;6.04
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;fluphenazine;36842;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;AC50;806.2;=;nM;6.09
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;perphenazine;16505;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;AC50;770.0;=;nM;6.11
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mequitazine;112175;c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2;AC50;3100.0;=;nM;5.51
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;buspirone;3599;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;AC50;7366.8;=;nM;5.13
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;phenindione;33727;O=C1c2ccccc2C(=O)C1c1ccccc1;AC50;17999.9;=;nM;4.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;aripiprazole;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;AC50;109.9;=;nM;6.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;benfluorex;418415;CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1;AC50;494.9;=;nM;6.3
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ethinylestradiol;31241;C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C;AC50;17999.9;=;nM;4.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;risperidone;7714;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;AC50;442.6;=;nM;6.35
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;rosiglitazone;20027;CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tiratricol;60268;O=C(O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1;AC50;5770.6;=;nM;5.24
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;promethazine;27368;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;AC50;1400.0;=;nM;5.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;troglitazone;666;Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2;AC50;2000.0;=;nM;5.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bazedoxifene;65648;Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12;AC50;2900.0;=;nM;5.54
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;minaprine;33583;Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1;AC50;5400.0;=;nM;5.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ponatinib;649637;Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12;AC50;3200.0;=;nM;5.5
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;benperidol;65455;O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;AC50;6586.7;=;nM;5.18
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;croconazole;37184;C=C(c1ccccc1OCc1cccc(Cl)c1)n1ccnc1;AC50;8500.0;=;nM;5.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;encorafenib;1763574;COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1;AC50;28000.1;=;nM;4.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;indeloxazine;1377292;C1=Cc2cccc(OCC3CNCCO3)c2C1;AC50;5300.1;=;nM;5.28
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;doxorubicin;78759;COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;phenazopyridine;231062;Nc1ccc(/N=N/c2ccccc2)c(N)n1;AC50;23999.9;=;nM;4.62
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;otilonium bromide;1376043;CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1.[Br-];AC50;3100.0;=;nM;5.51
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;molindone;3799;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;AC50;735.7;=;nM;6.13
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;benzbromarone;374182;CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1;AC50;1529.7;=;nM;5.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;terfenadine;19569;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;AC50;4300.0;=;nM;5.37
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;buphenine;186531;CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1;AC50;6900.0;=;nM;5.16
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;pyrvinium;675254;Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1;AC50;8799.9;=;nM;5.06
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ticlopidine;60319;Clc1ccccc1CN1CCc2sccc2C1;AC50;9600.0;=;nM;5.02
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;amoxapine;155045;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;AC50;120.0;=;nM;6.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;cannabidiol;318390;C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O;AC50;2280.3;=;nM;5.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;diethylstilbestrol;860;CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1;AC50;23065.1;=;nM;4.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;candesartan;116848;CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1;AC50;16000.0;=;nM;4.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;candesartan cilexetil;116349;CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1;AC50;7854.1;=;nM;5.11
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;benzquinamide;675201;CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O;AC50;320.0;=;nM;6.5
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ritonavir;88100;CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1;AC50;4300.0;=;nM;5.37
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;gestrinone;1209273;C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21CC;AC50;23999.9;=;nM;4.62
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nefazodone;26465;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1;AC50;1100.0;=;nM;5.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;pimozide;364141;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;AC50;44999.7;=;nM;4.35
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;domperidone;364745;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;AC50;10000.0;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;fluspirilene;66238;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;AC50;4600.0;=;nM;5.34
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;amlodipine;418414;CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;metaraminol;675270;C[C@H](N)[C@H](O)c1cccc(O)c1;AC50;7400.0;=;nM;5.13
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tipranavir;372438;CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1;AC50;7500.0;=;nM;5.12
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;dihydroergocornine;1541550;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;AC50;3000.0;=;nM;5.52
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;clebopride;182814;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1;AC50;980.0;=;nM;6.01
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;crizotinib;602271;C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl;AC50;2700.0;=;nM;5.57
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;dextrothyroxine;15990;N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O;AC50;25999.8;=;nM;4.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;amosulalol;255344;COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1;AC50;1600.0;=;nM;5.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;carvedilol;36662;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;AC50;532.4;=;nM;6.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ranolazine;341382;COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;olodaterol;603199;COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1;AC50;6648.3;=;nM;5.18
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nitazoxanide;338934;CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1;AC50;17000.0;=;nM;4.77
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;trazodone;26401;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;AC50;276.9;=;nM;6.56
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lasofoxifene;162444;Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1;AC50;9486.8;=;nM;5.02
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;amodiaquine;29097;CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O;AC50;1500.0;=;nM;5.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;prazosin;97;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;AC50;25999.8;=;nM;4.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;doxazosin;33373;COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC;AC50;6200.0;=;nM;5.21
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;agomelatine;8209;COc1ccc2cccc(CCNC(C)=O)c2c1;AC50;2074.8;=;nM;5.68
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;benzatropine;675154;CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2;AC50;2598.1;=;nM;5.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nimodipine;365248;COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tacrolimus;924;C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC;AC50;23000.1;=;nM;4.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tacrolimus;924;C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC;AC50;20000.0;=;nM;4.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nifedipine;419596;COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-];AC50;6800.0;=;nM;5.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nisoldipine;554892;COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-];AC50;17000.0;=;nM;4.77
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;rimonabant;16088;Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lopinavir;37316;Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O;AC50;6599.9;=;nM;5.18
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;domiphen;660961;CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;masoprocol;144744;C[C@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;olanzapine;34197;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1;AC50;54.9;=;nM;7.26
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;pyrimethamine;2080;CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1;AC50;11296.0;=;nM;4.95
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bepridil;112651;CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1;AC50;28000.1;=;nM;4.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;telmisartan;116949;CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1;AC50;6328.8;=;nM;5.2
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lurasidone;699372;O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1;AC50;71.0;=;nM;7.15
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;propiverine;618127;CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1;AC50;16000.0;=;nM;4.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;selexipag;406189;CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;phenoxybenzamine;41434;CC(COc1ccccc1)N(CCCl)Cc1ccccc1;AC50;6000.0;=;nM;5.22
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;rabeprazole;222203;COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ramosetron;1058607;Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21;AC50;20000.0;=;nM;4.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mexiletine;15958;Cc1cccc(C)c1OCC(C)N;AC50;8500.0;=;nM;5.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ampiroxicam;990133;CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21;AC50;10000.0;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ketoconazole;255904;CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nebivolol;27569;OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1;AC50;8799.9;=;nM;5.06
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;unoprostone isopropyl;674612;CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O;AC50;890.0;=;nM;6.05
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;piperacetazine;453721;CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2;AC50;4700.0;=;nM;5.33
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;acetophenazine;147927;CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2;AC50;4490.0;=;nM;5.35
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;yohimbine;15191;COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O;AC50;260.0;=;nM;6.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;clopidogrel;598402;COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1;AC50;2000.0;=;nM;5.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;benzethonium;656160;CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;paclitaxel;8062;CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O;AC50;8799.9;=;nM;5.06
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;loxapine;59519;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;AC50;120.0;=;nM;6.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;clotiapine;103542;CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1;AC50;1300.0;=;nM;5.89
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;clozapine;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;AC50;46.4;=;nM;7.33
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;cisapride;557741;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;AC50;3633.2;=;nM;5.44
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;terguride;117385;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;AC50;580.0;=;nM;6.24
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;ziprasidone;33664;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;AC50;229.1;=;nM;6.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;indomethacin;173;COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1;AC50;35999.8;=;nM;4.44
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lidamidine;62789;CN=C(N)NC(=O)Nc1c(C)cccc1C;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;sorafenib;276734;CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1;AC50;10000.0;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;fluoxetine;2223;CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;zotepine;34266;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;AC50;64.8;=;nM;7.19
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;diphenhydramine;27629;CN(C)CCOC(c1ccccc1)c1ccccc1;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;salmeterol;242716;OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mefloquine;51162;OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;naftopidil;237007;COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1;AC50;840.0;=;nM;6.08
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;methyltestosterone;328400;C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O;AC50;21999.9;=;nM;4.66
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;dilazep;209510;COc1cc(C(=O)OCCCN2CCCN(CCCOC(=O)c3cc(OC)c(OC)c(OC)c3)CC2)cc(OC)c1OC;AC50;14966.7;=;nM;4.83
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;morniflumate;1377329;O=C(OCCN1CCOCC1)c1cccnc1Nc1cccc(C(F)(F)F)c1;AC50;10000.0;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;asenapine;1676656;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;AC50;1.3;=;nM;8.89
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mianserin;573;CN1CCN2c3ccccc3Cc3ccccc3C2C1;AC50;30.0;=;nM;7.52
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mirtazapine;27610;CN1CCN2c3ncccc3Cc3ccccc3C2C1;AC50;6800.0;=;nM;5.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;glibenclamide;5582;COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;colchicine;14440;COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2;AC50;6100.0;=;nM;5.21
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tetrabenazine;193281;COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2;AC50;8600.0;=;nM;5.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;vandetanib;33576;COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;gallopamil;78582;COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC;AC50;860.0;=;nM;6.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;iloperidone;13949;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;AC50;1800.0;=;nM;5.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;urapidil;33469;COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1;AC50;20000.0;=;nM;4.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;phenmetrazine;675159;CC1NCCOC1c1ccccc1;AC50;23000.1;=;nM;4.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;alosetron;153342;Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O;AC50;190.0;=;nM;6.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tegaserod;122247;CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12;AC50;342.8;=;nM;6.46
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;exalamide;829857;CCCCCCOc1ccccc1C(N)=O;AC50;1100.0;=;nM;5.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nefopam;458338;CN1CCOC(c2ccccc2)c2ccccc2C1;AC50;2600.0;=;nM;5.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;zolpidem;80965;Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1;AC50;29000.1;=;nM;4.54
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;abemaciclib;1763572;CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1;AC50;18999.8;=;nM;4.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;quetiapine;34234;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;AC50;4214.9;=;nM;5.38
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;hydroxyzine;77459;OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;AC50;2200.0;=;nM;5.66
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;zafirlukast;21523;COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;trifluoperazine;1325;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;AC50;1846.7;=;nM;5.73
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;prochlorperazine;37266;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;AC50;2800.0;=;nM;5.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;methysergide;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;AC50;4.4;=;nM;8.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;fexofenadine;81683;CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;AC50;5787.9;=;nM;5.24
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;irsogladine;229088;Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1;AC50;21999.9;=;nM;4.66
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;simvastatin;138562;CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21;AC50;3800.0;=;nM;5.42
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;apomorphine;3854;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;AC50;4700.0;=;nM;5.33
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;apremilast;458773;CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC;AC50;4500.0;=;nM;5.35
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tamsulosin;61181;CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1;AC50;6400.0;=;nM;5.19
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lidoflazine;150806;Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;AC50;2800.0;=;nM;5.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;gemfibrozil;2994;Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1;AC50;4400.0;=;nM;5.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bunitrolol;100738;CC(C)(C)NCC(O)COc1ccccc1C#N;AC50;21000.0;=;nM;4.68
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;saquinavir;17169;CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1;AC50;43999.7;=;nM;4.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;thioridazine;5970;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;AC50;2653.3;=;nM;5.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;verapamil;1219;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;AC50;1200.0;=;nM;5.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bevantolol;138698;COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;carbenoxolone;454298;CC1(C)[C@@H](OC(=O)CCC(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;mizolastine;152819;CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1;AC50;17000.0;=;nM;4.77
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;nemonapride;25298;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;AC50;180.0;=;nM;6.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;letermovir;701175;COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1;AC50;10039.9;=;nM;5.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lorlatinib;1757351;C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;diflucortolone;454305;C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO;AC50;17999.9;=;nM;4.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bromocriptine;7065;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;AC50;538.3;=;nM;6.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bopindolol;255377;Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1;AC50;18999.8;=;nM;4.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;bromperidol;34949;O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1;AC50;7300.0;=;nM;5.14
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;haloperidol;3859;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;AC50;6714.0;=;nM;5.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;darifenacin;291960;NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1;AC50;25999.8;=;nM;4.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;erdafitinib;1927225;COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1;AC50;4100.0;=;nM;5.39
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;sultopride;25760;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC;AC50;1300.0;=;nM;5.89
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;amisulpride;389011;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;AC50;700.0;=;nM;6.16
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;remoxipride;27616;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;AC50;3062.7;=;nM;5.51
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lovastatin;9495;CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21;AC50;23000.1;=;nM;4.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;paroxetine;6643;Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1;AC50;19078.8;=;nM;4.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;dasatinib;2856578;Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O;AC50;6300.0;=;nM;5.2
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;desloratadine;191342;Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1;AC50;150.0;=;nM;6.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tropisetron;88800;CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;piribedil;795654;c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1;AC50;2300.0;=;nM;5.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;lomerizine;39516;COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC;AC50;5900.0;=;nM;5.23
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;diperodon;209571;O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1;AC50;15000.0;=;nM;4.82
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;alectinib;1117844;CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O;AC50;480.0;=;nM;6.32
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;spironolactone;328201;CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12;AC50;29000.1;=;nM;4.54
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;tiapride;132933;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;AC50;29000.1;=;nM;4.54
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;metoclopramide;7736;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;AC50;4300.0;=;nM;5.37
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;sunitinib;13048;CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C;AC50;5200.0;=;nM;5.28
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;dicycloverine;165774;CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1;AC50;5400.0;=;nM;5.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;oxypertine;1379281;COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC;AC50;120.0;=;nM;6.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305001;progesterone;12825;CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C;AC50;10999.9;=;nM;4.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;doxepin;1051118;CN(C)CCC=C1c2ccccc2COc2ccccc21;AC50;140.4;=;nM;6.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;rizatriptan;79047;CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12;AC50;12000.0;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;almotriptan;420985;CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12;AC50;510.0;=;nM;6.29
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;chlorphenamine;10358;CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1;AC50;4060.4;=;nM;5.39
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;amitriptyline;27072;CN(C)CCC=C1c2ccccc2CCc2ccccc21;AC50;82.6;=;nM;7.08
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;citalopram;14367;CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;AC50;273.1;=;nM;6.56
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;iprindole;209838;CN(C)CCCn1c2c(c3ccccc31)CCCCCC2;AC50;409.2;=;nM;6.39
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;imipramine;605;CN(C)CCCN1c2ccccc2CCc2ccccc21;AC50;319.0;=;nM;6.5
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;promazine;16391;CN(C)CCCN1c2ccccc2Sc2ccccc21;AC50;192.4;=;nM;6.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;chlorpromazine;6216;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;AC50;94.5;=;nM;7.03
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;nitracrine;32553;CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12;AC50;200.0;=;nM;6.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;amiodarone;27185;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;AC50;1883.7;=;nM;5.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;thiothixene;209829;CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;AC50;857.3;=;nM;6.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;loratadine;110803;CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1;AC50;1233.5;=;nM;5.91
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;meclozine;469632;Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1;AC50;1137.5;=;nM;5.94
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;chlorhexidine;48849;N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1;AC50;683.2;=;nM;6.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;cetirizine;111185;O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;AC50;8927.3;=;nM;5.05
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;tetracaine;32027;CCCCNc1ccc(C(=O)OCCN(C)C)cc1;AC50;1418.2;=;nM;5.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;dextromethorphan;77456;COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3;AC50;5795.8;=;nM;5.24
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;astemizole;65605;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;AC50;110.5;=;nM;6.96
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;chlorphentermine;675220;CC(C)(N)Cc1ccc(Cl)cc1;AC50;2996.6;=;nM;5.52
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;nortriptyline;2262;CNCCC=C1c2ccccc2CCc2ccccc21;AC50;17.2;=;nM;7.76
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;propranolol;1370;CC(C)NCC(O)COc1cccc2ccccc12;AC50;208.3;=;nM;6.68
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;cinitapride;1376793;CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1;AC50;2.3;=;nM;8.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;ketotifen;12957;CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1;AC50;32.8;=;nM;7.48
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;glycopyrronium bromide;674978;C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-];AC50;4066.8;=;nM;5.39
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;sertindole;10813;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;AC50;12.0;=;nM;7.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;zuclopenthixol;80351;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1;AC50;14.4;=;nM;7.84
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;fluphenazine;36842;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;AC50;53.8;=;nM;7.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;aripiprazole;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;AC50;41.6;=;nM;7.38
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;risperidone;7714;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;AC50;69.5;=;nM;7.16
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;promethazine;27368;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;AC50;67.9;=;nM;7.17
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;quinagolide;1449134;CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21;AC50;324.1;=;nM;6.49
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;bazedoxifene;65648;Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12;AC50;631.0;=;nM;6.2
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;minaprine;33583;Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1;AC50;1395.8;=;nM;5.86
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;phenformin;282509;N=C(N)NC(=N)NCCc1ccccc1;AC50;8904.9;=;nM;5.05
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;amiloride;89526;N=C(N)NC(=O)c1nc(Cl)c(N)nc1N;AC50;5633.0;=;nM;5.25
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;guanfacine;66029;N=C(N)NC(=O)Cc1c(Cl)cccc1Cl;AC50;1341.6;=;nM;5.87
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;spiperone;4634;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;AC50;660.0;=;nM;6.18
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;otilonium bromide;1376043;CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1.[Br-];AC50;711.5;=;nM;6.15
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;molindone;3799;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;AC50;120.0;=;nM;6.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;terfenadine;19569;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;AC50;665.0;=;nM;6.18
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;buphenine;186531;CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1;AC50;733.4;=;nM;6.13
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;quinidine;255477;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;AC50;2000.0;=;nM;5.7
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;quercetin;3666;O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12;AC50;19388.8;=;nM;4.71
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;amoxapine;155045;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;AC50;7.6;=;nM;8.12
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;nefazodone;26465;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1;AC50;84.0;=;nM;7.08
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;pimozide;364141;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;AC50;252.3;=;nM;6.6
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;amlodipine;418414;CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl;AC50;4321.5;=;nM;5.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;tamoxifen;6968;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;AC50;896.2;=;nM;6.05
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;clebopride;182814;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1;AC50;7.9;=;nM;8.1
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;xylometazoline;114810;Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1;AC50;1558.9;=;nM;5.81
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;sibutramine;358192;CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1;AC50;13215.4;=;nM;4.88
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;crizotinib;602271;C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl;AC50;316.1;=;nM;6.5
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;cefalexin;555972;CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1;AC50;6305.9;=;nM;5.2
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;carvedilol;36662;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;AC50;10.1;=;nM;8.0
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;trazodone;26401;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;AC50;78.3;=;nM;7.11
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;lasofoxifene;162444;Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1;AC50;272.0;=;nM;6.57
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;fenfluramine;139434;CCNC(C)Cc1cccc(C(F)(F)F)c1;AC50;4358.0;=;nM;5.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;prazosin;97;COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC;AC50;2565.9;=;nM;5.59
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;doxazosin;33373;COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC;AC50;439.9;=;nM;6.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;agomelatine;8209;COc1ccc2cccc(CCNC(C)=O)c2c1;AC50;879.5;=;nM;6.06
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;melatonin;3012;COc1ccc2[nH]cc(CCNC(C)=O)c2c1;AC50;17127.7;=;nM;4.77
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;benzatropine;675154;CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2;AC50;136.9;=;nM;6.86
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;olanzapine;34197;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1;AC50;22.8;=;nM;7.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;hydrochlorothiazide;2045;NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O;AC50;6914.3;=;nM;5.16
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;ropinirole;19316;CCCN(CCC)CCc1cccc2c1CC(=O)N2;AC50;26999.8;=;nM;4.57
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;fasudil;50822;O=S(=O)(c1cccc2cnccc12)N1CCCNCC1;AC50;13082.2;=;nM;4.88
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;mitoxantrone;4504;O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21;AC50;7110.2;=;nM;5.15
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;yohimbine;15191;COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O;AC50;86.2;=;nM;7.06
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;cabergoline;675038;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;8.6;=;nM;8.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;raloxifene;6914;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;AC50;170.4;=;nM;6.77
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;phentolamine;20131;Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1;AC50;4639.2;=;nM;5.33
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;loxapine;59519;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;AC50;17.8;=;nM;7.75
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;clozapine;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;AC50;8.1;=;nM;8.09
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;cisapride;557741;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;AC50;189.3;=;nM;6.72
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;ziprasidone;33664;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;AC50;13.7;=;nM;7.86
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;sumatriptan;27111;CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1;AC50;14000.1;=;nM;4.85
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;fluoxetine;2223;CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1;AC50;3906.6;=;nM;5.41
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;zotepine;34266;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;AC50;23.0;=;nM;7.64
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;diphenhydramine;27629;CN(C)CCOC(c1ccccc1)c1ccccc1;AC50;667.4;=;nM;6.18
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;naftopidil;237007;COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1;AC50;47.0;=;nM;7.33
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;mianserin;573;CN1CCN2c3ccccc3Cc3ccccc3C2C1;AC50;7.8;=;nM;8.11
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;pergolide;12494;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;20.5;=;nM;7.69
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;gallopamil;78582;COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC;AC50;81.9;=;nM;7.09
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;alosetron;153342;Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O;AC50;31.4;=;nM;7.5
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;tegaserod;122247;CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12;AC50;20.6;=;nM;7.69
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;exalamide;829857;CCCCCCOc1ccccc1C(N)=O;AC50;270.0;=;nM;6.57
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;quetiapine;34234;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;AC50;281.9;=;nM;6.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;hydroxyzine;77459;OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;AC50;156.7;=;nM;6.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;trifluoperazine;1325;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;AC50;84.4;=;nM;7.07
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;methylergometrine;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;AC50;3.7;=;nM;8.43
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;methysergide;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;AC50;4.4;=;nM;8.36
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;apomorphine;3854;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;AC50;1268.1;=;nM;5.9
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;dihydroergotamine;558566;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;63.8;=;nM;7.2
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;viloxazine;114406;CCOc1ccccc1OCC1CNCCO1;AC50;2343.3;=;nM;5.63
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;verapamil;1219;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;AC50;50.2;=;nM;7.3
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;nemonapride;25298;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;AC50;6.0;=;nM;8.22
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;bromocriptine;7065;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;AC50;411.9;=;nM;6.38
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;haloperidol;3859;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;AC50;1074.1;=;nM;5.97
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;darifenacin;291960;NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1;AC50;2633.0;=;nM;5.58
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;remoxipride;27616;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;AC50;1031.7;=;nM;5.99
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;paroxetine;6643;Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1;AC50;11887.2;=;nM;4.92
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;dasatinib;2856578;Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O;AC50;7596.3;=;nM;5.12
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;desloratadine;191342;Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1;AC50;32.7;=;nM;7.49
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;idebenone;418736;COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O;AC50;8989.8;=;nM;5.05
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;diperodon;209571;O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1;AC50;1959.1;=;nM;5.71
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;metoclopramide;7736;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;AC50;314.0;=;nM;6.5
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;sunitinib;13048;CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C;AC50;158.2;=;nM;6.8
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;donepezil;9372;COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2;AC50;8206.2;=;nM;5.09
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305002;encainide;139046;COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1;AC50;3661.7;=;nM;5.44
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;citalopram;14367;CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;AC50;300.0;=;nM;6.52
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;thymol;38579;Cc1ccc(C(C)C)c(O)c1;AC50;9100.0;=;nM;5.04
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;pramipexole;88815;CCCN[C@H]1CCc2nc(N)sc2C1;AC50;18384.6;=;nM;4.74
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;benfluorex;418415;CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1;AC50;933.0;=;nM;6.03
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;guanfacine;66029;N=C(N)NC(=O)Cc1c(Cl)cccc1Cl;AC50;1013.0;=;nM;5.99
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;lorcaserin;301194;C[C@H]1CNCCc2ccc(Cl)cc21;AC50;331.6;=;nM;6.48
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;quinidine;255477;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;AC50;976.5;=;nM;6.01
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;ropinirole;19316;CCCN(CCC)CCc1cccc2c1CC(=O)N2;AC50;13422.0;=;nM;4.87
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;cabergoline;675038;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;14.8;=;nM;7.83
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;fluoxetine;2223;CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1;AC50;5256.0;=;nM;5.28
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;pergolide;12494;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;8.4;=;nM;8.08
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;methylergometrine;675307;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;AC50;5.4;=;nM;8.27
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;methysergide;138605;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;AC50;2.8;=;nM;8.55
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;dihydroergotamine;558566;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;AC50;44.4;=;nM;7.35
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;pramocaine;209224;CCCCOc1ccc(OCCCN2CCOCC2)cc1;AC50;9299.9;=;nM;5.03
126186;10.1038/s41467-023-40064-9;A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.;2305095;paroxetine;6643;Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1;AC50;10640.5;=;nM;4.97
126350;10.1021/acs.jmedchem.2c01769;Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer.;2309515;"14; JR1-157";2835569;CCN(CC)CCCC(C)Nc1cnc(C(=O)Nc2ccc(Cl)c3cccnc23)cn1;Ki;427.0;=;nM;6.37
126504;10.1021/acs.jmedchem.3c00734;Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.;2315019;Serotonin;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;2.4;=;nM;8.62
126504;10.1021/acs.jmedchem.3c00734;Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.;2315020;"16f; CAB-01-019";2841044;c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1;IC50;532.0;=;nM;6.27
126504;10.1021/acs.jmedchem.3c00734;Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.;2315020;LY272015 HCl;2859892;COc1ccc(CC2NCCc3c2[nH]c2ccc(C)cc32)cc1OC.Cl;IC50;0.37;=;nM;9.43
126504;10.1021/acs.jmedchem.3c00734;Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.;2315091;"16f; CAB-01-019";2841044;c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1;Ki;13.0;=;nM;7.89
126864;10.1016/j.bmcl.2024.129654;2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design.;2327065;10;2872613;NC[C@@H]1C[C@@H]1c1cc(F)ccc1OCC1CC1;EC50;289.0;=;nM;6.54
126940;10.1016/j.ejmech.2022.114696;Targeting σ<sub>2</sub>R/TMEM97 with novel aminotetralins.;2329160;JVW-1601;2843572;CCCN1CCN(c2ccc3c(c2)C(N(C)C(=O)OCc2ccccc2)CCC3)CC1;Ki;100.0;=;nM;7.0
127122;10.1039/d3md00677h;Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.;2336048;"1; DHE";558566;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;Ki;3.7;=;nM;8.43
127122;10.1039/d3md00677h;Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.;2336048;2;3183;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O;Ki;2.5;=;nM;8.6
127127;10.1039/d4md00043a;Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond.;2336158;9;2856810;CCOP(=O)(OCC)c1ccc2[nH]cc(CCN(C)C)c2c1;Ki;140.0;=;nM;6.85
127127;10.1039/d4md00043a;Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond.;2336159;Psilocin;102382;CN(C)CCc1c[nH]c2cccc(O)c12;Ki;4.6;=;nM;8.34
127127;10.1039/d4md00043a;Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond.;2336159;Psilocybin;331146;CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12;Ki;98.7;=;nM;7.01
127467;10.1021/acsmedchemlett.3c00427;Dual <i>N</i><sup>6</sup>/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.;2348202;8a;2850126;OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccccc4)ncnc32)[C@H](O)[C@@H]1O;Ki;500.0;=;nM;6.3
127467;10.1021/acsmedchemlett.3c00427;Dual <i>N</i><sup>6</sup>/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.;2348202;8c;2858343;C[C@@H](Nc1ncnc2c1c(C(F)(F)F)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O)c1ccccc1;Ki;710.0;=;nM;6.15
127467;10.1021/acsmedchemlett.3c00427;Dual <i>N</i><sup>6</sup>/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.;2348202;8e;2852132;OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccc(Cl)cc4)ncnc32)[C@H](O)[C@@H]1O;Ki;830.0;=;nM;6.08
127467;10.1021/acsmedchemlett.3c00427;Dual <i>N</i><sup>6</sup>/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.;2348202;8d;2836608;OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccccc4Cl)ncnc32)[C@H](O)[C@@H]1O;Ki;550.0;=;nM;6.26
127467;10.1021/acsmedchemlett.3c00427;Dual <i>N</i><sup>6</sup>/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.;2348202;8f;2852351;OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4cccc(Cl)c4)ncnc32)[C@H](O)[C@@H]1O;Ki;620.0;=;nM;6.21
127467;10.1021/acsmedchemlett.3c00427;Dual <i>N</i><sup>6</sup>/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.;2348202;8g;2840985;OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccccc4F)ncnc32)[C@H](O)[C@@H]1O;Ki;1200.0;=;nM;5.92
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;4;2597903;C1=CC2(CCNCC2)Oc2ccccc21;EC50;1000.0;=;nM;6.0
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;4;2597903;C1=CC2(CCNCC2)Oc2ccccc21;EC50;897.0;=;nM;6.05
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.259;=;nM;8.9
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;5-HT;2214;NCCc1c[nH]c2ccc(O)cc12;EC50;1.19;=;nM;8.92
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;6;2856968;Clc1cccc2c1C=CC1(CCNCC1)O2;EC50;63.1;=;nM;7.2
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;6;2856968;Clc1cccc2c1C=CC1(CCNCC1)O2;EC50;68.4;=;nM;7.17
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;9;2836786;Clc1cccc2c1OC1(C=C2)CCNCC1;EC50;501.19;=;nM;6.3
127468;10.1021/acsmedchemlett.3c00454;Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G<sub>q</sub>-Biased 5-HT<sub>2C</sub> Receptor Partial Agonists.;2348205;9;2836786;Clc1cccc2c1OC1(C=C2)CCNCC1;EC50;469.7;=;nM;6.33
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;"2; 5-MeO-DMT";2232;COc1ccc2[nH]cc(CCN(C)C)c2c1;EC50;5.87;=;nM;8.23
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;6a;2845856;COc1ccc2[nH]nc(CCN(C)C)c2c1;EC50;483.0;=;nM;6.32
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;6b;2879480;[2H]C([2H])(Cc1n[nH]c2ccc(OC)cc12)N(C)C;EC50;189.0;=;nM;6.72
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;16;2865940;CN(C)CCc1n[nH]c2ccc(O)cc12;EC50;35.0;=;nM;7.46
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;"22; (R)-69";2840136;C[C@@H]1C=C(c2c[nH]c3ncccc23)CNC1;EC50;187.0;=;nM;6.73
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19a;2846340;C1=C(c2n[nH]c3ccccc23)CNCC1;EC50;16.0;=;nM;7.8
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19b;2844778;Cn1nc(C2=CCCNC2)c2ccccc21;EC50;53.0;=;nM;7.28
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;"19d; VU6067416";2864343;Brc1ccc2[nH]nc(C3=CCCNC3)c2c1;EC50;14.0;=;nM;7.85
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19e;2877198;Nc1ccc2[nH]nc(C3=CCCNC3)c2c1;EC50;10.0;=;nM;8.0
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19f;2874602;COc1ccc2[nH]nc(C3=CCCNC3)c2c1;EC50;11.0;=;nM;7.96
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;"2; 5-MeO-DMT";2232;COc1ccc2[nH]cc(CCN(C)C)c2c1;EC50;8.128;=;nM;8.09
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;6a;2845856;COc1ccc2[nH]nc(CCN(C)C)c2c1;EC50;478.63;=;nM;6.32
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;6b;2879480;[2H]C([2H])(Cc1n[nH]c2ccc(OC)cc12)N(C)C;EC50;190.55;=;nM;6.72
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;16;2865940;CN(C)CCc1n[nH]c2ccc(O)cc12;EC50;34.67;=;nM;7.46
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19a;2846340;C1=C(c2n[nH]c3ccccc23)CNCC1;EC50;16.22;=;nM;7.79
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19b;2844778;Cn1nc(C2=CCCNC2)c2ccccc21;EC50;52.48;=;nM;7.28
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;"19d; VU6067416";2864343;Brc1ccc2[nH]nc(C3=CCCNC3)c2c1;EC50;5.623;=;nM;8.25
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19e;2877198;Nc1ccc2[nH]nc(C3=CCCNC3)c2c1;EC50;10.0;=;nM;8.0
127538;10.1021/acsmedchemlett.3c00566;Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.;2349491;19f;2874602;COc1ccc2[nH]nc(C3=CCCNC3)c2c1;EC50;10.72;=;nM;7.97
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354252;norDF;418519;C[C@H](N)Cc1cccc(C(F)(F)F)c1;Ki;11.2;=;nM;7.95
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354253;norDF;418519;C[C@H](N)Cc1cccc(C(F)(F)F)c1;EC50;23.0;=;nM;7.64
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354254;norDF;418519;C[C@H](N)Cc1cccc(C(F)(F)F)c1;EC50;23.0;=;nM;7.64
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354255;norDF;418519;C[C@H](N)Cc1cccc(C(F)(F)F)c1;EC50;23.0;=;nM;7.64
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354256;SB-204741;153148;Cc1cc(NC(=O)Nc2ccc3c(ccn3C)c2)sn1;Ki;11.22;=;nM;7.95
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354258;Mianserin;573;CN1CCN2c3ccccc3Cc3ccccc3C2C1;Ki;9.0;=;nM;8.05
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354258;Trazodone;26401;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;Ki;74.0;=;nM;7.13
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354258;Clozapine;2261;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;Ki;7.2;=;nM;8.14
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354258;Yohimbine;15191;COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O;Ki;43.0;=;nM;7.37
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354259;Cyproheptadine;11005;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;Ki;1.5;=;nM;8.82
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354259;Lisuride;263558;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;Ki;1.1;=;nM;8.96
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354261;Amisulpride;389011;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;Ki;13.0;=;nM;7.89
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354262;Aripiprazole;155006;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;Ki;0.36;=;nM;9.44
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354262;Asenapine;1676656;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;Ki;0.21;=;nM;9.68
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354262;Lurasidone;2865906;O=C1[C@@H]2[C@@H]3C[C@@H](C[C@H]3O)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1;Ki;24.0;=;nM;7.62
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354262;Quetiapine;34234;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;Ki;86.0;=;nM;7.07
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354263;Olanzapine;34197;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1;Ki;12.0;=;nM;7.92
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354263;Risperidone;7714;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;Ki;29.0;=;nM;7.54
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354264;Xanomeline;26653;CCCCCCOc1nsnc1C1=CCCN(C)C1;Ki;20.0;=;nM;7.7
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354265;VU6047534;2860151;Cn1ccc2cc(-n3c(=O)[nH]c4sc5c(c4c3=O)CCCC5)ccc21;IC50;480.0;=;nM;6.32
127696;10.1021/acs.jmedchem.3c01178;2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.;2354265;VU6055320;2874495;CS(=O)(=O)CCn1ccc2cc(-n3c(=O)[nH]c4sc5c(c4c3=O)CCCC5)ccc21;IC50;790.0;=;nM;6.1
127879;10.1016/j.ejmech.2023.115414;Aporphines: A privileged scaffold in CNS drug discovery.;2359854;22;1310578;COc1ccc2c(c1OC)C[C@@H]1c3c(cc4c(c3-2)OCO4)CCN1C;IC50;1693.0;=;nM;5.77
127879;10.1016/j.ejmech.2023.115414;Aporphines: A privileged scaffold in CNS drug discovery.;2359863;26;2872208;Oc1cc2c3c(c1Cl)-c1ccccc1CC3NCC2;EC50;278.4;=;nM;6.55
127935;10.1021/acsmedchemlett.3c00143;Discovery and <i>In Vitro</i> Characterization of SPL028: Deuterated <i>N</i>,<i>N</i>-Dimethyltryptamine.;2361422;9i;2838798;O=C(O)/C=C/C(=O)O.[2H]C([2H])(Cc1c[nH]c2ccccc12)N(C)C;IC50;410.0;=;nM;6.39
127935;10.1021/acsmedchemlett.3c00143;Discovery and <i>In Vitro</i> Characterization of SPL028: Deuterated <i>N</i>,<i>N</i>-Dimethyltryptamine.;2361422;7;1672346;CN(C)CCc1c[nH]c2ccccc12.O=C(O)/C=C/C(=O)O;IC50;480.0;=;nM;6.32
127935;10.1021/acsmedchemlett.3c00143;Discovery and <i>In Vitro</i> Characterization of SPL028: Deuterated <i>N</i>,<i>N</i>-Dimethyltryptamine.;2361440;9i;2838798;O=C(O)/C=C/C(=O)O.[2H]C([2H])(Cc1c[nH]c2ccccc12)N(C)C;Ki;300.0;=;nM;6.52
127935;10.1021/acsmedchemlett.3c00143;Discovery and <i>In Vitro</i> Characterization of SPL028: Deuterated <i>N</i>,<i>N</i>-Dimethyltryptamine.;2361440;7;1672346;CN(C)CCc1c[nH]c2ccccc12.O=C(O)/C=C/C(=O)O;Ki;350.0;=;nM;6.46
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;Cariprazine;1340277;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;Ki;0.151;=;nM;9.82
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;11a;2869994;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccnc2ccccc12;Ki;1.99;=;nM;8.7
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;13a;2871271;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;Ki;1.47;=;nM;8.83
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;11b;2844222;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4ccnc5ccccc45)CC3)CC2)c1Cl;Ki;1.27;=;nM;8.9
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;13b;2848391;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)COC)CC3)CC2)c1Cl;Ki;1.71;=;nM;8.77
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;6c;2867863;COc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)CC2)c1F;Ki;34.2;=;nM;7.47
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;13c;2843436;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(OC)c3F)CC2)CC1;Ki;29.6;=;nM;7.53
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;11d;2876809;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(C(F)(F)F)n3)CC2)CC1)c1ccnc2ccccc12;Ki;18.8;=;nM;7.73
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;13d;2874397;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(C(F)(F)F)n3)CC2)CC1;Ki;11.3;=;nM;7.95
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;6e;2849302;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)CC2)c1;Ki;7.3;=;nM;8.14
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;7e;2877828;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)NC)CC3)CC2)c1;Ki;6.2;=;nM;8.21
128137;10.1021/acs.jmedchem.2c01624;Dopamine D<sub>3</sub>/D<sub>2</sub> Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.;2369367;13e;2865065;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)CCOC)CC3)CC2)c1;Ki;5.8;=;nM;8.24
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000358a;16048;CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1;Ki;2684.72;=;nM;5.57
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000375a;46378;COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl;Ki;844.11;=;nM;6.07
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000378aBDA;940358;CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12.O=C(O)/C=C\C(=O)O;Ki;15.62;=;nM;7.81
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000381a;33307;C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F;Ki;2091.7;=;nM;5.68
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000383a;5371;Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1;Ki;6207.26;=;nM;5.21
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000393aCl;1704654;COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1.Cl.Cl;Ki;250.88;=;nM;6.6
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000403aCl;705992;CCCCN1CCC(COC(=O)c2cc(Cl)c(N)c3c2OCCO3)CC1.Cl;Ki;52.01;=;nM;7.28
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000408aCl;1379842;COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1.Cl;Ki;42.95;=;nM;7.37
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000414a;94171;CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2C1O3;Ki;500.15;=;nM;6.3
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000416aCl;545283;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl;Ki;804.45;=;nM;6.09
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000427aCl;533334;CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1.Cl;Ki;226.94;=;nM;6.64
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000437aCl;674727;C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl;Ki;39.66;=;nM;7.4
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000438a;26693;CC(=O)N1CCc2ccc(N(C(=O)/C=C/c3cccc(C#N)c3)C3CCN(CCC4CCCC4)CC3)cc21;Ki;4327.13;=;nM;5.36
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000439a;758349;Cc1cc(NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2n1;Ki;1700.78;=;nM;5.77
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000440a;1382803;Cc1nc(C(=O)N2CCC[C@H]2Cc2nnc(-c3ccccc3)o2)c(-c2ccccc2F)s1;Ki;3047.19;=;nM;5.52
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000444a;129410;O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2;Ki;1137.63;=;nM;5.94
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000445aCl;1038357;Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1;Ki;65.01;=;nM;7.19
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000447aCl;548913;CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl;Ki;362.25;=;nM;6.44
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000452aCl;860270;Cc1c(C(=O)NC2CCCCC2)sc2nc3ccc(N)cc3n12.Cl;Ki;656.45;=;nM;6.18
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000455a;358648;COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1;Ki;527.78;=;nM;6.28
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000456aCl;2490407;Cl.Clc1cccc(COc2cncc(N3CCNCC3)n2)c1;Ki;9.943;=;nM;8.0
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000467a;429641;O=C(c1cc2c(cc1F)OC(c1ccc(F)cc1)(c1ccc(Cl)cc1Cl)O2)N1CCOCC1;Ki;607.3;=;nM;6.22
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000471a;515852;Nc1nc2c(c(N3CCNCC3)n1)CCC1=C2[C@@H]2CCCC[C@@H]2O1;Ki;279.58;=;nM;6.55
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000473a;1180380;CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1;Ki;400.17;=;nM;6.4
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000480a;590783;Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1;Ki;603.18;=;nM;6.22
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000483aCl;1377250;Cl.N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12;Ki;1039.92;=;nM;5.98
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000501a;1604173;Cc1cc([C@@H](C)Nc2cccc(-c3cc(C)c(C(=O)N[C@@H](C)C(=O)O)c(C)c3)c2)ccc1Cl;Ki;2475.43;=;nM;5.61
128593;10.6019/CHEMBL5442175;EUbOPEN Chemogenomics Library - PDSP Secondary Binding;2381863;EUB0000520a;1794501;CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1;Ki;646.69;=;nM;6.19
128726;10.6019/CHEMBL5465560;Selectivity Literature for EUbOPEN Chemogenomic Library;2413308;EUB0000877a;1976141;CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1;IC50;7700.0;=;nM;5.11
